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Production of a SARS-CoV-2 Spike Protein Vaccine Using the Baculovirus
Expression Vector System
Abstract
Various COVID-19 vaccines are currently in development, as the COVID-19 pandemic has created an
unmet need for protection against the SARS-CoV-2 virus. While there are many different types of vaccines,
we focused on developing one that would be safe, affordable, and quickly available for emergency use. A
vaccine synthesized using recombinant proteins utilizes a reliable and well-studied technological
platform, avoids the safety risks inherent to viral vectors, and provides a cost-effective, scalable method
of production of antigen used to induce an immune response. Other vaccines on the market notably
include Pfizer’s and Moderna’s mRNA based vaccines. Although these are widely used, there is still a large
demand for an inexpensive yet safe and effective vaccine. Herein, we propose the production of 500
million doses of a recombinant spike protein-based COVID-19 vaccine in a quick time frame and costeffective manner, using the baculovirus expression vector system (BEVS). Our upstream process involves
a three-stage cellular scale-up from shake flasks to WAVE bioreactors to perfusion to production
bioreactors, as well as an additional two-stage viral amplification from flasks to WAVE bioreactors. Our
downstream process involves a six-stage protein recovery with depth filtration, his-tag chromatography,
viral inactivation, ion-exchange chromatography, viral filtration, and diafiltration. We will be partnering with
a contract manufacturing organization (CMO) for this project, as we do not have the time to quickly build
a plant to get these vaccines out for emergency use. This arrangement makes this process highly
profitable. Selling each dose for $16 yields net earnings near $2 billion and an extremely high IRR due to
the lack of permanent and fixed costs other than our rental fee. The IRR for the CMO is estimated to be at
least 16% with the NPV of the plant at $855,000 and an ROI of 18%.
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Letter of Transmittal
University of Pennsylvania, School of Engineering and Applied Science
Department of Chemical and Biomolecular Engineering
220 South 33rd Street
Philadelphia, PA 19104
April 20, 2021
Dear Dr. Miriam Wattenbarger, Prof. Bruce Vrana, and Dr. Jeffrey Cohen,
This report proposes a process design that produces a recombinant spike-protein-based
COVID-19 vaccine. The final drug substance recovered contains 2.60 kg of highly purified
protein, sufficient for more than the 500 million doses requested in the original project statement.
The process design involves scale-up of cells from shake flasks to bioreactors, viral
amplification, and protein recovery through steps including filtration, viral inactivation, and
chromatography. This design ensures a product that is both safe and affordable for consumers,
while easily replicable for the CMO to manufacture.
An economic analysis of this process shows favorable profitability. By partnering with a
CMO in North Carolina, the manufacture of SARS-CoV-2 spike protein-based vaccine brings in
$2 billion in net earnings at a net present value of $1.5 billion. The CMO plant has a return on
investment of 18%, an investor’s rate of return of at least 16%, and a net present value of
$855,000. These numbers suggest that the project is profitable, and a CMO would respond
favorably to a manufacturing partnership. We recommend that the design move forward
following the specifications in this report. The economics can be supplemented by considerations
of research and development investments and formulation and packaging costs, which were
outside the scope of this project.
Thank you so much for all the assistance with this senior design project. We greatly
appreciate your guidance in this unprecedented Spring 2021 semester amidst COVID-19.
Sincerely,

Rachel Adler

Nathan Kelsey

Michelle Maik
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1. Abstract
Various COVID-19 vaccines are currently in development, as the COVID-19 pandemic
has created an unmet need for protection against the SARS-CoV-2 virus. While there are many
different types of vaccines, we focused on developing one that would be safe, affordable, and
quickly available for emergency use. A vaccine synthesized using recombinant proteins utilizes a
reliable and well-studied technological platform, avoids the safety risks inherent to viral vectors,
and provides a cost-effective, scalable method of production of antigen used to induce an
immune response. Other vaccines on the market notably include Pfizer’s and Moderna’s mRNA
based vaccines. Although these are widely used, there is still a large demand for an inexpensive
yet safe and effective vaccine. Herein, we propose the production of 500 million doses of a
recombinant spike protein-based COVID-19 vaccine in a quick time frame and cost-effective
manner, using the baculovirus expression vector system (BEVS). Our upstream process involves
a three-stage cellular scale-up from shake flasks to WAVE bioreactors to perfusion to production
bioreactors, as well as an additional two-stage viral amplification from flasks to WAVE
bioreactors. Our downstream process involves a six-stage protein recovery with depth filtration,
his-tag chromatography, viral inactivation, ion-exchange chromatography, viral filtration, and
diafiltration. We will be partnering with a contract manufacturing organization (CMO) for this
project, as we do not have the time to quickly build a plant to get these vaccines out for
emergency use. This arrangement makes this process highly profitable. Selling each dose for $16
yields net earnings near $2 billion and an extremely high IRR due to the lack of permanent and
fixed costs other than our rental fee. The IRR for the CMO is estimated to be at least 16% with
the NPV of the plant at $855,000 and an ROI of 18%.

9

2. Introduction and Objective-time Chart
2.1 Project Background
The COVID-19 global pandemic has been caused by the rapid global transmission of
SARS-CoV-2, a novel coronavirus that was first reported in December 2019 following an initial
outbreak in Wuhan, Hubei Province, China [1]. As of March 28, 2021, there have been over 126
million confirmed cases and nearly 2.8 million deaths worldwide [2]. In the United States alone,
there have been over 30 million cases and nearly 550,000 deaths [3]. These numbers stress the
urgent need for vaccine development, manufacture, and global distribution.
Vaccines are designed to help the human body build an immune response to a particular
pathogen. By inducing an immunogenic response, the body can respond to any future infection
by minimizing or eliminating symptoms and/or the disease itself. In developing vaccines,
scientists consider the immune response, the target population, and the best available technology.
This process normally takes years: it took 16 years to develop a hepatitis B vaccine and 5 years
to develop an Ebola vaccine [4].
Due to the urgency of the pandemic, there is immense pressure to develop a vaccine
against SARS-CoV-2 within 18 months. In addition to accelerated vaccine development, the
quick scale-up of a viable manufacturing and purification process is crucial to producing large
quantities of vaccines to meet global demand. Previous research, such as that for SARS-CoV
vaccine development [5] has established the spike protein of SARS-CoV-2 as a clear target
candidate for vaccines [1].
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2.2 Project Goals and Scope
The goal of this project will be to select a vaccine technology and design both an
upstream and downstream manufacturing process to produce 500 million doses of a COVID-19
vaccine. Of the available vaccine technologies, the traditional live-attenuated and inactivated
virus vaccines, which use the weakened or killed virus, respectively, were deemed too dangerous
due to their usage of actual SARS-CoV-2 virus. The more recent mRNA, viral vector, and
subunit vaccine technologies will be considered and discussed in Section 10.1 [6][7].
The upstream process will consist of a series of flasks and bioreactors used to grow a
large population of cells, followed by inoculation of the final cell population with viral material
to produce the desired active pharmaceutical ingredient (API). The subsequent downstream
process will include a series of unit operations to isolate, purify, and package the bulk API. The
genetic modification of the cell line and viral material, and the formulation and packaging of the
API into doses is outside the scope of this project. The capital investment and operating costs for
the upstream and downstream processes will be estimated to price the production of a large
volume of vaccine. This economic analysis will allow the team to approach a CMO with the
available equipment and resources to negotiate a reasonable contract. The urgency of the
COVID-19 pandemic necessitates that vaccines be produced as soon as possible by a capable
CMO as opposed to the traditional design of a new manufacturing facility.

11

2.3 Objective-Time Chart
Figure 2.1 shows the established timeline the team followed in completing this project. In
January, we met with project author Dr. Jeffrey Cohen and faculty advisor Dr. Miriam
Wattenbarger to discuss and review the literature available. This research and their expertise
informed and guided our preliminary process synthesis of the manufacturing process in late
January and early February. The month of February was dedicated to designing the overall
upstream (i.e. harvest) and downstream (i.e. purification) processes. The team also began writing
the report mid-February to document information and decisions made along the way. The end of
February and the month of March focused on the specific design of the equipment used in each
unit operation. The first week of March was used to present our progress since the beginning of
the project and the next steps to be taken. The rest of March emphasized the market and
economic aspects of costing and profitability analysis. In the first half of April, the process flow
diagrams (PFDs), material balances, energy balances, and profitability analysis were completed
to wrap up the project and finish the written report. Afterwards, the written report and
presentation were revised and finalized.

Figure 2.1. Objective-Time Chart for the COVID-19 Vaccine Manufacturing Process Project.

12

3. Innovation Map
N/A
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4. Market and Competitive Analysis
The market demand for SARS-CoV-2 vaccines remains very high. With over 1 million
total cases, and the number of new cases still averaging about 500,000 a day, the vaccine is
clearly essential. This global pandemic has weakened our health systems, economic systems, and
social progression as a whole. In order for businesses and schools to reopen, it is key that as
many people as possible are vaccinated against this virus. The global vaccine market revenue is
currently estimated at $59 billion USD [8]. By the end of 2021, some have predicted that the
market will grow to be worth $75 billion USD [9]. Evidently, there is a huge need for COVID-19
vaccines and our manufacturing process can help to fill this gap.
There may be an initial drop in 2022 because boosters may not be needed, and there may
be a price reduction due to intense competition. However, as years pass, the market is expected
to open and grow again due to an unmet need for vaccine boosters [8]. The market is
subsequently expected to grow at a compound annual growth rate (CAGR) of over 9%, and reach
$47.5 billion USD by 2026.
Currently, the market is segmented by technology and geography. Many types of vaccines
are in development, as highlighted later in Section 10.1. Additionally, the US, UK, India, Spain,
Italy, and China were some of the most affected countries. Currently, 58% of the vaccine market
belongs to APAC countries, 15% to Europe, and 12% to North America [10]. However, North
America’s share of the market is expected to increase to about 46% [9].
There are some pharmaceutical companies who have already begun manufacturing and
distributing a vaccine. Notably, Pfizer/BioNTech, Moderna, AstraZeneca/Oxford, Novavax, and
GSK are among the largest players. Pfizer/BioNTech agreed to provide the UK with 500 million
doses by the end of 2021 [9]. In total, over 1 billion doses of Pfizer/BioNTech’s vaccine have
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been ordered. Topping this, 3 billion doses from AstraZeneca/Oxford’s vaccine, 1 billion doses
from Novavax’s vaccine, and 800 million doses from Moderna’s vaccine have been ordered.
Others include Johnson & Johnson’s vaccine which has received 300 million dose orders [11].
With almost 8 billion people in the world and most vaccines requiring two doses, there is
clearly a large unmet need for vaccines. Our vaccine only requires refrigeration, as opposed to
the mRNA vaccines that require frozen storage, which low resource countries do not have the
infrastructure for. As of March 24th, about 300 million people worldwide have received at least
one dose of a vaccine [12]. This only corresponds to 3.56% of the world's population. Thus,
assuming at least 50% of the population will want a vaccine, billions more doses are necessary.
Our project aims to produce 500 million doses of a vaccine to contribute to about 250 million
complete vaccinations. While competition undoubtedly exists, the most important thing right
now is to ensure that as many people as possible are vaccinated as soon as possible. Our project
provides a safe, effective, low cost, easily scalable, and highly competitive manufacturing
process.
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5. Customer Requirements
5.1 Customer Analysis
The magnitude and swiftness of the COVID-19 pandemic presents a problem of unique
proportions in both a public health and economic sense. Customers are effectively the entire
global population, particularly the most vulnerable members of society. Since the vaccine is
injected into the human body, extra precaution must be taken to ensure that the vaccine is
completely safe. Additionally, the refrigeration requirements of our vaccine provide availability
to low resource countries that lack cold storage for mRNA vaccines. A vaccine presents the
means of stopping the spread, protecting the vulnerable population, and enabling an economic
reopening. This occurs when herd immunity is achieved [13]. Therefore, the sooner sufficient
vaccination is carried out, the better.

5.2 Product Safety
The vaccine must meet stringent safeguards in accordance with Good Manufacturing
Practices (GMP) to obtain FDA approval [14]. Therefore, the first priority of this process is to
ensure that a product is of utmost safety and purity. Accordingly, this proposal prioritizes purity
rather than yield for downstream processes and ensures adequate purification steps to reduce
viral content and other contaminants present in the process. Additionally, the upstream process
incorporates safety measures such as replicate batches with independent supply lines and media
filters to adhere to quality control standards.
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5.3 Rapid Timeline
Safe but rapid delivery of the vaccine dosage will be critical in limiting the spread of
COVID-19. In this proposal, we focus on producing the vaccine quickly with adherence to strict
quality control, even if greater capital expenditures are required. We thus incorporate larger-scale
systems into our proposal to enable production in one batch rather than in multiple smaller
batches to ensure that the desired amount of doses reaches consumers as quickly as possible. For
instance, the downstream process is anticipated to take 3 days rather than time-intensive
alternatives with drastic capital expenditure reductions. Furthermore, we prepare multiple lines
in the manual handling stages of the manufacturing process to prevent delays due to line quality.
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6. Critical-To-Quality Variables
N/A
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7. Product Concepts
N/A

19

8. Superior Product Concepts
N/A
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9. Competitive Patent Analysis
The three main types of vaccines currently in development are the subunit vaccine, the
viral vector vaccine, and the mRNA vaccine. The recombinant protein, a subunit vaccine, is the
most conventional type where antigens on the viral surface are used to trigger immune responses.
Viral vector vaccines use genetically engineered capsids of other viruses to deliver antigenic
genes. The mRNA vaccine is a relatively recent technology that uses lipid nanoparticles (LNPs)
to encapsulate mRNA containing the genetic information for the antigen.
In the manufacturing process of recombinant protein vaccines, insect cells or mammalian
cells are first transfected with plasmid containing the antigen. Transfected cells are next grown in
a cell culture seed train for mass production. After the cells have grown to the desired amount in
the harvest bioreactor, they are infected with viral stock to induce expression of protein. Then,
the protein of interest is separated and purified to formulate the vaccine. Published in 2007, an
international patent [15] is owned by Merck for its influenza recombinant subunit vaccine. The
invention of influenza recombinant subunit vaccine involves the usage of insect cell expression
system and saponin adjuvant, which validated our manufacturing model.
For the manufacturing process of mRNA vaccines, many copies of the mRNA of interest
are first produced in vitro through transcription of DNA in a reactor. Then, the encapsulation of
mRNA copies in LNP components involves microfluidic technology to undergo self-assembly.
To formulate the vaccine, the LNPs encapsulating the mRNA are isolated and purified. Pfizer
and Moderna are companies that have developed the production of LNPs to encapsulate mRNA
for the SARS-CoV-2 virus. Published in 2020, a US patent [16] is owned by Moderna for its
betacoronavirus mRNA vaccine.
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The manufacturing process of viral vector vaccines is similar to that of recombinant
protein vaccines in that cells are grown in bioreactors, but different in that cells are infected with
viral vectors for propagation. The viral vectors are separated and purified afterward to formulate
the vaccine. Published in 2011, an international patent [17] is owned by Janssen for its method of
producing Ad26 adenoviral vectors. The method for large-scale production of Ad26 adenoviral
vectors involves perfusion systems that grow cells to very high density before infection and
propagation of adenoviral vectors after infection. Janssen’s patent was used as a reference to
apply the perfusion system to our second-to-last bioreactor.
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10. Preliminary Process Synthesis
10.1 Types of Vaccines
10.1.1 mRNA
Messenger RNA, or mRNA, vaccines deliver the genetic information encoding the spike
protein [18]. Gene constructs can be quickly transcribed in vitro using just the genetic sequence,
making production a purely chemical process that does not require cellular growth [19]. The
manufacturing process is scalable, which allows for rapid production of vaccines [20]. However,
the Pfizer/BioNTech and Moderna vaccines currently in distribution require extreme frozen
storage to account for RNA instability, which poses difficulties in the storage and transportation
of dosages [21]. Challenges in large-scale production and long-term storage do not have past
precedent, thus issues that arise will pose significant costs [20][21]. While mRNA technology is
promising, no mRNA vaccines have been licensed in the past for human use and not much data
is widely available. Therefore, we did not choose mRNA vaccine platform for our project [18].

10.1.2 Viral Vectors
An alternative method is the viral vector vaccine. In this approach, the genetic sequence
of a virus is modified such that it is not pathogenic to the host while still stimulating a strong
immunogenic response [22]. The virus is designed in such a way that its pathogenicity is
attenuated but still capable of generating antigenic material to which the host reacts, producing a
lasting immunogenic response [23]. Unlike traditional attenuated vaccines, the actual viral vector
need not be the actual virus itself, but is often a chimeric version of a less potent virus with the
particular genetic sequence of the virus of interest [22]. Additionally, to further limit
pathogenicity, specific replication-defective vectors have been engineered by precise genetic
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editing of the chimeric viruses [24]. However, these replication-deficient vectors have weakened
immunogenicity [25]. Additionally, there is a fair amount of concern regarding the ability of viral
vector vaccines to combine with wild-type viruses and mutate, thereby regaining full scale
pathogenicity [23]. Lastly, very few viral vector vaccines have been approved anywhere in the
world, limiting the ability of our senior design group to properly assess such a process [23]. Due
to these concerns, the viral vector vaccine’s advantages in immunogenicity are outweighed by
safety concerns and the lack of prior experience.

10.1.3 Subunit
Current subunit vaccines include recombinant protein, receptor-binding domain (RBD),
and virus-like particles (VLPs). We chose to use a recombinant protein-based vaccine using the
spike protein as the antigen. The spike protein was the most potent antigen for SARS-CoV and
MERS-CoV vaccines [26], and spike protein-based vaccines are known to develop high-titer
spike protein-specific antibodies with neutralizing activity [27]. Novavax, the current leader in
making recombinant protein-based vaccines for SARS-CoV-2, uses the spike protein as the
antigen. The RBD of the spike protein was not chosen as the antigen since it lacks other
neutralizing epitopes that are on the full length spike, and adverse events have occurred for some
RBD-based vaccines in clinical trials [28]. VLPs were not chosen as the antigen since enveloped
baculoviruses and VLPs share similar chemical and physical characteristics, which poses a major
drawback in the purification step [29].
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10.2 Protein-Based Vaccine
10.2.1 Spike Protein
The recombinant protein-based vaccine is a highly conventional vaccine platform, which
has been studied for a long time [30]. Spike protein vaccine technology has proven to be safe for
immunocompromised people, as the manufacturing of the vaccine does not involve working with
live pathogens or genetic material [31]. Recombinant protein-based vaccines do not require
frozen storage conditions, which is another major advantage. Novavax is currently developing its
recombinant protein-based vaccine with required storage conditions between 2˚C to 8˚C [32],
which is much more economical than the frozen storage requirements of mRNA vaccines.
However, recombinant protein-based vaccines require the usage of an adjuvant, which is an
agent mixed with the vaccine to promote effective immune response. The most common side
effects of adjuvants are known to be malaise, fatigue, and headache [21]. Despite these
considerations, for our senior design project, we have decided to use the recombinant
protein-based vaccine as our vaccine platform.

10.2.2 Baculovirus Expression Vector System
The Baculovirus Expression Vector System (BEVS) will be used to develop the
recombinant protein. CERVARIX manufactured by GlaxoSmithKline (GSK) was the first human
recombinant protein vaccine produced using the BEVS system [31]. In the BEVS system, insect
cells are infected using a recombinant baculovirus with the desired gene. This gene of interest
can be made synthetically by obtaining the sequence from a public database, or it can be
transcribed from an inactivated virus obtained from the CDC and amplified by Reverse
Transcriptase Polymerase Chain Reaction (RT-PCR) [33]. As shown in Figure 10.2, the gene is
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then inserted into the baculovirus plasmid DNA to make the bacmid, which is amplified in a
bacterial culture to increase the number of bacmid. The bacteria are lysed to harvest and purify
the intracellular bacmid, which is then inserted into adherent insect cells using a transfection
reagent. The cells with the bacmid are grown in medium and produce the baculovirus, which are
secreted into the supernatant. Cellular debris is removed by ultracentrifugation, and genomic
DNA and RNA is digested with nuclease, leaving behind only the baculovirus in the supernatant
to be harvested and stored [34].

Figure 10.2. The Baculovirus Expression Vector System. The gene of interest is inserted into the baculovirus
genome to create the recombinant bacmid. The bacmid is transfected into insect cells, which produce and secrete the
recombinant baculovirus into the supernatant. (ThermoFisher Scientific)

Various advantages are associated with the BEVS system. High protein yields, large
scalability, and fast production are notable benefits [35]. Additionally, there is inherent safety, as
the virus only infects invertebrates [35]. Using insect cells is also ideal because they are cheaper
than CHO cells yet still perform proper post-translational modification. Although bacteria and
yeast cells yield high protein expression at a low cost, they were not considered as viable options
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because of their inability to properly perform post-translational modifications. There are some
disadvantages to the BEVS system, including quick cell lysis, at 72-96 hours post infection [36].
This can be combated by deleting the gene that produces the apoptotic protein, as well as via
various other methods. The required media can also be expensive, but is still cheaper than those
for CHO cells. Overall, the BEVS system is optimal, so our group has decided to utilize BEVS to
develop a safe and cost-effective vaccine.

10.2.3 Cell Line
The insect cell-baculovirus expression vector system (IC-BEVS) can be manufactured
efficiently and scaled up for large-scale production of recombinant proteins. The process consists
of cell growth, cell infection with the recombinant baculovirus vector, and purification and
recovery of the recombinant protein. The Spodoptera frugiperda (Sf) cell line is an industry
standard cultivated in suspension using serum-free media and is easily detached from cultivation
surfaces with gentle agitation, eliminating the need for trypsinization [37]. Our team chose Sf-9
cells because they have higher baculovirus amplification rates, have faster growth rates, and are
less fragile — specifically more tolerant to osmotic, pH, and shear stress conditions — than
Sf-21 cells [37].

10.2.4 Medium
Sf-9 cells require specific media conditions to grow optimally, thus a variety of media
lines from different companies were assessed. Several considerations were examined: maximum
cell density, available scale for purchase, GMP capability, and availability of growth condition
information. The Thermo Fisher ExpiSf™ system has the largest maximum cell density at
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20×106 cells/mL using a specialized line of Sf-9 cells [38]. Other versions from Thermo Fisher,
such as the Sf-900TM II SFM and Sf-900TM III SFM, have cell densities that were also decent
(~10×106 cells/mL). Beyond Thermo Fisher, Expression Systems have ESF 921TM media with
purported maximum cell densities of 15×106 cells/mL [39][40][41]. However, certain
bioprocessing companies, such as Oxford Expressions Technologies, warn that while cell
densities greater than 107 are certainly possible to achieve, they are also harder to sustain for
growth cycles [42]. A study of Thermo Fisher’s ExpiSf™ line even found that optimal cell
density was actually closer to 5×106 cells/mL [43]. This indicates that maximum cell density
above 106 is less significant than cell density below that threshold. Regarding the available scale
for purchase, only ExpiSf™ was not sold at industrial scale, whereas other media types had
custom orders at sizes up to ten thousands of liters (see brochure from Thermo Fisher Scientific
on the Sf-900TM III SFM [40]). Most media appeared to meet the GMP standards, one from
Oxford Expressions Technology was not produced at GMP levels, disqualifying this media from
our selection [44]. The choice ultimately came down to Sf-900TM II, Sf-900TM III SFM, or ESF
921TM. Due to the wider availability of research papers on Sf-900TM II SFM, this media was
chosen to ensure our process modeling would be as accurate as possible.

10.2.5 Adjuvant
Since proteins do not induce an adequate immune response on their own, a saponin-based
adjuvant is necessary to enhance the response for a protein-based vaccine. While the addition of
an adjuvant is outside the scope of our project, adjuvants are necessary for the final product.
Saponins produce high antibody titers and better responses for T-independent antigens and CD8+
T cells [45]. They also promote both humoral and cellular immunity, both of which are required

28

to control viral infections, making saponins ideal for use in subunit vaccines [46]. The Matrix
M1™ saponin-based adjuvant in the Novavax SARS-CoV-2 recombinant protein vaccine
induced neutralizing antibodies to both SARS and MERS spike proteins more effectively than
alum adjuvant [47]. ISCOM™ and ISCOMATRIX™ saponin-based adjuvants were more
immunogenic than liposome and protein micelle systems [46]. Saponins were safe and potent in
intranasal influenza HA vaccines [46]. They also have a wide range of biological properties, such
as anti-inflammatory and antimicrobial activity [48]. However, Quillaja saponins have shown
haemolytic activity [48], toxicity, and aqueous instability, which are properties that have limited
their usage as vaccine adjuvants [46]. In light of these issues, other plant-derived saponin
candidates have been investigated with promising results [46][49]. Additionally, while the use of
adjuvants elicits side effects, saponins only cause minor local reactions, namely mild to moderate
temporary pain, tenderness, and induration at the site of injection [46]. The advantages and
potential of saponin adjuvants far outweigh their disadvantages and the benefits of other adjuvant
alternatives.

10.3 Bioreactors
When assessing the choices of bioreactors available, we evaluated the options along the
size variability, sanitation quality, and information provided about the bioreactor. Out of the
many bioreactor models, the regular HyPerforma series was chosen for our project. DynaDrive is
an alternative bioreactor model that we have considered. The DynaDrive model comes in sizes of
50 L, 500 L, 3000 L, and 5000 L. Because this model has blades that are more robust, it can

29

support cells with much higher oxygen uptake rate through more intense agitation. However,
since DynaDrive is relatively new, many CMO companies would not have this equipment.

10.3.1 Sf-9 Cell Seed Train Design
Our Sf-9 cell seed train consists of 6 stages: (4x) 125 mL flasks, (4x) 500 mL flasks, (3x)
5 L flasks, (3x) 200 L WAVE bioreactors, (1x) 500 L perfusion bioreactor, and (1x) 2000 L batch
bioreactor. Quadruplicates are formulated for the 125 mL and 500 mL flasks: one of them is used
for baculovirus amplification, and the other three are prepared in consideration of possible
damage or contamination to a sample during manual inoculation in between stages. Triplicates
are not needed for the 500 L perfusion bioreactor and 2000 L production bioreactor, since the
content is transferred through sterile tube welders that prevent the occurrence of contamination.
The working volume is scaled up by 10-fold to reduce the number of stages required, thereby
reducing the capital cost of equipment. The scale up from the 500 L perfusion bioreactor to the
2000 L batch bioreactor is only 4-fold, since the 2000 L bioreactor is large enough to produce
sufficient amount of protein.

Figure 10.3.1. Overview of the Sf-9 Seed Train Design. Sf-9 cells are grown from a master cell bank and scaled up
from flasks to bioreactors.
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Approximately 4 million cells are grown to around 16 trillion cells to produce 3.75 kg of
spike protein, which accounts for the 30% yield loss in the downstream process. Media is
pre-filled up to the maximum working volume minus the inoculum volume for all stages except
the 125 mL flasks with a 50 mL working volume and the 200 L WAVE bioreactors with a 50 L
working volume. The headspace in the bioreactors allows for the addition of materials such as
glucose, base, and antifoam as well as the transfer of oxygen and carbon dioxide at the liquid-gas
interface. The total amount of media required for the growth stages is 2800 L, and the total
amount of media required for the production stage is 1500 L. The extra volume of media
required for the 500 L perfusion bioreactor was calculated by using the ratio between the number
of cells to the amount of media in the previous stage.
During the growth and production stages, the cells consume oxygen and produce carbon
dioxide, which could then react with water to produce carbonic acid and drop the pH level. To
maintain the optimum pH of 6.3, sodium hydroxide is added as base if the pH becomes too low.
Oxygen, glucose, and glutamine are added to provide nutrients for the cells, air is added to strip
carbon dioxide, and antifoam is added to prevent foaming. The time required for the growth
stages is around 19 days, and the time required for the production stage is 5 days, totaling an
estimate of 24 days for the upstream process.

10.3.2 Multiplicity of Infection
Multiplicity of Infection (MOI) refers to the number of virions added per cell during the
infection stage. An MOI value greater than 1 is considered high while an MOI value smaller than
1 is considered low. For our project, we will use a MOI value of 0.01, which is on the lower end.
A low MOI value has several advantages in that smaller volumes of virus stock can be purchased
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and fewer virus amplification steps are required [50], reducing the operating costs significantly.
However, using a low MOI value leads to a two-stage infection process where not all cells are
infected immediately after virus addition. Thus, we assumed that 5 days of infection phase would
be sufficient for one virion to infect 100 cells, as suggested by our project author Dr. Cohen.

10.3.3 Baculovirus Preparation
Live baculovirus preserved in liquid will be purchased from Applied Biological Materials
Incorporated in 10 mL quantities with densities of 106 infectious units/mL [51]. Our baculovirus
preparation consists of 3 stages: (2x) 250 mL flasks, (2x) 20 L WAVE bioreactors, and the (1x)
2000 L batch bioreactor used in the Sf-9 seed train detailed above. Duplicates are formulated for
the 250 mL flasks and 20 L WAVE bioreactors to account for possible damage or contamination
to a sample during manual inoculation in between stages. The 2000 L batch bioreactor does not
require duplicates, since all material transfer occurs through sterile tube welders that prevent
contamination. The working volume is scaled up 100 fold to reduce the number of stages
required, thereby reducing the capital cost of equipment.
Baculovirus preparation starts with a duplicate of two 10 mL virus inoculums, as shown
in Figure 10.3.3. The virus will first be grown in the 250 mL flasks and subsequently propagated
through viral infection in the 20 L WAVE bioreactors before transfer to the production
bioreactor. As previously mentioned, we will use an MOI value of 0.01 at each stage to scale up
from approximately 20 million viral infectious units to 200 billion infectious units for the 2000 L
batch bioreactor to produce the required 3.75 kg of protein. A working volume of 200 mL
(including inoculum) will be used for the 250 mL shake flasks, and a working volume of 20 L
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will be used for the WAVE bioreactors. For information on the 2000 L bioreactor, refer to the
Sf-9 cell seed train (Section 10.3.1) above.
During the infection of cells with baculovirus, cell growth is not likely to occur, as the
virus will take over cellular machinery for replication and prevent cell growth. The WAVE
bioreactors will require air to provide oxygen delivery and carbon dioxide stripping for the cells.
No fresh media is required for the baculovirus amplification, since media will all come from the
Sf-9 cell seed train. Total time required for baculovirus amplification, before the 2000 L
bioreactor stage, is about 11 days.

Figure 10.3.3. Overview of the Baculovirus Amplification Process. Recombinant baculovirus is amplified from a
master bank and scaled up from flasks to bioreactors.

10.4 Membrane Filtration
Membrane processes are filtration systems that are scaled by stacking multiple cartridges
in parallel. They are adaptable to disposable formats, which eliminate the risk of contamination
and the need for cleaning validation between runs. Recovery yields are frequently above 90%
[52]. The filters are asymmetric, meaning larger pores are on the entry side and smaller pores are
on the exit side for efficient filtration [53]. Depth filtration and tangential flow diafiltration are
employed in the clarification, purification, and polishing processes. Dead-end disposable depth
filters efficiently retain larger cell debris, bacteria, and some viral particles, allowing for the
smaller spike protein to pass through the membranes [53]. Diafiltration separates the spike
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protein in the retentate from smaller solutes, such as salts and sugars in the permeate. Fresh
diafiltration buffer is continuously added at the same rate of permeate removal, thus the tank
volume remains constant throughout the process. Diafiltration is run in a tangential flow
configuration to minimize plugging for more efficient filtration. Equation {1} was used to
determine the membrane area required, assuming no salt is rejected by the membrane [54].



ln ccs =
s0

where

V
cs
cs0
Q
t

Qt
V

{1}

= volume of solution being desalted (L)
= concentration of salt in volume V (g/L)
= initial concentration of salt (g/L)
= filtration rate (L/hr)
= time required for diafiltration (hr)

10.5 Chromatography Columns
Chromatography columns are packed with specialized resins to selectively isolate the
protein of interest. In order to design the chromatography columns, the type of resin-protein
interactions, the specific resin to be used, the amount of resin, the sizing of the column, the
buffer volumes, the flow rates, and the process times were selected or calculated. An affinity
chromatography column plus an ion-exchange chromatography column was the most commonly
used combination in literature [55]. Use of a gel filtration (size-exclusion chromatography)
column was rejected because of the additional yield losses it would cause [55].
For the affinity chromatography column, immobilized metal-affinity chromatography
(IMAC), otherwise known as his-tag chromatography, appeared to be relatively inexpensive for
affinity resins that typically experience high costs, and the histidine residue seemed well adapted
for insertion into a recombinant protein [56]. For IMAC resins, there are two broad categories:
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cobalt-based resins and nickel-based resins. The cobalt resins have higher binding specificity, but
the nickel resins have higher binding capacity, meaning more protein binds to the resin [57].
Because purity is prioritized in pharmaceutical manufacturing, cobalt-based resins are a better
choice for IMAC resins. The Cobalt Superflow Agarose resin, specifically, was selected because
of its high binding capacity and optimal flow rate.
The two categories of ion-exchange chromatography resins are cation exchange resins
and anion exchange resins. From research, anion-exchange resins had superior binding capacity
and higher percent recovery than cation-exchange resin for certain products, so anion-exchange
resins were chosen [58]. The Poros XQ resin, in particular, was selected because of its high
binding capacity and endurance across pH ranges.
Having determined the type of resins, the dynamic binding capacity was used to estimate
the total amount of resin needed. The approximate amount of protein that needed to be bound at
each stage was calculated using percent recovery yields of downstream units from literature
sources. The total amount of resin required for the chromatography columns was then calculated
using Equation {2}.
P
DBC

where

P
DBC
R

=R

{2}

= total amount of protein needed to be bound (mg)
= dynamic binding capacity (mg/mL)
= amount of resin required (mL)

DBC specifies the mass of protein that can be bound to a volumetric quantity of resin.
Based upon the amount of resin required, the number of reuses available per resin, and the
economics of the system, conducting 5 runs per cycle for the IMAC resins and just 1 run for the
ion-exchange resins was reasonable. To calculate the total amount of resin required, the number
of cycles were divided using Equation {3}.
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R
N

where

R
N
R’

= R′

{3}

= amount of total resin required (mL)
= number of cycles
= volumetric amount of resin required per cycle (mL)

Next, the chromatography columns were sized. Based on the advice of consultant Dr.
Stijn Koshari, the packed-bed heights were kept around 250 cm, the diameters were calculated to
fit R’, and then the nearest sized columns from Millipore and Cytiva were identified. By
recycling resin over multiple cycles, both resin amount and column size could be cut down.
Buffer volumes for chromatography columns are predominantly dependent on column
volume, typically from 5 to 10 column volumes of buffer. Once column volumes were obtained,
the required amounts of buffer for the two chromatography processes were calculated.
With column volumes determined, process flow times for the chromatography columns
could also be calculated. Using the linear flow rate and column diameter provided by the vendor,
the volumetric flow rate could be calculated.
For the IMAC resins, the recommended linear flow of 150 cm/hr was used for stages that
include recombinant protein, which is squarely in the recommended operational range. For stages
that exclude the protein, a doubled flow rate of 300 cm/hr was used, which is at the maximal
recommended operation range.
For the ion exchange resins, a recommended linear flow rate of 300 cm/hr was used. The
pressure drop at this linear flow rate is less than 3 bar, which keeps the operation within the safe
operational range.
Using the volumetric flow rates described above, the necessary process time for the two
chromatography stages was calculated with Equations {4} and {5}. Again, the buffer volume
required was column volume dependent, whereas the amount of protein extract flowing through
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was resin dependent. For the IMAC chromatography, where the resin was used over 5 cycles, the
protein extract was brought over in installments of ⅕ at a time.
v

v

Cycle Process Time (Per run): t = Σ v buf f er′ +
buf f er

*

v

Total Process Time: t = N Σ v buf f er′ +
where

vx
vx’
t
N

buf f er

protein extract
N

v protein extract ′

v protein extract
v protein extract ′

{4}
{5}

= volume of buffer or protein extract (L)
= volumetric flow rate of buffer or protein extract (L/hr)
= time to flow through
= number of cycles

There is one key difference in calculations between the IMAC and ion-exchange resins.
For the IMAC resins, where multiple cycles occurred, we accounted for the per-cycle cleaning
time because the column had to be regenerated each cycle. For the ion-exchange resins, where
only one run is required, the cleaning time could be ignored, since cleaning could be done later
in parallel with other parts of the downstream process.

10.6 Downstream Process Alternatives
10.6.1 Cell Lysis
Cell lysis is a process that involves breaking open the insect cells to obtain intracellular
protein content for further purification. There are many cell lysis techniques, including both
chemical and physical mechanisms. However, the baculovirus has genes (chitinase and
v-cathepsin) that encode for proteins involved in early cell lysis and death [36]. Specifically, the
cells will lyse 3 to 4 days post-infection. For many situations, early lysis is undesirable and its
genome is altered in order to delay lysis [36]. However, based on the designed seed train, cell
lysis would have occurred by the 5th day post-infection. Therefore, cell lysis is not a necessary
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step of our downstream process. We assume that 100% of the cells will be lysed by the time we
begin our downstream process and protein purification.

10.6.2 Centrifugation
Historically, the first phase of downstream processes included Liquid-Liquid Extraction
(LLE), centrifugation and microfiltration, but membrane-filtration technologies are far more used
nowadays [59]. Ultracentrifugation has been commonly used in the past, but it is highly
inefficient in that combination of ultracentrifugation, and size exclusion chromatography can
only obtain up to 75% recovery [60], which is far below desired percent recovery for a clinical
grade product [59]. Also, ultracentrifugation is time-consuming and labor intensive , with poor
reproducibility and limited scalability [59][60].
Centrifugation is recommended as the first step in the downstream process only if cell
density is high. High cell density generally refers to VCD greater than 10 million cells / mL, but
the VCD for our harvest batch is 8 million cells / mL. Since our cell density is low, centrifuging
to get rid of the cell debris pellet is inefficient. Therefore, centrifugation was not implemented in
our downstream process design.

10.7 Plant Locations
China, India, South Korea, and the United States were considered for manufacturing
before deciding on the United States. Consultation with Dr. Alex Marchut provided the following
insights. First, companies have become more wary of arranging manufacturing in China, as its
government has swiftly changed policies in the past that have caused many CMOs to shut down.
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India and South Korea have more lenient governments, thus companies are more open to
working with CMOs in these countries. Finally, reshoring in the United States has become more
popular, especially during the pandemic, and trends have shown manufacturing shifting to the
Southeastern region.
None of the required manufacturing equipment, materials, utilities, or labor requirements
are geographically restricting. Thus, the location of the manufacturing facility was completely
dependent on the location of the plant(s) operated by the CMO approached. Dr. Cohen noted that
BioGen is a favorite choice for CMO, which heavily motivated our selection of the company.
BioGen has two facilities dedicated to pharmaceutical operations and technology: one in North
Carolina and the other in Switzerland. The plant in North Carolina utilizes single-use technology
that replaces the traditional stainless steel systems, which aligns with much of our upstream and
downstream processes [61]. Single-use technology eliminates contamination risk and cleaning
validation required by traditional stainless steel equipment, and it also allows for more process
flexibility, which has made it such a popular choice in the biopharmaceutical industry.
Additionally, the plant is located in the Southeastern region of the US, as recommended by Dr.
Marchut. These factors made the BioGen facility in North Carolina a suitable choice as the plant
location.
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11. Assembly of Database
11.1 Cell Bank
A cell bank containing 1 mL of cell stock in 2 mL vials is at a temperature of -80˚C [62].
Glycerol or DMSO is included in the cell stock as antifreeze to protect cells from low
temperatures. An important precaution is that the population of cells in each cell bank vial has
some amount of uncertainty and variability. Cell bank inoculum with 50 million cells per vial is
available for purchase online.

11.2 Cell Growth Conditions
11.2.1 pH
The optimum pH for Sf-9 cells in both growth and infection phases is between 6.2 and
6.4 [63]. Therefore, the pH control and deadband for all stages of the upstream process are set at
6.3 and 0.2, respectively.

11.2.2 Temperature
The optimum temperature for Sf-9 cells in terms of both growth rate and viable cell
density (VCD) is around 27˚C [64] and 28˚C [66]. Growth rate decreases gradually with
temperature, and is significantly lower at 25˚C. VCD decreases at 30˚C [65]. For the production
phase, recombinant proteins are similarly expressed at 22˚C, 25˚C, and 27˚C. Although total
protein yields are similar in all three temperatures, lower temperature causes cells to get infected
at a slower rate. Thus, the temperature control and deadband for growth stages are set at 27.5˚C
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and 1.0˚C, respectively, and those for the production stage are set at 26.0˚C and 2.0˚C,
respectively.

11.2.3 Dissolved Carbon Dioxide
The optimum dissolved CO2 level for Sf-9 cell growth is between 0 to 37 mmHg CO2
[67]. For our project, the dissolved CO2 level is set at 30 mmHg for the bioreactors in growth and
production stages.

11.2.4 Nutrients
The carbon source and nitrogen source used for Sf-cells are glucose and glutamine,
respectively. Since prepared media transfer through sterile filters to fill flasks and bioreactors,
the nutrients inside prepared media must be fully dissolved. Hence, glutamine is used as the
nitrogen source because it is fully soluble in water, compared to the commonly used yeast extract
that is not fully soluble in water.

11.2.5 Base
The base used to control the pH level for our bioreactors is 1 M sodium hydroxide. The
amount of base used in our project is based on a test by Thermo Fisher Scientific, where 27 mL
of 0.1 M sodium hydroxide was used as base for its 5 L HyPerforma® rocking bioreactor [68].

11.2.6 Antifoam
The antifoam used to prevent foaming is in an emulsion form. Since the foam covers the
cell surface and may affect cell growth and metabolism, the use of antifoam minimizes the
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amount of foam present. However, since antifoam cannot differentiate between cell surface, wall
surface, and liquid surface, using too much antifoam can decrease the interfacial surface energy
of cells and thereby slow down cell metabolism. Thus, the amount of antifoam used in our
project is 0.3% of total volume for each bioreactor [69].

11.2.7 Osmolality
One of the advantages of insect cells over mammalian cells is that insect cells are less
sensitive to increase in osmolality than mammalian cells [37]. The osmolality for Sf-9 cells is
adjusted between 360 and 380 mOsm/kg using NaCl [65].

11.2.8 Shear Stress
Agitation Rate
In order to maintain a growth rate of at least 0.032 hr-1, the shear stress should be kept to
less than 1 N/m2 [70]. Agitation rate of 250 RPM negatively impacted cell growth due to high
shear stress, whereas agitation rates of 50 RPM and 100 RPM did not [63].
Aeration Rate
Aeration rate must also be monitored to ensure that the specific growth rate does not
decrease. Specifically, data suggests that if agitation rate is operating at 200 RPM, the aeration
rate must be kept below 0.04 vvm (volume air per volume liquid per minute) to maintain the
maximum specific growth rate [70].
Bubble Diameter
Bubble diameter is also crucial to monitor because bubbles can cause cells to rupture.
When the bubble diameter is too small, the specific death rate increases. Figure 11.1 below
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depicts the effect of bubble diameter on death rate of Sf-9 cells when sparged at a gas flow rate
of 10 mL/min [70]. The optimal bubble diameter should be greater than 0.2 cm, which can be
controlled by the sparger.

Figure 11.1. Specific Sf-9 Cell Death Rate vs. Gas Bubble Diameter [70]. As the bubble diameter of the entering gas
increases, the specific death rate of Sf-9 insect cells in the column decreases.

11.3 Cell Growth Kinetics
Rhiel et al. [71] cultivated Sf-9 cells in Sf-900™ II SFM at a temperature of 27°C and a
pH between 6.30 and 6.32. Sf-9 cells grown in Sf-900™ II SFM, represented by the hollow
circles in Figure 11.2, had a growth rate of 0.033 hr-1 and a doubling time of 21 hr, reaching a
maximum VCD of 8.1×106 cells/mL after growing for 4 days.
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Figure 11.2. Viable Insect Cell Density vs. Time in Culture [71]. As insect cells are grown in suspension, the viable
cell density increases, peaks, then decreases. The growth kinetics are dependent on the medium used.

11.4 Cell Metabolic Rates
11.4.1 Oxygen Consumption
Cells were grown in 65% O2 concentration and were infected at 50% O2 concentration.
Studies, overall, seemed to indicate that cells were not so affected by variations in environmental
oxygen concentration, as long as the oxygen concentration stayed above 10% and was less than
110% for the growth phase [72]. Optimally, cells are to be grown between 40% and 70% O2, but
deleterious effects were not seen when O2 concentration slightly deviated from this range [73].
Studies also indicated that while cell oxygen consumption during the infection phase does
increase to as much as 1.3 times the rate of consumption during growth phase [74], the optimal
oxygen concentration for the infection phase is, paradoxically, slightly less at around 50% [75].
The specific oxygen uptake rate (sOUR) is around 0.22 to 0.26 µM O2/106 cell/hr during the
growth phase [63] and 0.2 to 0.76 µM/106 cell/hr for the infection phase [37]. For the infection
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phase, the high end value of sOUR is more reasonable due to the increase in oxygen
consumption during infection.

11.4.2 Carbon Dioxide Production
The specific carbon dioxide production rate (qCO2) for uninfected Sf-9 cells is between
2.6 and 7.4 mmol/109 cells/day, and that for virus-infected Sf-9 cells increases to 10.3 mmol/109
cells/day [76].

11.4.3 Respiratory Quotient
Respiratory Quotient (RQ) is the ratio of carbon dioxide produced by the cells to oxygen
consumed by the cells. The RQ for uninfected Sf-9 cells is 1.07 ± 0.06, and that for
virus-infected Sf-9 cells is 1.12 ± 0.03 [76].

11.4.4 Metabolic Consumption and Production
Insect cells consume glucose and glutamine while producing lactate and ammonia as part
of their metabolic process. Rhiel et al. [71] cultivated Sf-9 cells in Sf-900™ II SFM at a
temperature of 27°C and a pH between 6.30 and 6.32. Under these conditions, the cells
consumed 2.4×10-17 and 1.7×10-17 moles of glucose per cell per second in the growth phase and
infection phase, respectively. The cells consumed 1.7×10-17 and 0.5×10-17 moles of glutamine per
cell per second in the growth phase and infection phase, respectively. The lactate and ammonia
by-products are produced in negligible amounts.
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11.4.5 Protein Production
Sf-9 cells in TNM-FH medium produce on average 230 µg of protein per 106 cells over
the course of 5 days [77]. Since data on protein production in Sf-900™ II SFM could not be
obtained, we assumed the cells would behave similarly in the media and would thereby produce
the same amount of protein per million cells.

11.5 Protein Stability Concerns
11.5.1 Temperature
The spike protein must be kept in a certain temperature and pH range to ensure that it
does not denature. When the temperature is above 40˚C, the RBD will begin to adapt to a closed
conformation [78]. Fortunately, the S1 and S2 domains proved stable at temperature conditions
ranging from 10˚C to 50˚C, so there are little temperature stability concerns.

11.5.2 pH
A study on the ability of the spike protein to bind to the ACE2 receptor at different pH
levels found that stability was maintained at pH levels above 5.5 [79]. The spike protein will thus
be inactive at low pH levels. However, the protein folding is only temporary, and stability is
regained when the pH is increased.
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12. Process Flow Diagram and Material Balance
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Figure 12.1. Process Flow Diagram for the Upstream Process (Section 1)
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Table 12.1. Material Balance for Upstream Process (Section 1)
Upstream (Section 1)
S-101a/b/c/d
S-102a/b/c/d
S-103a/b/c
Temperature (˚C)
27.5
27.5
27.5
Pressure (bar)
1.01
1.01
1.01
Cell Matter (L)
0.001
0.05
0.5
S-106a/b/c
S-106d
S-107a/b/c/d
Temperature (˚C)
27.5
27.5
27.5
Pressure (bar)
1.01
1.01
1.01
Media (L)
49.999
0.499
0.049
S-111
S-112a/b/c
S-113
Temperature (˚C)
25
25
27.5
Pressure (bar)
1.21
1.21
1.01
Cell Matter (L)
0.36
Air (kg)
33
11
S-116b
S-116c
S-116d
Temperature (˚C)
27.5
27.5
27.5
Pressure (bar)
1.01
1.01
1.01
Cell Matter (L)

50

10.4

0.14
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S-104a/b/c
27.5
1.01
5
S-108a/b/c/d
27.5
1.01
0.45
S-114

S-105
27.5
1.21
50
S-109a/b/c
27.5
1.01
4.5
S-115a/b/c

27.5
1.21
39.6
-

27.5
1.01
11

S-110a/b/c
27.5
1.01
45

Figure 12.2. Process Flow Diagram for the Upstream Process (Baculovirus Preparation)
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Table 12.2. Material Balance for Upstream Process (Baculovirus Preparation)
Upstream (Baculovirus Preparation)
S-113
S-114
S-201a/b
Temperature (˚C)
27.5
27.5
27.5
Pressure (bar)
1.01
1.21
1.01
Baculovirus Matter (L)
0.02
Cell Matter (L)
0.36
39.6
S-205a/b
S-206a/b
S-207
Temperature (˚C)
27.5
27.5
25
Pressure (bar)
1.01
1.21
1.11
Baculovirus Matter (L)
Cell Matter (L)
0.18
19.8
Air (kg)
4.4
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S-202a/b
27.5
1.01
0.2
S-208a/b
25
1.11
2.2

S-203
27.5
1.11
20
S-209a/b
27.5
1.01
2.2

S-204
27.5
1.11
20
S-210
27.5
1.01
20
-

Figure 12.3. Process Flow Diagram for the Upstream Process (Section 2)
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Table 12.3. Material Balance for Upstream Process (Section 2)
Upstream (Section 2)
S-105
S-204
S-301
Temperature (˚C)
27.5
27.5
27.5
Pressure (bar)
1.21
1.11
1.36
Cell Matter (L)
50
50
Baculovirus Matter (L)
20
Protein Extract (L)
Protein (kg)
S-305a/306a
S-305b/306b
S-305c
Temperature (˚C)
27.5
26
27.5
Pressure (bar)
1.01
1.01
1.01
Media (L)
450
1472.9
2190.4
Air (kg)
S-308a
S-308b
S-309a/310a
Temperature (˚C)
25
25
27.5
Pressure (bar)
1.01
1.01
1.01
Oxygen (kg)
82.4 (50% O2) 61.8 (100% O2)
Glucose (kg)
30.5
Glutamine (kg)
S-313a/314a
S-313b/314b
S-315a/316a
Temperature (˚C)
27.5
26
27.5
Pressure (bar)
1.01
1.01
1.01
Base (L)
1.5
1.1
Antifoam (L)
8.1
Baculovirus Matter (L)
S-318
S-319
S-320
Temperature (˚C)
27.5
27.5
4.44
53

S-302

S-303
27.5
1.04
500
-

S-307a
25
2.16
229.6
S-309b/310b
26
1.01
21.6
S-315b/316b
26
1.01
6
S-321
27.5

S-304
27.5
1.54
500
-

26
1.04
2000
3.75

S-307b
25
2.23
1377.6
S-311a/312a
27.5
1.01
11.3
S-317
27.5
1.34
20
S-322
4.44

S-311b/312b
26
1.01
5.15

S-323
26

Pressure (bar)
Media (L)
Chilled Water (kg)

1.04
2200
S-324

Temperature (˚C)
Pressure (bar)
Air (kg)
Oxygen (kg)
Carbon Dioxide (kg)
Media (L)

1.04
2200
S-325

27.5
26
1.01
1.01
229.6
1377.6
74.4 (50% O2) 55.8 (100% O2)
23.6
17.7
-

1.01
2964.1
S-326
27.5
1.01
2200
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1.01
2964.1

1.01
3314

1.01
3314

Figure 12.4. Process Flow Diagram for the Downstream Process
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Table 12.4. Material Balance for Downstream Process
Downstream
S-304
Temperature (˚C)
26
Pressure (bar)
1.04
Protein (kg)
3.75
Protein Extract (L)
2000
S-406
Temperature (˚C)
25
Pressure (bar)
1.04
Protein (kg)
3.04
Protein Extract (L)
1353
S-412
Temperature (˚C)
25
Pressure (bar)
1.04
Protein (kg)
2.63
Protein Extract (L)
395.9
S-418
Temperature (˚C)
25
Pressure (bar)
3.11
Depth Filtration Wetting Buffer
458.5
(L)
Depth Filtration Flushing Buffer
458.5
(L)
His-Tag Equilibration Buffer (L)
His-Tag Wash Buffer (L)
His-Tag Elution Buffer (L)
His-Tag Regeneration Buffer (L)
His-Tag Water Buffer (L)
-

S-401

S-402

S-403

S-404

S-405

26
3.14
3.75
2000
S-407
25
3.44
3.04
1353
S-413
25
1.04
2.63
395.9
S-419
25
2.99

25
1.04
3.38
2366
S-408
25
3.44
2.98
1353
S-414
25
1.28
2.63
395.9
S-420
25
1.04

25
1.04
3.38
2366
S-409
25
1.04
2.68
370.4
S-415
25
1.01
2.60
401.7
S-421
25
3.41

25
2.03
3.38
2366
S-410
25
1.04
2.68
370.4
S-416
25
1.09
2.60
401.7
S-422
25
3.11

25
1.04
3.04
1257
S-411
25
3.14
2.68
370.4
S-417
25
1.01
2.60
204.7
S-423
25
1.25

-

-

-

-

-

1257
2513
1257
1257
1257

-

-

-

-
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Viral Inactivation Acid (L)
Viral Inactivation Base (L)
IEX Equilibration Buffer (L)
IEX Elution Buffer (L)
IEX Equilibration Wash Buffer (L)
IEX NaCl Buffer (L)
IEX Ultrapure Water (L)
IEX Acetic Acid Wash (L)
Viral Filtration Wetting Buffer (L)
Viral Filtration Flushing Buffer (L)
Diafiltration Base Buffer (L)
Diafiltration Salt Buffer (L)

S-424

Temperature (˚C)
Pressure (bar)
Protein (kg)
Waste (L)

S-425

25
1.01
0.37
344

31.4
65.3
S-426

25
1.01
0.34
8650
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25
1.01
0.3
2835

265
307
159
265
529
265
S-427

26
26
S-428

25
1.01
0.05
26

25
1.01
0.03
2110

68
2048

Upstream
Process
Day

Time (Days)
1

2

3

4

5

6

7

8

9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30

125 mL Flask (Sf-9)
250 mL Flask (BV)
500 mL Flask (Sf-9)
5 L Flask (Sf-9)
20 L Wave (BV)
50 L Wave (Sf-9)
N-1 Bioreactor
N Bioreactor
Figure 12.5. Gantt Chart for a Single Upstream Process Run. The blue marks the Sf-9 cell seed train while the red marks the baculovirus amplification.

Figure 12.5 shows that the upstream process is anticipated to take 24 days in total, with parallel processes of the baculovirus
and Sf-9 cell scale-up occurring simultaneously over days 9 through 19. Scale-up procedure from one stage to another typically takes
3 or 5 days.
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Downstream
Process
Hour

Time (Hours)
1

2

3

4

5

6

7

8

9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36

Depth Filtration
HT Chromatography
Viral Inactivation
IEX Chromatography
Viral Filtration
Dia iltration
Hour

37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72

Depth Filtration
HT Chromatography
Viral Inactivation
IEX Chromatography
Viral Filtration
Dia iltration
Figure 12.6. Gantt Chart for a Single Downstream Process Run.

In contrast, the downstream process is significantly shorter than the upstream process. Figure 12.6 shows that the downstream
process is expected to take about three days to complete (66 hours). The majority of this time, hours 3 to 45, is taken up by the his-tag
chromatography process, which requires 5 runs to complete the process. The cleaning time added between each cycle, as well as the
low flow rates required to operate the column effectively, combine to make the his-tag chromatography process much longer than the
other downstream units. Most of the other downstream units are about 4 hours long, with some that are long as 7 hours.
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Overall
Process
Day

Time (Days)
3

6

9 12 15 18 21 24 27 30 33 36 39 42 45 48 51 54 57 60 63 66 69 72 75 78 81 84 87 90

Upstream 1
Downstream 1
Upstream 2
Downstream 2
Upstream 3
Downstream 3
Upstream 4
Downstream 4
Figure 12.7. Gantt chart for multiple upstream and downstream process runs.

Overall, the entire upstream and downstream process takes about 27 days to complete. While we propose completing this cycle
once for our project, in the event that repeated cycles are desired or necessary, we suggest that 18 days in between cycles should be
sufficient time to clean equipment and account for manufacturing problems in the prior process. As shown in Figure 12.7, we
anticipate that at least 4 production cycles can be run to completion in under 3 months (81 days), if multiple campaigns are desired.
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13. Process Description
13.1. Upstream Process
13.1.1 Sf-9 Cell Seed Train
Cell Bank to Flasks
At the start of the seed train, four frozen aliquots all with the same specified viable cell
density are taken out of a cell bank. These frozen aliquots are each incubated at 27.5˚C and
inoculated into the four 125 mL flasks with working volumes of 50 mL. After 5.2 days of growth
in the 125 mL flasks, the contents are then each inoculated into the 500 mL flasks. The cells are
grown in each flask at 27.5˚C on a shaker table.

Flasks to WAVE Bioreactor
After 3 days of growth in the 500 mL flasks at 27.5˚C, cell content in one of the 500 mL
flasks is sent to the baculovirus preparation line for virus amplification. Cell content in the other
three flasks are sent to the 5 L flasks for another 3 days of growth, after which the contents are
each inoculated into the three 200 L WAVE bioreactors with working volumes of 50 L. The
rocking motion of WAVE bioreactors allows efficient mixing, carbon dioxide stripping, and
oxygen transfer to the cells for optimal growth.

WAVE Bioreactor to Perfusion Bioreactor
After 3 days of growth in the 200 L WAVE bioreactors at 27.5°C, cell content in one of
the WAVE bioreactors is sent to the baculovirus preparation line for further virus amplification,
and cell content with the healthiest growth in a different WAVE bioreactor is inoculated to the
500 L perfusion bioreactor. The 500 L perfusion bioreactor is different from regular batch
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bioreactors in that the perfusion system allows for much higher viable cell density than normal
by constantly feeding fresh medium while removing used medium.

Perfusion Bioreactor to Production Bioreactor
After 5 days of growth in the 500 L perfusion bioreactor at 27.5˚C, the content is finally
transferred to the 2000 L batch bioreactor at 26.0˚C and infected with baculovirus at a MOI
value of 0.01 for protein production. Once the content of the perfusion bioreactor is inoculated
into the 2000 L bioreactor, the viable cell density is already at its maximum. Thus, cells are in
the stationary phase, spending energy only for protein production and not for additional growth.
After 5 days of production in the 2000 L bioreactor, the content is transferred to the downstream
process.

13.1.2 Baculovirus Amplification
Cell Bank to Flasks
After 3 days of Sf-9 cell growth in the 500 mL shake flasks at 27.5˚C, 180 mL of cell
culture is sent to both 250 mL shake flasks for infection with baculovirus. The cell cultures in
each shake flask will be infected with 20 mL of purchased baculovirus at an MOI value of 0.01.
Baculovirus will be incubated in the cell culture for 6 days at 27.5˚C on a shaker table.

Flasks to WAVE Bioreactor
After 6 days of growth in the 250 mL shake flasks at 27.5˚C, lysed cells and virus will be
transferred to the 20 L WAVE bioreactors and amplified there starting with an MOI of 0.01.
Then, 18 L of grown cell culture will be taken from a 50 L WAVE bioreactor as described above
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and will be provided for viral infection. Baculovirus will be incubated by infecting the cell
culture and amplified for 5 days.

WAVE Bioreactor to Production Bioreactor
After 5 days of growth in the 20 L WAVE bioreactor at 27.5˚C, the incubated baculovirus
will be pumped into the 2000 L production bioreactor where it will infect the cells and produce
proteins. Protein will be produced in the earlier baculovirus scale-up phases as well but in
marginal quantities. Once again, the MOI will be 0.01 and the incubation period will be 5 days
before transfer to the downstream process.

13.2 Downstream Process
13.2.1 Depth Filtration
Depth filtration is the first step in our downstream process. The cells have already lysed
on their own before entering the depth filters, so protein of interest is extracellular. Depth
filtration is efficient in that it is much more easier to develop than an intricate tangential-flow
filtration system. Also, single-use disposable depth filters are economical, since the process is
not run for multiple times. Fouling is not an issue because our cell density is low at 8 million
cells / mL. By using a series of filters with large pore size followed by filters with small pore
size, depth filtration is able to filter out large cell debris, bacteria, and some viruses. The percent
recovery of depth filtration step is approximately 90%. The supernatant is sent to the his-tag
chromatography for further filtration.
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13.2.2 His-tag Chromatography
After the supernatant leaves the depth filter, it will flow through the His-tag
chromatography column. The chromatography column works by binding specifically to the
genetically engineered his-residues added to the protein, allowing everything else to flow
through. This step will be the most capital and time intensive step of the downstream process.
The packed column will be equilibrated before material flows through. In the affinity stage, there
will be five runs total, so only one fifth of the total amount of supernatant will flow through
during each run. Once the supernatant flows through, the column will be washed and then eluted.
The eluate will be sent to the viral inactivation phase for the next process. The flow rate will be
189 L/hr for the loading, washing, and elution stages, and 377 L/hr for the cleaning and
regeneration stages. Dr. Stjin Koshari advised using a slower flow rate for the loading, washing,
and elution stages to avoid protein loss. The process will be repeated 4 times. We estimate total
run time will be about 2 days and each run will take about 9 hours including washing. Yield is
anticipated to be about 90% with purity of around 95%.

13.2.3 Viral Inactivation
Viral inactivation is necessary in order to denature the virus while keeping the protein
intact. This is commonly done using low pH, specifically a pH of 3.5. The Cadence Virus
Inactivation System by Pall was highly considered, as it is a fully automated system that lowers
the pH using a continual elution stream and then brings the pH back up to around 8. However,
Dr. Koshari recommended doing this manually, as the cost for the system is not worth it. Thus,
we will be inactivating our virus in the ThermoFisher HyPerforma Single Use 2000 L Mixer. The
mixer will also have a jacket in order to monitor and maintain an appropriate temperature. In
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order to bring the pH down to 3.5, about 2.5% of the original volume of 1M Acetic acid should
be added. In order to bring the pH back up, 5.2% of the original volume of 1M Tris base should
be added [80]. Directly following this step, sterile membrane filtration will ensue and result in a
98% yield.

13.2.4 Ion Exchange Chromatography
Once material is finished with the viral inactivation phase, it will flow through the ion
exchange chromatography column. The chromatography column will be pre-packed and
equilibrated before this run. Material will flow through at 289 L/hr and a pH above 7.24 to
ensure the protein, in its anionic form binds to the anion-exchange resins. Once the protein
extract has been loaded in the column, the column pH will be steadily decreased to the protein’s
isoelectric point at 6.24 using a pH gradient elution buffer to release the protein. The eluate will
be sent on to the viral filtration stage and the column will be cleaned during that stage.We
estimate that total process time without cleaning (as that can be done in parallel) is 7 hours with
expected yield of 90% and purity of 85%.

13.2.5 Viral Filtration
Viral filtration step is required to make sure that viral clearance of the final product is
greater than log reduction value (LRV) of 6. Filters with very precise pores are used, and a
pre-filter is used beforehand to prevent fouling and clogging in the actual filter. Depth filters are
preferred over sterile membrane filters, since depth filters can contain more particulates, clog
less, and have charge characteristics that can bind additional DNA and host cell proteins. The
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percent recovery of viral filtration step is approximately 98%. The protein solution is sent to the
diafiltration step for final purification.

13.2.6. Diafiltration
Any small particles that are not filtered out in the viral filtration enter as feed in the
diafiltration process. Membrane cassettes will be used to retain and recirculate the Spike protein
while filtering out any smaller solutes, such as any small salts and sugars. A tangential flow
filtration configuration will be used to minimize clogging of the membranes. A diafiltration
buffer will be added to the feed tank at the same rate as the permeate leaves to maintain a
constant volume in the feed tank. This buffer exchange will ensure the stability of the Spike
protein for shipping. The final buffer displacement recovers 99.3% of the protein [81] and has a
99.3% reduction in salt, assuming no protein goes through the membrane and that no salts are
rejected. We do not need to concentrate our Spike protein because our final protein concentration
of 6.5 g/L is considered low for industry. Our final drug product will contain Spike protein in an
appropriate diafiltration buffer, which will be packaged and shipped in bulk for formulation
elsewhere.
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14. Energy Balance and Utility Requirements
14.1 Upstream Energy Balance
The number of cells in each cell culture vessel was calculated by multiplying the working
volume with the peak viable cell density. Then, the heat generated by cells was calculated by
multiplying the number of cells with peak specific enthalpy of reaction. Suggested by our project
author, the peak specific enthalpy of reaction for Sf-9 cells was assumed to be 40 pW/cell. Table
14.1 shows the energy requirements for the upstream process.
Table 14.1. Upstream Energy Balance
Equipment
125 mL Erlenmeyer Shake Flask
250 mL Erlenmeyer Shake Flask
500 mL Erlenmeyer Shake Flask
5 L Erlenmeyer Shake Flask
WAVE Bioreactor System 20/50EH
WAVE Bioreactor System 200EH
500 L Perfusion Bioreactor
2000 L Production Bioreactor

Heat Generated Impeller Heat Duty of Associated
by Cells (W) Power (W)
Cooling Jacket (W)
0.01
0.04
0.11
1.16
4.98
12.44
652
652

10
40

662
692

14.2 Process Energy Usage
Since the cell growth and metabolism are low due to slow oxygen uptake of Sf-9 cells,
low gas flow rates are sufficient, which results in very small power requirement and total work
per run for the air compressors in general. Power requirement and total work per run is generally
very small for peristaltic pumps as well, since high liquid flow rates are not used in
pharmaceutical processes and transport. Table 14.2 shows the energy requirements for each
process.
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Table 14.2. Process Energy Usage
Equipment
WAVE™ Bioreactor System 20/50EH
WAVE™ Bioreactor System 200EH
500 L Perfusion Bioreactor
2000 L Production Bioreactor
2000 L Single-Use Mixer
Diafiltration Assembly
Air Compressor
(for WAVE Brx 20/50EH)
Air Compressor
(for WAVE Brx 200EH)
Air Compressor
(for 500 L Perfusion Brx)
Air Compressor
(for 2000 L Production Brx)
Upstream Peristaltic Pump
(BV WAVE to N Brx)
Upstream Peristaltic Pump
(Sf-9 WAVE to N-1 Brx)
Upstream Peristaltic Pump
(N-1 Brx to N Brx)
Downstream Peristaltic Pump
(for Depth Filtration)
Downstream Peristaltic Pump
(for His-tag Column)
Downstream Peristaltic Pump
(for IEX Column)
Downstream Peristaltic Pump
(for Viral Filtration)
Downstream Peristaltic Pump
(for Diafiltration in)
Downstream Peristaltic Pump
(for Diafiltration out)
200 L Media Vessel
2000 L Media Vessel
3000 L Media Vessel
100 L Glucose Vessel
500 L Glutamine Vessel

Power Requirement Operation Time Work per Run
Upstream
0.69 kW
3.6 kW
2.4 kW
2.4 kW
Downstream
2.5 kW
4.4 kW
Transport

5 days
3 days
5 days
5 days

82.8 kWh
259.2 kWh
288 kWh
288 kWh

4 hrs
7 hrs

10 kWh
30.8 kWh

0.12 W

5 days

14.94 Wh

1.84 W

3 days

132.62 Wh

35.64 W

5 days

4277.33 Wh

224.46 W

5 days

26934.68 Wh

0.50 W

15 mins

0.12 Wh

0.42 W

30 mins

0.21 Wh

6.26 W

30 mins

3.13 Wh

15.66 W

2 hrs

31.32 Wh

0.97 W

2 days

46.53 Wh

0.97 W

7 hrs

6.79 Wh

0.54 W

3 hrs

1.61 Wh

2.24 W

30 mins

1.12 Wh

2.76 W

30 mins

1.38 Wh

Storage
1.5 kW
2.5 kW
2.5 kW
0.75 kW
1.5 kW

25 days
25 days
25 days
10 days
10 days

900 kWh
1500 kWh
1500 kWh
180 kWh
360 kWh
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14.3 Electricity Use
Electricity use was calculated not based on the power requirement, but based on the
maximum power as a conservative method to estimate the upper limit of total electricity. Table
14.3 shows the electricity requirements for each process.
Table 14.3. Electricity Use
Maximum Power
(kW)
Upstream
WAVE™ Bioreactor System 20/50EH
0.69
WAVE™ Bioreactor System 200EH
3.6
500 L Perfusion Bioreactor
2.4
2000 L Production Bioreactor
2.4
Downstream
2000 L Single-Use Mixer
2.5
Diafiltration Assembly
4.4
Transport
Air Compressor
0.516
(for WAVE Brx 20/50EH)
Air Compressor
0.516
(for WAVE Brx 200EH)
Air Compressor
0.516
(for 500 L Perfusion Brx)
Air Compressor
1.128
(for 2000 L Production Brx)
Upstream Peristaltic Pump
0.656
(BV WAVE to N Brx)
Upstream Peristaltic Pump
0.656
(Sf-9 WAVE to N-1 Brx)
Upstream Peristaltic Pump
0.656
(N-1 Brx to N Brx)
Downstream Peristaltic Pump
0.656
(for Depth Filtration)
Downstream Peristaltic Pump
0.656
(for His-tag Column)
Downstream Peristaltic Pump
0.656
(for IEX Column)
Downstream Peristaltic Pump
0.656
(for Viral Filtration)
Downstream Peristaltic Pump
0.656
(for Diafiltration in)
Equipment
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Operation
Time

Electricity per Run
(kWh)

5 days
3 days
5 days
5 days

82.8
259.2
288.0
288.0

4 hrs
7 hrs

10.0
30.8

5 days

61.9

3 days

37.2

5 days

61.9

5 days

135.4

15 mins

0.2

30 mins

0.3

30 mins

0.3

2 hrs

1.3

2 days

31.5

7 hrs

4.6

3 hrs

2.0

30 mins

0.3

Downstream Peristaltic Pump
(for Diafiltration out)
200 L Media Vessel
2000 L Media Vessel
3000 L Media Vessel
100 L Glucose Vessel
500 L Glutamine Vessel

0.656

30 mins

0.3

Storage
1.5
2.5
2.5
0.75
1.5

25 days
25 days
25 days
10 days
10 days

900.0
1500.0
1500.0
180.0
360.0

14.4 Other Utilities
Table 14.4 shows the chilled and purified water requirements by process.
Table 14.4. Other Utilities
Equipment
500 L Perfusion Bioreactor
2000 L Production Bioreactor
Depth Filtration
His-Tag Chromatography
Ion-Exchange Chromatography
Viral Filtration
Diafiltration
Diafiltration
100 L Glucose Vessel
100 L Glutamine Vessel

Utility
Upstream
Chilled Water, 40˚F
Chilled Water, 40˚F
Downstream
Purified Water, 25˚C
Purified Water, 25˚C
Purified Water, 25˚C
Purified Water, 25˚C
Purified Water, 25˚C
Chilled Water, 40˚F
Storage
Purified Water, 25˚C
Purified Water, 25˚C
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Usage

Amount per Run

Coolant
Coolant

2964.1 kg
3314.0 kg

Buffer
Buffer
Buffer
Buffer
Buffer
Coolant

917 L
7555 L
1023 L
26 L
2116 L
996.0 kg

Diluent
Diluent

82.4 L
484.3 L

15. Equipment List and Unit Descriptions
15.1 Feed Materials
15.1.1 Biological/Chemical Laboratory Facility
In order to manually inoculate cells from one flask to another, a biohood is required to
carry out sterile pipetting. A shaker table that is covered in a hood at 27.5˚C is needed for cells to
be well-mixed in the flasks. Cost analysis was done not based on the individual biohood and
shaker table, but based on the entire biological/chemical lab facility. Assuming roughly 5% of
the total capital and operating costs, the biological/chemical lab cost is approximately $270,623.

15.1.2 Air Compressors
Air compressor AC-101 is used to provide air from the surrounding environment for the
three WAVE Bioreactor 200EH over 3 days. Air flow is needed to ensure sufficient oxygen
content for cell growth as well as stripping CO2 from the system. Air at 6 standard liters per
minute (SLPM) will be compressed to 5.01 LPM and divided equally among the three
bioreactors. Pressure will increase from 1.01 bar to 1.21 bar. The system will require 0.00247 hp
to operate at the desired rate. The purchase cost is approximately $1212.50.
Air compressor AC-201 is used to provide air from the surrounding environment for the
two WAVE Bioreactor 20/50EH over 5 days. Air flow is needed to ensure sufficient oxygen
content for cell growth as well as stripping CO2 from the system. Air at 0.8 SLPM will be
compressed to 0.72 LPM and divided equally among the two bioreactors. Pressure will increase
from 1.01 bar to 1.11 bar. The system will require 0.000167 hp to operate at the desired rate. The
purchase cost is approximately $1212.50.
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Air compressor AC-301 is used in this step to provide air from the surrounding
environment for the 500 L Perfusion Bioreactor over 5 days. Air flow is needed to help ensure
sufficient oxygen content (along with the 50% oxygen supply) for cell growth as well as
stripping CO2 from the system. Air at 25 SLPM will be compressed to 11.69 LPM before
entering the perfusion bioreactor. Pressure will increase from 1.01 bar to 2.16 bar. The system
will require 0.0478 hp to operate at the desired rate. The purchase cost is approximately
$1212.50.
Air compressor AC-302 is used in this step to provide air from the surrounding
environment for the 2000 L production bioreactor over 5 days. Air flow is needed to help ensure
sufficient oxygen content (along with the 100% oxygen supply) for cell growth as well as
stripping CO2 from the system. Air at 150 SLPM will be compressed to 67.94 LPM before
entering the production bioreactor. Pressure will increase from 1.01 bar to 2.23 bar. The system
will require 0.301 hp to operate at the desired rate. The purchase cost is approximately $1095.92.

15.1.3 Sterile Filters
A sterile filter is a crucial piece of equipment used to purify liquid media before it enters
the sterile environment of a bioreactor. In order to ensure sterility, liquid filters need to have
nominal pore size of less than 1 micron, since microorganisms are typically greater than 1
micron. All the sterile filters used in our process have a 0.8/0.2 µm double pore size, stepped
barb attachments, no associated energy cost, and expected purchase price of $152.60 each. The
filters are all made of polyethersulfone (PES). More specifically, each filter has the following
properties:
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Sterile filter SF-101a, SF-101b, and SF-101c are used to purify fresh liquid media for the
Sf-9 seed trains (50 mL, 500 mL, 5 L, 50 L) coming from the main media tank used in
the Sf-9 cell culture scale-up. The filters process 50 L of media total.

Sterile filter SF-101d is used to purify fresh liquid media for the fourth Sf-9 seed train (50
mL, 500 mL) coming from the main media tank used in the Sf-9 cell culture scale-up.
This sterile filter processes 500 mL of media total.

Sterile filter SF-201 is used to purify fresh liquid media emerging from the 20/50EH
WAVE bioreactor of the baculovirus scale-up process that is heading towards the
production bioreactor. This sterile filter processes 20 L of media total.

Sterile filter SF-301 is used to purify fresh liquid media entering the 500 L, N-1 perfusion
bioreactor. This sterile filter processes 450 L of media total. Note that no additional
sterile filter is provided for the media entering the perfusion system itself as the perfusion
system contains its own liquid filter.

Sterile filter SF-302 is used to purify fresh liquid media entering the 2000 L production
bioreactor. This sterile filter processes 1473 L of media total.

Sterile filter SF-303 is used to purify fresh glucose entering the 500 L, N-1 perfusion
bioreactor. This sterile filter processes 30.5 kg of aqueous glucose total.
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Sterile filter SF-304 is used to purify fresh glutamine entering the 500 L, N-1 perfusion
bioreactor. This sterile filter processes 11.3 kg of aqueous glutamine total.

Sterile filter SF-305 is used to purify fresh base media entering the 500 L, N-1 perfusion
bioreactor. This sterile filter processes 1.5 L of media total.

Sterile filter SF-306 is used to purify fresh antifoam entering the 500 L, N-1 perfusion
bioreactor. This sterile filter processes 8.1 L of media total.

Sterile filter SF-307 is used to purify fresh glucose entering the 2000 L production
bioreactor. This sterile filter processes 21.6 kg of aqueous glucose total.

Sterile filter SF-308 is used to purify fresh glutamine entering the 2000 L production
bioreactor. This sterile filter processes 5.15 kg of aqueous glutamine total.

Sterile filter SF-309 is used to purify fresh base entering the 2000 L production
bioreactor. This sterile filter processes 1.1 L of base total.

Sterile filter SF-310 is used to purify fresh antifoam entering the 2000 L production
bioreactor. This sterile filter processes 6 L of antifoam total.
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15.1.4 Media Prep Vessels
The media prep vessels are crucial features in providing storage for the media until it can
be used in the shake flasks and bioreactors. While the stainless steel media and its storage vessel
must be clean, they are not inherently sterile, which is why sterile filters are used for all material
emerging from the storage tank. The storage vessels also have small energy requirements
originating from monitors and mixers present within the system.

The 200 L media storage tank (M-101) is used to hold media for all the Sf-9 seed trains in
the initial scaleup phase (50 mL, 500 mL, 5 L, and 50 L). It has an energy requirement of
2.01 hp. It will hold about 151 L of media, and 200 L is the standard production size. The
purchasing cost is $4000.00.

The 3000 L storage tank (M-301) is used to hold all the media required for the 500 L,
N-1 perfusion bioreactor combined with its perfusion system. It has an energy
requirement of 3.4 hp. It will hold about 2650 L of media, and 3000 L is the standard
production size for that quantity. The purchasing cost is about $12,421.00.

The 2000 L storage tank (M-302) is used to hold all the media required for the 2000 L
production bioreactor. It has an energy requirement of 3.4 hp. It will hold about 1473 L of
media, and 2000 L is the standard production size for that quantity. The purchasing cost
is about $10,210.00.
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15.1.5 Oxygen Tanks
Oxygen transfer is a crucial determinant of cell growth in the bioreactors. As bioreactors
increase in size, oxygen transfer through diffusion from the atmosphere is no longer sufficient,
requiring the specific addition of concentrated oxygen into the bioreactor. Oxygen tanks provide
that extra oxygen supply to the bioreactor. The oxygen tanks don’t have energy requirements.
Oxygen will be purchased in large quantities for the entire system at a total cost of $7186.60
including the tanks to hold it. Oxygen will come in both 50% and 100% concentrations to
accommodate the needs of each bioreactor. No added filtration will be required for the oxygen as
air filters are built into the bioreactors.

Oxygen tank (O-301) provides 82.4 kg of 50% oxygen supply to the perfusion bioreactor.
The oxygen will first be compressed before entering the bioreactor.

Oxygen tank (O-302) provides 61.8 kg of 100% oxygen supply to the perfusion
bioreactor. The oxygen will first be compressed before entering the bioreactor.

15.1.6 Glucose Vessel
Glucose is a critical nutrient used by Sf-9 cells for cell metabolism. While in low cell
concentrations and in small volumes the Sf-900 II SFM media contains sufficient nutrients for
the cells to grow. At the larger scale of the bioreactors, additional nutritional elements are
required to provide continued fuel for cell metabolism and production. The stainless steel
glucose vessel (GC-301) used to hold the glucose will be 100 L and contain 75 kg of glucose
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solubilized in purified water. The glucose vessel has a mixer and other electrical implements that
require about 1 hp of electricity. The vessel has a purchase cost of $2000.00.

15.1.7 Glutamine Vessel
In addition to glucose, glutamine is another crucial metabolite for cell growth and will be
contained in the stainless steel 500 L vessel (GT-301) to provide glutamine to the perfusion and
production bioreactor. The vessel will carry 20 kg of glutamine solubilized in purified water.
This glucose vessel has a mixer and other electrical implements that require about 2 hp of
electricity to operate. The vessel has a purchase cost of $3000.00.

15.1.8 Base Container
Base is a necessary component used to counteract the acidity of the CO2 produced by the
Sf-9 cells in the perfusion and production bioreactor. At high levels of CO2 production in the
perfusion and production bioreactor, the pH will drop and cell growth can be stunted. Base can
be added to increase the pH to optimal value. As the volume of the base required is small, no
additional tank is needed beyond the 4 L container (B-301), in which the base is purchased. A
total of 2.6 L will actually be used of this total amount. No energy requirements are associated
with this container, and the purchase cost of this amount of base is $105.45.

15.1.9 Antifoam Vessel
As cell growth, mixing, and sparging of gas occur in the bioreactors, a risk of foam
forming at the top of the perfusion or production bioreactor is a distinct possibility. As the foam
collapses, it can create pressure waves that are harmful to the cells in the bioreactor. In order to
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prevent this, anti-foam is added and will be stored in (AF-301). The vessel itself is 20 L, which is
more than sufficient to store the required 14.1 L of antifoam needed for the system. The antifoam
vessel has no associated energy requirement and has a purchase cost of $269.90.

15.2 Upstream Processes
15.2.1 Erlenmeyer Shake Flasks
Erlenmeyer shake flasks are generally made of plastic or glass material and have either
baffled or plain bottom. For our project, we chose polycarbonate flasks that have been sterilized
in advance by gamma radiation. Although baffled types have depressions in the wall that allow
better oxygen supply, plain types were chosen for our purposes because the growth rate of Sf-9
cells is slow. The flasks all have a microporous vent lid that keeps the content sterile and permits
passage of gas. Room air is sufficient for enough oxygen to flow in and carbon dioxide to flow
out. All flasks are maintained at 27.5˚C on a shaker table.

The four 125 mL flasks (F-101) are used to grow Sf-9 cells from 4.05 million cells to 249
million cells over 5.2 days of batch time. For these F-101 flasks, because the working
volume is only 50 mL, the shaker table is shaked slowly to prevent evaporation. The
purchase cost of F-101 is $15.70 each.

The four 500 mL flasks (F-102) are used to grow Sf-9 cells from 249 million cells to 2.68
billion cells over 3 days of batch time. The working volume of the F-102 flasks is 500
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mL. Out of the four F-101 flasks, one of them is sent to the baculovirus preparation line
for virus amplification. The purchase cost of F-102 is $27.10 each.

The three 5 L flasks (F-103) are used to grow Sf-9 cells from 2.68 billion cells to 28.9
billion cells over 3 days of batch time. The working volume of the F-103 flasks is 5 L.
The purchase cost of F-103 is $166.00 each.

The two 250 mL flasks (F-201) are used to amplify baculovirus from 20 million viruses
to 2 billion viruses by infecting 2 billion cells over 6 days of batch time. The working
volume of the F-201 flasks is 200 mL. The purchase cost of F-201 is $17.70 each.

15.2.2 WAVE Bioreactors
For the WAVE bioreactors, AC-101, AC-201, AC-301, and AC-302 flow air through the
headspace in the WAVE cellbags. Because the viable cell density is not high in the WAVE
bioreactors, air flow needs to be slow, otherwise carbon dioxide will be over-stripped by the fast
air flow.

The three WAVE Bioreactor 200EH (W-101) units are used to grow Sf-9 cells from 28.9
billion cells to 311 billion cells over 3 days of batch time. The working volume of W-101
bioreactors is 50 L, the rocking speed is 25 rocks/min, and the rocking angle is 8˚. The
aeration rate used for the W-101 units is 2 LPM, as suggested by the user guide manual
from GE Healthcare® [82]. Out of the three W-101 units, one of them is sent to the
baculovirus preparation line for further virus amplification, and only one of the other two
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W-101 units is sent to the 500 L perfusion bioreactor for further cell growth. The material
of construction for the W-101 bioreactors is stainless steel, the maximum electrical power
requirement is 0.69 kW, and the purchase cost is $16,000 each. Three 200 L cell culture
bags, which cost $1288.64 each, need to be purchased for disposable single usage.

The two WAVE Bioreactor 20/50EH (W-201) units are used to amplify baculovirus from
2 billion viruses to 200 billion viruses by infecting 200 billion cells over 5 days of batch
time. The working volume of the W-201 bioreactors is 20 L, the rocking speed is 20
rocks/min, and the rocking angle is 7˚. The aeration rate used for the W-201 units is 0.4
LPM, as suggested by the user guide manual from GE Healthcare® [82]. Out of the two
W-201 bioreactors, only one of them is sent through SF-201 to allow baculovirus to pass
but capture cell debris, and then pumped to the 2000 L production bioreactor for infection
and protein expression. The material of construction for the W-201 units is stainless steel,
the maximum electrical power requirement is 3.6 kW, and the purchase cost is $4,000
each. Two 50 L cell culture bags, which cost $322.16 each, need to be purchased for
disposable single usage.

15.2.3 Perfusion Bioreactor and System
The perfusion bioreactor (PBrx-301) with the perfusion system (PS-301) is used to grow
Sf-9 cells from 311 billion cells to 16.3 trillion cells over 5 days of perfusion time. The working
volume of PBrx-301 is 500 L. Liquid media, nutrients, base, and antifoam flow through
SF-6/8~11 before entering PBrx-301. PS-301 has its own sterile filter for replenishing 2200 L of
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fresh media into PBrx-301, allowing the maximum VCD as well as number of cells to increase
4-fold. PBrx-301 has its own built-in sterile filters for gas materials, i.e. air and oxygen.
PBrx-301 is equipped with one pitched blade impeller with three blades. The impeller is
used mainly for homogenizing temperature, pH, and liquid composition. The impeller can also
aid in preventing cells from settling to the bottom, but because the cells typically sink at a very
slow rate, the sparger alone is usually sufficient. The agitation speed of the impeller is 101 RPM,
which leads to a mixing time of 27 seconds to reach 95% homogeneity, as shown in Section 25.4
calculations.
PBrx-301 is also equipped with a dual sparger-configuration with one porous frit sparger
and one drilled hole sparger. Oxygen supply at 50% oxygen is sparged through the frit sparger at
8 SLPM; air is used for carbon dioxide stripping, which is sparged through the drilled hole
sparger at 25 SLPM. The air flow rate out was assumed to be the same as air flow rate in at 25
SLPM in order to find out the maximum size of vent filter needed, as well as the permit for
maximum air vent.
The heat generated by Sf cells is 652 W and that by the impeller is 10 W, which means
that PBrx-301’s cooling jacket (CJ-301) needs to use a total of 662 W to control the temperature
to 27.5˚C. PBrx-301 has its own pH probe that monitors the change in pH level due to cellular
respiration, and if the pH becomes too low, 1 M sodium hydroxide is added as base to maintain
the pH level at 6.3.
The material of construction for PBrx-301 is stainless steel, the maximum electrical
power requirement is 2.4 kW The purchase cost is $91,473.39 for PBrx-301 and $18,560.00 for
PS-301. One 500 L BioProcess Container (BPC), which costs $4,453.99, needs to be purchased
for disposable single usage. The 500 L BPC has been sterilized in advance by gamma radiation.
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15.2.4 Production Bioreactor
The production bioreactor (Brx-301) is used to express 3.75 kg of spike protein over 5
days of batch time by infecting 16.3 trillion Sf-9 cells with 200 billion baculovirus from one of
the two W-201 units. Taking into consideration the 30% yield loss in the downstream process,
the amount of expressed spike protein is 50% more than what is needed for 500 million doses.
The working volume of Brx-301 is 2000 L. Liquid media, nutrients, base, and antifoam flow
through SF-7/12~15 before entering the Brx-301.
Brx-301 is equipped with one pitched blade impeller with three blades as well, but with a
larger size. The impeller is, again, used mainly for homogenizing temperature, pH, and liquid
composition. The agitation speed of the impeller is 75 RPM, which leads to a mixing time of 36
seconds to reach 95% homogeneity, as shown in Section 25.4 calculations.
Brx-301 is also equipped with a dual sparger-configuration with one porous frit sparger
and one drilled hole sparger. Oxygen supply at 100% oxygen is sparged through the frit sparger
at 6 SLPM; air is used for carbon dioxide stripping, which is sparged through the drilled hole
sparger at 150 SLPM. The air flow rate out was assumed to be the same as air flow rate in at 150
SLPM in order to find out the maximum size of vent filter needed, as well as the permit for
maximum air vent.
The heat generated by Sf cells is 652 W and that by the impeller is 40 W, which means
that Brx-301’s cooling jacket (CJ-302) needs to use a total of 692 W to control the temperature to
26˚C. Brx-301 also has its own pH probe that monitors the change in pH level due to cellular
respiration, and again if the pH becomes too low, 1 M sodium hydroxide is added as base to
maintain the pH level at 6.3.

82

The material of construction for Brx-301 is stainless steel, the maximum electrical power
requirement is 2.4 kW, and the purchase cost is $214,065.99. One 2000 L BPC, which costs
$10,233.13, needs to be purchased for disposable single usage. The 2000 L BPC has been
sterilized in advance by gamma radiation.

15.3 Downstream Processes
15.3.1 Depth Filtration
The depth filtration unit (DeF-401) filters out large cell debris, bacteria, and some viruses
in feed stream S-401 that comes from Brx-301 by using a two-stage depth filter train.
Traditionally, non-synthetic HC filters have been used, but these filters have leachables that
impact the product quality. Thus, industries are leaning towards using synthetic SP filters, which
have similar functionality but no leachables. The 26 D0SP filters and 13 X0SP filters from
Millipore are used in our two-stage depth filter train. The D0SP filters have a pore size of 10 µm
that filter out large sized cell debris, and the X0SP filters have a pore size of 0.1 µm that filter
out bacteria and some viruses. The size of our protein of interest is around 180 to 200 kDa
[1][83], which is much smaller than the pore size of X0SP filters and allows the protein to pass
through. A process-scale pod (PSP) device format of two 2-rack holders, which can process up to
20 filters each, is used. One of the 2-rack holders holds 20 D0SP filters, and the other one holds
6 D0SP filters and 13 X0SP filters.
After setting up the PSP device, 459 L of buffer (purified water) is added for wetting.
Then, the 2000 L harvest batch with 3.75 kg of protein enters the depth filters at a flow rate of
2002 L/hr. The titer from the harvest batch is 1.875 g of protein/L medium, which is suitable for
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entry into depth filtration. Next, 75% of the buffer (344 L of buffer) is discarded, and the
remaining 25% of the buffer (115 L of buffer) is obtained with the 2000 L feed by flushing the
depth filters again using 459 L of buffer. Additional 251 L of volume is recovered after air
blowdown, totaling a final volume of 2366 L for processing in the next downstream operation
unit. The time required for depth filtration is roughly 1 hour of feed process time and 1 hour of
wetting/flushing time, which adds up to 2 hours. The percent yield of depth filtration is around
90%, which means 3.38 kg of protein is recovered in exit stream S-402 for further downstream
processing.
The material of construction for the PSP 2-rack holders is 316L stainless steel. D0SP
filters are made of non-woven, silica filter aid / polyacrylic fiber pulp, and X0SP filters are made
of silica filter aid / polyacrylic fiber pulp. The purchase cost is $52,090 for the 2-rack process
pod holder, $834 for each of the D0SP filters, and $1,050 for each of the X0SP filters.

15.3.2 His-tag Chromatography
Before the protein solution from DeF-401 is added to the Cytiva Chromaflow
Chromatography Column (HC-401), which has a diameter of 400 mm and a height of 400 mm,
the column will be packed using 33.75 L of the HisPur™ Cobalt Superflow Agarose resin. The
column will then be equilibrated by using 10 column volumes, or 503 L, of an equilibration
buffer flowed through at 300 cm/hr (377 L/hr), and only then 473 L of the protein extract from
S-404 will flow through the column. As five runs will be conducted, only one fifth of the loading
material i.e. will need to flow through the column per run, hence 473 L. The protein extract will
be run through at a rate of 150 cm/hr or 188.5 L/hr when sizing appropriately for the column.
Once all the material has run through, 10 column volumes, 503 L, of the washing buffer will be
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applied to the column at 188.5 L/hr. 10 column volumes of the elution buffer will next be applied
to the column at 188.5 L/hr and the eluate will be transferred to the 2000 L single-use mixer
(VI-401) in viral inactivation stage. The column will then be washed with 10 column volumes of
a washing buffer, followed by 10 column volumes of a regeneration buffer. Both of these
cleaning buffers can be run faster at 377 L/hr, as there is no concern for protein loss.
The process will repeat from the equilibration buffer phase onwards until all protein
extract has been processed. Total run time will be approximately 2 days and each run will take
about 9 hours including washing. Yield is anticipated to be about 90% with purity of around 95%
[84], which means that about 3.04 kg of protein exits the stream S-405. The purchase cost of
his-tag chromatography column is approximately $76,000.

15.3.3 Viral Inactivation and Filtration
The viral inactivation step will denature the virus particles remaining in stream [S-405].
The ThermoFisher HyPerforma Single Use 2000 L Jacketed Mixer (VI-401) will be used. The
tank is 135 cm in diameter and 185 cm tall. The feed volume will be 1257 L. First, 31.4 L of 1 M
acetic acid will be added to VI-401 in stream S-420 to bring the pH down to 3.5. The average
acid-addition flow rate will be 30 L/hr, with a faster slow rate at the start and slower flow rate at
the end. This will take approximately 1 hour. Then, a holding time of 1 hour will ensue. Next,
65.3 L of 1 M tris base will be added through stream S-420 at an average flow rate of 60 L/hr,
done so in the same fashion as the acid-addition with a fast start and slow finish. The base can be
added at double the flow rate as the acid because it is not as strong as the acid, according to Dr.
Koshari. The base-addition will therefore take about 1 hour. The purchase cost for VI-401 is
estimated to be about $160,550. The electrical requirement for the single-use mixer is 2.5 kWh.
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The next step will be a sterile membrane filtration. We will use the Millipore Express
SHF Hydrophilic Filter with Opticap XL 10 Capsule (MF-401), which has a surface area of 0.54
m2 and a flux of 20 ml/min-cm2. This correlates to 200L/min-m2, which in turn yields a flow rate
of 108 L/min. This is quite high, as we believe that the data available on small scale flux would
not directly correlate. Therefore, we assume the flow rate to be about 30L/hr and will take at
most 1 hour to complete. The yield is 98% with 2.98 kg of protein leaving stream S-406. The
cost for the sterile membrane filter is $970. The total time for viral inactivation and sterile
membrane filtration will be 4 hours.

15.3.4 Ion Exchange Chromatography
The Millipore QuickScale Biochromatography Column (IEX-401) has a diameter of 350
mm and a height of 550 mm. It will be packed with 21.3 L of resin and equilibrated with 5
column volumes of equilibration buffer at 289 L/hr. Then, material in S-408 will be run through
IEX-401 all at once at 300 cm/hr or 289 L/hr. Once the protein extract has run through the
column, the elution buffer will be applied to change the pH in the column, and gradually release
the protein. The 370 L eluate will be collected and sent on to VF-401. The column will then be
washed and regenerated for another cycle.
Total process time without cleaning (which could be done in parallel) is anticipated to be
7 hours with expected yield of 90% [85] and purity of 85% [86], which means that about 2.68 kg
of protein exit stream S-409. The purchase cost of IEX-401 is approximately $43,320.
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15.3.5 Viral Filtration
The viral filtration unit (VF-401) removes viruses in feed stream S-411 coming from
IEX-401, and the Viresolve® adsorptive depth prefilter is used with Magnus 2.1 filter for the
VF-401. These filters together have been shown to provide log reduction value greater than 4 for
28 nm sized bacteriophage challenged at 107 pfu/cm2 [87]. The nucleocapsids of baculovirus in
our solution average 30 to 70 nm in diameter and 200 to 400 nm in length [88], which suggests
that final log reduction value of 6 for viral clearance is very likely to be achieved, since some
viruses have already been filtered out in the depth filtration and chromatography steps.
After setting up the prefilter and Magnus 2.1 device, 26 L of purified water is added for
wetting. Then, the 370 L with 2.68 kg of protein from the ion exchange chromatography column
enters the viral filters at a flow rate of 155.3 L/hr. The titer load entering the viral filtration step
is 7.23 g of protein/L medium, which corresponds to a mass throughput of 8.4 kg/m2 as shown in
the Viresolve® Pro Solution Performance Guide [89]. Then, 26 L of 50 mM acetate buffer is
added last for flushing, totaling a final volume of 396 L for processing in the next downstream
operation unit. The time required for viral filtration is around 3 hours with 98% yield, which
means 2.63 kg of protein is leaving stream S-412 for further downstream processing.
The adsorptive depth prefilter is composed of diatomaceous earth (DE), cellulose fibers,
and a binder containing cationic imine groups. Materials of construction for the Magnus 2.1 filter
are polyethersulfone (PES) for the membrane, polyvinylidene fluoride (PVDF) for the housing,
and silicone for the gaskets. The purchase cost is $10,270 for the Magnus 2.1 filter, and $1,340
for the adsorptive depth prefilter.
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15.3.6 Diafiltration
The diafiltration unit (DiF-401) retains the Spike protein and filters out any small
particles from the feed stream S-414 pumped from the viral filtration outlet stream S-413. Since
the Spike protein is 180 kDa in size [1][83], a nominal molecular weight limit of 30 kDa was
chosen for the membrane cassettes using Millipore supplier guidelines to retain the protein and
filter out any smaller solutes. The Millipore® Ultracel® membrane made of regenerated
cellulose was chosen due to its extremely low protein binding, since our protein product is highly
valuable. This membrane line provides the highest product recovery from Millipore® and is
ideal for solutions with protein concentrations below 20 g/L. Three 1.14m2 Millipore® Pellicon®
cassette filters are stacked and run in parallel for a total membrane area of 3.42m2, accounting for
a 20% safety factor for the membrane area [90].
The 400 L feed stream S-414 contains 6.6 g Spike protein / L buffer. The process will be
run twice, each at 200 L of feed and 5 diavolumes to remove 99.3% of smaller solutes [90][91].
This means 1000 L of diafiltration buffer will be used each run, totaling to 2000 L of buffer
required for two runs entering in S-423 and exiting in S-428. The diafiltration buffer will consist
of 150mM NaCl and 2.5mM NaPO4 in WFI (water for injection), at a pH between 6.8 and 7.2,
based on a diafiltration buffer used in the development of a SARS recombinant spike protein
vaccine [92]. Each run takes 3.5 hours at a feed flow of 4 L/min and a permeate flow of 4.7
L/min, totaling to 7 hours of combined processing time. The final buffer displacement will
recover 99.3% of the protein [81] using 3 L of buffer for each run, totaling to a 6 L dilution using
additional buffer. The final product contains 6.5 g Spike protein / L buffer, which totals to a final
mass of 2.6 kg Spike protein. This is more than the 2.5 kg of protein required to produce 500
million doses, which leaves room for unforeseen losses in between processes.
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Based on energy balance calculations, the heat generated by the mixing and pumping of
liquid will lead to an 8°C increase in temperature, which will be brought back down to the
operating temperature of 25°C using a heating jacket that comes with the system. The system
requires 4.4 kW of electrical utility to run and 3.4 kW to cool. After consultation with Dr.
Koshari, the diafiltration system was estimated to be between $200,000 and $400,000 as a
single-use operation based on the $1.2 million cost of a stainless steel version. To be
conservative, this system was estimated to cost about $300,000.

15.4 Storage and Transfer
15.4.1 Peristaltic Pumps
Pumps are used to transport liquid between vessels. Although centrifugal pumps can
handle very high flow rate and high discharge pressure, peristaltic pumps are favored over
centrifugal pumps in that peristaltic pumps preserve sterility, since fluid never touches the
equipment itself and only flows through peristaltic tubes. These peristaltic pumps are positive
displacement pumps that are capable of emptying all liquid with air, which means that there is no
dead volume waste. They are also specifically designed to be compatible with the B/T 87 and
B/T 91 series of tubing.

Pump (PP-301) is used to transport the feed stream (S-105) from the WAVE bioreactor
200EH (W-101a) to the perfusion bioreactor (PBrx-301). PP-301 transports 50 L at 1.67
LPM while increasing the pressure from 1.21 bar to 1.36 bar. It requires 0.00056 hp to
operate and has a purchasing cost of $7390.00.
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Pump (PP-302) is used to transport the feed stream (S-302) from the 500 L N-1 perfusion
bioreactor (PBrx-301) to the 2000 L production bioreactor (Brx-301). PP-302 transports
500 L at 16.67 LPM while increasing the pressure from 1.04 bar to 1.54 bar. It requires
0.0084 hp to operate and has a purchasing cost of $7390.00.

Pump (PP-303) is used to transport the feed stream (S-203) from the WAVE bioreactor
20/50EH (W-201a) to the 2000 L production bioreactor (Brx-301). This pump transports
20 L at 1.33 LPM while increasing the pressure from 1.11 bar to 1.54 bar. The pump
requires 0.00067 hp to operate and has a purchasing cost of $7390.00.

Pump (PP-401) is used to transport the protein extract (S-304) from the 2000 L
production bioreactor (Brx-301) through the depth filtration (DeF-401) to the 3000 L
storage tank (ST-401). PP-401 transports 2000 L at 33.37 LPM while increasing the
pressure from 1.04 bar to 3.14 bar. It requires 0.021 hp to operate and has a purchasing
cost of $7390.00.

Pump (PP-402) is used to transport the protein extract (S-403) from the 3000 L storage
tank (ST-401) through the his-tag chromatography column (HC-401) to the 2000 L single
use mixer (VI-401) at the viral inactivation tank. PP-402 transports 2366 L at 3.13 LPM
while increasing the pressure from 1.04 bar to 2.03 bar. It requires 0.0013 hp to operate
and has a purchasing cost of $7390.00.
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Pump (PP-403) is used to transport the protein extract (S-406) from the 2000 L single use
mixer (VI-401) at the viral inactivation tank through the ion-exchange chromatography
column (IEX-401) to the 500 L storage tank (ST-402). PP-403 transports 1353 L at 4.82
LPM while increasing the pressure from 1.04 bar to 3.44 bar. It requires 0.0013 hp to
operate and has a purchasing cost of $7390.00.

Pump (PP-404) is used to transport the protein extract (S-410) from the first 500 L
storage tank (ST-402) through the viral filtration unit (VF-401) to the second 500 L
storage tank (ST-403). PP-404 transports 370.4 L at 2.59 LPM while increasing the
pressure from 1.04 bar to 3.14 bar. It requires 0.00072 hp to operate and has a purchasing
cost of $7390.00.

Pump (PP-405) is used to transport the protein extract (S-413) from the second 500 L
storage tank (ST-403) to the diafiltration unit (DiF-401). PP-405 transports 396 L at 13.33
LPM while increasing the pressure from 1.04 bar to 1.28 bar. It requires 0.0030 hp to
operate and has a purchasing cost of $7390.00.

Pump (PP-406) is used to transport the protein extract (S-415) from the diafiltration unit
(DiF-401) to the third 500 L storage tank (ST-404). PP-406 transports 402 L at 13.33
LPM while increasing the pressure from 1.01 bar to 1.09 bar. It requires 0.0037 hp to
operate and has a purchasing cost of $7390.00.
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15.4.2 Peristaltic Tubes
The peristaltic tubes used in the process are a crucial part of ensuring product sterility
during transfer between production phases. The peristaltic tubing used is made of platinum-cured
silicone to ensure compatibility with pharmaceutical grade products as well as a sterile
environment. The tubing is also sufficiently flexible to withstand the compressions occurring
during the pumping. Straight hose barb unions will be used to connect the tubing to ensure sterile
connections. Each unit of tubing is 10 ft long. However, in order to ensure sufficient spacing
between pieces of equipment, 20 ft (i.e. 2 pieces of tubing) will be used between equipment
items. The tubing itself has no associated energy costs although energy will be required to pump
material through. The tubing itself is designed to be smooth to minimize flow obstruction. Due to
differences in the required flow rate throughout the process, two tubing sizes will be used: the
B/T 87 and the B/T 91.

The B/T 87 has an internal diameter of ½ inch and is used for smaller flow rates as it has
a flow rate capacity of up to 18.9 LPM. It can withstand up to 2.4 bar of pressure. It is
used for all tubing requirements except for the tubing between the production phase
bioreactor and the first storage tank. The tubing has a purchase cost of $484.00/10 ft.

The B/T 91 has an internal diameter of ¾ inch and is used for larger flow rates as it has a
flow rate capacity of up to 42 LPM. It can withstand up to 2.06 bar of pressure. It is used
for the tubing between the production phase bioreactor and the first storage tank.
$691.00/10 ft.
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15.4.3 Storage Vessels
Storage vessels are large stainless steel containers that are meant to hold material until it
can be transferred to another stage of the process. These containers are built to be sturdy and
stable in the presence of biological matter.

The material coming out of the depth filtration step (S-402) requires a large storage
vessel that can hold all protein extract mixed with the depth filtration buffer. Storage
Tank 1 (ST-401) is 3000 L to hold all 2400 L of solution and to be of a standard
production size. ST-401 is made out of stainless steel for its durability. It will not have
any associated energy requirements and has a purchase price of $12,400.

The 370 L of protein-containing elution buffer flowing from the ion-exchange
chromatography step (S-409) will be sent to Storage Tank 2 (ST-402) for storage before
continuing through to the viral filtration stage (VF-401) at a different flow rate. ST-402 is
500 L to ensure the vessel is of standard production size. It will not have any associated
energy requirements and has a purchase price of $1,500.

The 395 L of protein extract flowing from the viral filtration system (S-412) will flow
into Storage Tank 3 (ST-403) before processing in the diafiltration stage (DiF-401).
ST-403 is 500 L to ensure the vessel is of standard production size. It will not have any
associated energy requirements and has a purchase price of $1,500.
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The 402 L of protein extract flowing from the diafiltration system (S-415) will flow into
Storage Tank 4 (ST-404) until formulation can be carried out. ST-404 is 500 L to ensure
the vessel is of standard production size. It will not have any associated energy
requirements and has a purchase price of $1,500.
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16. Specification Sheets
SPECIFICATION SHEET
Corning® 125 mL Erlenmeyer Shake Flasks (with Vent Cap)

Equipment

Materials

Design Data

ID

F-101a/b/c/d

Quantity

4

Function

Grow cells to VCD of 4.98 million cells / mL

Operation

Batch, 5.2 days of growth
In

Out

Feed (with Sf-9 Cells)

1 mL

50 mL

Media (Sf-900TM II SFM)

49 mL

-

Flask Material

Polycarbonate

Cap Material

Polypropylene

Bottom Style

Plain

Cap Style

Vent

Sterile

Yes

Feature

Disposable

Temperature

27.5 ± 0.5 ˚C

pH

6.3 ± 0.1

Pressure

1.01 bar

Height

4.54 in (with cap)
4.45 in (w/o cap)

Base Diameter

2.58 in

Working Volume

50 mL

Utilities

N/A

Comments: Purchase cost is $15.70 each; flask is sterilized by gamma radiation and certified non-pyrogenic.
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SPECIFICATION SHEET
Corning® 250 mL Erlenmeyer Shake Flasks (with Vent Cap)

Equipment

Materials

Design Data

ID

F-201a/b

Quantity

2

Function

Grow 2 million baculoviruses to 100-fold

Operation

Batch, 6 days of growth
In

Out

Feed (with Baculovirus)

20 mL

200 mL

Media with Sf-9 Cells

180 mL

-

Flask Material

Polycarbonate

Cap Material

Polypropylene

Bottom Style

Plain

Cap Style

Vent

Sterile

Yes

Feature

Disposable

Temperature

27.5 ± 0.5 ˚C

pH

6.3 ± 0.1

Pressure

1.01 bar

Height

5.50 in (with cap)
5.42 in (w/o cap)

Base Diameter

3.28 in

Working Volume

200 mL

Utilities

N/A

Comments: Purchase cost is $17.70 each; flask is sterilized by gamma radiation and certified non-pyrogenic.
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SPECIFICATION SHEET
Corning® 500 mL Erlenmeyer Shake Flasks (with Vent Cap)

Equipment

Materials

ID

F-102a/b/c/d

Quantity

4

Function

Grow cells to VCD of 5.36 million cells / mL

Operation

Batch, 3 days of growth

Feed (with Sf-9 Cells)
Media (Sf-900

TM

Design Data

II SFM)

In

Out

50 mL

500 mL

450 mL

-

Flask Material

Polycarbonate

Cap Material

Polypropylene

Bottom Style

Plain

Cap Style

Vent

Sterile

Yes

Feature

Disposable

Temperature

27.5 ± 0.5 ˚C

pH

6.3 ± 0.1

Pressure

1.01 bar

Height

7.05 in (with cap)
6.96 in (w/o cap)

Base Diameter

3.99 in

Working Volume

500 mL

Utilities

N/A

Comments: Purchase cost is $27.10 each; flask is sterilized by gamma radiation and certified non-pyrogenic.
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SPECIFICATION SHEET
Corning® 5 L Erlenmeyer Shake Flasks (with Vent Cap)

Equipment

Materials

ID

F-103a/b/c

Quantity

3

Function

Grow cells to VCD of 5.78 million cells / mL

Operation

Batch, 3 days of growth

Feed (with Sf-9 Cells)
Media (Sf-900

TM

Design Data

II SFM)

In

Out

0.5 L

5L

4.5 L

-

Flask Material

Polycarbonate

Cap Material

Polypropylene

Bottom Style

Plain

Cap Style

Vent

Sterile

Yes

Feature

Disposable

Temperature

27.5 ± 0.5 ˚C

pH

6.3 ± 0.1

Pressure

1.01 bar

Height

11.33 in (with cap)
11.24 in (w/o cap)

Base Diameter

9.05 in

Working Volume

5L

Utilities

N/A

Comments: Purchase cost is $166.00 each; flask is sterilized by gamma radiation and certified non-pyrogenic.

98

SPECIFICATION SHEET
Cytiva® WAVE™ Bioreactor System 20/50EH

Equipment

Materials

Design Data

Utilities

ID

W-201a/b

Quantity

2

Function

Grow 2 billion baculoviruses to 100-fold

Operation

Batch, 5 days of growth
In

Out

Feed (with Baculovirus)

0.2 L

20 L

Media with Sf-9 Cells

19.8 L

-

Air

2.2 kg (0.4 LPM)

2.2 kg (0.4 LPM)

Material

Stainless Steel

Temperature

27.5 ± 0.5 ˚C

pH

6.3 ± 0.1

Pressure

1.11 bar

Length

0.775 m

Width

0.700 m

Height

0.254 m

Weight

15.5 kg

Working Volume

20 L

Rocking Speed

25 rocks/min

Rocking Angle

8 degrees

Voltage

110/230 VAC

Frequency

50/60 Hz

Current

6/3 A

Comments: Purchase cost is $4000.00 each

99

SPECIFICATION SHEET
Cytiva® WAVE™ Bioreactor System 200EH

Equipment

Materials

Design Data

Utilities

ID

W-101a/b/c

Quantity

3

Function

Grow cells to VCD of 6.22 million cells / mL

Operation

Batch, 3 days of growth
In

Out

Feed (with Sf-9 Cells)

5L

50 L

Media (Sf-900TM II SFM)

45 L

-

Air

11.0 kg (2 LPM)

11.0 kg (2 LPM)

Material

Stainless Steel

Temperature

27.5 ± 0.5 ˚C

pH

6.3 ± 0.1

Pressure

1.21 bar

Length

1.852 m

Width

1.096 m

Height

1.120 m

Weight

350 kg

Working Volume

50 L

Rocking Speed

20 rocks/min

Rocking Angle

7 degrees

Voltage

100-120/220-240 VAC

Frequency

50/60 Hz

Current

Max: 15 A

Power

12 KVA

Comments: Purchase cost is $16,000.00 each
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SPECIFICATION SHEET
ThermoFisher® HyPerforma® 2:1 500 L Single-Use Bioreactor (Jacketed)

Equipment

Materials

Design Data

ID

PBrx-301 (+ PS-301)

Quantity

1

Function

Grow cells to higher VCD of 32.65 million cells / mL

Operation

Perfusion, 5 days of growth
In

Out

Feed (with Sf-9 Cells)

50 L

500 L

Media (Sf-900TM II SFM)

2640.4 L

2200 L

Air

229.6 kg (25 LPM)

229.6 kg (25 LPM)

Oxygen (50%)

82.4 kg (8 LPM)

74.4 kg (7.24 LPM)

Carbon Dioxide

-

23.6 kg (1.67 LPM)

Glucose

30.5 kg (0.254 kg/hr)

-

Glutamine

11.3 kg (0.0943 kg/hr)

-

Base (1M NaOH)

1.5 L

-

Antifoam

8.1 L

-

Material

Stainless Steel

Temperature

27.5 ± 0.5 ˚C

pH

6.3 ± 0.1

Pressure

1.04 bar

Sparger

Frit + Drilled Hole (Dual-Sparger Configuration)

Bioreactor
Geometry

Impellor

Agitation

Utilities

Diameter

75.6 cm

Height

152.4 cm (Liquid Height: 113.4 cm)

Volume

660 L (Working Volume: 500 L)

Type

Pitched Blade (Quantity: 1 / # of Blades: 3)

Diameter

25.1 cm

Power Num.

2.1

Mixing Rate

101 RPM

Tip Speed

137.2 cm/s

Agitation Rating

20 W/m3

Heating/Cooling Load

5,000 W

Motor Power Rating

372.8 W (AC), 400 W (DC)

Comments: Purchase cost of bioreactor is $91,473.39 / perfusion system is $18,560.00
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SPECIFICATION SHEET
ThermoFisher® HyPerforma® 2:1 2000 L Single-Use Bioreactor (Jacketed)

Equipment

Materials

Design Data

ID

Brx-301

Quantity

1

Function

Produce proteins at VCD of 8.15 million cells / mL

Operation

Batch, 5 days of production
In

Out

Protein of Interest

-

3.75 kg

Feed (with Sf-9 Cells +
Baculovirus)

500 L (Sf-9 Cells)
20 L (Baculovirus)

2000 L

Media (Sf-900TM II SFM)

1472.9 L

-

Air

1377.6 kg (150 LPM)

1377.6 kg (150 LPM)

Oxygen (100%)

61.8 kg (6 LPM)

55.8 kg (5.43 LPM)

Carbon Dioxide

-

17.7 kg (1.25 LPM)

Glucose

21.6 kg (0.180 kg/hr)

-

Glutamine

5.15 kg (0.0429 kg/hr)

-

Base (1M NaOH)

1.1 L

-

Antifoam

6L

-

Material

Stainless Steel

Temperature

26.0 ± 1.0 ˚C

pH

6.3 ± 0.1

Pressure

1.04 bar

Sparger

Frit + Drilled Hole (Dual-Sparger Configuration)

Bioreactor
Geometry

Impeller

Agitation

Utilities

Diameter

119.4 cm

Height

229.9 cm (Liquid Height: 178.7 cm)

Volume

2575 L (Working Volume: 2000 L)

Type

Pitched Blade (Quantity: 1 / # of Blades: 3)

Diameter

39.8 cm

Power Num.

2.1

Mixing Rate

75 RPM

Tip Speed

154.9 cm/s

Agitation Rating

20 W/m3

Heating/Cooling Load

18,000 W

Motor Power Rating

372.8 W (AC), 400 W (DC)

Comments: Purchase cost is $214,065.99
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SPECIFICATION SHEET
Grainger - Stationary Air Compressor, 2.0 (for WAVE Bioreactor 20/50EH)

Equipment

Materials

Design Data

Utilities

ID

AC-201

Quantity

1

Function

Supply air for two 20 L, working-volume, wave bioreactors

Operation

5 days

Air

Inlet

Outlet

Flow Rate

0.4 LPM (Total: 0.8 LPM)

0.36 LPM (Total: 0.72 LPM)

Pressure

1.01 bar

1.11 bar

Temperature

25.0˚C

25.0˚C

Tank Size

7.6 L

Dimensions (LxWxH)

0.46 x 0.20 x 0.43 m

Power Requirement

0.000167 hp

Maximum Power

0.17 hp

Voltage

120 VAC

Current

4.3 A

Comments: Purchase cost is $1212.50
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SPECIFICATION SHEET
Grainger - Stationary Air Compressor, 2.0 (for WAVE Bioreactor 200EH)

Equipment

Materials

Design Data

Utilities

ID

AC-101

Quantity

1

Function

Supply air for three 50 L, working-volume, wave bioreactors

Operation

3 days

Air

Inlet

Outlet

Flow Rate

2 LPM (Total: 6 LPM)

1.67 LPM (Total: 5.01 LPM)

Pressure

1.01 bar

1.21 bar

Temperature

25.0˚C

25.0˚C

Tank Size

7.6 L

Dimensions (LxWxH)

0.46 x 0.20 x 0.43 m

Power Requirement

0.00247 hp

Maximum Power

0.17 hp

Voltage

120 VAC

Current

4.3 A

Comments: Purchase cost is $1212.50
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SPECIFICATION SHEET
Grainger - Stationary Air Compressor, 2.0 (for 500 L Perfusion Bioreactor)

Equipment

Materials

Design Data

Utilities

ID

AC-301

Quantity

1

Function

Supply air for 500 L perfusion bioreactor

Operation

5 days

Air

Inlet

Outlet

Flow Rate

25 LPM

11.69 LPM

Pressure

1.01 bar

2.16 bar

Temperature

25.0˚C

25.0˚C

Tank Size

7.6 L

Dimensions (LxWxH)

0.46 x 0.20 x 0.43 m

Power Requirement

0.0478 hp

Maximum Power

0.17 hp

Voltage

120 VAC

Current

4.3 A

Comments: Purchase cost is $1212.50
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SPECIFICATION SHEET
Grainger-Fire Sprinkler Air Compressor (for 2000 L Production Bioreactor)

Equipment

Materials

Design Data

Utilities

ID

AC-302

Quantity

1

Function

Supply air for 2000 L production bioreactor

Operation

5 days

Air

Inlet

Outlet

Flow Rate

150 LPM

67.94 LPM

Pressure

1.01 bar

2.23 bar

Temperature

25.0˚C

25.0˚C

Tank Size

114 L

Dimensions (LxWxH)

0.46 x 0.20 x 0.43 m

Power Requirement

0.301 hp

Maximum Power

0.5 hp

Voltage

120 VAC

Current

9.4 A

Comments: Purchase cost is $1095.92
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SPECIFICATION SHEET
Millipore® Process-Scale Pod (2-Rack Holders)

Equipment

Materials

Design Data

ID

DeF-401

Quantity

2

Function

Filter out large cell debris, bacteria, and some viruses by using
two-stage depth filter train

Operation

2 hours
In

Out

Protein of Interest

3.75 kg

3.38 kg

Feed

2000 L

2366 L

Buffer (Purified Water)

917 L (Wetting + Flushing)

344 L (+ Hold-up: 207 L)

Material

316L Stainless Steel

Temperature

25.0 ± 1.0 ˚C

Pressure Drop

2.1 bar

Process Flux

100 LMH

Flow Rate

2002 L/hr

Filters

D0SP

X0SP

Filter Material

Nonwoven, Silica Filter Aid /
Polyacrylic Fiber Pulp

Silica Filter Aid / Polyacrylic
Fiber Pulp

Filter Quantity

26

13
2

Capacity

100 L/m

150 L/m2

Pore Size

10 µm

0.1 µm

2

Effective Surface Area

0.77 m each

1.1 m2 each

Hold-up Volume

12.9 L each
6.30 L each (after gravity drain)
5.04 L each (after blow down)

9.47 L each
6.72 L each (after gravity drain)
5.85 L each (after blow down)

Utilities

N/A

Comments: Purchase cost is $52,090.00
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SPECIFICATION SHEET
Cytiva® Chromaflow® Chromatography Column

Equipment

Materials

Design Data

ID

HC-401

Quantity

1

Function

Separates out recombinant protein from solution by using his-tag
based resins

Operation

43 hours
In

Out

Protein of Interest

3.38 kg

3.04 kg

Feed

2366 L (473 L/run)

1257 L

Waste

-

2366 L

Equilibration Buffer

1257 L (251 L/run)

1257 L (251 L/run)

Wash Buffer

2513 L (503 L/run)

2513 L (503 L/run)

Elution Buffer

1257 L (251 L/run)

-

Regeneration Buffer

1257 L (251 L/run)

1257 L (251 L/run)

Regeneration Water Wash

1257 L (251 L/run)

1257 L (251 L/run)

Material

Polypropylene, 316L, S32205 Stainless Steel

Temperature

25.0 ± 1.0 ˚C

Pressure Drop

Min: 0.99 bar
Max: 1.98 bar

Diameter

40 cm

Column Height

40 cm

Packed Bed Height

27.5 cm

Overall Height

158.6 cm

Volume

50.3 L

Packed Bed Volume

33.8 L

Total Resin Volume

168.8 L

Binding Capacity

20 mg/mL

Flow Rate

150 cm/hr

# of Runs

5

Utilities

N/A

Comments: Purchase cost is $76,000.00
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SPECIFICATION SHEET
ThermoFisher® HyPerforma® 5:1 2000L Single-Use Mixer (Non-Jacketed)

Equipment

Materials

Design Data

Utilities

ID

VI-401

Quantity

1

Function

Perform viral inactivation, followed by sterile membrane
filtration

Operation

4 hours
In

Out

Protein of Interest

3.04 kg

2.98 kg

Feed

1257 L

1354 L (Feed + Acid + Base)

1M Acetic Acid

31.4 L (30 L/hr)

-

1M Tris Base

65.3 L (60 L/hr)

-

Material

AISI 304 (Stainless Steel)

Temperature

25.0 ± 1.0 ˚C

Pressure

1.04 bar

Diameter

135 cm

Height

185 cm

Volume

1353 L

Impeller Diameter

25.02 cm

Agitation Speed

100 - 200 RPM

Tip Speed

39.4 - 459.7 cm/s

Motor Power Rating

745.7 W

Motor Torque Rating

18 N-m

Electrical Power Rating

100-120 VAC, 50/60 Hz, Single, 15 A
220-240 VAC, 50/60 Hz, Single, 10.4 A

Comments: Purchase cost is $160,549.49 (sterile membrane filter is $970.00)
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SPECIFICATION SHEET
Millipore® QuikScale® Biochromatography Column

Equipment

Materials

Design Data

ID

IEX-401

Quantity

1

Function

Separates out recombinant protein from solution by using charge
differences in different pH’s

Operation

7 hours
In

Out

Protein of Interest

2.98 kg

2.68 kg

Feed

1353 L

370 L

Waste

-

1353 L

Equilibration Buffer

265 L

265 L

Elution Buffer

370 L

-

Equilibration Wash Buffer

159 L

159 L

1 M NaCl Wash Buffer

265 L

265 L

Ultrapure Water

529 L

529 L

1 M Acetic Acid Wash
Buffer

265 L

265 L

Material

Stainless Steel 1.4539

Temperature

25.0 ± 1.0 ˚C

Pressure Drop

2.4 bar

Diameter

35 cm

Height

55 cm

Packed Bed Height

25 cm

Volume

53 L

Packed Bed Volume

21.3 L

Total Resin Volume

21.3 L

Binding Capacity

140 mg/mL

Flow Rate

300 cm/hr

# of Runs

1

Utilities

N/A

Comments: Purchase cost is $43,320.00
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SPECIFICATION SHEET
Millipore® Viresolve® Pre-filter + Pro Device

Equipment

Materials

Design Data

ID

VF-401

Quantity

1

Function

Filter out viruses to satisfy final log reduction value (LRV) of 6
for viral clearance

Operation

3 hours
In

Out

Protein of Interest

2.68 kg

2.63 kg

Feed

370 L

396 L

Buffer
(Wetting: Purified Water /
Flushing: 50 mM Acetate)

52 L

26 L

Temperature

25.0 ± 1.0 ˚C

Pressure Drop

2.1 bar

Dimensions (L × W × H)

34.29 × 20.96 × 4.42 cm

Process Flux

304.5 LMH

Flow Rate

155.3 L/hr

Filter

Adsorptive depth prefilter

Magnus 2.1

Filter Quantity

1

1

Filter Material

Diatomaceous Earth (DE)
+ Cellulose Fibers
+ Cationic Imine Groups

Membrane: PES
Housing: PVDF
Gaskets: Silicone

Mass Throughput

8.4 kg/m2

Effective Surface Area

1.1 m2 (Prefilter) + 0.51 m2 (Magnus 2.1)

Wetting / Flushing
Capacity

50 L/m2

Utilities

N/A

Comments: Purchase cost of Viresolve® Prefilter is $1,340.00 / Viresolve® Magnus 2.1 is $10,270.00
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SPECIFICATION SHEET
Millipore® Mobius® Smart Flexware® Assemblies for TFF, Model TF3S, Jacketed

Equipment

Materials

Design Data

Utilities

ID

DiF-401

Quantity

1

Function

Diafiltration to remove small solutes in solution and retain
spike protein at a final drug concentration of 6.5 g/L

Operation

Batch, 3.5 hours for 2 runs, totaling 7 hours processing time
In

Out

Protein of Interest

2.63 kg

2.60 kg

Feed

396 L

402 L

0.1N NaOH

68 L

68 L

150mM NaCl / 2.5mM NaPO4

2048 L

2042 L

Bulk Medium

4 L/min Feed
(200 L Feed)

4 L/min Retentate
4.7 L/min Permeate

Temperature

25.0 ± 1.0°C

Pressure

Feed bag: atmospheric
Feed and Retentate pump: 4 bar
Transmembrane and Permeate: 2 bar

Dimensions (L × W × H)

2022 × 2160 × 1014 mm

Feed Container

LLDPE (linear low-density polyethylene) with jacket

Feed Volume

200 L

Recirculation Volume

2.2 L

Membrane Hold-up Volume

0.7 L

Unrecoverable Volume

Virtually zero using a displacement by buffer

Membrane Area

3.42 m2 total using three (3) cassettes, each 1.14 m2

SmartCart

1 kW

Tank Cart

0.4 kW

Pump Cart

3 kW

Comments: Purchase cost is $300,000.00
The system will be cleaned with 0.1N NaOH, then equilibrated with diafiltration buffer before running the
process. There will be 2 runs, each with 200 L of feed.
The diafiltration buffer will be 150 mM NaCl, 2.5 mM NaPO4, pH 6.8–7.2 in WFI (water for injection).
Three filters of Pellicon® 3 Cassettes with Ultracel® 30kDa Membrane, D screen, 1.14 m2 will be used.
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SPECIFICATION SHEET
Masterflex B/T® Digital Drive, Modular, Washdown Pump

Equipment

Operations

Design Data

Utilities

ID

PP-301

Quantity

1

Function

Transport liquid from WAVE bioreactor 200EH to
perfusion bioreactor

Operation

30 mins
In

Out

Feed

50 L (1.67 LPM)

50 L (1.67 LPM)

Pressure

1.21 bar

1.36 bar

Temperature

27.5˚C

27.5˚C

Control Type

Digital Variable Speed

Washdown Capable

Yes

Flow Rate

Min: 1.3 LPM
Max: 42 LPM

Controller Dimensions (LxWxH)

0.28 x 0.11 x 0.23 m

Drive Dimensions (LxWxH)

0.40 x 0.38 x 0.69 m

Power Requirement

0.00056 hp

Maximum Power

0.75 hp

Voltage

115 VAC (90 to 130)

Current

5.7 A

Frequency

50/60 Hz

Comments: Purchase cost is $7390.00
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SPECIFICATION SHEET
Masterflex B/T® Digital Drive, Modular, Washdown Pump

Equipment

Operations

Design Data

Utilities

ID

PP-302

Quantity

1

Function

Transport liquid from perfusion bioreactor to production
bioreactor

Operation

30 mins
In

Out

Feed

500 L (16.67 LPM)

500 L (16.67 LPM)

Pressure

1.04 bar

1.54 bar

Temperature

27.5˚C

27.5˚C

Control Type

Digital Variable Speed

Washdown Capable

Yes

Flow Rate

Min: 1.3 LPM
Max: 42 LPM

Controller Dimensions (LxWxH)

0.28 x 0.11 x 0.23 m

Drive Dimensions (LxWxH)

0.40 x 0.38 x 0.69 m

Power Requirement

0.0084 hp

Maximum Power

0.75 hp

Voltage

115 VAC (90 to 130)

Current

5.7 A

Frequency

50/60 Hz

Comments: Purchase cost is $7390.00
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SPECIFICATION SHEET
Masterflex B/T® Digital Drive, Modular, Washdown Pump

Equipment

Operations

Design Data

Utilities

ID

PP-303

Quantity

1

Function

Transport liquid from WAVE bioreactor 20/50EH to
production bioreactor

Operation

15 mins
In

Out

Feed

20 L (1.33 LPM)

20 L (1.33 LPM)

Pressure

1.11 bar

1.34 bar

Temperature

27.5˚C

27.5˚C

Control Type

Digital Variable Speed

Washdown Capable

Yes

Flow Rate

Min: 1.3 LPM
Max: 42 LPM

Controller Dimensions (LxWxH)

0.28 x 0.11 x 0.23 m

Drive Dimensions (LxWxH)

0.40 x 0.38 x 0.69 m

Power Requirement

0.00067 hp

Maximum Power

0.75 hp

Voltage

115 VAC (90 to 130)

Current

5.7 A

Frequency

50/60 Hz

Comments: Purchase cost is $7390.00
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SPECIFICATION SHEET
Masterflex B/T® Digital Drive, Modular, Washdown Pump

Equipment

Operations

Design Data

Utilities

ID

PP-401

Quantity

1

Function

Transport liquid from production bioreactor through depth
filtration to 3000 L storage tank

Operation

2 hours
In

Out

Feed

2000 L (33.37 LPM)

2000 L (33.37 LPM)

Pressure

1.04 bar

3.14 bar

Temperature

26.0˚C

26.0˚C

Control Type

Digital Variable Speed

Washdown Capable

Yes

Flow Rate

Min: 1.3 LPM
Max: 42 LPM

Controller Dimensions (LxWxH)

0.28 x 0.11 x 0.23 m

Drive Dimensions (LxWxH)

0.40 x 0.38 x 0.69 m

Power Requirement

0.021 hp

Maximum Power

0.75 hp

Voltage

115 VAC (90 to 130)

Current

5.7 A

Frequency

50/60 Hz

Comments: Purchase cost is $7390.00
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SPECIFICATION SHEET
Masterflex B/T® Digital Drive, Modular, Washdown Pump

Equipment

Operations

Design Data

Utilities

ID

PP-402

Quantity

1

Function

Transport liquid from 3000 L storage tank through his-tag
chromatography column to 2000 L single-use mixer

Operation

2 days
In

Out

Feed

2366 L (3.13 LPM)

2366 L (3.13 LPM)

Pressure

1.04 bar

2.03 bar

Temperature

25.0˚C

25.0˚C

Control Type

Digital Variable Speed

Washdown Capable

Yes

Flow Rate

Min: 1.3 LPM
Max: 42 LPM

Controller Dimensions (LxWxH)

0.28 x 0.11 x 0.23 m

Drive Dimensions (LxWxH)

0.40 x 0.38 x 0.69 m

Power Requirement

0.0013 hp

Maximum Power

0.75 hp

Voltage

115 VAC (90 to 130)

Current

5.7 A

Frequency

50/60 Hz

Comments: Purchase cost is $7390.00
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SPECIFICATION SHEET
Masterflex B/T® Digital Drive, Modular, Washdown Pump

Equipment

Operations

Design Data

Utilities

ID

PP-403

Quantity

1

Function

Transport liquid from 2000 L single-use mixer through IEX
chromatography column to 500 L storage tank 1

Operation

7 hours
In

Out

Feed

1353 L (4.82 LPM)

1353 L (4.82 LPM)

Pressure

1.04 bar

3.44 bar

Temperature

25.0˚C

25.0˚C

Control Type

Digital Variable Speed

Washdown Capable

Yes

Flow Rate

Min: 1.3 LPM
Max: 42 LPM

Controller Dimensions (LxWxH)

0.28 x 0.11 x 0.23 m

Drive Dimensions (LxWxH)

0.40 x 0.38 x 0.69 m

Power Requirement

0.0013 hp

Maximum Power

0.75 hp

Voltage

115 VAC (90 to 130)

Current

5.7 A

Frequency

50/60 Hz

Comments: Purchase cost is $7390.00
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SPECIFICATION SHEET
Masterflex B/T® Digital Drive, Modular, Washdown Pump

Equipment

Operations

Design Data

Utilities

ID

PP-404

Quantity

1

Function

Transport liquid from 500 L storage tank 1 through viral
filtration to 500 L storage tank 2

Operation

3 hours
In

Out

Feed

370.4 L (2.59 LPM)

370.4 L (2.59 LPM)

Pressure

1.04 bar

3.14 bar

Temperature

25.0˚C

25.0˚C

Control Type

Digital Variable Speed

Washdown Capable

Yes

Flow Rate

Min: 1.3 LPM
Max: 42 LPM

Controller Dimensions (LxWxH)

0.28 x 0.11 x 0.23 m

Drive Dimensions (LxWxH)

0.40 x 0.38 x 0.69 m

Power Requirement

0.00072 hp

Maximum Power

0.75 hp

Voltage

115 VAC (90 to 130)

Current

5.7 A

Frequency

50/60 Hz

Comments: Purchase cost is $7390.00
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SPECIFICATION SHEET
Masterflex B/T® Digital Drive, Modular, Washdown Pump

Equipment

Operations

Design Data

Utilities

ID

PP-405

Quantity

1

Function

Transport liquid from 500 L Storage Tank 2 to diafiltration
feed tank

Operation

30 mins
In

Out

Feed

395.9 L (13.33 LPM)

395.9 L (13.33 LPM)

Pressure

1.04 bar

1.28 bar

Temperature

25.0˚C

25.0˚C

Control Type

Digital Variable Speed

Washdown Capable

Yes

Flow Rate

Min: 1.3 LPM
Max: 42 LPM

Controller Dimensions (LxWxH)

0.28 x 0.11 x 0.23 m

Drive Dimensions (LxWxH)

0.40 x 0.38 x 0.69 m

Power Requirement

0.0030 hp

Maximum Power

0.75 hp

Voltage

115 VAC (90 to 130)

Current

5.7 A

Frequency

50/60 Hz

Comments: Purchase cost is $7390.00
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SPECIFICATION SHEET
Masterflex B/T® Digital Drive, Modular, Washdown Pump

Equipment

Operations

Design Data

Utilities

ID

PP-406

Quantity

1

Function

Transport liquid from diafiltration feed tank to 500 L
Storage Tank 3

Operation

30 mins
In

Out

Feed

401.7 L (13.33 LPM)

401.7 L (13.33 LPM)

Pressure

1.01 bar

1.09 bar

Temperature

25.0˚C

25.0˚C

Control Type

Digital Variable Speed

Washdown Capable

Yes

Flow Rate

Min: 1.3 LPM
Max: 42 LPM

Controller Dimensions (LxWxH)

0.28 x 0.11 x 0.23 m

Drive Dimensions (LxWxH)

0.40 x 0.38 x 0.69 m

Power Requirement

0.0037 hp

Maximum Power

0.75 hp

Voltage

115 VAC (90 to 130)

Current

5.7 A

Frequency

50/60 Hz

Comments: Purchase cost is $7390.00
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SPECIFICATION SHEET
Masterflex B/T® PerfectPosition™ Pump Tubing

Equipment

ID

N/A

Quantity

90 (B/T 87) + 10 (B/T 91)

Function

Transport of fluid between process units

Operation

Continuous

Length

10 ft (3 m)

Inner Diameter

0.5 in (12.7 mm)

Material

Platinum-Cured Silicone

Sterilization

Autoclave

B/T 87

Min

Max

Flow Rate

0.67 LPM

18.9 LPM

Temperature (Dynamic)

-40°C

100°C

Temperature

-50°C

230°C

Pressure

N/A

2.4 bar

Length

10 ft (3 m)

Inner Diameter

0.75 in (19 mm)

Material

Platinum-Cured Silicone

Sterilization

Autoclave

B/T 91

Min

Max

Flow Rate

1.4 LPM

42 LPM

Temperature (Dynamic)

-40°C

100°C

Temperature

-50°C

230°C

Pressure

N/A

2.06 bar

Utilities

N/A

Comments: Purchase cost of B/T 87 is $484.00 per pack of 10 / B/T 91 is $691.00 per pack of 10
B/T tubing goes with the B/T peristaltic pumps. The products are available as B/T 87 and B/T 91 tubes.
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17. Equipment Cost Summary
Table 17.1 lists the purchase and bare module costs of all the required equipment for this
process. While we will not actually buy the equipment, we are assuming these units or similar
pieces are available at the CMO. By calculating the total bare module cost, we can estimate the
CMO costs and subsequently estimate a reasonable monthly fee to use their equipment. The bare
module costs were calculated using the purchase costs obtained from vendors and the bare
module factors from Table 16.11 in Seider et al. (2017) [93]. For equipment not included in
Table 16.11, bare module factors were estimated. Specifically, for storage tanks, bare module
factor of 4.0 was assumed in the equipment costing spreadsheet. A factor of 4.16 was assumed
for mixers and bioreactors, which was considered to be similar in function to a fermenter. Other
pieces of equipment without a bare module factor were assigned the default value of 3.21 in the
spreadsheet. A CEI index of 600 for 2021 was used. The single-use mixer cost was assumed to
be ¾ the price of the bioreactor cost. Finally, the biological and chemical lab was assumed to be
5% of the total capital and operating costs.
Table 17.1. Purchase and Bare Module Costs of Equipment
Equipment

ID

Purchase Cost

Quantity

Bare
Module
Factor

Bare Module
Cost

Raw Material Storage
200 L Media Vessel
2000 L Media Vessel
3000 L Media Vessel
100 L Glucose Vessel
500 L Glutamine Vessel
20 L Antifoam Vessel
500 L Storage Tank
3000 L Storage Tank

M-101
M-302
M-301
GC-301
GT-301
AF-301
ST-402
ST-403
ST-404
ST-401

$ 4,000.00
$ 10,210.53
$ 12,421.05
$ 2,000.00
$ 3,000.00
$ 269.90

1
1
1
1
1
1

4.0
4.0
4.0
4.0
4.0
4.0

$ 16,000.00
$ 40,842.12
$ 49,684.20
$ 8,000.00
$ 12,000.00
$ 1,079.60

$ 1,500.00

3

4.0

$ 18,000.00

$ 6,000.00

1

4.0

$ 24,000.00
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Upstream Equipment
WAVE™ Bioreactor
System 20/50EH
WAVE™ Bioreactor
System 200EH
500 L Bioreactor
(Jacketed)
500 L Perfusion System
2000 L Bioreactor
(Jacketed)

W-201a
W-201b
W-101a
W-101b
W-101c

$ 4,000.00

2

3.21

$ 25,680.00

$ 16,000.00

3

3.21

$ 154,080.00

PBrx-301

$ 91,473.39

1

4.16

$ 380,529.30

PS-301

$ 18,560.00

1

3.21

$ 59,577.60

Brx-301

$ 214,065.99

1

4.16

$ 890,514.53

$ 52,090.00

1

2.32

$ 120,848.80

$ 76,000.00

1

4.16

$ 316,160.00

$ 160,549.49

1

4.16

$ 667,885.90

$ 43,320.00

1

4.16

$ 180,211.20

$ 300,000.00

1

3.21

$ 963,000.00

Downstream Equipment
2-Rack Process Pod
DeF-401
(Filter Frame)
His-tag Chromatography
HC-401
Column
2000 L Single-Use Mixer
VI-401
(Non-Jacketed)
Ion Exchange
IEX-401
Chromatography Column
Diafiltration Assembly
DiF-401
(Jacketed)

Transport Equipment
Air Compressor with
Tank (for WAVE
Bioreactor 20/50EH)
Air Compressor with
Tank (for WAVE
Bioreactor 200EH)
Air Compressor with
Tank (for 500 L Perfusion
Bioreactor)
Air Compressor with
Tank (for 2000 L
Production Bioreactor)

Peristaltic Pump

AC-201

$ 1,212.50

1

2.15

$ 2,606.88

AC-101

$ 1,212.50

1

2.15

$ 2,606.88

AC-301

$ 1,212.50

1

2.15

$ 2,606.88

AC-302

$ 1,095.92

1

2.15

$ 2,356.23

PP-301
PP-302
PP-303
PP-401
PP-402
PP-403
PP-404
PP-405

$ 7,390.00

9

3.30

$ 219,483.00
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PP-406
Miscellaneous
Biological/Chemical Lab

-

$ 270,622.93

1

-

$ 270,622.93

Total

$ 4,428,376.03

The most significant investments include the diafiltration unit, 2000 L bioreactor, and
2000 L single-use mixer. This is expected, as these are the largest or most complex pieces of
equipment. Unfortunately, they are completely necessary and cannot be substituted for cheaper
solutions. Additionally, they should be able to be used for many years, as we are using single-use
bags that should preserve the equipment quality. The other bioreactors and chromatography
columns also account for a large portion of the investment costs. Finally, we are purchasing
storage tanks, drums, and vessels which accumulate to be a large portion of our capital
investment.
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18. Fixed Capital Investment Summary
The company will partner with a CMO to manufacture the vaccine for emergency use.
Based on consultation with Professor Bruce Vrana, economics were analyzed using two
spreadsheets made from the Profitability 4.0 Excel spreadsheet template: one for the CMO to
determine our rental fee, and one for our company to price the variable costs. All fixed costs
were incorporated into the CMO spreadsheet. In this costing exercise, the CMO was assumed to
have invested the necessary capital in 2015 for the plant to operate for 15 years. The CMO was
assumed to make 1 product a month, totaling 12 products each year.

18.1 Total Bare Module Cost
All of the required equipment bare module costs were input into the CMO spreadsheet to
determine the fixed costs for our process. Each piece of equipment was classified as either
storage or process machinery. Process machinery was equipment bought from a vendor in
standard sizes. There was no fabricated equipment, as none of the units required custom design.
The biochemical lab was considered to be a part of other equipment. The total bare module costs
for our process are listed in Figure 18.1 below.

Figure 18.1. Total Bare Module Costs for the CMO facility.
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The total bare module cost for fixed equipment is roughly $4.4 million. This consists
primarily of the process machinery required to run this process. Spares were not accounted for,
but this cost is wrapped into a multiplier used later in the estimation of what the CMO might
charge the company. The storage units do not make up a significant amount of our costs, as they
are not nearly as expensive as the process equipment.

18.2 Total Permanent Investment
Other fixed costs such as royalties and facilities were considered to calculate the total
permanent investment of the CMO. No default spreadsheet values for these factors were
changed. Figure 18.2.1 below breaks down how the additional fixed costs were calculated.
Guthrie’s factored-cost methods were used, thus our cost of site preparation and service facilities,
for example, were taken as percentages of our bare module costs [93].

Figure 18.2.1. Total Permanent Investment inputs from Profitability 4.0 Spreadsheet

The royalties remained zero, as we do not expect royalty costs. Additionally, the costs for
utility plants were not included since municipal utilities will be used instead. The total permanent
investment comes out to about $6.7 million for the CMO. Professor Vrana suggested using a
sight factor of 1.05 for North Carolina. Seider et al. (2017) defines an investment site factor of
1.00 for states on the Gulf Coast and 1.10 for states in the Northeast [93]. Since North Carolina
lies between these regions, 1.05 was taken to be a reasonable estimate. Figure 18.2.2 shows the
overall investment summary for this project based on CMO fixed costs.
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Figure 18.2.2. Total Permanent Investment Summary

18.3 Remaining Fixed Costs
Figure 18.3 below summarizes the remaining fixed costs used to determine the total
capital investment for the CMO. Notably, it includes operations, maintenance, overhead,
property taxes, and depreciation. No spreadsheet defaults were changed other than the
specification of 5 operators per shift assuming 5 shifts.
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Figure 18.3. Remaining Fixed Costs of the CMO.

18.4 Total Fixed Cost Summary
Figure 18.4 below summarizes the total fixed cost for the CMO to operate, which is
estimated to be about $7 million.
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Figure 18.4. Fixed Cost Summary for the CMO

18.5 Working Capital
Figure 18.5.1 shows the CMO working capital calculation parameters for accounts
receivable, cash reserves, accounts payable, vaccine inventory, and raw materials. The default
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values were not changed. Figure 18.5.2 shows the total capital investment comes out to $7.9
million for the CMO. No raw materials or variable costs are included, as these costs were
assumed to be transferred to the company partnering with the CMO.

Figure 18.5.1. Calculation Parameters for Working Capital for the CMO.

Figure 18.5.2. Total Working Capital Summary for the CMO.

After completing the analysis for the CMO, an estimation was needed for the fee that the
CMO chould charge our company to use their space for 3 months. Two months would be used
for experiments and training personnel, while the last month would be used for actual
production. The plant was assumed to be operational for 15 years, and an IRR of minimally 15%
was required for the CMO to be satisfied. To achieve this, the CMO needs to earn approximately
$1.15 million per month assuming the facility operates at 80% design capacity. This fee was
multiplied by 3 to account for the 3 month rental, then multiplied by 5 to account for current
competition in the CMO market and the profit the CMO would want to incur. This number was
taken to be a rental fee in our company spreadsheet, where the variable costs and other remaining
costs were input and explained in Section 19 and summarized in Figure 19.5.
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19. Operating Cost
19.1 Process Materials
Table 19.1 lists the cost of process materials for one operation campaign, with
components listed by its usage in each unit operation: storage materials, transport materials,
upstream materials, and downstream materials. The plant spends about $928,000 on raw
products and process materials per campaign. Each dose will take $0.0019 of process materials
to manufacture, which is significantly below the selling price of $16 per dose [94].
Table 19.1. Cost of Process Materials per Run, Grouped by Unit Operation
Materials
Unit Cost
Quantity
Unit

Purchase Cost

Storage Materials
50 L WAVE Bioreactor
Cell Culture Bags
200 L WAVE Bioreactor
Cell Culture Bags
500 L BioProcess
Containers
2000 L BioProcess
Containers
2500 L BioProcess
Containers

$ 322.16/Cellbag

2

Cellbag

$ 644.32

$ 1,288.64/Cellbag

3

Cellbag

$ 3,865.92

$ 4,453.99/BPC

4

BPC

$ 17,815.95

$ 10,233.13/BPC

2

BPC

$ 20,466.26

$ 14,058.37/BPC

1

BPC

$ 14,058.37

15

filter

$ 2,289.00

900

ft

$ 43,560.00

100

ft

$ 6,910.00

50

fitting

$ 106.25

10

fitting

$ 26.50

4

flask

$ 62.80

Transport Materials
Sterile Filter (for Liquid)
$ 152.60/filter
10 ft Peristaltic Tube
$ 48.40/ft (per 10 ft)
(B/T 87)
10 ft Peristaltic Tube
$ 69.10/ft (per 10 ft)
(B/T 91)
10x Fitting, Nylon,
$ 2.13/fitting (pack of 10)
Straight, Hose Barb
Union (0.5 in)
10x Fitting, Nylon,
$ 2.65/fitting (pack of 10)
Straight, Hose Barb
Union (0.75 in)
Upstream Materials
125 mL Erlenmeyer
Shake Flask

$ 15.70/flask
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250 mL Erlenmeyer
Shake Flask
500 mL Erlenmeyer
Shake Flask
5 L Erlenmeyer Shake
Flask
Cell Bank Inoculum
Baculovirus Stock
Sf-900 II SFM
Oxygen (+ Tank)
Glucose
Glutamine
Base (1M NaOH)
Antifoam
Purified Water / 100 L
Glucose Vessel
Purified Water / 100 L
Glutamine Vessel

$ 17.70/flask

2

flask

$ 35.40

$ 27.10/flask

4

flask

$ 108.40

$ 166.00/flask

3

flask

$ 498.00

$ 450.00/vial (50M cells)
$ 112.50/mL (per 10 mL)
$ 67.50/L (per 20 L)
$ 0.0677/L (per 7079 L)
$ 10.72/kg (per 25 kg)
$ 509.00/kg
$ 26.36/L (per 4 L)
$ 1,164.00/L (per 50 mL)

4
40
4300
106,185
75
20
4
14.1

vial
mL
L
L
kg
kg
L
L

$ 1,800.00
$ 4,500.00
$ 290,250.00
$ 7,186.80
$ 804.00
$ 10,180.00
$ 105.45
$ 16,412.40

$ 5.12/L (per 200 L)

82.4

L

$ 421.4884

$ 5.12/L (per 200 L)

484.3

L

$ 2,479.6160

Downstream Materials
D0SP Filter
X0SP Filter
Depth Filtration Wetting /
Flushing Buffer
(Purified Water)
His-tag Resin
His-tag Sodium
Phosphate
His-tag NaCl
His-tag Imidazole
His-tag MES
His-tag Purified Water
1M Acetic Acid
1M Tris Base
Sterile Membrane Filter
Ion-Exchange Resin
Ion-Exchange NaCl for
Buffers
Ion-Exchange Wash
Buffer (Purified Water)
Ion-Exchange Elution
Buffer (Acetic Acid)
Ion-Exchange Elution

$ 834.00/filter
$ 1,050.00/filter

26
13

filter
filter

$ 21,684.00
$ 13,650.00

$ 5.12/L (per 200 L)

917

L

$ 4,690.59

$ 6,660.00/L

34

L

$ 226,440.00

$ 206.44/kg

16.1

kg

$ 3,323.68

$ 40.26/kg
$ 154.00/kg
$ 472.00/kg
$ 5.12/L (per 200 L)
$ 26.75/L (per 20 L)
$ 91.00/kg (per 5 kg)
$ 970.00/filter
$ 3,600.00/L

95.6
15.9
5.4
7555
40
10
1
26.5

kg
kg
kg
L
L
L
filter
L

$ 3,848.51
$ 2,448.60
$ 2,548.80
$ 38,644.96
$ 1,070.00
$ 910.00
$ 970.00
$ 95,400.00

$ 52.20/kg

34

kg

$ 1,774.80

$ 5.12/L (per 200 L)

159

L

$ 813.31

$ 14.24/L (per 2.5 L)

7.5

L

$ 106.80

$ 10.20/L (per 10 L)

30

L

$ 306.00
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Buffer (Sodium Acetate)
Ion-Exchange Elution
Buffer (Purified Water)
Ion-Exchange Cleaning
Buffer (Purified Water)
Ion-Exchange Cleaning
Buffer (Acetic Acid)
Adsorptive Pre-Filter
(Viral Pre-filter)
Magnus 2.1 Pro Device
(Viral Filter)
Viral Filtration Wetting
Buffer (Purified Water)
Viral Filtration Flushing
Buffer (50 mM Acetate)
Diafiltration Filter
(Pellicon 3, 30kD
Ultracel, D Screen)
Diafiltration Buffer
(NaCl)
Diafiltration Buffer
(NaH2PO4 · H2O)
Diafiltration Buffer
(Na2HPO4 · 12H2O)
Diafiltration Buffer
(Purified Water)
Diafiltration Cleaning
Buffer (0.1N NaOH)

$ 5.12/L (per 200 L)

334

L

$ 1,708.46

$ 5.12/L (per 200 L)

530

L

$ 2,711.03

$ 14.24/L (per 2.5 L)

265

L

$ 3,773.60

$ 1,340.00/filter

1

filter

$ 1,340.00

$ 10,270.00/filter

1

filter

$ 10,270.00

$ 5.12/L (per 200 L)

26

L

$ 132.99

$ 210.08/L (per 250 mL)

26

L

$ 5,462.08

$ 7,160.00/cassette

3

cassette

$ 21,480.00

$ 16.48/kg (per 25 kg)

412

kg

$ 6,789.76

$ 151.14/kg (per 500 g)

0.5

kg

$ 75.57

$ 184.80/kg (per 500 g)

0.5

kg

$ 92.40

$ 5.12/L (per 200 L)

2116

L

$ 10,823.66

$ 133.80/kg (per 500 g)

0.5

kg

$ 66.90

19.2 Utilities
Data from the U.S. Energy Information Administration lists the average price of
electricity for the industrial sector in North Carolina as $0.0575 per kilowatt-hour in January
2021 [95]. For the treatment of solid waste, the cost for treating biowaste at a local incinerator
company was calculated as ten times the cost of treating municipal waste, as per consultation
with Dr. Cohen. The CMO facility is located in Durham, North Carolina, where the cost of
treating municipal waste is $47.50 per ton [96][97], which we estimated would cost $475 to treat
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one ton of biowaste. Our utilities costs are summarized below in Table 19.2. The most significant
costs include the electricity for the media vessels and wastewater treatment. In total, the utilities
cost about $6,000 per run.
Table 19.2. Cost of Utilities By Unit Operation
Utilities
Unit Cost
Amount
Utilities per Process Unit
Chilled Water /
$ 0.0178/kWh
79.44
500 L Perfusion Bioreactor
Chilled Water /
$ 0.0178/kWh
83.04
2000 L Bioreactor
Chilled Water /
$ 0.0178/kWh
23.80
Diafiltration Assembly
Electricity / WAVE™
$ 0.0575/kWh
82.80
Bioreactor System 20/50EH
Electricity / WAVE™
$ 0.0575/kWh
259.20
Bioreactor System 200EH
Electricity / 500 L Perfusion
$ 0.0575/kWh
288.00
Bioreactor
Electricity / 2000 L
$ 0.0575/kWh
288.00
Bioreactor
Electricity / 2000 L
$ 0.0575/kWh
10.00
Single-Use Mixer
Electricity / Diafiltration
$ 0.0575/kWh
30.80
Assembly
Electricity / Air Compressor
$ 0.0575/kWh
15.30
(for WAVE Brx 20/50EH)
Electricity / Air Compressor
$ 0.0575/kWh
9.18
(for WAVE Brx 200EH)
Electricity / Air Compressor
$ 0.0575/kWh
15.30
(for 500 L Perfusion Brx)
Electricity / Air Compressor
$ 0.0575/kWh
45.00
(for 2000 L Production Brx)
Electricity / Upstream
Peristaltic Pump
$ 0.0575/kWh
0.14
(BV WAVE to N Brx)
Electricity / Upstream
Peristaltic Pump
$ 0.0575/kWh
0.28
(Sf-9 WAVE to N-1 Brx)
Electricity / Upstream
Peristaltic Pump
$ 0.0575/kWh
0.28
(N-1 Brx to N Brx)
Electricity / Downstream
$ 0.0575/kWh
1.13
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Unit

Utilities Cost

kWh

$ 1.41

kWh

$ 1.48

kWh

$ 0.42

kWh

$ 4.76

kWh

$ 14.90

kWh

$ 16.56

kWh

$ 16.56

kWh

$ 0.5750

kWh

$ 1.7710

kWh

$ 0.8798

kWh

$ 0.5279

kWh

$ 0.8798

kWh

$ 2.5875

kWh

$ 0.0081

kWh

$ 0.0162

kWh

$ 0.0162

kWh

$ 0.0647

Peristaltic Pump
(for Depth Filtration)
Electricity / Downstream
Peristaltic Pump
(for His-tag Column)
Electricity / Downstream
Peristaltic Pump
(for IEX Column)
Electricity / Downstream
Peristaltic Pump
(for Viral Filtration)
Electricity / Downstream
Peristaltic Pump
(for Diafiltration in)
Electricity / Downstream
Peristaltic Pump
(for Diafiltration out)

$ 0.0575/kWh

27.00

kWh

$ 1.5525

$ 0.0575/kWh

3.94

kWh

$ 0.2264

$ 0.0575/kWh

1.69

kWh

$ 0.0970

$ 0.0575/kWh

0.28

kWh

$ 0.0162

$ 0.0575/kWh

0.28

kWh

$ 0.0162

Utilities per Storage Unit
Electricity /
200 L Media Vessel
Electricity /
2000 L Media Vessel
Electricity /
3000 L Media Vessel
Electricity /
100 L Glucose Vessel
Electricity /
500 L Glutamine Vessel
Chilled Water
Electricity
Solid Waste Treatment
Wastewater Treatment

$ 0.0575/kWh

900

kWh

$ 51.7500

$ 0.0575/kWh

1500

kWh

$ 86.2500

$ 0.0575/kWh

1500

kWh

$ 86.2500

$ 0.0575/kWh

180

kWh

$ 10.3500

$ 0.0575/kWh

360

kWh

$ 20.7000

Total Utilities
$ 0.0178/kWh

186.28

kWh

$ 3.31

$ 0.0575/kWh

5435.80

kWh

$ 317.32

lb
kg

$ 11.88
$ 5429.67

Waste Treatment
$ 0.24/lb
50
$ 0.33/kg
16453.54

19.3 Labor Costs
Our plant will require 5 operators and 1 engineering manager per shift. There will be a
total of 5 shifts per day at 8 hours each for continuous operation of 24/7, including weekends.
Operators will receive a salary of $60,000, and the manager will receive a salary of $75,000. The

136

costs for the 5 operators per shift were included in the CMO analysis in Section 18. The cost for
our own engineering manager, who will oversee plant operations and quality control to ensure
adherence to GMP standards, was included in our company spreadsheet.

19.4 Variable Costs
Other variable costs for the company include selling and transfer expenses, research,
administrative expenses, and management incentive compensation. These costs were included in
addition the monthly fee for the CMO in the company spreadsheet. Both the company and the
CMO were assumed to bear research and administrative expenses. Figure 19.4.1 shows the
parameters used.

Figure 19.4.1. Calculation Parameters for Variable Costs

Figure 19.4.2 summarizes the variable costs from our company spreadsheet to account
for raw materials, utilities and general expenses. The total variable cost is $925 million.

Figure 19.4.2. Variable Cost Summary for the Company
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19.5 Remaining Fixed Costs
The fixed costs for our company include the CMO rental fee and minor costs for
operation and overhead. Figure 19.5 summarizes the fixed costs, which total $18.8 million.

Figure 19.5. Fixed Cost Summary for the Company

138

19.6 Working Capital
Figure 19.6 shows the total working capital investment for the company. The calculation
parameters are the same as those in the CMO spreadsheet. Our total capital investment for
working capital comes out to $553 million.

Figure 19.6. Working Capital Summary for the Company
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20. Other Important Considerations
20.1 Environmental Factors
Gaseous Waste
In bioreactors, cells require oxygen to grow and produce protein, releasing carbon
dioxide in the process. Carbon dioxide, produced in excessive amounts, presents concerns with
respect to limiting cell growth, protein production, and greenhouse gas emissions. To limit this
concentration, the 500L and 2000L bioreactors will be equipped with spargers that feed nitrogen
in the form of air to strip the carbon dioxide. Since we anticipate that the cells will produce
carbon dioxide at a greater rate than it can be sparged, a base (sodium hydroxide, NaOH) will be
added as needed to neutralize the excess carbonic acid that forms from the carbon dioxide in
water. Dr. Cohen advised us that standard industrial practice is to vent bioreactor gases back into
the room after the stream passes through a filter in the bioreactor. This gas stream contains
oxygen, nitrogen, and carbon dioxide present in negligible amounts.

Liquid Waste
The upstream and downstream processes produce liquid waste streams that contain insect
cells, cell debris, and inactivated viral particles. The upstream seed train produces four parallel
streams of insect cells. One of these will be an extra stream in case of equipment malfunction or
mechanical failure in one of the other lines, and will be treated with chlorine bleach to kill the
live cells. The downstream purification processes produce large volumes of buffer and resins.
The two chromatography columns use both resins and buffers that will contain larger cell debris
and some viral particles. The diafiltration unit will produce buffers that contain small cellular
components. These streams will also be treated with chlorine bleach. Dr. Cohen confirmed that
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liquid streams treated with chlorine bleach can be disposed of as municipal waste poured down
the drain.

Solid Waste
The upstream and downstream processes produce solid waste in the form of membrane
filters that contain cell debris and inactivated viral particles. Two of the insect cell seed streams
will be used in the baculovirus seed train, and the dead cell debris will be filtered out of the
supernatant using a sterile filter. The depth filtration, virus filtration, and diafiltration units use
membrane filters to separate out large and small cell debris and viral particles. These filters are
treated as hazardous waste that will be disposed of in red biohazard bags. Consultation with Dr.
Cohen revealed that solid biowaste is sent to a local incinerator that will burn the solids to ashes.
Many unit operations in the biopharmaceutical industry have single-use technologies to
increase operation flexibility, reduce contamination risks, and eliminate the need for cleaning
validation. This saves time and money by lessening the need for certain chemical resources and
personnel. However, the tradeoff is the increased generation of plastic waste in the form of
single-use plastic bioreactor bags and plastic piping. To minimize our plastic waste generation,
we have designed the manufacturing process to produce and purify a sufficient amount of
vaccines in one campaign.
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20.2 Public and Employee Safety
Baculovirus
Our manufacturing process requires the use of a baculovirus to infect cells to produce the
desired Spike protein. Despite being a virus, the baculovirus only infects insects and poses no
harm to humans. It only contains the genetic information to make the Spike protein. There is no
live handling of SARS-CoV-2, thus employees are in no danger of getting COVID-19 from this
process. The process will also pose no biological threat to the public.

Chemical Handling
Different processes will require handling of acids, bases, and chemical powders. The viral
inactivation operation requires the direct addition of acid and base, which will be connected to
the mixer by piping. Large volumes of buffers for chromatography and diafiltration must be
made by laboratory staff using various acids, bases, and powders. Any employee that handles
these chemicals must be properly trained on the correct preparation and cleaning procedures, as
well as be informed on any necessary emergency procedures.

20.3 Regulatory Requirements
The safety and efficacy of any vaccine must be scientifically tested and proven before
being administered to the public. The data must be backed by the appropriate pre-clinical and
clinical trials and undergo the necessary vetting and authorization processes for approval. The
CMO facility must follow current good manufacturing practices (cGMPs) and meet the statutory
and regulatory requirements for quality, development, manufacturing, and control. This will
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ensure that the facility and equipment are sterile and qualified, and the potency and stability of
the vaccine is maintained [14].

20.4 Social and Ethical Considerations
Company and CMO practices should ensure safe working conditions and environments
that protect and support mental and physical health of employees, surrounding communities, and
the public. In particular, employees must be properly trained to handle and dispose of waste.
Additionally, allocation of vaccines should be done in a fair and equitable manner after
manufacturing and formulation is complete. All nations should have access to the vaccine at an
affordable price, regardless of wealth or global standing. COVAX (COVID-19 Vaccines Global
Access) is a global initiative working toward this goal in collaboration with CEPI (Coalition for
Epidemic Preparedness Innovation), GAVI (Gavi, the Vaccine Alliance, previously the Global
Alliance for Vaccines and Immunization), WHO (World Health Organization), and other
organizations with community outreach programs. Local distribution should prioritize recipients
of vaccines based on their respective priority groups. Public health departments should work to
mitigate health inequities for vulnerable populations to remove unjust, unfair, or unavoidable
barriers to health and well-being [98].

20.5 Formulation and Packaging
The drug substance in the final storage tank after the last stage of the downstream process
comprises 2.6 kg of recombinant spike protein with a buffer volume of 401.7 L. According to the
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clinical study protocol for Novavax’s SARS-CoV-2 recombinant protein vaccine, the dose level
is 5 µg of protein with 50 µg of Matrix-M1 saponin-based adjuvant (ratio of 1:10) in a 0.5 mL
solution [99]. Since the Novavax vaccine utilizes similar technology to our project, their protein
concentration was sufficient to use as an estimate. Therefore, 2.6 kg of spike protein would need
to be formulated with 26 kg of adjuvant, and the total amount of additional volume required
would be about 259,522 L, which includes components such as buffers, preservatives, stabilizers,
and antibiotics. Before sending the drug substance for formulation of drug product and
packaging in vials, the drug substance is typically frozen or lyophilized for stability.

20.6 Batch Sizes
The number and size of production bioreactors are important design choices. One large
bioreactor may have lower capital costs, but multiple smaller reactors likely have less financial
losses due to quality concerns in the production bioreactor. According to a recent article on
SARS-CoV-2 vaccine manufacturing, 15 million vaccine doses were discarded because workers
used the incorrect ingredients [100]. If multiple smaller batches were used for the vaccine
manufacturing process, less vaccine doses would have been wasted. However, because
SARS-CoV-2 is an emergency measure and time is critical, there would be a bigger life threat if
vaccines are developed more slowly. Thus, we believe that if workers are vigilant, with ready
oversight provided on the factory floor, it is reasonable to choose a single, large batch for our
production of COVID-19 vaccine to achieve timely production. Also, the 2000 L production
bioreactor in our process design is relatively small compared to larger bioreactors currently in
operation at various CMOs. Of course, if needed, our process can be divided into multiple small
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batches run over a longer period of time to alleviate any financial concerns surrounding the
investment of capital into a single large batch.

145

21. Profitability Analysis
21.1 CMO Profitability
Two profitability analyses were concurrently used to evaluate this project in consultation
with Professor Bruce Vrana. The first analysis considered fixed costs for the CMO while the
second analysis assessed the variable costs specific to this manufacturing process for our
company. The CMO facility was assumed to have been designed in 2015 and constructed in
2016, with production and sales starting in 2017. The plant was assumed to operate at 40%
capacity in 2017, 60% capacity in 2018, and 80% capacity from 2019 onwards. The COVID-19
vaccine production process is set to operate in 2021, where the CMO would be fully operational
at 80% capacity.
To account for additional business that the CMO is involved in, the plant was assumed to
manufacture 12 products per year for 15 years, with each product priced at a total of $1.15
million. The fixed costs under the CMO included equipment, labor, maintenance, and technical
assistance. The CMO was assumed to charge a multiple of 3 times more than the total bare
module cost for our equipment, in addition to a profit and in consideration of CMO competition
for another factor of 2. This multiplying factor was taken into account in the CMO rental fee cost
for our company to produce one campaign of vaccines. The CMO cash flow summary in Figure
21.1 was generated under the mentioned assumptions using a 2% general inflation rate and a
discount rate of 15% for capital.
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Figure 21.1. Cash Flow Summary for the CMO

Operation of the CMO facility is profitable, with the capital investment recovered within
the 15 year production timeline. Figure 21.2 shows that the plant has a net present value (NPV)
of $855,000, a return on investment (ROI) of 18.08%, and an investor’s rate of return (IRR) of
16.83%. Since the IRR is above 15%, this plant is considered profitable and attractive. These
numbers motivate the operation of this plant through 2031, which ensures the facility can be
operational in 2021 for the manufacture of our vaccine.

Figure 21.2. Profitability Measures for the CMO

Figure 21.3 shows a sensitivity analysis on IRR for the CMO based on the price per
project product and the variable costs. Clearly, decreasing variable costs and/or increasing
product price would result in a higher IRR. Since the CMO’s variable costs of a project are paid
by the partnering company, its own variable costs can only be reduced by selling and transferring
expenses, research, and administrative expenses. The product price of $1.15 million per project
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is an arbitrary number, the CMO can absolutely bring in more revenue by increasing the fee that
partnering companies are charged. However, dropping the product price below $1.15 million or
increasing variable costs by about $500,000 to $2 million would cause the IRR to dip below
15%, rendering the plant unattractive for investment. If the CMO consistently operates with
factors that result in an IRR of at least 15%, the CMO would be more open to negotiating with
our company on manufacture of the vaccine.

Figure 21.3. Sensitivity Analysis of IRR Using Product Price and CMO Variable Costs.

Figure 21.4 shows a sensitivity analysis on IRR for the CMO based on the price per
project product and the general inflation rate. Lower inflation rates and/or increasing product
price would result in a higher IRR. However, dropping the product price below $1.15 million or
having the inflation climb above 2.60% would cause the IRR to dip below 15%, rendering the
plant unattractive for investment and closed to partnerships with companies like ours.

Figure 21.4. Sensitivity Analysis of IRR Using Product Price and General Inflation Rate.

21.2 Company Profitability
The company cash flow summary in Figure 21.5 was generated using a selling price of
$16 per dose [94]. Inflation was considered negligible in the short timespan of one campaign,
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and a discount rate of 15% for capital was used. Since the scope of the project is limited to the
manufacture of 500 million vaccine doses, company cash flows were not considered outside of
this campaign. Therefore, the cash flow summary only has valid inputs for the first year. From
one production campaign, the project is estimated to have a net present value of $1.5 billion
dollars, with positive net earnings of $2 billion and cash flow of $1.5 billion in the same year as
production. However, the short lifespan of this project was difficult to incorporate into the
profitability analysis, which is typically done for much longer projects, such as in the case of the
proposed CMO facility.

Figure 21.5. Cash Flow Summary for the Company

None of the previous IRR, NPV, or ROI values could be calculated, as our IRR would
appear ridiculously large. Dr. Arthur Etchells observed that this was due to the fact that our
company had no investment input for bare module costs, direct permanent investment,
depreciable capital, or total permanent investment. Despite the presence of variable costs, fixed
costs, and working capital investments, the spreadsheet was unable to determine any of the
profitability values for the company. Dr. Koshari reminded the team that typically there are years
of research and development (R&D), pre-clinical, and clinical trial costs invested in prior years,
which were not accounted for in this spreadsheet. There is also a portion of profit that
formulation and packaging takes after completion of manufacture, which would decrease the
profits of the company but were not accounted for. Due to these complications, a sensitivity
analysis on the vaccine selling price could not be performed. However, a project worth $1.5
billion for the one year it is implemented is clearly very profitable.
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22. Conclusions and Recommendations
The manufacture of 500 million doses of recombinant SARS-CoV-2 spike protein-based
vaccines using BEVS is economically profitable for both the CMO and our company. We will
achieve an extremely large IRR, as our permanent investment is negligible, as this cost will be
taken up by the CMO. The IRR for the CMO plant is 16.83% assuming the CMO charges us
$1.15 million per month to use their facilities. Our company will then incur the variable costs,
working capital costs, and the rental fee for the CMO. Charging $16 per dosage of vaccine
results in $8 billion in revenue. Our net earnings for the process accumulate to be about $2
billion. Hence, the project is extremely profitable and we recommend the manufacture of this
vaccine immediately for emergency use.
Overall, the process is expected to produce 3.75 kg of spike protein in the upstream
process with a 30% yield loss in the downstream process, producing a final drug substance of 2.6
kg of spike protein. The upstream process takes 24 days to complete, the downstream process
about 3 days. Since the overall process is about 27 days, a month should be an effective estimate
of production time. While multiple production cycles are not anticipated, a total of four cycles
could be anticipated to reach completion within the course of 3 months, assuming that each cycle
starts midway through the prior cycle. The process has low energy requirements due to low flow
rates needed to safely operate and maintain both upstream and downstream processes at room
temperature and pressure. The main drivers of energy costs are the operations of the perfusion
and production bioreactors.
As a next step, we recommend completing an economic analysis under the assumption
that COVID-19 vaccines will be needed on an annual basis like the flu vaccine. Currently,
scientists are unsure if yearly vaccination will be required, if a booster will be necessary, or if
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immunity from a single vaccine will be sufficient. Optimally a vaccine would not be needed
yearly, but we recognize the likelihood of this possibility. Thus, the consideration of long-term
operation would be fruitful, either building a company facility to produce vaccines in-house, or
establishing a years-long contract with a CMO. Secondly, this project is designed for one
campaign, but we recommend supplemental analyses for smaller manufacturing batches over a
longer production period. Finally, we recommend that our company includes the R&D
investments and considers profits lost to formulation and processing, which are outside the scope
of this project but would provide a more accurate assessment of the economics of this project.
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25. Appendix
A. Supplemental Calculations
A.1 Cellular Growth Kinetics
Cell growth in exponential phase is defined as:
dx
dt

= µx

{6}

dx
x

= µ · dt

{7}

where

µ
xo
x
∆t

dx
x

= µ · ∫ dt

{8}

ln xxo = µ · ∆ t

{9}

∫

= specific cell growth rate
= initial cell population
= final cell population
= batch time

As previously mentioned in Section 11.3, the specific cell growth rate (µ) of Sf-9 cells is
0.033 hr-1, which corresponds to a doubling time of 21 hr by using Equation {9}. Setting the
batch times of each stage in the upstream process and knowing the initial cell population in the
inoculum vial from the cell bank, the final number of cells in each stage can be calculated, again
by using Equation {9}. Since the maximum VCD of Sf-9 cells is 8.1×106 cells/mL, the batch
times were set accordingly so that the final cell population in each stage does not exceed the
maximum VCD, except for the 500 L perfusion bioreactor as explained in Section 13.1 and
Section 15.15. Table 25.1 below summarizes the number of cells and batch times in each stage of
the upstream process.
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Table 25.1. Number of cells and batch times in each stage of the upstream process.
Stock
Vial

125 mL
Flask

500 mL
Flask

5L
Flask

50 L
WAVE

500 L
Brx

2000 L
Brx

Final VCD
(×106 cells/mL)

4.05

4.98

5.36

5.78

6.22

32.65

8.15

Working Volume (L)

0.001

0.05

0.5

5

50

500

2000

Initial # of Sf-9 Cells

-

4.05E6

2.49E8

2.68E9

Final # of Sf-9 Cells

4.05E6

2.49E8

2.68E9

2.89E10 3.11E11 1.63E13

Batch Time (Days)

-

5.2

3

3

2.89E10 3.11E11 1.63E13

3

5

5

A.2 Gas-Liquid Mass Transfer Coefficient
Gas-liquid mass transfer coefficient (kLa) is a measurement of the efficiency with which
the bioreactor is capable of delivering oxygen into or stripping carbon dioxide from cell culture.
The most critical variable that affects kLa is aeration rate of spargers; agitation rate of impellers
does not affect kLa much. In order to make sure whether a bioreactor can support corresponding
aeration rates, kLa values for oxygen delivery and carbon dioxide stripping must be calculated.
The oxygen uptake rate (OUR) is defined as:
OU R = sOU R · V CD
where

{10}

OUR = oxygen uptake rate
sOUR = specific oxygen uptake rate
VCD = viable cell density

As previously mentioned in Section 11.4, the specific oxygen uptake rate is 0.22 to 0.26
µM O2/106 cell/hr during the growth phase [63] and 0.2 to 0.76 µM/106 cell/hr for the infection
phase [37]. For the 500 L perfusion bioreactor that has cells in growth phase, 0.26 µM O2/106
cell/hr was used as the sOUR value. For the 2000 L production bioreactor that has cells in

165

infection phase, 0.76 µM O2/106 cell/hr was used as the sOUR value. The upper bounds for the
sOUR values were used as a conservative approach. Final VCD values of the perfusion and
production bioreactors in Table 25.1 were used for Equation {10} calculations.
The oxygen transfer rate (OTR) is defined as:
OT R = k L a O2 · (p O2,liq
where

OTR
kLaO2
pO2
HO2/H2O

p

O2,gas )

·H

O2/H2O

{11}

= O2 Transfer Rate
= O2 Gas-Liquid Mass Transfer Coefficient
= O2 Partial Pressure in Liquid or Gas
= Henry’s Law Constant of O2 in Water

As previously mentioned in Section 11.4, cells were grown in 65% O2 concentration and
infected in 50% O2 concentration, which correspond to the pO2,liquid values of the 500 L perfusion
bioreactor and 2000 L production bioreactor, respectively. For the pO2,gas value of the perfusion
bioreactor, gas sparged through the frit sparger for oxygen delivery was set to have 50% O2. For
the pO2,gas value of the production bioreactor, gas sparged through the frit sparger for oxygen
delivery was set to have 100% O2. Henry’s law constant of O2 in water (HO2/H2O) can be found
from Figure 25.1 below. The HO2/H2O values for both the perfusion bioreactor at 27.5˚C and the
production bioreactor at 26˚C are about 0.037.

Figure 25.1. Henry’s law constant of O2 in Water as a function of temperature. (Engineering Toolbox)
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By setting the OUR in Equation {10} and OTR in Equation {11} equal to each other,
oxygen delivery kLa (kLaO2) can be calculated. The required kLaO2 for the 500 L perfusion
bioreactor is 20.16 hr-1, and that for the 2000 L production bioreactor is 5.98 hr-1. From Figure
25.2 below, we can see that the corresponding aeration rate of oxygen delivery for the perfusion
bioreactor is 8 SLPM, and that for the production bioreactor is 6 SLPM.

Figure 25.2. Oxygen delivery kLa with frit sparger for the perfusion and production bioreactors. (Thermo Scientific
HyPerforma Single-Use Bioreactor Systems Validation Guide)

The carbon dioxide evolution rate (CER) is defined as:
C ER = sOU R · V CD · RQ
where

CER
sOUR
VCD
RQ

{12}

= carbon dioxide evolution rate
= specific oxygen uptake rate
= viable cell density
= respiratory quotient (mol CO2/mol O2)

The sOUR and VCD values used for Equation {12} calculations are the same as those
used for Equation {10} calculations. As described in Section 11.4, the respiratory quotient (RQ)
for uninfected Sf-9 cells is 1.07 ± 0.06, and that for virus-infected cells is 1.12 ± 0.03 [76].
Therefore, the RQ value used for the 500 L perfusion bioreactor was 1.07, and that used for the
2000 L production bioreactor was 1.12.
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The carbon dioxide transfer rate (CTR) is defined as:
C T R = k L a CO2 · (p CO2,liq
where

CTR
kLaCO2
pCO2
HCO2/H2O

p

CO2,gas )

·H

CO2/H2O

{13}

= CO2 transfer rate
= CO2 gas-liquid mass transfer coefficient
= CO2 partial pressure in liquid or gas
= Henry’s law constant of CO2 in water

As described in Section 11.2, the pCO2,liq level is set at 30 mmHg for both the perfusion
and production bioreactors. For the pCO2,gas values of both bioreactors, the air sparged through the
drilled hole sparger for carbon dioxide stripping was assumed to have 0 mmHg CO2. Henry’s law
constant of CO2 in water (HCO2/H2O) can be found from Figure 25.3 below. The HCO2/H2O values for
the perfusion bioreactor at 27.5˚C and the production bioreactor at 26˚C are both around 1.35.

Figure 25.3. Henry’s law constant of CO2 in Water as a function of temperature. (Engineering Toolbox)

By setting the CER in Equation {11} and CTR in Equation {13} equal to each other, CO2
stripping kLa (kLaCO2) can be calculated. The required kLaCO2 for the 500 L perfusion bioreactor is
7.5 hr-1, and that for the 2000 L production bioreactor is 5.73 hr-1. CO2 stripping is a composite
mass transfer process, where both the air supply from drilled hole sparger and the oxygen supply
from frit sparger strip carbon dioxide. From Figure 25.4 and Figure 25.5 below, we can see that
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the 500 L perfusion bioreactor requires an aeration rate of 25 SLPM through the drilled hole
sparger (kLaCO2 of 5 hr-1) with the aeration rate of 8 SLPM through the porous frit sparger (kLaCO2
of 2.5 hr-1) mentioned earlier in the KLaO2 analysis. Also, we can see that the 2000 L production
bioreactor needs an aeration rate of about 150 SLPM through the drilled hole sparger (kLaCO2 of
5.7 hr-1) with the aeration rate of 6 SLPM through the frit sparger (kLaCO2 of 0.5 hr-1), again
mentioned earlier in the KLaO2 analysis.

Figure 25.4. CO2 stripping kLa with DH sparger for the perfusion and production bioreactors. (Thermo Scientific
HyPerforma Single-Use Bioreactor Systems Validation Guide)

Figure 25.5. CO2 stripping kLa with frit sparger for the perfusion and production bioreactors. (Thermo Scientific
HyPerforma Single-Use Bioreactor Systems Validation Guide)
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A.3 Kolmogorov Eddy Length
Engineers hypothesize that if Kolmogorov eddy length is smaller than the cell diameter,
the cells may be sheared and die. In other words, as long as the Kolmogorov eddy length is larger
than the cell diameter, the cells would not be in danger of shearing. If the calculated Kolmogorov
eddy length turns out to be smaller than the cell diameter, the agitation rate of the impeller needs
to be slowed down to increase the eddy size.

The Kolmogorov eddy length is defined as:
η = ( vε )1/4
3

where

η
𝜈
ε

{14}

= Kolmogorov length scale
= kinematic viscosity
= agitation power / mass

Kinematic viscosity (𝜈) of media was assumed to be properties of water, since the media
solution is mostly aqueous and very dilute. The mass in ε was assumed to be the spherical mass
of the media that directly contacts the impeller.

To calculate the agitation power (P) in ε:
NP =
where

NP
P
ρ
n
D

P
3 5
ρ·n ·D

{15}

= power number
= agitation power
= fluid density
= agitation rate
= impeller diameter

According to the specifications sheets provided by Thermo Fisher Scientific, the power
number (NP), impeller diameter (D), and nominal agitation rate (n) are each given for both 500 L
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perfusion and 2000 L production bioreactors. Fluid density (ρ) of media was assumed to be the
same as water density, again because the solution is mostly aqueous and very dilute.
Table 25.3 below summarizes Kolmogorov eddy lengths of both the perfusion and
production bioreactors, calculated by using Equation {14} and Equation {15} shown above.
Since the calculated Kolmogorov eddy lengths for both bioreactors are larger than the average
diameter of Sf-9 cells, which is 18 µm [101], the nominal agitation rates are safe for usage.
Table 25.3. Kolmogorov eddy lengths of the perfusion and production bioreactors
500 L Perfusion Bioreactor

2000 L Production Bioreactor

Agitation Rate (n)

101 RPM

75 RPM

Power Number (NP)

2.1

2.1

Impeller Diameter (D)

25.1 cm

39.8 cm

Fluid Density (ρ)

1 g/mL

1 g/mL

Kinematic Viscosity (𝜈)

1 cp

1 cp

Kolmogorov Eddy
Length (η)

28 µm

28 µm

A.4 Mixing Time
After determining whether the nominal agitation rate is safe for usage by calculating the
Kolmogorov eddy lengths, mixing time to reach 95% homogeneity (θ95) must also be considered,
since cells need to be in bioreactors with good mixing for even supply of nutrients. Typically, θ95
of less than 1 minute is considered good mixing, suggested by our project author Dr. Cohen.
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To calculate θ95, Equation (9-1) in Handbook of Industrial Mixing (2004) was used [102]:
N P1/3 · n · θ 95 ·
where

NP
n
θ95
D
T
H

T

1.5

D2
· H 0.5

{16}

= 5.20

= power number
= agitation rate
= mixing time to reach 95% homogeneity
= impeller diameter
= tank inner diameter
= fluid height

Again, the power number (NP), impeller diameter (D), as well as tank inner diameter (T)
are provided by the Thermo Fisher Scientific specifications sheets for both 500 L perfusion and
2000 L production bioreactors. The same agitation rate (n) values used to check the Kolmogorov
eddy lengths previously were used. Fluid height (H) was calculated by using the working volume
and tank inner diameter for each bioreactor.
Table 25.4 below summarizes the mixing time to reach 95% homogeneity for both the
perfusion and production bioreactors, calculated by using Equation {16} above. Since θ95 for
both bioreactors are less than 1 minute, the agitation rates are sufficient to provide good mixing.
Table 25.4. Mixing time to reach 95% homogeneity for the perfusion and production bioreactors
500 L Perfusion Bioreactor
(Working Volume: 500 L)

2000 L Production Bioreactor
(Working Volume: 2000 L)

Agitation Rate (n)

101 RPM

75 RPM

Power Number (NP)

2.1

2.1

Impeller Diameter (D)

25.1 cm

39.8 cm

Tank Inner Diameter (T)

75.6 cm

119.4 cm

Fluid Height (H)

111.4 cm

178.6 cm

Mixing Time to Reach
95% Homogeneity (θ95)

27 seconds

36 seconds
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Sf-900™ II SFM
Description
Sf-900™ II SFM is a complete, serum-free, protein-free, ready-to-use insect cell culture medium developed for high cell-density growth and
high-level recombinant protein expression using the Baculovirus Expression Vector System (BEVS). Sf-900™ II SFM has optimized amino
acid, carbohydrate, vitamin, and lipid components, as well as a biologically active raw material providing significant improvement in cell
growth, virus production and recombinant protein expression over other serum-free or serum-supplemented media. Sf-900™ II SFM
supports long term growth (>20 passages) of Spodoptera frugiperda (Sf9, Sf21), Trichoplusia ni (Tn-368), and Lymantia dispar (Ld) cells in both
suspension and monolayer culture.
Product

Catalog No.

Amount

Storage

Shelf life*

Sf-900™ II SFM (1X), liquid

10902-096
10902-153
10902-088
10902-104

500 mL
10 × 500 mL
1000 mL
6 × 1000 mL

2°C to 8°C; Protect from light

12 months

Sf-900™ II SFM (1X), liquid, Universal Bag

10902-161
10902-179
10902-187

5L
10 L
20 L

2°C to 8°C; Protect from light

12 months

Sf-900™ II SFM (1X), liquid w/out methionine or cysteine

21012-026

500 mL

2°C to 8°C; Protect from light

12 months

* Shelf life duration is determined from Date of Manufacture.

Product use

Subculture suspension cultures

For Research Use Only. Not for use in diagnostic procedures.

Insect cells are sensitive to physical shearing. Ensure that
impeller mechanisms rotate freely and do not contact vessel
walls or base (adjust prior to autoclaving).
1. Determine viable cell density using a Countess® Automated
Cell Counter or alternative automated or manual method.
2. Seed cells at 3–5 × 105 viable cells/mL in sterile culture
vessels containing pre-warmed Sf-900™ II SFM. (30 mL per
125-mL shake flask, 75–100 mL per 100-mL spinner bottle).
3. Incubate at 27°C to 28°C in a non-humidified, air regulated
non-CO2 atmosphere. Loosen caps to allow for gas exchange.
4. Rotate shake flask cultures on an orbital shaker platform at
120–140 rpm, set impeller stirring rate to 85–95 rpm for
spinner bottles (optimum impeller speed must be empirically
determined for each spinner apparatus for robust cell growth
and viability).
5. Subculture cells when viable cell density reaches
>2 × 106 viable cells/mL (about twice a week) into clean,
sterile flask(s) with fresh pre-warmed Sf-900™ II SFM.

Important information
Sf-900™ II SFM is a complete, ready to use medium. Do not add
L-Glutamine or surfactants such as Pluronic® F-68.

Safety information
Read the Safety Data Sheets (SDSs) and follow the handling
instructions. Wear appropriate protective eyewear, clothing, and
gloves.

Culture Conditions
Media: Sf-900™ II SFM
Cell line: Sf9, Sf21, Ld, Tn-368 cells
Culture type: Suspension or Adherent
Culture vessels: Shake flask, spinner bottle or T-flask.
Temperature range: 27°C to 28°C
Incubator atmosphere: Non-humidified, air regulated non-CO2
atmosphere. Ensure proper gas exchange and minimize exposure
of cultures to light.

Recovery
1.
2.

3.

4.

Rapidly thaw (<1 minute) frozen cells in a 37°C water bath.
Transfer entire contents of the cryovial into the
appropriately sized vessel so that the cells are seeded at
3–5 × 105 cells/mL of pre-warmed Sf-900™ II SFM.
Incubate at 28°C in a non-humidified, air regulated non-CO2
atmosphere, on an orbital shaker platform rotating at
120–140 rpm. Loosen flask caps to allow for gas exchange.
Subculture when cells reach >2 × 106 viable cells/mL. We
recommend subculturing cells a minimum of 3 passages
before using in downstream applications.

Note: If cell debris is observed, gently centrifuge the cell
suspension at 100 × g for 5–10 minutes and resuspend the cell
pellet in fresh Sf-900™ II SFM to reduce accumulation of cell
debris and metabolic waste by-products.
Note: We recommend thawing a fresh low-passage vial of cells
every 3 months or 30 passages.

Subculture monolayer cultures
1.

2.

3.

Publication Number MAN0007285

Observe cell monolayer to ensure 80–90% confluence.
Aspirate medium and floating cells from a confluent
monolayer.
Add 4 mL (per 25 cm2) pre-warmed Sf-900™ II SFM to the
flask and resuspend cells by repeatedly pipetting the
medium across the monolayer.
Observe cell monolayer to ensure cell detachment from the
surface of the flask. Firmly rap the side of the flask on the
palm of your hand or a hard flat surface if necessary.
Rev. 1.00

4.

5.
6.
7.
8.

Transfer entire cell suspension to a sterile conical tube; any
cell clumps quickly settle to the bottom after 1–2 minutes.
Pipet the clumps into a 10-mL pipette and gently break up
the clumps by pressing the pipette tip against the bottom of
the tube and gently expell the cells back into the medium,
repeat if necessary to break up remaining clumps. Pipetting
too harshly will decrease cell viability due to sensitivity of
cells to shear force.
Determine viable cell density using a Countess® Automated
Cell Counter.
Inoculate 2–5 × 104 viable cells/cm2 into new culture flasks
containing pre-warmed Sf-900™ II SFM (5 mL/25 cm2).
Incubate at 27°C to 28°C in a non-humidified, air regulated
non-CO2 atmosphere. Loosen caps to allow for gas exchange.
Three days post-plating, aspirate medium from the cell
monolayer and re-feed the culture with an equal volume of
fresh medium gently added to the side of the flask.

Note: Sf9 cells are not anchorage dependent and may be
transferred between monolayer and spinner/shaker culture
repeatedly without noticeable change in viability, morphology,
or growth rate.

2.

3.

4.

5.
6.

7.

Determine the viable cell density and calculate the required
volume of cryopreservation medium to give a final cell
density of >1 × 107 cells/mL.
Prepare the required volume of cryopreservation medium of
92.5% Sf-900™ II SFM (50:50 ratio of fresh to conditioned
media) + 7.5% DMSO on day of intended use, store at 4°C
until use.
Centrifuge cell suspension at 100 × g for 5–10 minutes.
Resuspend the cell pellet in the pre-determined volume of
4°C cryopreservation medium.
Dispense aliquots of this cell suspension into cryovials
according to the manufacturer’s specifications.
Cryopreserve in an automated or manual controlled rate
freezing apparatus following standard procedures (1°C
decrease per minute).
Transfer frozen cells to liquid nitrogen, (vapor phase)
storage at –200°C to –125°C.

Related products
Product

Catalog no.

Sf9 Cells Adapted in Sf-900™ II SFM

12659

Adapt cells to Sf-900 II SFM

Sf21 Cells Adapted in Sf-900 II SFM

12682

It is critical that cell viability be ≥90% and the growth rate be in
mid-logarithmic phase prior to initiating adaptation procedures.

BaculoDirect N-Term Expression Kit

12562-054

BaculoDirect™ N-Term Transfection Kit

12562-062

BaculoDirect™ C-Term Expression Kit

12562-013

BaculoDirect C-Term Transfection Kit

12562-039

™

Direct adaptation
Monolayer cultures need only have the culture media exchanged
with prewarmed Sf-900™ II SFM as described in Subculture
monolayer cultures.
Transfer suspension cultures into Sf-900™ II SFM as follows:
1. Centrifuge the cell suspension at 100 × g for 5–10 minutes.
Aspirate and discard the supernatant.
2. Resuspend the cell pellet in pre-warmed Sf-900™ II SFM at a
viable cell density of >5 × 105 cells/mL and transfer to
appropriate culture vessel.
3. Return to incubator and monitor cell growth.
Note: If suboptimal performance is achieved using the direct
adaptation method, use the sequential adaptation method.

™

™

™

Bac-N-Blue Transfection Kit

K855-01

™

Bac-to-Bac® Baculovirus Expression System

10359

Bac-to-Bac® Vector Kit

10360

Countess Automated Cell Counter

C10227

®

Explanation of symbols and warnings
The symbols present on the product label are explained below:

Temperature Limitation

Manufacturer

Batch code

Use By:

Catalog number

Sequential adaptation
Follow the procedures for subculture of suspension or
monolayer cultures with the following modifications.
1. During the adaptation procedure use a seeding density of
>5 × 105 viable cells/mL.
2. Subculture cells into stepwise increasing ratios of Sf-900™ II
SFM to original medium with each subsequent passage
(25:75, 50:50, 75:25, 90:10 followed by 100% Sf-900™ II SFM).
Multiple passages at each step may be needed.
After several passages in 100% Sf-900™ II SFM, the viable cell count
should exceed 2–4 × 106 cells/mL with a viability exceeding 85%
within 4–6 days of culture.

Cryopreservation
1.

Prepare the desired quantity of cells, harvesting in mid-log
phase of growth with viability >90%. Reserve the
conditioned medium to prepare cryopreservation medium.

Caution, consult
accompanying documents

Consult instructions
for use

Keep away
from light

Sterilized using aseptic
processing techniques

Limited product warranty
Life Technologies Corporation and/or its affiliate(s) warrant
their products as set forth in the Life Technologies’ General
Terms and Conditions of Sale found on Life Technologies’
website at www.lifetechnologies.com/termsandconditions. If
you have any questions, please contact Life Technologies at
www.lifetechnologies.com/support.

Important licensing information
These products may be covered by one or more Limited Use
Label Licenses. By use of these products, you accept the terms
and conditions of all applicable Limited Use Label Licenses.

For additional technical information such as Safety Data Sheets (SDS), Certificates of Analysis, visit www.lifetechnologies.com/support
For further assistance, email techsupport@lifetech.com
All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. Pluronic is a trademark of BASF Corporation.
©2014 Thermo Fisher Scientific Inc. All rights reserved.
DISCLAIMER - LIFE TECHNOLOGIES CORPORATION AND/OR ITS AFFILIATE(S) DISCLAIM ALL WARRANTIES WITH RESPECT TO THIS DOCUMENT, EXPRESSED OR IMPLIED, INCLUDING
BUT NOT LIMITED TO THOSE OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT. TO THE EXTENT ALLOWED BY LAW, IN NO EVENT SHALL
LIFE TECHNOLOGIES AND/OR ITS AFFILIATE(S) BE LIABLE, WHETHER IN CONTRACT, TORT, WARRANTY, OR UNDER ANY STATUTE OR ON ANY OTHER BASIS FOR SPECIAL, INCIDENTAL,
INDIRECT, PUNITIVE, MULTIPLE OR CONSEQUENTIAL DAMAGES IN CONNECTION WITH OR ARISING FROM THIS DOCUMENT, INCLUDING BUT NOT LIMITED TO THE USE THEREOF.

www.lifetechnologies.com

APPLICATION NOTE

HyPerforma Rocker Bioreactor

Cultivation of Sf9 insect cells and rSEAP
expression in the HyPerforma Rocker Bioreactor
Summary
This application note describes the cultivation of Sf9
suspension cells in the Thermo Scientific™ HyPerforma™
Rocker Bioreactor with a maximum working volume
of 5.0 L. Using a serum-free medium without
components of animal origin, viable cell densities of
up to 6.2 x 10 6 cells/mL were achieved. Expression of
recombinant secreted alkaline phosphatase (rSEAP) was
induced using a baculovirus expression vector system.
rSEAP activity up to a maximum of 58.5 U/mL was
achieved. The results are in the typical range observed in
previous cultivations using wave-mixed bioreactor types.
Introduction
The HyPerforma Rocker Bioreactor (Figure 1) is a lab-scale
rocker-type bioreactor that is characterized by low shear
stresses and is often used for seed train production in
biopharmaceutical production processes.
The HyPerforma Rocker Bioreactor can be controlled using
the Thermo Scientific™ HyPerforma™ G3Lab™ Controller
in conjunction with Thermo Scientific™ TruBio™ software
powered by the Emerson™ DeltaV™ system (Figure 1).
The scope of the study was to demonstrate the
applicability of the HyPerforma Rocker Bioreactor for
cultivating a Spodoptera frugiperda (Sf9) insect cell line in
a biphasic production process using serum-free medium
and expressing a model protein, rSEAP. The production
process was based on a baculovirus expression vector
system (BEVS).

Figure 1. TruBio software with the HyPerforma G3Lab Controller and
the HyPerforma Rocker Bioreactor.

Materials and methods
Overview of procedure setup
• Day –6/–1: Inoculum production with Sf9 suspension
cells in shaker flasks.
• Day 0: Bioreactor preparation, inoculation with
seeding density of 1 x 10 6 cells/mL in 3.0 L of
Gibco™ Sf-900™ III SFM.
• Day 1: Sampling, starting of control loop for pH.
• Day 2: Sampling; addition of the virus suspension
and fresh medium to achieve a final volume of 5.0 L
and infected cell density (ICD) of 2 x 106 cells/mL at a
multiplicity of infection (MOI) of 0.01 PFU/cell.
• Day 3: Sampling, analytics, and harvesting. Production
was stopped 7 days postinfection. This corresponds to a
time of harvest (TOH) of 164 hours.

Medium
Gibco™ Sf9 cells were cultivated in Sf-900 III SFM
containing Gibco™ Pluronic™ F-68 and L-glutamine. The
expression of rSEAP was induced by a baculovirus
expression vector system (Sil9.1.1_GFP_SEAP_His MP 9.8
V2, provided by ZHAW IBT Molecular Biology) with a virus
titer of 1.5 x 109 PFU/cell.
Inoculum preparation
The inoculum for the HyPerforma Rocker Bioreactor was
produced in single-use 250 and 500 mL shaker flasks at
working volumes of 100 and 200 mL. The cells (passage
#33) were inoculated at cell densities of about
0.7–1.0 x 106 cells/mL. The flasks were placed in a shaking
incubator (Ecotron™, Infors™ HT, CH) at 27°C with a
shaking rate of 100 rpm and an amplitude of 25 mm. A cell
suspension of 1,200 mL with a cell density of approximately
3.3 x 106 cells/mL was produced for inoculation of the
HyPerforma Rocker Bioreactor.
Bioreactor preparation
A NaOH solution was produced, put in Duran™ glass
bottles, and autoclaved for 20 minutes at 121°C. The
HyPerforma Rocker BioProcess Container (BPC) was
filled with 1 L of the fresh medium using a sterile syringe
connected to the luer lock connector, and placed on
the rocking platform. After the aeration (0.25 slpm) and
heating (27°C) were switched on, one-point calibration
was performed for the pH sensor. A sample was taken
and the pH was determined using an external pH meter
(Mettler-Toledo). The pO2 sensor was calibrated to
100% saturation.
Inoculation preparation
The inoculation procedure was performed under a laminar
flow, where the Duran glass bottle with the NaOH solution
(0.1 M) was connected to the HyPerforma Rocker BPC via
a luer lock connector directly before inoculation. In order to
achieve the desired cell density of 1 x 10 6 cells/mL, 0.95 L
of the cell suspension was added to the bioreactor through
a sterile funnel, followed by 1.05 L of fresh medium, to
achieve the initial working volume of 3.0 L. Afterwards, the
bioreactor was reconnected to the control unit and all the
control loops for dissolved oxygen (DO) and temperature
were started. The settings were defined as given below.
The control loop for pH was started after 24 hours of
process time.

Process parameters
Temperature was controlled automatically via an integrated
heater in the rocking platform. DO concentration was
controlled using a cascade function with rocking rate as
the primary factor, and the addition of pure oxygen as the
secondary factor. To automatically control the pH during
the growth phase, a control loop with the addition of
0.1 M NaOH solution at a maximum pump speed of 50 rpm
(corresponding to a flow rate of 16 min/mL) was set up. The
pH control was started 24 hours after inoculation.

Culture conditions
Temperature

27°C

DO concentration

50% saturation

pH

6.2

Rocking rate

18–32 rpm

Rocking angle

6°

Air flow rate (headspace)

0.25 min/L

Maximum O2 flow rate (headspace)

0.25 min/L

Initiation of rSEAP production
The production of rSEAP was induced by infection of
the Sf9 cells with the baculovirus. Virus quantification
was performed using three different methods: plaque
assay (PA), endpoint dilution assay (EDA), and cell growth
cessation assay (CGCA), as described [1]. The effective
virus titer VTeff was then calculated from a combination of
the outcomes of these assays, as follows:

where VTPA, VTEDA, and VTCGCA are the virus titers
(in PFU/mL) from the individual virus assays. The infection
parameters, multiplicity of infection (MOI) of 0.01 PFU/cell
and infected cell density (ICD) of 2 x 106 cells/mL, were
selected based on preliminary studies performed in our
laboratory. Two days after inoculation, when the live cell
density in the HyPerforma Rocker BPC had reached
3.6 x 106 cells/mL, the control loops were switched off
and the HyPerforma Rocker BPC was disconnected from
the control unit.
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Results
During the first 48.5 hours, the cell density in the
HyPerforma Rocker BPC increased from 1 x 10 6 cells/mL
to 3.9 x 106 cells/mL with a specific growth rate of
0.029 per hour, corresponding to a doubling time of 23.9
hours (Figure 2A). After infection with the baculovirus, the
cells grew exponentially over the next 2 days and reached
a maximum viable cell density of 6.1 x 106 cells/mL. The
cell viability in the HyPerforma Rocker Bioreactor was 98.9
± 0.4% up to this point in time. The process was aborted
after 163 hours postinfection (213 hours total time), when
the cell viability dropped to zero.
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The rSEAP activity was measured indirectly via enzymatic
transformation of p-nitrophenyl phosphate into
p-nitrophenyl at 405 nm, using a magnesium chloride
buffer (magnesium chloride, homoarginine hydrochloride,
and diethanolamine adjusted to pH 9.8) and p-nitrophenyl
phosphate (disodium salt, hexahydrate) as a substrate
solution. The quality of the expressed product was
not investigated.
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Process analysis
Samples of at least 4 mL (6 mL during the production
phase) were taken at least once a day from the HyPerforma
Rocker BPC via the luer lock sampling port using sterile
10 mL syringes. Cell densities and viability were determined
using a NucleoCounter™ NC-100™ Mammalian Cell Counter
(ChemoMetec). Dilutions were performed with PBS, after
the cell density reached 6 x 106 cells/mL. A Cedex™ HiRes
cell counting device (Roche Diagnostics) was used to 6
determine cell diameter. Nutrients and metabolites were
measured using a BioProfile™ 100 Plus multi-biosensor
analysis system (Labor-Systeme Flükiger AG).

A slightly increased cell diameter of 14.9 μm and minor
rSEAP activity of about 0.1 U/mL were detected 2 days
postinfection (Figure 2B). Afterwards, the rSEAP activity
increased rapidly and reached 59 ± 4 U/mL at the end of
the process (163 hours postinfection). This is approximately
40 hours later than in previous experiments conducted
in our laboratory, despite comparable peak cell densities
[2]. The reason could have been the fact that less of the
virus was added, which caused fewer cells to be infected
by primary infection. Hence, more infection cycles were
required until all the cells in the HyPerforma Rocker BPC
had been infected. The increase in rSEAP activity was
accompanied by an increase in the average cell diameter to
a maximum of 16.3 μm after 142 hours postinfection.
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(% saturation)
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Rocking rate
Rocking
(rpm)rate (rpm)

The infection procedure was performed under a laminar
flowhood. After ensuring a live-cell density of 2 x 106 cells/
mL in a working volume of 5 L, the Rocker BPC was
placed on scales, and 66.7 mL of the virus preparation
at a dilution of 1:1,000 was added via a sterile syringe
to achieve the desired MOI of 0.01 PFU/cell. The culture
volume was topped with 2.35 L of fresh medium to achieve
a total volume of 5 L. Afterwards, the HyPerforma Rocker
BPC was placed on the rocking platform and all the
controllers were switched on. The rocking rate was set to
25 rpm for 1 hour.
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Conclusions
The HyPerforma Rocker Bioreactor was successfully
tested in a biphasic Sf9 cell–based growth and rSEAP
production process. The maximum viable cell density in
the HyPerforma Rocker BPC of 6.1 x 106 cells/mL was
measured after 48.3 hours postinfection. The maximum
rSEAP activity of 59 ± 4 U/mL in the HyPerforma Rocker
BPC was measured 163 hours postinfection (213 hours of
process time). The results for cell growth, peak cell density,
and maximum rSEAP activity are in the typical ranges
observed in previous cultivation using other wave-mixed
bioreactor types.
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Corning Incorporated
Life Sciences

Product Description

Registered
ISO 9001

Catalog Number:

431143

Product Description:

Corning® 125 mL disposable Erlenmeyer flask, vent cap

Component Materials:
Flask
Cap

Product Dimensions:
Height of flask with cap
Diameter of flask @
widest
Diameter of cap

-

Virgin Polycarbonate, meets USP, Class VI requirements for plastic containers and
closures.
Virgin Polypropylene, meets USP, Class VI requirements for plastic containers and
closures. Heavy metal free (meets CONEG req.) color concentrate.
0.2 µM microporous PTFE membrane, meets USP, Class VI requirements for plastic
containers and closures.
-

4.54 in.
2.58 in.

-

1.51 in.

Height of flask w/o cap
Tolerances

-

4.45 in.
+/- 0.05 in.

Sterilization:
The product has been irradiated and dosimetrically released based on ANSI/AAMI/ISO 11137 Sterilization of
healthcare products-Requirements for validation and routine control-Radiation sterilization.
Sterility Assurance Level: SAL 10-6
Pyrogens:
The product has been tested and has met the criteria established in the current version of ANSI/AAMI ST 72:
Bacterial Endotoxins - Test methodologies, routine testing, and alternative to batch testing. Results: less than
0.1EU/mL.
Bovine Spongiform Encephalopathy and Transmissible Spongiform Encephalopathy:
This product complies with the latest revision of EMEA/410/01 "Note for Guidance on minimizing the risk of
transmitting animal spongiform encephalopathy agents via human veterinary medicinal products" by virtue of all
bovine derived material having been processed per specific conditions of section 6.4 of EMEA/410/01.
RNase/DNase Testing:
This product has been tested and is free of any detectable RNase/DNase contamination.
Performance Testing:
Each manufacturing lot is sampled and tested in accordance with Standard Operating Procedures.
Integrity Testing:
Forward pressurization of the product to 10 inches of water column.
Visual Attributes:
Visual examination of the product.
Packaging:
Inspection for seal and barrier integrity, accurate labeling, and correct
product configuration.
Lot Number Designation:
8 Digit Lot Number: First 3 digits - Julian date, start of manufacturing; Next 2 digits - Year of manufacture; Last 3
digits - Run number for that year.
Revision Date:
-1 Rev No: 11

Corning Incorporated
Life Sciences

Product Description

Registered
ISO 9001

Catalog Number:

431144

Product Description:

Corning® 250 mL disposable Erlenmeyer flask, vent cap

Component Materials:
Flask
Cap

Product Dimensions:
Height of flask with cap
Diameter of flask @
widest point
Diameter of cap

-

Virgin Polycarbonate, meets USP, Class VI requirements for plastic containers and
closures.
Virgin Polypropylene, meets USP, Class VI requirements for plastic containers and
closures. Heavy metal free (meets CONEG req.) color concentrate.
0.2 µM microporous PTFE membrane, meets USP, Class VI requirements for plastic
containers and closures.
-

5.50 in.
3.28 in.

-

1.69 in.

Height of flask w/o cap
Tolerances

-

5.42 in.
+/- 0.05 in.

Sterilization:
The product has been irradiated and dosimetrically released based on ANSI/AAMI/ISO 11137 Sterilization of
healthcare products-Requirements for validation and routine control-Radiation sterilization.
Sterility Assurance Level: SAL 10-6
Pyrogens:
The product has been tested and has met the criteria established in the current version of ANSI/AAMI ST 72:
Bacterial Endotoxins - Test methodologies, routine testing, and alternative to batch testing. Results: less than
0.1EU/mL.
RNase/DNase Testing:
This product has been tested and is free of any detectable RNase/DNase contamination.
Bovine Spongiform Encephalopathy and Transmissible Spongiform Encephalopathy:
This product complies with the latest revision of EMEA/410/01 "Note for Guidance on minimizing the risk of
transmitting animal spongiform encephalopathy agents via human veterinary medicinal products" by virtue of all
bovine derived material having been processed per specific conditions of section 6.4 of EMEA/410/01.
Performance Testing:
Each manufacturing lot is sampled and tested in accordance with Standard Operating Procedures.
Integrity Testing:
Forward pressurization of the product to 10 inches of water column.
Visual Attributes:
Visual examination of the product.
Packaging:
Inspection for seal and barrier integrity, accurate labeling, and correct
product configuration.
Lot Number Designation:
8 Digit Lot Number: First 3 digits - Julian date, start of manufacturing; Next 2 digits - Year of manufacture; Last 3
digits - Run number for that year.
Revision Date:
- -2
Rev No: 12

Corning Incorporated
Life Sciences

Product Description

Registered
ISO 9001

Catalog Number:

431145

Product Description:

Corning® 500 mL disposable Erlenmeyer flask, vent cap

Component Materials:
Flask
Cap

Product Dimensions:
Height of flask with cap
Diameter of flask @
widest point
Diameter of cap

-

Virgin Polycarbonate, meets USP, Class VI requirements for plastic containers and
closures.
Virgin Polypropylene, meets USP, Class VI requirements for plastic containers and
closures. Heavy metal free (meets CONEG req.) color concentrate.
0.2 µM microporous PTFE membrane, meets USP, Class VI requirements for plastic
containers and closures.
-

7.05 in.
3.99 in.

-

1.91 in.

Height of flask w/o cap
Tolerances

-

6.96 in.
+/- 0.05 in.

Sterilization:
The product has been irradiated and dosimetrically released based on ANSI/AAMI/ISO 11137 Sterilization of
healthcare products-Requirements for validation and routine control-Radiation sterilization.
Sterility Assurance Level: SAL 10-6
Pyrogens:
The product has been tested and has met the criteria established in the current version of ANSI/AAMI ST 72:
Bacterial Endotoxins - Test methodologies, routine testing, and alternative to batch testing. Results: less than
0.1EU/mL.
RNase/DNase Testing:
This product has been tested and is free of any detectable RNase/DNase contamination.
Bovine Spongiform Encephalopathy and Transmissible Spongiform Encephalopathy:
This product complies with the latest revision of EMEA/410/01 "Note for Guidance on minimizing the risk of
transmitting animal spongiform encephalopathy agents via human veterinary medicinal products" by virtue of all
bovine derived material having been processed per specific conditions of section 6.4 of EMEA/410/01.
Performance Testing:
Each manufacturing lot is sampled and tested in accordance with Standard Operating Procedures.
Integrity Testing:
Forward pressurization of the product to 10 inches of water column.
Visual Attributes:
Visual examination of the product.
Packaging:
Inspection for seal and barrier integrity, accurate labeling, and correct
product configuration.
Lot Number Designation:
8 Digit Lot Number: First 3 digits - Julian date, start of manufacturing; Next 2 digits - Year of manufacture; Last 3
digits - Run number for that year.
Revision Date:
- -2
Rev No: 12

Corning Incorporated
Life Sciences

Product Description

Registered
ISO 9001

Catalog Number:

431685

Product Description:

Corning® 5 Liter disposable Erlenmeyer Flask, easy grip vent cap with liner

Component Materials:
Flask
Vent Cap

Product Dimensions:
Height of flask with cap
Height of flask w/o cap
Diameter of flask @
widest point

-

Virgin Polycarbonate, meets USP, Class VI requirements for plastic containers and
closures.
Virgin Polypropylene, meets USP, Class VI requirements for plastic containers and
closures. Heavy metal free (meets CONEG req.) color concentrate.
0.2 µM microporous PTFE membrane, meets USP, Class VI requirements for plastic
containers and closures. Thermoplastic elastomer liner, meets USP, Class VI
requirements for plastic containers and closures.
-

11.33 in.
11.24 in.
9.05 in.

Diameter of cap (OD)
Diameter of neck (OD)
Tolerances

-

4.16 in.
3.88 in.
+/- 0.05 in.

Sterilization:
The product has been irradiated and dosimetrically released based on ANSI/AAMI/ISO 11137 (TIR 33)
Sterilization of healthcare products-Requirements for validation and routine control-Radiation sterilization.
Sterility Assurance Level: SAL 10-6
Pyrogens:
The product has been tested and has met the criteria established in the current version of ANSI/AAMI ST 72:
Bacterial Endotoxins - Test methodologies, routine testing, and alternative to batch testing. Results: less than
0.1EU/mL
RNase/DNase Testing:
This product has been tested and is free of any detectable RNase/DNase contamination.
Bovine Spongiform Encephalopathy and Transmissible Spongiform Encephalopathy:
This product complies with the latest revision of EMEA/410/01 "Note for Guidance on minimizing the risk of
transmitting animal spongiform encephalopathy agents via human veterinary medicinal products" by virtue of all
bovine derived material having been processed per specific conditions of section 6.4 of EMEA/410/01.
Performance Testing:
Each manufacturing lot is sampled and tested in accordance with Standard Operating Procedures.
Integrity Testing:
Inverted leak test with an alcohol based solution.
Visual Attributes:
Visual examination of the product.
Packaging:
Inspection for seal and barrier integrity, accurate labeling, and correct
product configuration.
Lot Number Designation:
8 Digit Lot Number: First 3 digits - Julian date, start of manufacturing; Next 2 digits - Year of manufacture; Last 3
digits - Run number for that year.
Revision Date:
- -2
Rev No: 2

WAVE Bioreactor Systems
2/10 and 20/50
CELL PREPARATION

The WAVE Bioreactor™ system is a cell culture platform suitable
for applications in gene and cell therapy and regenerative
medicine. Culture medium and cells only come into contact
with a presterilized, disposable chamber known as the Cellbag™
bioreactor, which is placed on a rocking platform (Fig 1). The
rocking motion of the platform induces waves to mix and transfer
oxygen to the culture medium to create an optimal environment
for cell growth (Fig 2). As a result, a single Cellbag bioreactor
can be used to produce cell concentrations that are suitable for
clinical trials (1, 2, 3).
Key performance characteristics are:
•

Functionally closed system for single-use: no cleaning,
cross-contamination, and minimal validation. Cells only come
into contact with disposable sterile biocompatible plastics.

•

The system is suitable for cGMP production without the use of
an incubator and can be easily connected to other closed cell
processing devices by sterile welding

•

Cellbag bioreactors that include all fittings and filters are
supplied sterile and ready for use

•

Allows rapid production of up to 107 viable cells per mL of
culture

•

Multiple instrument configurations for suspension,
microcarrier, batch, fed-batch, or perfusion culture

•

Full scalability — the featured systems are capable of handling
culture volumes from 200 mL to 25 L

A new way of working
There is a considerable difference between using Cellbag
bioreactors and conventional bags. The gentle wave action limits
shear stress on the cells in comparison to traditional stirred tank
bioreactors. For volumes up to 25 L, only one Cellbag bioreactor
is needed. This makes the system easy to use and considerably

cytiva.com

Fig 1. WAVE Bioreactor Systems 2/10 (left) and 20/50 (right).

less laborious than using static cultures where multiple bags
or flasks are often needed. The perfusion culture functionality
allows for automated feeding of cultures and maximizes the
removal of waste products while keeping culture volumes to a
minimum.
The system minimizes contamination risk and makes it suitable
for cGMP production. The ability to automatically monitor
and control multiple parameters also contributes to low
contamination risks, shorter processing time and low costs.
Systems 2/10 and 20/50 can deliver key economic benefits.
Since cell cultures can reach target concentrations in one
Cellbag bioreactor, the costs of disposables can be a fraction
of those incurred when using other methods. The Cellbag
bioreactor is easy to customize and allows the user to
incorporate the WAVE Bioreactor system into their current
workflow.
Inflated plastic bag
forms a disposable
cultivation chamber
Cell
culture
media

Wave action sweeps up
cells and prevents setting

wave

wave
Rocking
Motion

Fig 2. Wave action sweeps up cells and prevents settling.

System selection
To select the correct WAVE Bioreactor system for your application,
first determine the Cellbag bioreactor size you need by estimating
the culture volume you require and then select the appropriate
instrumentation and options (see Table 1).
Table 1. Specifications for WAVE Bioreactor Systems 2/10 and 20/50

BASE 2/10EH

BASE 20/50EHT

Working volume (L)

0.2–5

0.2–25

Integral features

Speed/Angle control
Temperature control
Aeration

Speed/Angle control
Temperature control
Aeration

Options

CO2MIX
O2MIX
DOOPT20
pH
PERFUSION CTRL

WAVEPOD
CO2MIX
O2MIX
DOOPT20
pH
LOADCELL
AIR/TEMP DUAL
KIT20EHTD
KIT50EHTD

Weight

4.2 kg (9 lbs)

15.5 kg (34 lbs)

Dimensions of base

230 × 330 × 160 mm

573 × 465 × 179 mm

Dimensions with kits

KIT2EH
489 × 330 × 200 mm

KIT20EHT
711 × 575 × 254 mm
KIT50EHT
775 × 700 × 254 mm

Utilities

110/230 VAC

110/230 VAC
6/3 A 50/60 Hz

WAVE Bioreactor 2/10EH is designed for quick set-up and can
be used with working culture volumes of between 200 mL and
5 L. This compact unit is fitted with integral features such as
aeration, heating, and temperature control. The System 2/10EH
has an integral air pump with mass flow meter and is equipped
with temperature control (heater and sensor). Other options
include weight controllers for perfusion culture, dissolved oxygen
amplifiers, and pH controllers. The data acquisition software
product PCDAQ/S is available for recording temperature, rocking
speed/angle and weight.
WAVE Bioreactor System 20/50 is intended for working culture
volumes between 200 mL and 25 L. This system is very versatile
and is suitable for research and development as well as for
production use. The System 20/50 is modular, consisting of a
base unit that is electrically powered and a kit for holding the
Cellbag bioreactor. System 20/50 has the following options:
KIT20EHT for up to 10 L of culture or KIT50EHT for up to 25 L
culture volume.
Other options include weight controllers for perfusion culture,
dissolved oxygen amplifiers, and pH controllers. For added
convenience the WAVE 20/50 system can be used with the
WAVEPOD™ Controller (Fig 3) that allows simplified control of all
culture parameters including oxygen, pH, and CO2/O2 gas mixing
in a single module. The System 20/50 can also be configured
to allow independent control of two individual cultures using a
single base unit.

2

Fig 3. WAVEPOD Integrated controllers are available with left- or right-facing
probe connections for ease of use.

Bioreactor bags
Cellbag bioreactors (Fig 4) are intended for single-use and are
suitable for cGMP production of human cells for cell therapy
applications. The components are similar to those used for
biological storage bags and meet USP Class VI specifications
for plastics.
Cellbag bioreactors are manufactured from multilayer laminated
clear plastic films designed to provide high mechanical strength
and bioinert fluid contact. Typically, the fluid contact layer is a
medical grade, low density polyethylene. The second or outer
layer provides mechanical strength and a gas-impermeable
barrier. This non-contact layer is typically made of low density
polyethylene, EVA, or Nylon/EVOH copolymers.
Cellbag bioreactors are sterilized by gamma radiation at 25–40 kGy.
Individual radiation indicators are affixed to each Cellbag
bioreactor. Each lot is also tested for bacterial endotoxin levels.
Lot release requires an endotoxin level below 0.125 EU/mL.
Validation data and Cellbag Drug Master File data are available
to demonstrate biocompatibility; the user is however advised to
validate suitability for specific applications.
Cellbag bioreactors can be used from 0°C to 50°C. Each chamber
is tested for leakage by a pressure-hold test prior to sterilization
(maximum operating pressure is 1.5 psig [0.1 bar]).

Outlet
air filter

Inlet
air filter
Oxywell2

Inoculation/
harvest lines
Needleless
sampling
port

Cellbag rod

Spare
Luer port/
optional
pH probe

Fig 4. The Cellbag bioreactor can be fitted with a number of optional features.
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Description

Quantity

Code No

BASE 2/10EH

1

28-9377-86

Perfusion Controller with load cell

1

28-9884-64

CO2MIX 20

1

28-9377-95

Protective Lid, allows use of
system with light-sensitive cells

1

28-9376-33

Cellbag 200 mL to 1 L with internal
perfusion filter and Oxywell2

1

28-9376-52

Cellbag 500 mL to 5 L with internal
perfusion filter and Oxywell2

1

28-9376-62

PCDAQ/S

1

28-4116-49

WAVE Bioreactor System 20/50
Description

Quantity

Code No

BASE 20/50EHT-CO2-L, 100-120V

1

28-9436-96

BASE 20/50EHT-CO2-L, 220-240V

1

28-9436-97

KIT20EHT, 100-120V

1

28-9376-34

KIT20EHT, 220-240V

1

28-9481-58

KIT50EHT, 100-120V

1

28-9384-26

KIT50EHT, 220-240V

1

28-9481-65

Protective Lid, allows use of 20 EHT Kit
with light-sensitive cells

1

28-9376-35

Peristaltic Feed/Harvest Pump

1

28-9376-51

Cellbag 500 mL to 5 L with internal
perfusion filter and Oxywell2

1

28-9376-62

Cellbag 1 L to 10 L with internal
perfusion filter and Oxywell2

1

28-9376-64

Cellbag bioreactors
Description

Quantity

Code No

Cellbag 200 mL to 1 L, Basic

1

28-9378-00

Cellbag 500 mL to 5 L, Basic

1

28-9378-01

Cellbag 1 L to 10 L, Basic

1

28-9378-02

Cellbag 5 L to 25 L, Basic

1

28-9376-66

Cellbag 200 mL to 1 L with internal
perfusion filter and Oxywell2

1

28-9376-52

Cellbag 500 mL to 5 L with internal
perfusion filter and Oxywell2

1

28-9376-62

Cellbag 1 L to 10 L with internal
perfusion filter and Oxywell2

1

28-9376-64

Cellbag 5 L to 25 L with internal
perfusion filter and Oxywell2

1

28-9376-68

Related literature
Code No
Rapid production of clinical grade T
lymphocytes in the WAVE Bioreactor.
Case study

28-9331-49

Perfusion culture of T lymphocytes
in the WAVE Bioreactor System 2/10.
Application note

28-9650-52

Perfusion culture of human natural
killer cells in the WAVE Bioreactor
2/10 system. Application note

28-9936-25
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DATA SHEET

HyPerforma 2:1 500 L Single-Use Bioreactor

HyPerforma 2:1 500 L Single-Use Bioreactor
The next generation of performance
The Thermo Scientific™ HyPerforma™ Single-Use Bioreactor
(S.U.B.) provides enhanced functionality, ease of use,
and efficiency. The complete HyPerforma S.U.B. system
consists of a bioreactor tank and Thermo Scientific™
HyPerforma™ S.U.B. BioProcess Container (BPC), which
is available in 50, 100, 250, 500, 1,000, and 2,000 L sizes
with a 2:1 turndown ratio. The redesigned HyPerforma
S.U.B. maintains traditional stirred-tank bioreactor design
principles including specific height-to-diameter ratios and
optimized mixer location that deliver optimum cell viability,
performance, and scalability from process development
through production.
This data sheet provides information on the 500 L S.U.B.
system, which includes the tank and standard S.U.B.
BPC. The BPC utilizes dual-sparger configurations with a
porous-frit sparger and drilled-hole or open-pipe sparger
that have been rigorously tested to provide high kLa values
and optimal CO2 stripping for improved pH control and
decreased foaming.
The S.U.B. system consists of the
following components:
S.U.B. hardware unit—available in turnkey format
• Complete mixing system with water-jacketed vessel
• Drive shaft inserts into the S.U.B. BPC through the mixing
drive motor and locks into the BPC agitator assembly
S.U.B. BPC—supplied sterile and ready to use
• Agitator assembly is a single-use (polyethylene) impeller
with a bearing-and-seal assembly linked to an external
mixer drive
• Dual gas spargers available with either drilled-hole or
open-pipe sparger and standard porous-frit sparger
• Vent filter outlet for system exhaust

• Integrally sealed ports in the S.U.B. BPC allow for
addition of sensor probes and line sets
• Available in Thermo Scientific™ CX5-14 Film and
Thermo Scientific™ Aegis™ 5-14 Film options
System options—adaptable to your needs
• Optional electrical box for remote agitation control
– Water-jacketed S.U.B.s require a separate external
temperature control unit
• Exhaust gas vent filter heaters
• Load cells (standard on 1,000 and 2,000 L S.U.B.s)
• Cable management tree
• Process control system
• See Table 12 for auxiliary components for S.U.B. control
management; choose an open-architecture approach or
a turnkey, ready-to-use Thermo Scientific S.U.B. system

Standard S.U.B. hardware units
The 500 L standard S.U.B. hardware units are available in
the following configurations (Table 1).
• Water jacket with DC motor

Table 1. 500 L standard S.U.B. hardware unit with casters
(leveling feet).

Description

Cat. No.

Water jacketed, DC motor

SUB0500.9002

Water jacketed, 240 VAC, AC motor

SUB0500.9006

• Water jacket with AC motor
Additional options are listed in Tables 3–7.

Design features
1

Back view

Front/top view
2

13

12

4
3

5
6

14

7

8
15
16

9
10

11
17

Figure 1. 500 L S.U.B. hardware unit with water jacket.

1. Exhaust vent filter holder

10. Leveling casters

2. Mixing assembly with shield

11. Cart assembly

3. Bearing port receiver with clamp

12. 3/8 in. dimpled water jacket

4. Mixer motor
5. Liquid sight windows

13. Standard tool set: 3/8 in. x 150 in.-lb square torque
wrench; load cell and motor cap lockout wrench

6. Drive shaft (stored)

14. Stainless steel outer support container

7. Electrical control panel (optional)

15. Bleed valve

8. Probe hanger bracket

16. Bottom cutouts/pins for BPC attachment and alignment

9. Probe access windows

17. Quick-connect water inlet/outlet ports

Note: Load cells are standard only on 1,000 and 2,000 L S.U.B. hardware units.

Top view

32.0 in.
(81 cm)
cart width

14.8 in. (38 cm)
electrical
box width

Front view

98.9 in. (251 cm) filter height

77.3 in. (196 cm) motor height
66.9 in. (170 cm) tank height

32.1 in. (82 cm)
cart length

49.7 in. (126 cm)
overall length

50.8 in. (129 cm)
overall width

9.9 in. (25 cm) tank bottom
6.1 in. (16 cm) cart height
0 in. (0 cm)

Figure 2. 500 L S.U.B. hardware unit dimensions.
Table 2. 500 L S.U.B. system specifications.

Specifications for water-jacketed systems with AC and DC motors

Bioreactor geometry

AC motor
Rated liquid working volume

500 L

Minimum liquid working volume

250 L

Total bioreactor volume (liquid and gas)

75.6 cm (29.8 in.)

BPC chamber shoulder height

152.4 cm (60.0 in.)

Liquid height at rated working volume

113.4 cm (44.6 in.)

Fluid geometry at working volume (height:diameter ratio)

1.5:1

Overall bioreactor geometry (height:diameter ratio)

1.9:1

Impeller (quantity x blade count)
Impeller

660 L

BPC chamber diameter

Tank baffles

No
1x3

Impeller scaling (impeller diameter/tank diameter)

1/3

Impeller blade pitch (angle)

45°

Impeller diameter
Impeller calculated power number (N)
Maximum mixing rate
Nominal agitation rating (power/volume)

Agitation

DC motor

25.1 cm (9.9 in.)
2.1
30 –150 rpm
20 W/m3

Nominal agitation

50% working volume: 80 rpm
100% working volume: 101 rpm

Nominal tip speed

137.2 cm/s (270 ft/min)

Counterclockwise mixing flow direction
Agitation shaft resolved angle
Agitation shaft centerline offset
Overall drive shaft length

Down-pumping
19.6°
5.1 cm (2.0 in.)
127.0 cm (50.0 in.)

Drive shaft diameter

1.9 cm (0.75 in.)

Drive shaft poly-sheath outside diameter

3.5 cm (1.4 in.)

Impeller clearance from tank bottom

25.1 cm (9.9 in.)

Table 2. 500 L S.U.B. system specifications (continued).

Specifications for water-jacketed systems with AC and DC motors
Agitation motor drive (type, voltage, phase),
AC motor only

Motor

Agitation motor drive (type, voltage), DC motor only

AC motor

DC motor

Induction, 208 VAC, 3

–

–

Brushless, 48 VDC

Motor power rating (AC motor)

0.5 hp (372.8 W)

–

Motor power rating (DC motor)

–

0.536 hp (400 W)

9.5 N-m (82 in.-lb)

–

Motor torque rating
Gear reduction

10:1

Programmable VFD, remote panel interface, power
fault auto restart
Motor communication methods (for external
controller)

General

Support
container

Water jacket
Misc.

Temperature control

Jacket area: full/half volume

–

0–10 V, 4–20 mA, ModBus

–

2.0/0.8 m2 (21.4/8.4 ft2)

Jacket volume

15.2 L

Jacket flow rate at 50 psi (3.4 bar)

136 L/min

Process connection

1 in. sanitary tri-clamp

Nominal heating/cooling load (W)

6.7 hp (5,000 W)

Approximate liquid heat-up time (5–37°C)

2.7 hr

RTD or thermocouple, 1/8 in. (3.2 mm) OD

RTD: Pt-100 (standard)

Overall width

125.2 cm (49.3 in.) with E-Box

Overall length

124.4 cm (47.8 in.) with E-Box

Overall height

86.4 cm (34.0 in.)
116 cm (45.7 in.)
251 cm (99 in.)

Dry skid weight (mass)

354 kg (780 lb)

Wet skid weight, rated working volume (mass)

854 kg (1,882 lb)

Ceiling height required for drive shaft loading

267 cm (105 in.)

Electrical power supply requirement (voltage,
phase, current)

208–240 VAC, single, 10 A

Tested system reliability (minimum)
pH and DO probe, autoclavable type (Applisens ,
Broadley James™, Mettler Toledo™)

Operating temperature range

Dependent on controller
0.9 at 90%

™

Noise level
Recommended operating
parameters

Standard

12 mm diameter x 215–235 mm insertion length x 13.5 PG (pipe) thread
< 70 dB at 1.5 m
Ambient to 40 ± 0.1°C (104 ± 0.2°F)

Motor speed

30–150 rpm

Volume range

250–500 L

Maximum BioProcess Container pressure
Continuous operating time

0.5 psi (0.03 bar)
21 days mixing time at nominal volume only

System options
Table 3 lists available options for the 500 L S.U.B.

Table 3. 500 L S.U.B. system options.

Description

Cat. No.

• Sparger support line (Figure 3)—keeps gas lines in an
upright position for optimal gas transfer

Cable management tree

SV50992.03

Load cell with summation box, without display

SV50988.03

• Heavy-duty tubing clamps (Figure 4)—used for each
probe port not in use, eliminating process fluid holdup

Autoclave tray

SV50177.01

Bioreactor probe assembly (nonsterile for use
in autoclave) with KPC connector

SH30720.01

• Sterile sampling manifolds—available in 50 and
100 mL size for off-line sample retention

Bioreactor probe assembly (nonsterile for use
in autoclave) with AseptiQuik™ connector

SH30720.02

Sparger line support

SV50177B.14

Heavy-duty tubing clamp (each)

SV20664.01

Heavy-duty tubing clamps (10 pack)

SV20664.03

Sterile sampling manifold with Luer lock (each)

SH30845.01

Sterile sampling manifold with Luer lock
(10 pack)

SH30845.02

S.U.B. temperature/sample port

SV20750.01

• Load cells (Figure 5)—Mettler Toledo™ FlexMount™
load cells allow for reading of batch liquid weight; three
load cells are mounted with summing box on the S.U.B.
hardware unit
• Bioreactor probe assemby (Figure 6)—required for
each sterile electrochemical probe insertion
• Autoclave tray (Figure 7)—aids in holding the probe
assembly during the autoclave process

Additional information on autoclave tray:
• Fabricated from stainless steel

• S.U.B. temperature sample port (Figure 8)—provides
off-line temperature probe calibration prior to system
startup

• Contains plastic carry handle for easy transport right out
of the autoclave

• Cable management tree (Figure 9)—allows the end
user to organize the S.U.B. BPC tubing lines for operator
ease of use

• Positions probes on 15% incline for greater longevity
• Prevents probe bellows from collapsing
during sterilization
• Accommodates two probes

Figure 3. Sparger
support line.

Figure 4. Heavy-duty
tubing clamps.

Figure 5. Load cells.

Figure 6. Bioreactor probe assembly.

Figure 8. S.U.B. temperature sample port.

Figure 9. Cable management tree.

Probe
Handle

Bioreactor probe
assembly
Autoclave tray
Figure 7. Autoclave tray for probe kits.

Vent heaters
Vent heaters aid in reducing moisture buildup in exhaust
filters from system off-gassing. Vent heaters are factorypreset at 50°C to allow condensation to return to the
vessel. Recommended gassing strategies of the S.U.B.
system are in the S.U.B. Validation Guide. Table 4 lists
available vent heaters.
Table 4. Vent heater required for each exhaust filter on the
S.U.B. BPC.

Description

Voltage

Controller

Cat. No.

Meissner™ 10 in. series
46 vent filter heater

120 VAC

Preset

SV50191.33

Meissner 10 in. series
46 vent filter heater

240 VAC

Preset

SV50191.34

Meissner 10 in. series
46 vent filter heater

120 VAC

Integrated

SV50191.47

Meissner 10 in. series
46 vent filter heater

240 VAC

Integrated

SV50191.48

Pall™ Kleenpak™ KA3
series 46 vent filter
heater

120 VAC

Preset

SV50191.31

Pall Kleenpak KA3
series 46 vent filter
heater

240 VAC

Preset

SV50191.32

Pall Kleenpak KA3
series 46 vent filter
heater

120 VAC

Integrated

SV50191.45

Pall Kleenpak KA3
series 46 vent filter
heater

240 VAC

Integrated

SV50191.46

Spare parts
Table 6 lists the available spare parts of the 500 L
S.U.B. systems.
Table 6. Available spare parts list.

Description

Cat. No.

DC motor

SV50237.22

AC motor

SV50237.18

Drive shaft

SV50177.36

RTD 120 in. with Bulgin connector

SV50177.363

Probe holders

SV50177.23

Autoclave tray (stainless steel with plastic
carry handle)

SV50177.01

Adjustable filter bracket

SV50177.313

Standard 500 L dual-sparger S.U.B. BPC systems
Table 7 shows the available dual-sparger options for the
500 L S.U.B. BPC system in either configuration: open-pipe
and porous-frit spargers (Figure 10, Table 9) or drilled-hole
and porous-frit spargers (Figure 11, Table 10). Standard
S.U.B. BPC packaging is shown in Table 8.
Table 7. Standard 500 L dual-sparger S.U.B. BPCs.

Harsh mount load cell display
Required for remote weight readout from the Mettler Toledo™
summing box, various signal output options are provided
for external control monitoring (Table 5). More information
can be found in the Load Cell Data Sheet.
Table 5. Harsh mount load cell display options.

Film

Dual-sparger configuration

Cat. No.

CX5-14 film

Open-pipe and porous-frit
spargers

SH30774.04

Aegis5-14 film Open-pipe and porous-frit
spargers

SH30972.04

CX5-14 film

Drilled-hole and porous-frit
spargers

SH30985.04

Aegis5-14 film Drilled-hole and porous-frit
spargers

SH30999.04

Table 8. Standard 500 L S.U.B. BPC packaging.

Outer packaging

Supplied “flat-packed”
Two polyethylene outer layers

Label

Description
Product code
Lot number
Expiry date on outer packaging and
shipping container

Sterilization

Irradiation (25–40 kGy) inside
outer packaging

Description

Cat. No.

Mettler Toledo IND331 display, with analog
interface (STD), 120 VAC U.S. line cord/plug

SV50177.306

Mettler Toledo IND331 display, with AllenBradley RIO interface, 120 VAC U.S. line
cord/plug

SV50177.307

Mettler Toledo IND331 display, with DeviceNet
interface, 120 VAC U.S. line cord/plug

SV50177.308

Shipping
container

Durable cardboard carton

Mettler Toledo IND331 display, with Ethernet/
IP and Modbus TCP interface, 120 VAC U.S.
line cord/plug

SV50177.309

Documentation

Certificate of Analysis provided with each
lot for each delivery

Mettler Toledo IND331 display, with Profibus
interface, 120 VAC U.S. line cord/plug

SV50177.310

3–7. Probe ports (5)

Impeller

9. Bottom drain harvest
Front face

8. Thermowell/small-volume sample

1. Overlay gas sparger

11, 12. Feed line

Back face

15. Porous-frit micro sparger

14. Open-pipe macro sparger
13. Exhaust line
2. Inoculum addition

10. Base addition

Figure 10. Standard 500 L dual-sparger S.U.B. BPC with open-pipe and porous-frit spargers.
Table 9. Specifications for the standard 500 L dual-sparger S.U.B. BPC with open-pipe and porous-frit spargers.
Line

Description

Tubing set (inner diameter x outer diameter x length)

End treatment

1

Overlay gas sparger

1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex™ tubing x 6 in. (15 cm)

Hydrophobic vent filter with
Emflon™ II membrane

2

Inoculum addition

1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 84 in. (213 cm) reduced
to 1/8 in. (3.2 mm) x 1/4 in. (6.4 mm) C-Flex tubing x 12 in. (30 cm)

SterilEnz™ pouch with injection site
assembly, 3/8 in. MPC body

3–7

Probe ports (5)

1/2 in. (12.7 mm) tube ports

Pall™ Kleenpak™ aseptic connectors—
KPCHT series (female)

8

Thermowell/smallvolume sample

Thermowell adapter for 1/4 in. (6.4 mm) diameter
1/8 in. (3.2 mm) x 1/4 in. (6.4 mm) C-Flex tubing x 24 in. (60 cm)

SterilEnz pouch with injection site
assembly

9

Bottom drain harvest

1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 60 in. (152 cm) reduced
to 3/8 in. (9.5 mm) x 5/8 in. (15.9 mm) C-Flex tubing x 12 in. (30 cm) splits to
1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 12 in. (30 cm) reduced
to 1/8 in. (3.2 mm) x 1/4 in. (6.4 mm) C-Flex tubing x 12 in. (30 cm) and
3/8 in. (9.5 mm) x 5/8 in. (15.9 mm) C-Flex tubing x 12 in. (30 cm)

Plugged
3/8 in. MPC insert

10

Base addition

1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 6 in. (15 cm) reduced to
1/8 in. (3.2 mm) x 1/4 in. (6.4 mm) C-Flex tubing x 84 in. (213 cm)

Plugged

11, 12

Feed lines

3/8 in. (9.5 mm) x 5/8 in. (15.9 mm) C-Flex tubing x 84 in. (213 cm) splits to
1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 12 in. (30 cm) reduced
to 1/8 in. (3.2 mm) x 1/4 in. (6.4 mm) C-Flex tubing x 12 in. (30 cm) and
3/8 in. (9.5 mm) x 5/8 in. (15.9 mm) C-Flex tubing x 12 in. (30 cm)

SterilEnz pouch with injection site
assembly, 3/8 in. MPC body

13

Exhaust line

1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 4 in. (10 cm) splits to
1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 10 in. (25 cm) and
1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 10 in. (25 cm)

(2x) Pall Kleenpak 0.2 µm exhaust
vent filter

14

Open-pipe macro
sparger

1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 3 in. (8 cm) reduced to
check valve and 1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 72 in.
(183 cm)

Hydrophobic vent filter with
Emflon II membrane

15

Porous-frit micro
sparger,
12 mm diameter
(25 µm pores)

1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 6 in. (15 cm) reduced to
check valve and 1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 72 in.
(183 cm)

Hydrophobic vent filter with
Emflon II membrane

Impeller

3–7. Probe ports (5)

9. Bottom drain harvest

Front face

8. Thermowell/small-volume sample
1. Overlay gas sparger

11, 12. Feed line
15. Porous-frit micro sparger

Back face

13. Exhaust line

14. Drilled-hole macro sparger

2. Inoculum addition

10. Base addition

Figure 11. Standard 500 L dual-sparger S.U.B. BPC with drilled-hole and porous-frit spargers.
Table 10. Specifications for the standard 500 L dual-sparger S.U.B. BPC with drilled-hole and porous-frit spargers.
Line

Description

Tubing set (inner diameter x outer diameter x length)

End treatment

1

Overlay gas sparger

1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 6 in. (15 cm)

Meissner Steridyne™ 0.2 µm
hydrophobic filter connected to
12 in. (30 cm) C-Flex tubing

2

Inoculum addition

1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 84 in. (213 cm)
reduced to 1/8 in. (3.2 mm) x 1/4 in. (6.4 mm) C-Flex tubing x 12 in.
(30 cm)

Plugged

3–7

Probe ports (5)

1/2 in. (12.7 mm) tube ports

Pall Kleenpak aseptic
connectors—KPCHT series (female)

8

Thermowell/
small-volume sample

Thermowell adapter for 1/4 in. (6.4 mm) diameter
1/8 in. (3.2 mm) x 1/4 in. (6.4 mm) C-Flex tubing x 24 in. (60 cm)

SterilEnz pouch with injection
site assembly

9

Bottom drain
harvest

1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 60 in. (152 cm)
reduced to 3/8 in. (9.5 mm) x 5/8 in. (15.9 mm) C-Flex tubing x 12 in.
(30 cm) splits to 1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x
12 in. (30 cm) reduced to 1/8 in. (3.2 mm) x 1/4 in. (6.4 mm) C-Flex
tubing x 12 in. (30 cm) and 3/8 in. (9.5 mm) x 5/8 in. (15.9 mm) C-Flex
tubing x 12 in. (30 cm)

Plugged
3/8 in. MPC insert

10

Base addition

1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 6 in. (15 cm)
reduced to 1/8 in. (3.2 mm) x 1/4 in. (6.4 mm) C-Flex tubing x 84 in.
(213 cm)

Plugged

Feed lines

3/8 in. (9.5 mm) x 5/8 in. (15.9 mm) C-Flex tubing x 84 in. (213 cm)
splits to 1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 12 in.
(30 cm) reduced to 1/8 in. (3.2 mm) x 1/4 in. (6.4 mm) C-Flex tubing x
12 in. (30 cm) and 3/8 in. (9.5 mm) x 5/8 in. (15.9 mm) C-Flex tubing x
12 in. (30 cm)

SterilEnz pouch with injection site
assembly, 3/8 in. MPC body

13

Exhaust line

1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 12 in. (30 cm) splits
to 1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 6 in. (15 cm) and
1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 6 in. (15 cm)

(2x) Meissner™ UltraCap™ 0.2 µm
hydrophobic filters connected to
6 in. (15 cm) C-Flex tubing

14

Drilled-hole macro
sparger
6.75 in. (17.1 cm) disk
with 1,180 holes with
a 0.018 in. (0.445 mm)
diameter

3/8 in. (9.5 mm) x 5/8 in. (15.9 mm) C-Flex tubing x 3 in. (8 cm)
connected to check valve and 3/8 in. (9.5 mm) x 5/8 in. (15.9 mm)
C-Flex tubing x 75 in. (190 cm)

Meissner Steridyne 0.2 µm
hydrophobic filter connected to
6 in. (15 cm) C-Flex tubing

15

Porous-frit micro sparger
12 mm diameter
(25 µm pores)

1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 6 in. (15 cm)
reduced to check valve and 1/4 in. (6.4 mm) x 7/16 in. (11.1 mm)
C-Flex tubing x 78 in. (198 cm)

Meissner Steridyne 0.2 µm
hydrophobic filter connected to
6 in. (15 cm) C-Flex tubing

11, 12

Custom S.U.B. BPC options
Table 11 lists available custom 500 L S.U.B. BPC system
options. Not all options are available for all ports. For
additional information, please see the selection guides in
the single-use products catalog.
Table 11. Custom 500 L S.U.B. BPC options.

Category

Options/capability

Notes

Tubing type

Thermoplastic elastomers: C-Flex, PharMed ,
PharmaPure™ tubing
Platinum-cured silicone
PVC

More information is available in the Tubing
Selection Guide

Tubing size

Ranging from 1/8 to 1 in. (0.318 to 2.54 cm) ID, in
customer-specified lengths

More information is available in the Tubing
Selection Guide

Connectors

Luers, quick-connects, SIP connectors, tri-clamp, aseptic
connectors, sterile connectors, steam-to, steam-through,
sample ports, plugs

More information is available in the
Connector Selection Guide. Note:
Reusable probe port connections use
Kleenpak™ connector only

Probe ports

Additional ports: second row of five

The reusable probe port connection uses
a Kleenpak connector only

Disposable sensors

Pressure sensor: PendoTECH and Finesse Solutions
DO and pH: Finesse Solutions and PreSens
pH: Mettler Toledo

Choice of qualified sensors available

Additional probe ports

Limited engineer-to-order customization only

Qualified location on second row of probe
ports only

Port sizes

Limited engineer-to-order customization only

Dependent on location in BPC and fit with
hardware (e.g., 1 in. (2.54 cm) port on
harvest line)

Rearrangement of lines
on existing ports

Limited customization possible (e.g., moving sample/
thermowell port to a probe tube port, or swapping overlay
inlet line with supplement line)

Dependent on location in BPC and fit with
hardware

Sparger

Dual sparger (macro open-pipe or drilled-hole and
micro porous-frit) standard

Sparger locations are fixed

Diptube lines

Limited customization possible

Length cannot interfere with impeller
and shaft

Overlay and sparger line
filters

Filter options available from standard component library

Choice of qualified filters available

Vent filters

Standard is Pall or Meissner 0.2 µm exhaust vent filter

Filters must be compatible with available
vent filter heater configurations

Vent filter tubing length

Extended filter height above the S.U.B. BPC is
made to order

Must be compatible with a vent filter
bracket option

Filters on media and
supplement inlets

Limited engineer-to-order customization only; choice of
filters used to sterilize incoming media or supplements
are available

Choice of qualified filters available

™

Table 12. Recommended S.U.B. parts list for first-time operators.

Description

Quantity

Cat. No./auxiliary part

S.U.B. hardware unit

1

Type to be configured

S.U.B. BPC

3

Type to be configured

Bioreactor probe assembly (nonsterile for use in autoclave)

12

SH30720.01

Heavy-duty tubing clamp

12

SV20664.01

1

SV50177.01

Autoclave tray for autoclaving probe assemblies

Auxiliary parts supporting the single-use bioreactor
(supplied by end user or requested turnkey)
Necessary for gas flow control, DO, and pH set points

1

Bioreactor control system

Autoclavable probe (13 mm x 13.5 PG thread with 195–235 mm insertion length)

*

DO probe

Autoclavable probe (13 mm x 13.5 PG thread with 195–235 mm insertion length)

*

pH probe

Tubing welder, steam-in-place system, sterilizer, or laminar flow hood

*

Sterile/aseptic connection

Used for fluid transfer between linesets on the containers

*

Stand-alone peristaltic pump

Necessary for water jacket temperature controls (not provided)

*

Temperature control unit (TCU)

* Quantity based on needs.

External controller options
The HyPerforma S.U.B. offers an open-architecture or
turnkey system. An open-architecture system allows you
to use any control system of your choice. The capital
investment can be reduced by using a control system
already utilized in your facility. A turnkey system is a readyto-use, out-of-the-box system with a choice of dedicated
controls from Finesse Solutions or Applikon. These
systems work on PC, DeltaV, Allen-Bradley, or Siemens
formats. Contact your local sales representative for
more information.

Find out more at thermofisher.com/sub
For Research Use or Further Manufacturing. Not for diagnostic use or direct administration into humans or animals.
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DATA SHEET

HyPerforma 2:1 2,000 L Single-Use Bioreactor

HyPerforma 2:1 2,000 L Single-Use Bioreactor
The next generation of performance
The Thermo Scientific™ HyPerforma™ Single-Use Bioreactor
(S.U.B.) provides enhanced functionality, ease of use,
and efficiency. The complete HyPerforma S.U.B. system
consists of a bioreactor tank and Thermo Scientific™
HyPerforma™ S.U.B. BioProcess Container (BPC), which
is available in 50, 100, 250, 500, 1,000, and 2,000 L sizes
with a 2:1 turndown ratio. The redesigned HyPerforma
S.U.B. maintains traditional stirred-tank bioreactor design
principles including specific height-to-diameter ratios and
optimized mixer location that deliver optimum cell viability,
performance, and scalability from process development
through production.
This data sheet provides information on the 2,000 L S.U.B.
system, which includes the tank and standard S.U.B.
BPC. The BPC utilizes dual-sparger configurations with a
porous-frit sparger and drilled-hole or open-pipe sparger
that have been rigorously tested to provide high kLa values
and optimal CO2 stripping for improved pH control and
decreased foaming.

• Integrally sealed ports in the S.U.B. BPC allow for
addition of sensor probes and line sets
• Available in Thermo Scientific™ CX5-14 Film and
Thermo Scientific™ Aegis™ 5-14 Film options
System options—adaptable to your needs
• Optional electrical box for remote agitation control
• Optional condenser system

The S.U.B. system consists of the following
components:
S.U.B. hardware unit—available in turnkey format
• Complete mixing system with a water-jacketed vessel

• Exhaust gas vent filter heaters

• Drive shaft inserts into the S.U.B. BPC through the mixing
drive motor and locks into the BPC agitator assembly

• Process control system

• Load cells
S.U.B. BPC—supplied sterile and ready to use
• Agitator assembly is a single-use (polyethylene) impeller
with a bearing-and-seal assembly linked to an external
mixer drive
• Dual gas spargers available with either drilled-hole or
open-pipe sparger and standard porous-frit sparger
• Vent filter outlet for system exhaust

• Load cell displays
• Cable management tree

• Mobile stairs
• See Table 12 for auxiliary components for S.U.B. control
management; choose an open-architecture approach or
a turnkey, ready-to-use Thermo Scientific™ S.U.B. system

Standard S.U.B. hardware units
2,000 L standard S.U.B. hardware units are available with
a water jacket only with either a DC or AC motor. The
Mettler Toledo™ FlexMount™ load cells allow for batch
liquid-weight reading. Three load cells are mounted
with summation box on the S.U.B. hardware unit. These
hardware units do not include other options listed in
Tables 3–7. Base part numbers listed in Table 1 will change
depending upon which options are chosen.

Table 1. 2,000 L standard S.U.B. hardware.

Description

Cat. No.

Water jacketed, DC motor

SUB2000.9002

Water jacketed, 240 VAC, AC motor

SUB2000.9008

Design features

2

5
Front/top view

1

Back view

4

3

3

2
1
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13

7
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8
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9

12
15
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14
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Figure 1. 2,000 L S.U.B. hardware unit with water jacket.

1. Mixer motor

10. Load cells (3)

2. Mixing assembly with shield

11. Probe access window

3. Auxiliary E-stop assembly

12. Probe clips

4. Stainless steel outer support container

13. Water jacket

5. Bag lift assembly

14. Bottom cutouts for BPC alignment

6. Standard tool set

15. Sparge access plate

7. Load cell display

16. Jacket quick-connect couplings

8. Control panel

17. Pneumatic bag lift control

9. Load cell summation box
Note: Load cells are standard on 2,000 L S.U.B. hardware units.

50.5 in.
(128 cm)
tank OD

Design features
Top view

25.2 in.
(64 cm)
small door
sensor probe
mount

58.9 in.
(150 cm)

63.7 in.
(162 cm)

Front view

1/2 hp
15:1 ratio
gear motor

135 in.
(343 cm)
11 ft 3 in. minimum
ceiling height

126.4 in.
(321 cm)
bag lift
height

102.4 in.
(260 cm)
tank
height

240 VAC
ETL/CE
compliant

Figure 2. 2,000 L S.U.B. hardware unit dimensions.

Table 2. 2,000 L S.U.B. system specifications.

Specifications for water-jacketed systems with AC and DC motors

Bioreactor geometry

AC motor

DC motor

Rated liquid working volume

2,000 L

Minimum liquid working volume

1,000 L

Total bioreactor volume (liquid and gas)

2,575 L

BPC chamber diameter

119.4 cm (47 in.)

BPC chamber shoulder height

229.9 cm (90.5 in.)

Liquid height at rated working volume

178.7 cm (70.4 in.)

Fluid geometry at working volume (height:diameter ratio)

1.5:1

Overall bioreactor geometry (height:diameter ratio)

1.9:1

Tank baffles

No

Impeller

Impeller (quantity x blade count)

1x3

Impeller scaling (impeller diameter/tank diameter)

1/3

Impeller blade pitch (angle)

45°

Impeller diameter

39.8 cm (15.7 in.)

Impeller calculated power number (N)
Maximum mixing rate

2.1
Standard: 20–75 rpm
Custom: up to 95 rpm above 90% working volume only

Agitation

Nominal agitation rating (power/volume)

20 W/m3

Nominal agitation

50% working volume: 60 rpm
100% working volume: 75 rpm

Nominal tip speed

154.9 cm/s (305 ft/min)

Counterclockwise mixing flow direction

Down-pumping

Agitation shaft resolved angle

19.6°

Agitation shaft centerline offset

6.7 cm (2.6 in.)

Overall drive shaft length (two-piece and four-piece)

210.6 cm (82.9 in.)

Drive shaft diameter

1.9 cm (0.8 in.)

Drive shaft poly-sheath outside diameter

3.5 cm (1.4 in.)

Impeller clearance from tank bottom
Agitation motor drive (type, voltage, phase) AC
motor only

Motor

Agitation motor drive (type, voltage) DC motor only

39.8 cm (15.7 in.)
Induction, 208 VAC, 3

–

–

Brushless, 48 VDC

Motor power rating (AC motor)

0.5 hp (372.8 W)

–

Motor power rating (DC motor)

–

0.536 hp (400 W)

27.7 N-m (245 in.-lb)

–

Motor torque rating
Gear reduction

15:1

20:1

Programmable VFD, remote panel interface, power fault
auto restart

Standard

–

Motor communication methods (for external controller)

0–10 V, 4–20 mA, ModBus

–

Table 2. 2,000 L S.U.B. system specifications (continued).

Specifications for water-jacketed systems with AC and DC motors
AC motor

Support container
General

Water jacket

Jacket volume
Jacket flow rate at 50 psi (3.4 bar)
Process connection
Nominal heating/cooling load (W)

RTD or thermocouple, 1/8 in.
(3.18 mm) OD

Overall width

44 L
75 L/min
1 in. male national pipe thread (NPT) nipple provided with
Hansen™ quick-connect check valves
18,000 W
4 hr
RTD: Pt-100 (standard)
179.7 cm (70.5 in.) with E-box

148.5 cm (58.5 in.)

Overall length

171.4 cm (67.5 in.)

Overall height

321 cm (126.4 in.)

Dry skid weight (mass)

962.1 kg (2,121 lb)

Wet skid weight, rated working volume (mass)

2,962.1 kg (6,530 lb)

Ceiling height required for 2-piece driveshaft loading

381 cm (150 in.)

Ceiling height required for 4-piece driveshaft loading

353.06 cm (139 in.)

Electrical power supply requirement (voltage, phase,
current)
Tested system reliability (minimum)
pH and DO probe, autoclavable type (Applisens™,
Broadley James™, Mettler Toledo™)
Noise level
Minimum acceleration and deceleration rate

Recommended
operating parameters

67.1/53.9 ft2

Approximate liquid heat-up time (5–37°C)
Misc.

Temperature control

Jacket area: full/half-volume

DC motor

Operating temperature range

208–240 VAC, single, 10 A

Dependent on controller

0.9 at 90%
12 mm diameter x 215–235 mm insertion length x 13.5 PG thread
< 70 dB at 1.5 m
60 seconds
Ambient to 40 ± 0.1°C (104 ± 0.2°F)

Motor speed

Standard: 20–75 rpm
Custom: up to 95 rpm above 90% working volume only

Volume range

1,000–2,000 L

Maximum BioProcess Container pressure
Continuous operating time

0.5 psi (0.03 bar)
21 days mixing time at nominal volume only

System options
Table 3 lists available S.U.B. system options for the
2,000 L size.
• Autoclave tray (Figure 3)—aids in holding the probe
assembly during the autoclave process
• Sparger support line (Figure 4)—keeps gas lines in an
upright position for optimal gas transfer
• Heavy-duty tubing clamps (Figure 5)—used for each
probe port not in use, eliminating process fluid holdup
• Sterile sampling manifolds—available in 50 and
100 mL sizes for off-line sample retention
• Mobile stairs (Figure 6)—facilitates access to the
bioreactor for top-mount drive shaft loading; the 2,000 L
S.U.B. requires a platform for top-mount drive shaft
loading (customer may provide their own solution)
• Bioreactor probe assemblies (Figure 7)—required for
each sterile electrochemical probe insertion
• S.U.B. temperature sample port (Figure 8)—
provides off-line temperature probe calibration prior to
system startup
• Condenser system (Figure 9)

Table 3. 2,000 L S.U.B. system options.

Description

Cat. No.

Complete condenser system (120 V) including cart,
chill plate and mounting post with filter brackets,
TCU, and pump

SV50232.01

Complete condenser system (240 V) including cart,
chill plate and mounting post with filter brackets,
TCU, and pump

SV50232.02

Autoclave tray

SV50177.01

Bioreactor probe assembly (nonsterile for use in
autoclave) with KPC connector

SH30720.01

Bioreactor probe assembly (nonsterile for use in
autoclave) with AseptiQuik™ connector

SH30720.02

Sparger line support

SV50177.65

Heavy-duty tubing clamp (each)

SV20664.01

Heavy-duty tubing clamps (10 pack)

SV20664.03

Sterile sampling manifold with Luer lock (each)

SH30845.01

Sterile sampling manifold with Luer lock (10 each)

SH30845.02

S.U.B. temperature/sample port

SV20750.01

Mobile stairs

SV50935.01

Additional information on autoclave tray:

• Fabricated from stainless steel
• Contains plastic carry handle for easy transport right out
of the autoclave
• Positions probes on 15% incline for greater longevity
• Prevents probe bellows from collapsing during
sterilization

Probe

• Accommodates two probes
Handle

Bioreactor probe
assembly
Autoclave tray

Figure 3. Autoclave tray for probe kits.
Figure 4. Sparger support line.

Figure 6. Mobile stairs.

Figure 7. Bioreactor probe assembly.

Figure 5. Heavy-duty tubing clamps.

Figure 8. S.U.B. temperature sample port.

Figure 9. Condenser system.

Vent heaters
Vent heaters aid in reducing moisture buildup in exhaust
filters from system off-gassing. Vent heaters are factorypreset at 50°C to allow condensation to return to the
vessel. Recommended gassing strategies of the S.U.B.
system are in the S.U.B. Validation Guide. Table 4 lists
available vent heaters.
Note: Vent heater is not required if condenser system
is purchased.
Table 4. Vent heater required for each exhaust filter on the
S.U.B. BPC.

Description

Voltage

Controller

Cat. No.

Meissner™ 10 in. series
46 vent filter heater

120 VAC

Preset

SV50191.33

Meissner 10 in. series 46
vent filter heater

240 VAC

Preset

SV50191.34

Meissner 10 in. series 46
vent filter heater

120 VAC

Integrated

SV50191.47

Meissner 10 in. series 46
vent filter heater

240 VAC

Integrated

SV50191.48

Pall™ Kleenpak™ KA3
series 46 vent filter heater

120 VAC

Preset

SV50191.31

Pall Kleenpak KA3 series
46 vent filter heater

240 VAC

Preset

SV50191.32

Pall Kleenpak KA3 series
46 vent filter heater

120 VAC

Integrated

SV50191.45

Pall Kleenpak KA3 series
46 vent filter heater

240 VAC

Integrated

SV50191.46

Harsh mount load cell display
Required for remote weight readout from the
Mettler Toledo™ summing box, various signal output
options are provided for external control monitoring
(Table 5). More information can be found in the Load Cell
Data Sheet.
Table 5. Harsh mount load cell display options.

Table 6. Available spare parts list.

Description

Cat. No.

DC motor

SV50237.22

AC motor

SV50237.19

Drive shaft

SV50177.155

RTD 120 in. with Bulgin connector

SV50177.363

Probe holders

SV50177.23

Autoclave tray (stainless steel with plastic
carry handle)

SV50177.01

Standard 2,000 L dual-sparger S.U.B. BPC systems
Table 7 shows the available dual-sparger options for
the 2,000 L S.U.B. BPC system in either configuration:
open-pipe and porous-frit spargers (Figure 10, Table 9) or
drilled-hole and porous-frit spargers (Figure 11, Table 10).
Standard S.U.B. BPC packaging is shown in Table 8.
Table 7. Standard 2,000 L dual-sparger S.U.B. BPCs.

Film

Dual-sparger
configuration

Condenser

Cat. No.

CX5-14 film

Open-pipe and
porous-frit spargers

No

SH30774.07

CX5-14 film

Open-pipe and
porous-frit spargers

Yes

SH30774.08

CX5-14 film

Drilled-hole and
porous-frit spargers

Yes

SH30985.07

CX5-14 film

Drilled-hole and
porous-frit spargers

No

SH30985.08

Aegis5-14 film Open-pipe and
porous-frit spargers

No

SH30972.07

Aegis5-14 film Open-pipe and
porous-frit spargers

Yes

SH30972.08

Aegis5-14 film Drilled-hole and
porous-frit spargers

Yes

SH30999.07

Aegis5-14 film Drilled-hole and
porous-frit spargers

No

SH30999.08

Table 8. Standard 2,000 L S.U.B. BPC packaging.

Description

Cat. No.

Mettler Toledo IND331 display, with analog interface
(STD), 120 VAC U.S. line cord/plug

SV50177.306

Mettler Toledo IND331 display, with Allen-Bradley
RIO interface, 120 VAC U.S. line cord/plug

SV50177.307

Mettler Toledo IND331 display, with DeviceNet
interface, 120 VAC U.S. line cord/plug

SV50177.308

Mettler Toledo IND331 display, with Ethernet/IP and
Modbus TCP interface, 120 VAC U.S. line cord/plug

SV50177.309

Mettler Toledo IND331 display, with Profibus
interface, 120 VAC U.S. line cord/plug

Spare parts
Table 6 lists the available spare parts of the 2,000 L
S.U.B. systems.

SV50177.310

Outer packaging

Supplied "flat-packed"
Two polyethylene outer layers

Label

Description
Product code
Lot number
Expiry date on outer packaging and
shipping container

Sterilization

Irradiation (25–40 kGy) inside outer packaging

Shipping container

Durable cardboard carton

Documentation

Certificate of Analysis provided with each lot
for each delivery

2. Inoculum addition/feed line

Front face

9. Media fill

15. Media fill/auxiliary drain
Impeller

9. Bottom drain harvest
11. Feed line

8. Thermowell/
small-volume sample

10. Base addition
3–7. Probe ports (5)
15. Media fill/auxiliary drain
1. Overlay gas sparger
12. Exhaust line

8. Feed line

16. Condensate return line
17. Condenser bag
assemby (optional)

Back face

14. Porous-frit
micro spargers (3)

18. Tri-clamp port (3 in.)

13. Open-pipe
macro sparger

Figure 10. Standard 2,000 L dual-sparger S.U.B. BPC with open-pipe and porous-frit spargers. Available with or without the condenser assembly.
Table 9. Specifications for the standard 2,000 L dual-sparger S.U.B. BPC with open-pipe and porous-frit spargers.
Line

Description

1

Overlay gas sparger

2

Inoculum addition/
feed line

3–7

Probe ports (5)

8

Thermowell/
small-volume sample

9

Bottom drain harvest

10

Base addition

11

Feed line

1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 4 in. (10 cm) splits to
1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 10 in. (25 cm) and
1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 10 in. (25 cm)

SterilEnz pouch with injection site
assembly and 3/8 in. MPC body

12

Exhaust line

Condenser bag assembly (optional)

–

13

Open-pipe macro
sparger

1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 72 in. (183 cm) reduced
to check valve and 1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 72 in. Kleenpak Emflon II capsule
(183 cm)

14

Porous-frit micro
spargers (3), 12 mm
diameter (25 µm
pores)

(2x) 12 mm PDVF porous sparge inserts connected to
1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 6 in. (15 cm) converge to
one 1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 72 in. (183 cm)

Kleenpak Emflon II capsule

15

Media fill/
auxiliary drain

3/4 in. (19.1 mm) x 1 in. (25.4 mm) C-Flex tubing x 84 in. (213 cm) splits to
1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 24 in. (61 cm) and
1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 24 in. (61 cm)

Pall Kleenpak connectors (female)

Condenser bag assembly (optional)

–

Condenser bag assembly (optional)

–

NA

Gasket, end cap, and clamp

16
17
18

Condensate
return line
Condenser
bag assembly
Tri-clamp port (3 in.)

Tubing set (inner diameter x outer diameter x length)

End treatment

1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex™ tubing x 4 in. (10 cm) reduced to Kleenpak™ Emflon™ II capsule and
3/8 in. (9.5 mm) x 5/8 in. (15.9 mm) C-Flex tubing x 84 in. (213 cm)
pressure transducer
1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 3 in. (8 cm) reduced to
1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 6 in. (15 cm) reduced to Plugged
1/8 in. (3.2 mm) x 1/4 in. (6.4 mm) C-Flex tubing x 84 in. (213 cm)
Pall™ Kleenpak™ aseptic connectors
1/2 in. (12.7 mm) tube ports
(female)
Thermowell adapter for 1/4 in. (6.4 mm) diameter
SterilEnz™ pouch with injection
1/8 in. (3.2 mm) x 1/4 in. (6.4 mm) C-Flex tubing x 24 in. (60 cm)
site assembly
3/4 in. (19.1 mm) x 1 in. (25.4 mm) C-Flex tubing x 48 in. (122 cm) splits to
1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 24 in. (61 cm) reduced to 1/4 in. MPC insert and Pall™ Kleenpak™
1/4 in. (6.4 mm) x 3/8 in. (9.5 mm) C-Flex tubing x 12 in. (30 cm) and 1/2 in.
connector (male)
(12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 24 in. (61 cm)
1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 3 in. (8 cm) reduced to
1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 84 in. (213 cm) reduced Plugged
to 1/8 in. (3.2 mm) x 1/4 in. (6.4 mm) C-Flex tubing x 12 in. (30 cm)

7. Overlay gas sparger
6. Inoculum addition
5. Base addition

2. Exhaust line

Impeller

Front face

4. Media fill/auxiliary drain
13. Feed line
15. Drilled-hole macro sparger
14. Thermowell/small-volume sample
13. Feed line

1. Condenser bag
assemblies

8–12. Probe ports (5)

4. Media fill/auxiliary drain

4. Media fill
3. Condensate return line
2. Exhaust line

Back face

15. Drilled-hole macro sparger
17. Bottom drain harvest

18. Tri-clamp
port (3 in.)
16. Porous-frit
micro sparger (2)

Figure 11. Standard 2,000 L dual-sparger S.U.B. BPC with drilled-hole and porous-frit spargers. Available with or without condenser assemblies.
Table 10. Specifications for the standard 2,000 L dual-sparger S.U.B. BPC with drilled-hole and porous-frit spargers.
Line Description

Tubing set (inner diameter x outer diameter x length)

End treatment

1

Condenser bag
assemblies (2)

Condenser bag assembly (optional)

–

2

Exhaust lines (2)

Condenser bag assembly (optional)

–

3

Condensate return line

Condenser bag assembly (optional)

–

4

Media fill/auxiliary drain
lines

(3x) 3/4 in. (19.1 mm) x 1 in. (25.4 mm) C-Flex tubing x 84 in. (213 cm) splits
to 1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 24 in. (61 cm) and
1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 24 in. (61 cm)

Pall Kleenpak aseptic connectors
(female)

5

Base addition

1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 3 in. (8 cm) reduced to
1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 84 in. (213 cm) reduced
to 1/8 in. (3.2 mm) x 1/4 in. (6.4 mm) C-Flex tubing x 12 in. (30 cm)

Plugged

6

Inoculum addition/
feed line

7

Overlay gas sparger

8–12 Probe ports (5)
13
14
16

Feed lines
Thermowell/
small-volume sample
Porous-frit micro sparger,
12 mm diameter (25 µm
pores)

1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 3 in. (8 cm) reduced to
1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 6 in. (15 cm) reduced to
1/8 in. (3.2 mm) x 1/4 in. (6.4 mm) C-Flex tubing x 84 in. (213 cm)
1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 4 in. (10 cm) reduced to
3/8 in. (9.5 mm) x 5/8 in. (15.9 mm) C-Flex tubing x 84 in. (213 cm)
1/2 in. (12.7 mm) tube ports
(2x) 1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 4 in. (10 cm) splits to
1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 10 in. (25 cm) and
1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 10 in. (25 cm)
Thermowell adapter for 1/4 in. (6.4 mm) diameter
1/8 in. (3.2 mm) x 1/4 in. (6.4 mm) C-Flex tubing x 24 in. (61 cm)
1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 6 in. (15 cm) reduced to
check valve and 1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x
72 in. (183 cm)

Plugged
Kleenpak Emflon II capsule
and pressure transducer
Pall Kleenpak aseptic connectors
(female)
SterilEnz pouch with injection site
assembly and 3/8 in. MPC body
SterilEnz pouch with injection site
assembly
(2x) Meissner™ Steridyne™ 0.2 µm
hydrophobic filter

17

Bottom drain harvest

3/4 in. (19.1 mm) x 1 in. (25.4 mm) C-Flex tubing x 48 in. (122 cm) splits to
1/2 in. (12.7 mm) x 34 in. (19.1 mm) C-Flex tubing x 24 in. (61 cm) reduced to 1/4 in. MPC insert and
1/4 in. (6.4 mm) x 3/8 in. (9.5 mm) C-Flex tubing x 12 in. (30 cm) and
Pall Kleenpak connector (male)
1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 24 in. (61 cm)

18

Tri-clamp port (3 in.)

NA

Gasket, end cap, and clamp

Custom S.U.B. BPC options
Table 11 lists available custom 2,000 L S.U.B. BPC system
options. Not all options are available for all ports. For
additional information, please see the selection guides in
the single-use products catalog.
Table 11. Custom 2,000 L S.U.B. BPC options.

Category

Options/capability

Notes

Tubing type

Thermoplastic elastomers: C-Flex, PharMed ,
PharmaPure™ tubing
Platinum-cured silicone
PVC

More information is available in the Tubing
Selection Guide

Tubing size

Ranging from 1/8 to 1 in. (0.318 to 2.54 cm) ID, in
customer-specified lengths

More information is available in the Tubing
Selection Guide

Connectors

Luers, quick-connects, SIP connectors, tri-clamp, aseptic
connectors, sterile connectors, steam-to, steam-through,
sample ports, plugs

More information is available in the
Connector Selection Guide. Note:
Reusable probe port connections use
Kleenpak™ connector only

Probe ports

Additional ports: second row of five

The reusable probe port connection uses
a Kleenpak connector only

Disposable sensors

Pressure sensor: PendoTECH and Finesse Solutions
DO and pH: Finesse Solutions and PreSens
pH: Mettler Toledo

Choice of qualified sensors available;
PendoTECH pressure sensors come
standard

Additional probe ports

Limited engineer-to-order customization only

To be designed

Port sizes

Limited engineer-to-order customization only

Dependent on location in BPC and fit with
hardware (e.g., 1 in. (2.54 cm) port on
harvest line)

Rearrangement of lines
on existing ports

Limited customization possible (e.g., moving sample/
thermowell port to a probe tube port, or swapping overlay
inlet line with supplement line)

Dependent on location in BPC and fit with
hardware

Sparger

Dual sparger (macro open-pipe or drilled-hole and
micro porous-frit) standard

Sparger locations are fixed

Diptube lines

Limited customization possible

Length cannot interfere with impeller
and shaft

Overlay and sparger line
filters

Filter options available from standard component library

Choice of qualified filters available

Vent filters

Standard is Pall or Meissner 0.2 µm exhaust vent filter

Filters must be compatible with available
vent filter heater configurations

Vent filter tubing length

Extended filter height above the S.U.B. BPC is
made to order

Must be compatible with a vent filter
bracket option

Filters on media and
supplement inlets

Limited engineer-to-order customization only; choice of
filters used to sterilize incoming media or supplements
are available

Choice of qualified filters available

™

Table 12. Recommended S.U.B. parts list for first-time operators.

Description

Quantity

Cat. No./auxiliary part

S.U.B. hardware unit

1

Type to be configured

S.U.B. BPC

3

Type to be configured

Bioreactor probe assembly (nonsterile for use in autoclave)

12

SH30720.01

Heavy-duty tubing clamp

12

SV20664.01

1

SV50177.01

Autoclave tray for autoclaving probe assemblies

Auxiliary parts supporting the single-use bioreactor
(supplied by end user or requested turnkey)
Necessary for gas flow control, DO, and pH set points

1

Bioreactor control system

Autoclavable probe (13 mm x 13.5 PG thread with 195–235 mm insertion length)

*

DO probe

Autoclavable probe (13 mm x 13.5 PG thread with 195–235 mm insertion length)

*

pH probe

Tubing welder, steam-in-place system, sterilizer, or laminar flow hood

*

Sterile/aseptic connection

Used for fluid transfer between linesets on the containers

*

Stand-alone peristaltic pump

Necessary for water jacket temperature controls (not provided)

*

Temperature control unit (TCU)

* Quantity based on needs.

External controller options
The HyPerforma S.U.B. offers an open-architecture or
turnkey system. An open-architecture system allows you
to use any control system of your choice. The capital
investment can be reduced by using a control system
already utilized in your facility. A turnkey system is a readyto-use, out-of-the-box system with a choice of dedicated
controls from Finesse Solutions or Applikon. These
systems work on PC, DeltaV, Allen-Bradley, or Siemens
formats. Contact your local sales representative for
more information.

Find out more at thermofisher.com/sub
For Research Use or Further Manufacturing. Not for diagnostic use or direct administration into humans or animals.
© 2018 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries
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2.6 Oxygen Transfer
Introduction

The S.U.B. BPC is designed to provide an acceptable range of kLa values
to support rapid growth for an array of common cell platforms using the
operating parameters shown in Table 2.7 for BPCs equipped with open
pipe and porous frit spargers, and Table 2.8 for BPCs equipped with
drilled hole and porous frit spargers.

S.U.B. BPCs Range of Operating Parameters with Open Pipe and Frit Spargers
50L

100L

250L

Temperature (°C)

500L

1,000L

2,000L

2.0 - 40.0 ± 0.1

Porous Frit

Overlay

Open Pipe

Porous Frit

Overlay

Open Pipe

Porous Frit

Overlay

Open Pipe

Porous Frit
(3)

Overlay

20 to 75

Open Pipe

1,000 to 2,000

20 to 110

Overlay

500 to 1,000

30 to 150

Porous Frit

250 to 500

30 to 150

Open Pipe

125 to 250

Overlay

50 to 100
30 to 200

Porous Frit

25 to 50
30 to 200
Open Pipe

Operating Volume (L)
Agitation Rate (rpm)

Air (slpm)

1

0.5

5

2

1

10

5

2.5

10

10

5

15

10

8

15

12

16

15

O2 (slpm)

-

0.25

-

-

0.5

-

-

1.25

-

-

2.5

-

-

4

-

-

8

-

CO2 (slpm)

-

0.1

-

-

0.2

-

-

0.5

-

-

1

-

-

1

-

-

1

-

Recommended Max.
Gas Flow Rates

N2 (slpm)

-

0.25

-

-

0.5

-

-

1.25

-

-

2.5

-

-

2.5

-

-

2.5

-

Total (slpm)

1

0.85

5

2

1.7

10

5

4.25

10

10

8.5

15

10

13

15

12

25

15

Exhaust Load (slpm)

20

20

20

40

40

90

Table 2.8 Operating parameters using open pipe and porous frit spargers
S.U.B. BPCs Range of Operating Parameters with Drilled Hole and Frit Spargers
50L
100L
250L
500L
1,000L
Temperature (°C)

2,000L

2.0 - 40.0 ± 0.1

N2 (slpm)
Total (slpm)
Exhaust Load (slpm)

14

-

2

-

-

4

-

-

0.5

-

-

1

-

Overlay

4

Porous Frit

-

12

Drilled
Hole

-

0.25

10

Overlay

1

-

2

Porous Frit

-

5

Drilled
Hole

5

Overlay

1

Porous Frit

O2 (slpm)
CO2 (slpm)

2.5

Drilled
Hole

Air (slpm)

Overlay

Recommended Max.
Gas Flow Rates

Porous Frit

20 to 751

Drilled
Hole

1,000 to 2,000

20 to 110

Overlay

500 to 1,000

30 to 150

Porous Frit

250 to 500

30 to 150

Drilled
Hole

125 to 250

Overlay

50 to 100
30 to 200

Porous Frit

25 to 50
30 to 200
Drilled
Hole

Operating Volume (L)
Agitation Rate (rpm)

25

6

35

100

8

60

200

16

1292

-

6

-

-

8

-

-

16

-

-

1.5

-

-

2

-

-

4

-

-

1

-

-

2

-

-

4

-

-

6

-

-

8

-

-

16

-

2.5

1.25

5

5

2.5

10

12

5

14

25

7.5

35

100

10

60

200

20

129

20

20

90

90

180

270

Table 2.9 Operating parameters using drilled hole and porous frit spagers

Study Method

Thermo Scientific

Experiments were designed to estimate and model mass transfer of gasses
in S.U.B. systems. For more information about methods and procedures,
see the test methods detail in section 6.4 in the appendix of this manual.

Single-Use Bioreactor (S.U.B.)
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Results Overview

Experiments were performed using 50, 250 and 2,000L vessels to
measure the mass transfer of oxygen and CO2 stripping and the results
for 100, 500 and 1,000L vessel sizes have been interpolated theoretically
from those results.
The results in this section show the mass transfer of oxygen and CO2
stripping, and are presented as kLa for various sparge flow rates for each
vessel size. Two dimensional plots are used to show individual sparger
results for oxygen delivery and CO2 stripping, separately. Three
dimensional plots are used to show the combined micro/macro (porous
frit/open pipe or porous frit/drilled hole) sparger oxygen delivery
behavior in terms of kLa response at different combined flow rates for
each vessel size.
Results, unless otherwise specified, are at an agitation power input per
volume (PIV) of 0.15 HP/1,000gal (29.6 W/m3).
Results for vessels using porous frit and open pipe spargers are presented
first. Results for vessels using porous frit and Drilled Hole Spargers are
presented in separate, subsequent sections.

Thermo Scientific

Single-Use Bioreactor (S.U.B.)
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500L Results for Porous Frit
and Drilled Hole Spargers

The data shown below for 500L vessels is estimated, and has been
interpolated from experimentally-derived 250 and 2,000L data and
biased by pore diameter of the drilled hole spargers.

Oxygen Delivery kLa with Frit Sparger

Oxygen Delivery kLa with Drilled Hole
Sparger

25.00

12.00
10.00

15.00

1/hr kLa

1/hr kLa

20.00

10.00
5.00

8.00
6.00
4.00
2.00

0.00

0.00
0

2

4

6
slpm flow rate

8

10

12

0

10

15
slpm flow rate

20

25

30

Graph 2.48 Interpolated Results for 500L S.U.B. with
drilled hole sparger

Graph 2.47 Interpolated Results for 500L S.U.B. with
porous frit sparger

Carbon Dioxide Stripping kLa with
Drilled Hole Sparger

Carbon Dioxide Stripping kLa with Frit
Sparger
6.00

3.50
3.00
2.50
2.00
1.50
1.00
0.50
0.00

5.00

1/hr kLa

1/hr kLa

5

4.00
3.00
2.00
1.00
0.00

0

2

4

6
slpm flow rate

8

10

0

12

Graph 2.49 Interpolated Results for 500L S.U.B. with
porous frit sparger

5

10

15
slpm flow rate

20

25

30

Graph 2.50 Interpolated Results for 500L S.U.B. with
drilled hole sparger

Combined kLa Oxygen Delivery At 0.15 HP / 1000gal Agitation

30
25-30

25

50
45
40
35
30
25
20

15
10

20-25
15-20

Macro Sparge sLPM

kLa 1/hrs

20

15
10

5

10-15
5-10
0-5

5
0

0
0

0.5

1

1.5

2

2.5

3

3.5

4

4.5

5

5.5

6

6.5

7

7.5

8

8.5

9

9.5

10

Micro Sparge sLPM

Graph 2.51 Interpolated Results for 500L S.U.B. with both porous frit and drilled hole spargers
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2,000L Results for Frit and
Drilled Hole Spargers

The results of experiments with 2,000L vessels using porous frit and
drilled hole spargers are shown below.

Oxygen Delivery kLa with Drilled Hole
Sparger
20.00
15.00

1/hr kLa

1/hr kLa

Oxygen Delivery kLa with Frit Sparger
16.00
14.00
12.00
10.00
8.00
6.00
4.00
2.00
0.00

10.00
5.00
0.00

0

5

10
15
slpm flow rate

20

25

0

50

100
150
slpm flow rate

200

250

Graph 2.57 Results for 2,000L S.U.B. with porous frit
sparger

Graph 2.58 Results for 2,000L S.U.B. with drilled hole
sparger

Carbon Dioxide Stripping kLa with Frit
Sparger

Carbon Dioxide Stripping kLa with
Drilled Hole Sparger

2.00

1/hr kLa

1/hr kLa

1.50
1.00
0.50
0.00
0

5

10
15
slpm flow rate

20

8.00
7.00
6.00
5.00
4.00
3.00
2.00
1.00
0.00

25

0

Graph 2.59 Results for 2,000L S.U.B. with porous frit
sparger

50

100
150
slpm flow rate

200

250

Graph 2.60 Results for 2,000L S.U.B. with drilled hole
sparger

Combined kLa Oxygen Delivery At 0.15 HP / 1000gal Agitation

30
25-30

25
200
180
160
140
120
100
80

15
10
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15-20

Macro Sparge sLPM

kLa 1/hrs

20
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5

10-15
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0-5

20
0

0
0

2
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Graph 2.61 Results for 2,000L S.U.B. with both porous frit and drilled hole spargers
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2.7 Mixing Studies

The recommended range of mixing rates for the range of S.U.B. systems is
as follows:
Operating Volume (L)
Agitation Rate (rpm)

50L

100L

250L

500L

25-50
30-200

50-100
30-200

125-250
30-150

250-500
30-150

1,000L

2,000L

500-1,000 1,000-2,000
20-110
20-75

Table 2.10 Recommended range of mixing rates

Study Method
(50 to 1,000L)

The mixing efficiency was estimated for the range of agitation rates by
measuring the conductivity of the liquid contents of the S.U.B. BPC at
different locations within the system after the addition of sodium chloride
solution. Conductivity was measured with three conductivity probes
positioned at the top, middle and bottom.
The time to achieve uniform distribution of sodium chloride throughout
the BPC was designated as the mixing time. Since multiple sensors were
used the average time was determined when concentration readings
of all the sample locations achieved a minimum of 95% of the final
concentration. The study was conducted at maximum and minimum
operating volumes for 50, 100, 250, 500 and 1,000L S.U.B. systems.
50L S.U.B.
Half Volume
Agitation
Mixing
Speed
Time
(rpm)
(sec)
50
80
100
20
150
15

Full Volume
Agitation
Mixing
Speed
Time
(rpm)
(sec)
50
150
100
50
150
40
200
10

250L S.U.B.
Half Volume
Agitation
Mixing
Speed
Time
(rpm)
(sec)
40
50
60
30
80
20

Full Volume
Agitation
Mixing
Speed
Time
(rpm)
(sec)
60
60
100
40
120
30
140
20

100L S.U.B.
Half Volume
Agitation
Mixing
Speed
Time
(rpm)
(sec)
50
55-60
100
30-35
150
20-25

Full Volume
Agitation
Mixing
Speed
Time
(rpm)
(sec)
50
80-85
100
40-45
150
35-40
200
30-35

500L S.U.B.
Half Volume
Agitation
Mixing
Speed
Time
(rpm)
(sec)
30
75
70
25
110
20
150
15

Full Volume
Agitation
Mixing
Speed
Time
(rpm)
(sec)
30
80
70
60
110
50
150
25

1,000L S.U.B.
Half Volume
Agitation
Mixing
Speed
Time
(rpm)
(sec)
30
68-89
45
37-40
60
35-39

Full Volume
Agitation
Mixing
Speed
Time
(rpm)
(sec)
60
37-47
70
30-39
80
30-43
90
26-34
100
20-29
110
19-28

Table 2.11 Summary of mixing study results for the 50 to 1,000L S.U.B. systems
Thermo Scientific
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Mixing Study
500L S.U.B. (Full Volume)
160
140

Concentration (%)

120
100
80
60
40
20
0
0

20

40

60

80

100

120

Time (sec)

30 rpm avg

70 rpm avg

110 rpm avg

150 rpm avg

Graph 2.68 Mixing study 500L S.U.B. – full volume

Mixing Study
500L S.U.B. (Half Volume)
200
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Concentration (%)
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100
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60
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0
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Time (sec)

30 rpm avg

70 rpm avg

110 rpm avg

150 rpm avg

Graph 2.69 Mixing study 500L S.U.B. – full volume
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Mixing Study (2,000L)
Theory

Mixing performance was evaluated using an electrolyte solution and
conductivity sensors. These sensors offer a very fast response time and
both stable and repeatable readings. Mixing time is defined as the time
elapsed between when stock solution is added and the average sample
location reading exceeds 95% of final concentration. These mixing tests
represent best case time estimates as the salt is added as a pre-mix solution.

Procedure

Each bag was filled with DI water to the test volume, heated to 40ºC,
and a salt solution was prepared. For the tests a 1 liter volume of solution
(300 grams per liter dissolved Sodium Chloride) was introduced at the
top of the BPC. Each test consisted of verifying the correct agitation speed
and starting values of conductivity, adding the appropriate amount of salt
solution, and then recording the readings on the probes utilizing the Kaye
Validator™ thermal validation system until the conductivity leveled off.
After the data were collected and entered, the percentages compared to the
final reading were calculated for each sample taken. The percentage values
from the probes were then averaged to approximate the mixing time. All
three probes were used for both full and half volume calculations.
Three conductivity sensors from the same model and manufacture were
attached to a rod installed into the BPC from the top. These sensors were
positioned next to the top mounted mixer drive motor. It is anticipated
that the location on this side of the tank represents worst case mixing
because they are located the greatest distance from the high shear region of
the impeller. The sensor positions represent three column height locations
of low, middle, and high. The low and high positions were each located
approximately 30.5cm (12.0”) from the respective ends of the fluid
column. The mid probe was located at the 1,000L mark (half volumes).
In an effort to obtain a representative reading the sensor tips protruded
into the tank no less than 2.54cm (1.0”) from the inside of the tank
wall. For half volume mix tests, the low and high probes were located
approximately 15.2cm (6.0”) from the respective ends of the fluid column
and the mid probe was located at the 500L mark.

Mixing Test #* Tank Volume

Impeller Location/Shaft
Length

Power/Vol (Hp/1,000
gal)

RPM

M1

Nominal, 2,000L

1 diameter from bottom / 82.9”

0.05

60

M2

Nominal, 2,000L

1 diameter from bottom / 82.9”

0.1

75

M3

Nominal, 2,000L

1 diameter from bottom / 82.9”

0.2

95

M10

½ Volume, 1,000L

1 diameter from bottom / 82.9”

0.05

47

M11

½ Volume, 1,000L

1 diameter from bottom / 82.9”

0.1

60

M12

½ Volume, 1,000L

1 diameter from bottom / 82.9”

0.2

75

Table 2.12 Mixing study test matrix 2,000 L S.U.B.
Thermo Scientific
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Results

All tests conducted were done in duplicate. The first column in results
Table 2.13, below, was calculated by determining which probe (top, mid,
or bottom) resulted in the slowest mix time for each respective test and
averaging those together. The second column was calculated by averaging
the all of the probes.
Mixing time performance at full volume is near equivalent at 75 and
95rpm.
Mixing at high impeller speed (>60rpm) at half volume is not
recommended and will result in less than desirable performance and
accelerated shaft wear (excessive power input, poor power dissipation
result in lack of turn-over in a non-baffled tank).
2,000L S.U.B. (Full Volume Mixing Time)
RPM

Average Mix Time - Worst Case (sec)

Average Mix Time - All Probes (sec)

60

44

31.5

75

31.5

24

95

31

22.8

2,000L S.U.B. (Half Volume Mixing Time)
RPM

Average Mix Time - Worst Case (sec)

Average Mix Time - All Probes (sec)

47

28

20.8

60

21

16.8

75

53

24.8

Table 2.13 Mixing study results 2,000L S.U.B.

Graph 2.72 Mixing study 2,000L S.U.B. - full volume
Thermo Scientific

Graph 2.73 Mixing study 2,000L S.U.B. - half volume
Single-Use Bioreactor (S.U.B.)
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2,000L S.U.B.
Porous Frit Sparger Only
RPM
20
20
20
20
20
35
35
35
35
35
55
55
55
55
55
75
75
75
75
75
95*
95*
95*
95*
95*

Frit Flow
(lpm)
8
12
16
20
24
8
12
16
20
24
8
12
16
20
24
8
12
16
20
24
8
12
16
20
24

Open Pipe
(lpm)
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

kLa
3.77
6.11
7.92
9.19
9.92
3.94
6.41
8.33
9.72
10.58
5.61
8.23
10.31
11.86
12.87
5.98
8.76
11.01
12.71
13.88
6.77
9.71
12.11
13.98
15.31

Porous Frit Sparger Plus 0.01 VVM (10 LPM)
Through Pipe
Frit Flow
Open Pipe
RPM
kLa
(lpm)
(lpm)
20
8
12
5.90
20
12
12
8.22
20
16
12
10.01
20
20
12
11.26
20
24
12
11.97
35
8
12
6.23
35
12
12
8.66
35
16
12
10.57
35
20
12
11.94
35
24
12
12.77
55
8
12
8.08
55
12
12
10.68
55
16
12
12.74
55
20
12
14.27
55
24
12
15.26
75
8
12
8.65
75
12
12
11.41
75
16
12
13.63
75
20
12
15.31
75
24
12
16.46
95*
8
12
9.63
95*
12
12
12.55
95*
16
12
14.93
95*
20
12
16.77
95*
24
12
18.08

Table 6.6 Results for 2,000L S.U.B.
*NOTE: Standard operating range is 20 to 75rpm. Custom operating
limit up to 95rpm at 90 to 110% working volume only.

kLa (1/hr)

Effect of Agitation Speed on kLa

Agitation speed (rpm)

Graph 6.4 Results for 2,000 L S.U.B.
Thermo Scientific
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Find the

Motors, Gearmotors & Compressors

. Find Solutions. Find Great Prices.

For Rotary Vane Air Motor Maintenance Kits, go to Grainger.com®

Rotary Vane Air Motors
Max. temp.: 250°F
Variable speed
Use these compact, low-maintenance air motors in applications that would normally require similar, but
more-expensive explosionproof electric motors. Can be operated in extreme temperatures. Cast-iron models
include discharge muffler.
▪
▪

Running Torque
Max.
Shaft
HP
@ Max. Pressure
Air Flow
No Load RPM
Dia.
Cast-Iron Air Gearmotors
1⁄2"
0.32
49.00 in.-lb.
21 cfm
400
1⁄2"
0.34
62.00 in.-lb.
21 cfm
350
7⁄8"
0.64
172.00 in.-lb.
20 cfm
110
5⁄8"
0.9
256.00 in.-lb.
27 cfm
150
1.25
400.00 in.-lb.
60 cfm
200
1"
1.26
274.00 in.-lb.
57.5 cfm
300
1"
Cast-Iron Air Motors
3⁄8"
2.75 in.-lb.
20.5 cfm
10,000
3⁄8"
5.25 in.-lb.
27 cfm
6000
0.45
3⁄8"
5.25 in.-lb.
27 cfm
6000
1⁄2"
19.50 in.-lb.
30 cfm
3000
5⁄8"
0.93
19.50 in.-lb.
30 cfm
3000
1⁄2"
19.50 in.-lb.
30 cfm
3000
5⁄8"
36.00 in.-lb.
78 cfm
3000
5⁄8"
36.00 in.-lb.
78 cfm
3000
1⁄2"
1.7
36.00 in.-lb.
78 cfm
3000
1⁄2"
36.00 in.-lb.
78 cfm
3000
1⁄2"
36.00 in.-lb.
78 cfm
3000
5⁄8"
84.00 in.-lb.
128 cfm
3000
5⁄8"
84.00 in.-lb.
128 cfm
3000
5⁄8"
4
84.00 in.-lb.
128 cfm
3000
5⁄8"
84.00 in.-lb.
128 cfm
3000
5⁄8"
84.00 in.-lb.
128 cfm
3000
3⁄4"
132.00 in.-lb.
175 cfm
2500
5.25
7⁄8"
132.00 in.-lb.
175 cfm
2500
290.00 in.-lb.
275 cfm
2000
1 1⁄8"
9.5
7⁄8"
290.00 in.-lb.
275 cfm
2000
Cast-Iron Oilless Air Motors
1⁄2"
13.50 in.-lb.
30 cfm
2000
0.42
1⁄2"
13.50 in.-lb.
30 cfm
2000
1⁄2"
0.82
25.50 in.-lb.
41 cfm
2000
5⁄8"
78.75 in.-lb.
68 cfm
2000
2.5
5⁄8"
78.75 in.-lb.
68 cfm
2000
Stainless Steel Air Motors
3⁄8"
0.45
2.75 in.-lb.
20.5 cfm
10,000
5⁄8"
1.7
36.00 in.-lb.
78 cfm
3000
* Clockwise (CW), Counterclockwise (CCW), Reversible (REV).

Mounting

Port
Size

Rotation*

Item
No.

Face
Face
Base
Base
Face and Foot
Face and Foot

1⁄8"

NPT
NPT
NPT
1⁄4" NPT
1⁄4" NPT
1⁄4" NPT

REV
REV
CCW
CCW
REV
REV

22UX55
22UX82
22UX56
22UX57
22UX81
22UX54

Hub
Hub
Hub
Hub
Flange
Foot
Face
Flange
Foot
Foot
Face
Foot
Flange
Flange
Foot
Face
Foot
Flange
Face and Foot
Foot and Flange

1⁄8"

CCW
CW
REV
CCW
REV
REV
REV
REV
REV
REV
REV
REV
REV
REV
REV
REV
REV
REV
REV
REV

22UX71
22UX41
22UX42
22UX43
22UX44
22UX72
22UX45
22UX46
22UX73
22UX74
22UX75
22UX47
22UX48
22UX49
22UX76
22UX77
22UX50
22UX51
22UX52
22UX53

1⁄8"
1⁄4"

NPT
NPT
NPT
1⁄4" NPT
1⁄4" NPT
1⁄4" NPT
3⁄8" NPT
1⁄4" NPT
1⁄4" NPT
1⁄4" NPT
1⁄4" NPT
1⁄2" NPT
1⁄2" NPT
1⁄2" NPT
1⁄2" NPT
1⁄2" NPT
1⁄2" NPT
1⁄2" NPT
1 1⁄4" NPT
1 1⁄4" NPT
1⁄8"
1⁄8"

Hub and Foot
Hub and Foot
Hub and Foot
Hub and Foot
Hub and Foot

1⁄4"

NPT
NPT
NPT
1⁄2" NPT
1⁄2" NPT

CCW
CW
CCW
CW
CCW

22UX58
22UX59
22UX60
22UX63
22UX62

Face
Face

1⁄8"

REV
REV

22UX65
22UX67

1⁄4"
1⁄4"

1⁄4"

NPT
NPT

No. 22UX55

No. 22UX45

No. 22UX58

Rotary Multivane Air Gearmotors
▪
▪

Max. air pressure: 90 psi Provide higher torque at low speeds and continuous-duty forward or reverse operation.
Keyed steel shafts with case-hardened gearing. Aluminum and steel construction.
Max. temp.: 150°F

Running Torque
Stall
HP @ Max. Pressure Torque
Flange
99.00 in.-lb.
198 in.-lb.
0.31
330.00 in.-lb. 396 in.-lb.
0.34
71.00 in.-lb.
142 in.-lb.
Face
612.00 in.-lb. 1224 in.-lb.
0.61
1212.00 in.-lb. 2424 in.-lb.
3
1800.00 in.-lb. 3600 in.-lb.
3.2
378.00 in.-lb. 756 in.-lb.

Max. No Load RPM @
Shaft Shaft Keyway
Air Flow RPM Max. Torque Dia. Length Length
18 cfm
18 cfm
18 cfm

280
85
450

140
42
225

3⁄8"

33 cfm
33 cfm
95 cfm
95 cfm

94
47
170
975

47
23
83
485

3⁄4"

3⁄8"
3⁄8"

3⁄4"

1"
1"

Port
Size

Gear Overall Outside
Ratio Length Dia.

Mfr.
Model

Item
No.

NPT 50:1
NPT 167:1
NPT 33:1

8.87"
8.87"
8.11"

1.76" M004RVR050AR3 1AAF9
1.76" M004RVR167AR3 1AAG1
1.76" M004RVR033AR3 1AAF8

NPT 188:1
1⁄4" NPT 374:1
1⁄2" NPT 51:1
1⁄2" NPT
9:1

13.13"
13.13"
14.50"
12.13"

2.69" M007RVR188BR6 1AAG2
2.69" M007RVR374BR6 1AAG3
4.00"
4840U
1AAG5
4.00"
4840M
1AAG4

1.00"
1.00"
1.00"

0.125"
0.125"
0.125"

1⁄4"

2.19"
2.19"
2.25"
2.25"

0.187"
0.187"
0.250"
0.250"

1⁄4"

1⁄4"
1⁄4"

No. 1AAG1

Tank-Mounted, Enclosed
Oilless Air Compressors
Field-adjustable
pressure switch
▪ Single phase
Innovative reservoir can provide
a blast of high pressure. Tank
dampens pulsation from the
reciprocating compressor.
All models except No. 5Z671
incorporate a Gast piston
compressor pump listed below.
Pressure switch setting: 70
psi-On/90 psi-Off. No. 5Z671 has
30 psi-On/50 psi-Off. Gray finish.
▪

1⁄8- and 1/6-HP
Compressors—Include pressure switch, manual drain,
pressure safety valve, pressure
gauge, and globe valve.
1⁄3-

1 1⁄2-HP

to
Compressors—
Include coded tank, pressure
switch, manual drain, pressure
safety valve, pressure gauge,
and globe valve. No. 5Z676 has
magnetic starter.

No. 5Z672

No. 5Z675

Free Air
Overall
CFM @ Max. Max.
Amps Tank (F)NPT
Mfr.
Item
Pressure Pressure Voltage
AC
Size Outlet L W
H
Model
No.
0.2
50 psi
115
4.2
2 gal. 1⁄4" 18" 8" 15"
DOA-P710T-AA
5Z671
0.4
100 psi
115
4.3
2 gal. 1⁄4" 18" 8" 17"
1HAB-84T-M100X
5Z672
1⁄6
0.9
50 psi
115
3.9
2 gal. 1⁄4" 18" 8" 17"
1LAA-251T-M100X
2CJH1
1⁄3
1.1
100 psi
115
6.6
12 gal. 1⁄4" 26" 14" 21"
3HBB-69T-M300AX 11X372
4.7
100 psi 115/230 15.8/7.9 2 gal. 1⁄4" 18" 13" 22" 5HCD-101T-M550NGX 5Z674
3⁄4
4.7
100 psi 115/230 15.8/7.9 20 gal. 1⁄4" 33" 16" 27" 5HCD-100TA-M550NGX 5Z675 *
5
100 psi
230
10.8 30 gal. 3⁄8" 38" 17" 29"
7HDD-70TA-M750X
5Z676
1 1⁄2
HP
1⁄8

* No. 5Z675 is factory wired for 230V, may be converted to 115V.

Sign in to Grainger.com to see YOUR Pricing and MORE
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Air Compressors

Details on page A1.

No. 31LC99

No. 31LC92

Fire Sprinkler Air
Compressors and Pumps

115/230V
Single stage with durable powder-coated finish.
▪

Fire Sprinkler Air Compressors—Single-stage,
splash-lubricated compressors are rugged cast-iron
construction with a large flywheel for extra cooling
and to ease start-up. Feature a directional air shroud
to reduce pump temp., large canister intake filter
with replaceable filter elements, totally enclosed
heavy-duty belt guard, and an open dripproof motor
with thermal overload protection.
▪ Max. pressure: 40 psi
Air Compressor Pumps—Cast-iron pumps have
stainless steel valves and use synthetic oil for longer
life. No. 35KV12 has head unloaders.
▪ Max. pressure: 150 psi

Free Air CFM @
HP Max. Pressure Phase
Amps
Tank Size
Fire Sprinkler Air Compressors
Base Mounted
0.50
3.80
1
9.4/4.7
—
1.00
7.40
1
12.5/6.3
—
1.50
10.9
1
15.8/7.9
—
2.00
12.4
1
21.6/10.8
—
Tank Mounted
0.50
3.70
1
9.4/4.7
30 gal.
1.00
7.40
1
12.5/6.3
30 gal.
1.50
10.9
1
15.8/7.9
30 gal.
2.00
10.5
1
21.3/10.7
30 gal.
Free Air CFM @ Pump Sheave Size
Oil
HP Max. Pressure RPM @ 1725 RPM
Cap.
Air Compressor Pumps
1⁄3, 1
2.1
1200
6 21⁄64"
8 oz.
32 oz.
6.7
1200
6 21⁄64"
1, 2
6.7
1200
6 21⁄64"
32 oz.
* Has head unloaders.

(F)NPT Overall
Outlet Length
1⁄2"

1⁄2"
1⁄2"
1⁄2"

25 3⁄4"
25 3⁄4"
25 3⁄4"
25 3⁄4"

Overall
Width

Overall
Height

Mfr.
Model

Item
No.

16 1⁄4"
16 1⁄4"
16 1⁄4"
16 1⁄4"

18 1⁄4"
18 1⁄4"
18 1⁄4"
18 1⁄4"

F12S-BS-115/1-ACGF
K1S-BS-115/1-ACGK
K15S-BS-115/1-ACGK
K2S-BS-115/1ACGK

31LC94
31LC95
31LC96
31LC97

F12S-30UMS-115/1
K1S-30UMS-115/1
K15S-30UMS-115/1
K2S-30UMS-115/1
Mfr.
Model

26JY13
31LC92
31LC93
26JY14
Item
No.

1⁄2"

40"
18"
33 1⁄2"
40"
18"
34"
40"
18"
34"
1⁄2"
40"
18"
34"
NPT Flywheel Groove Groove
Outlet
Dia.
Section Quantity
1⁄2"
1⁄2"

1⁄2"
1⁄2"
1⁄2"

10 1⁄8"
10 1⁄8"
10 1⁄8"

A
A
A

1
1
1

F-PUMP
K-PUMP
KU-PUMP

31LC98
31LC99
35KV12 *

Base-Plate Air Compressors
▪
▪
▪

Designed to cycle On/Off while providing
continuous air with an 80/20 duty cycle
All compressors must be hardwired
Max. pressure: 40 psi

Free Air CFM @
HP Max. Pressure Phase
2.00
11.6
1
No. 4B242

No.
5Z702

3.00

12.3

HP

3⁄4*

1
1 1⁄2
3

Input Voltage
120VAC, 240VAC
200 to 240VAC,
480VAC

3

2-cylinder cast-iron pumps can be used in many fire sprinkler applications (check local codes and regulations). Prewired (240V) with
pneumatic control package.

Amps
17.5/8.75

Thermal
Unit Code
—

(F)NPT Overall Overall Overall Item
Outlet Length Width Height No.
1⁄2"
22 1⁄2" 15 1⁄2" 14 3⁄4" 4B242

9.0-7.5/3.9 11V709, 11V710 1H609/3, 1H632/3

Pump
Oil Cap.
RPM Cylinders Bore Stroke (oz.)
980
1
1.97 2.56
15
1120
1
1.97 2.56
15
860
1
2.56 2.56
15
1050
2
2.56 2.36
24

Free Air CFM @ Tank
HP Max. Pressure Size
Input Voltage
Amps
Phase
Simplex
2.1
30 gal.
120VAC, 240VAC
10.2/5.1
1
0.75
2.1
30 gal. 208 to 240VAC, 480VAC 3.6-3.0/1.5
3
1.00
3.4
30 gal.
120VAC, 240VAC
13.4/6.7
1
1.50
4.5
60 gal. 208 to 240VAC, 480VAC 4.5-4.4/2.2
3
3.00
10.1
80 gal. 208 to 240VAC, 480VAC 8.9-8.1/4.1
3
Duplex
0.75
4.2
30 gal. 208 to 240VAC, 480VAC 7.4-6.2/3.1
3
1.00
6.8
30 gal. 208 to 240VAC, 480VAC 6.4-6.2/3.1
3
1.50
9
80 gal. 208 to 240VAC, 480VAC 9.3-9.0/4.5
3
3.00
11.0
80 gal. 208 to 240VAC, 480VAC 18.2-16.5/8.2 3
* For altitudes over 5000 ft., flow will be reduced; select 1 HP instead.

Motor
Starter No.
—

Overall Overall Overall Item
Length Width Height No.
42 1⁄2"
42 1⁄2"
42 1⁄2"
50 3⁄4"
65 1⁄2"

21 1⁄4"
21 1⁄4"
21 1⁄4"
22 1⁄4"
23 1⁄4"

38"
38"
38"
40"
34"

5Z696
5Z697
3JR83
5Z699
5Z701

41 1⁄2"
41 1⁄2"
64 1⁄4"
65 1⁄4"

21 1⁄4"
21 1⁄4"
22 1⁄4"
23 1⁄4"

38"
38"
39"
34"

5Z698
3JR81
5Z700
5Z702

1⁄2"

22 1⁄2"

15 1⁄2"

14 3⁄4" 4B243

Climate Control Air Compressors

3-phase duplex units require 115V for control panel power
Max. pressure: 90 psi
▪ Simplex: 70 psi On/90 psi Off
▪ Duplex: 70 psi On/90 psi Off (lead), 60 psi On/80 psi Off (lag)
▪ All compressors must be hardwired
▪ Horizontal tank with 3⁄4" (F)NPT outlet and brass ball valves
Deliver published cfm at stated rpm and pressure and to be below
2 ppm in oil carryover. Use for new, replacement, or upgrade HVAC
installations and instrument air applications. Simplex packages
include mounted and wired magnetic starter (except 1-phase); duplex
packages include mounted and wired alternator and 2 magnetic
starters. For duplex models, use twice the oil capacity (Compressor
Oil No. 4ZF21 is recommended, sold separately on page 2568).
▪
▪

Mobile Engine-Driven
Air Compressors and
Compressor/Generator

Rotary screw-type with electric start. Include a lifetime manufacturer’s warranty on the compressor and are Tier 4 compliant.
Viper Air Compressors—Can easily power a 90-lb. jackhammer and include a 12V cold weather protection kit. Diesel models
feature an automatic variable throttle control to help reduce fuel
consumption.

No. 39CC74
No. 39CC68
Free Air
CFM @
Max.
Max. (F)NPT Rated
Fuel Tank
Description Pressure Pressure Outlet Watts Fuel Type Capacity
Viper Air Compressors
3⁄4"
—
Gasoline 5.00 gal.
Viper G60
60.0
150 psi
3⁄4"
Viper G80
59.0
100 psi
—
Gasoline 5.00 gal.
3⁄4"
Viper D60
60.0
150 psi
—
Diesel 9.00 gal.
3
Viper D80
80.0
100 psi
⁄4"
—
Diesel 9.00 gal.
Viper Air Compressor/Generator
3⁄4"
5000/5200 Gasoline 5.00 gal.
—
40.0
100 psi
PowerFlex™ Air Compressor/Generator
Powerflex
3⁄4"
7000
Diesel 12.0 gal.
40.0
150 psi
AE
Air N Arc® Compressor/Generator/Welder/Battery Charge System
Air N Arc®
3⁄4"
40.0
175 psi
7000
Gasoline 12.0 gal.
300 Gas
Air N Arc®
3⁄4"
7000
Diesel 12.0 gal.
40.0
175 psi
300 Diesel
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No. 39CC70
Overall Overall Overall
Length Width Height Weight

Item
No.

480 lb. 39CC67
29 3⁄4" 480 lb. 39CC74
33" 800 lb. 39CC75
38" 800 lb. 39CC71

45 5⁄32"

23 1⁄2"

42"

33"

34 1⁄2" 685 lb. 4TZW4

47 39⁄64"

21"

33 13⁄32" 803 lb. 39CC70

47"

21"

31"

700 lb. 39CC68

47"

21"

33"

865 lb. 39CC73

45 5⁄32"
48"
47"

23 1⁄2"
21"
24"

29 3⁄4"

Viper Air Compressor/Generator—Features multi-functioning
capabilities and provides air and AC power in 1 portable unit. Can
run at full load for up to 4 hr. and is easy to transport via fork lift
or pallet truck.
PowerFlex™ Air Compressor/Generator—Diesel-powered
model provides air and AC power in one easily transportable unit.
Includes a 12V cold weather protection kit.
Air N Arc® Compressor/Generator/Welder/Battery Charge
System—Multifunction systems include a 12V cold weather
protection kit and 25-ft. weld and boost cables. Battery boost
cables are available on Grainger.com®.

Find even MORE on Grainger.com®
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Clarification
Portfolio Guide
Single- and multi-use products
for the successful development
and implementation of robust
clarification processes

The life science business
of Merck KGaA, Darmstadt,
Germany operates as
MilliporeSigma in the
U.S. and Canada.

Media Grades
60HX
40MS

Multi Layer

20MS
D0HC
D0SP
C0HC
C0SP

Clarisolve® grades

B1HC
A1HC
F0HC

Millistak+® HC grades with diatomaceous earth and cellulose
Millistak+® HC Pro grades with polyacrylic fiber and silica (synthetic)

X0HC
X0SP
DE25

CE20

DE40
DE45

CE25
CE30
CE35

Millistak+® grades with diatomaceous earth

40

20

DE55
DE60
DE65

CE50

Millistak+® grades with activated carbon

60 µm

DE50
CE40
CE45

Millistak+® grades with cellulose only

DE70
DE75

CR40

15

10

Single Layer

DE30
DE35

CE15

5

1

0.5

0.1

Nominal Micron Rating (µm)
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Pre-treated Feed
Primary
Clarification
Secondary
Clarification
DSP

Millistak+®, Millistak+® HC, Millistak+® HC Pro

Clarisolve®

Target Step

Media Grade

Single stage clarification of mAB pre-treated feed streams with particle size distribution
of 60 µm (Cationic Polymers such as Clarisolve® mPAA). Utility in some bacterial, viral
and polysaccharide vaccine applications.

60HX

Single stage clarification of mAb pre-treated feed streams with particle size distribution
of 40 µm (Cationic Polymers such as pDADMAC). Utility in some bacterial and viral
vaccine applications.

40MS

Single stage clarification of mAb pre-treated feed streams with particle size distribution
of 20 µm (Acid Precipitation). Utility in some bacterial and viral vaccine applications.

20MS

Primary clarification. In some cases, can be used as a single stage clarification step going
directly into a sterile filter.

C0HC
C0SP (synthetic)

Primary (coarse) clarification

CE

Primary clarification

D0HC
D0SP (synthetic)

Primary or secondary clarification

DE

Secondary clarification post tangential flow filtration or depth filtration

A1HC

Secondary clarification post-centrifugation

B1HC

Secondary clarification post–centrifugation or pre-treated feed streams

F0HC

Secondary clarification post depth filtration or centrifugation. Can also be utilized in
downstream processing steps to protect chromatography columns.

X0HC
X0SP (synthetic)

Removal of color and trace contaminants, as well as in downstream processing to reduce
HCP and other impurities present in Protein A elution pools.

Carbon (AC) CR40
X0SP (synthetic)

Device Formats
Pod Filter Systems
(Millistak+® and Clarisolve® media)
The Pod Filter System is a scalable format
accommodating applications from lab- to pilot- to
process-scale. The Pod format oﬀers flexibility because
of its unique, modular and 100% disposable design.
The same flow path and configuration ensures a linearly
scalable solution from bench- to process-scale.

Ordering
Information

Virtual
Pod Tool

• Patented, disposable design eliminates need
for housing, CIP or cleaning validation
• Self-contained Pod format protects operators
from exposure to biohazards
• Enables use of multiple grades in one holder
• Robust construction is easy to use and set up
• Smaller footprint facilitates use in tight spaces
The Pod holder system’s modular design makes it easy
to configure for a specific application and conveniently
reconfigure it as process capacity requirements
scale-up or -down. The flexible, modular format
oﬀers scalability up to 12,000 L or more.
Small-Scale

Lab-Scale

Pilot-Scale

Process-Scale

Lenticular Discs (Millistak+® media only)
The Millistak+® 16 in. lenticular format is available
in multiple stacked-cell configurations. The individual
cells of filter media are combined to form a convenient
and easy-to-install filtration unit. Each filter cell is
independently sealed by an injection molding process
to ensure integrity throughout each device. Edge seal
bosses provide robustness against cell collapse during
prolonged runs, minimizing the risk of bypass
and process deviations.

Ordering
Information

The Millistak+® 316 L stainless steel filter housings
are designed for high-capacity liquid clarification.
The housings’ versatile design and a wide oﬀering
of accessories allow users to operate the system with
as few as one or as many as eight stacked cartridges
installed. These options make it easy to configure for
a specific application and conveniently reconfigure it
as process capacity requirements scale-up or -down.
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Clarification Selection Guide for
Monoclonal Antibodies, Recombinant
Proteins, and Fc-fusion Proteins
The following decision trees are focused on batch and fed-batch feeding strategies
for mammalian cell bioreactors. The selection matrices are created for reference
only, based on historical experience and data.
The decision trees cover direct harvest, pretreatment, and centrifugation at
various scales. Studies have shown that direct harvest is more economical versus
centrifuge at scales below 1000 L*. There is a “grey area” between 1000 L
and 2000 L where either direct harvest or centrifuge may be the best choice,
depending on cell culture characteristics and facility considerations.

Direct Harvest Decision Tree
Molecule Types: mAb, recombinant, fusion,
other-hydrophobic proteins
Monoclonal antibodies, recombinant proteins, and
Fc-fusion proteins behave similarly with respect to
capacity. Filters containing diatomaceous earth may not
be the ideal solution for Fc-fusion proteins and highly
hydrophobic proteins, due to recovery challenges.
If product yield is an issue, reach out to your local
Account Manager or Process Development Specialist.
Two filtration options are included:
1. A single-stage depth filtration train.
2. A two-stage depth filtration train run in series.

The single-stage train is recommended in cases of
low-titer feeds and/or when there are concerns about
product binding.
The information in the following tables should be
considered as general guidance for performance
and preliminary economic assessments. Actual
performance should be confirmed prior to large-scale
implementation.
Please note: The single filter will need to be optimized
for both capacity and filtrate turbidity/sterile filter
capacity. The second filter in the filter train is tight
enough to protect the sterile filter in most cases.
Secondary depth filtration is included for additional
sterile filter and column protection in most cases.

*Process Cost and Facility Considerations in the Selection of Primary Cell Culture Clarification Technology, Felo et al., Biotechnol. Prog.,
2013, Vol. 29, No. 5.
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Cell Density

≤ 10E6 cells/mL (low)

Cell Viability*

Depth
Filter Train

Low Density/Low Viability

Single-stage

Low Density/High Viability

Two-stage

Single-stage

Two-stage

Millistak+®
Media Grade

C0HC

HC Pro C0SP†

D0HC/X0HC

HC Pro
D0SP/X0SP†

C0HC

HC Pro C0SP†

D0HC/X0HC

HC Pro
D0SP/X0SP†

Filter Loading

150 L/m2

300 L/m2

D0HC:
50 L/m2
X0HC:
150 L/m2

D0SP:
100 L/m2
X0SP:
150 L/m2

125 L/m2

250 L/m2

D0HC:
50 L/m2
X0HC:
250 L/m2

D0SP:
100 L/m2
X0SP:
250 L/m2

Scale‡

1L

µPod® device format

10 L

Lab-scale pod (LSP)
device format

100 L
1000 L
2000 L

Process-scale pod (PSP)
device format

10,000 L

see centrifuge

Cell Density

20–30E6 cells/mL (high)

Cell Viability*

Depth
Filter Train

High Density/Low Viability

Single-stage

High Density/High Viability

Two-stage

Single-stage

Two-stage

Millistak+®
Media Grade

C0HC

HC Pro C0SP†

D0HC/X0HC

HC Pro
D0SP/X0SP†

C0HC

HC Pro C0SP†

D0HC/X0HC

HC Pro
D0SP/X0SP†

Filter Loading

100 L/m2

200 L/m2

D0HC:
50 L/m2
X0HC:
150 L/m2

D0SP:
100 L/m2
X0SP:
150 L/m2

75 L/m2

150 L/m2

D0HC:
25 L/m2
X0HC:
250 L/m2

D0SP:
100 L/m2
X0SP:
250 L/m2

Scale‡

1L

10 L

µPod® device format

Lab-scale pod (LSP)
device format

100 L
1000 L
2000 L

Process-scale pod (PSP)
device format

10,000 L

see centrifuge

Note: If the filtrate turbidity is greater than 15–20 NTU or sterile sizing does not meet your target directly after the primary depth filter, consider
additional polishing via X0HC.
Protein titer (<1 g/L, >1 g/L). Recovery should be considered during the small-scale tests. Low-titer feeds historically have slightly lower recovery
values. This could be due to low levels of binding, hold-up volume losses during recovery (blow-down or buﬀer flush), and/or dilution from pre-use
flushing and post-use recovery.
*Cell density is a critical parameter in the consideration for filter selection and capacity. High-cell-density cultures contain a high level of cells
and with that cell debris, both soluble and insoluble. When the viability is high, most of the cells are intact and the particle size distribution shifts
towards larger particles. When the viability is low, the particle size shifts towards the smaller particles and insoluble (unmeasured) particles.
†
As a general guideline, the filter loadings for Millistak+® HC Pro Media grades (D0SP and C0SP only) are at least double (2X) the equivalent
Millistak+® HC D0HC and C0HC grades. The X0 grades for both have similar filter loadings.
‡
Process scales are typically 1 L–20,000 L. For simplicity, the process scale increases by 10x starting with 1 L. Direct harvest is economically
practical and feasible for manufacturing, depending on the cell density, up to approximately 2,000 L. Centrifuge is recommended at scales
≥2,000 L for direct harvest.
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Pretreatment Decision Tree
To meet the technical challenges of high titer mammalian cell culture processes, our novel chemical flocculants can
be used to pretreat high density cell harvests before clarification over Clarisolve® depth filters. Pretreatment, via
flocculation or precipitation, is recommended at cell densities greater than or equal to 30×106 cells/mL. However,
flocculation can be implemented at any cell density if the process requires such a step. The type of pretreatment
and dosing requirements (e.g., pH adjustment, salt addition, polymer addition) depends on the cell culture and
molecule characteristics. The Clarisolve® family of filters was developed for high-cell-density, pretreated feed
streams. The filter selection and sizing recommendations will be based on the type of pretreatment and the
particle size distribution of the pretreated feed stream.
Cell Density

> 30E6 cells/mL (volumes ≤ 5000L)

Acid treatment

Salt addition

pDADMAC
cationic polymer

Clarisolve® mPAA
stimulus responsive
cationic polymer

Clarisolve® 20MS* filter

1st choice

2nd choice

2nd choice

3rd choice

Clarisolve 40MS* filter

2nd choice

1st choice

1st choice

2nd choice

Clarisolve® 60HX* filter

—

—

3rd choice

1st choice

®

*If the filtrate turbidity is greater than 15–20 NTU or sterile sizing does not meet your target directly after the primary depth filter, consider
additional polishing via X0HC or XOSP.

Centrifuge Decision Tree
Centrate may diﬀer depending on the cell density/viability and the centrifuge optimization/operation. Centrate
turbidity is a good indicator as to which depth filter will have the highest capacity and best sterile filter protection.
Cell Density

< 30E6 cells/mL (low)
untreated

> 30E6 cells/mL (high)
pretreated

High centrate turbidity
(>100 NTU)

Low centrate turbidity
(<100 NTU)

High centrate turbidity
(>100 NTU)

Low centrate turbidity
(<100 NTU)

Typical loading:
200–400 L/m2
Device format:
Process-scale pod

—

Typical loading:
200–400 L/m2
Device format:
Process-scale pod

—

—

Typical loading:
200–400 L/m2
Device format:
Process-scale pod

—

Typical loading:
200–400 L/m2
Device format:
Process-scale pod

Typical loading:
200–400 L/m2
Device format:
Process-scale pod

—

Typical loading:
200–400 L/m2
Device format:
Process-scale pod

Typical loading:
200–400 L/m2
Device format:
Process-scale pod

—

Typical loading:
200–400 L/m2
Device format:
Process-scale pod

Typical loading:
200–400 L/m2
Device format:
Process-scale pod

Typical loading:
200–400 L/m2
Device format:
Process-scale pod

Typical loading:
200–400 L/m2
Device format:
Process-scale pod

Typical loading:
200–400 L/m2
Device format:
Process-scale pod

Typical loading:
200–400 L/m2
Device format:
Process-scale pod

—

—

Typical loading:
200–400 L/m2
Device format:
Process-scale pod

Typical loading:
200–400 L/m2
Device format:
Process-scale pod

Typical loading:
200–400 L/m2
Device format:
Process-scale pod

1000 L
Millistak+® filter,
F0HC media series (1st choice)
B1HC (2nd choice)
Millistak+® filter, X0HC/X0SP
media series (1st choice)
A1HC (2nd choice)

2000 L
Millistak+® filter,
F0HC media series (1st choice)
B1HC (2nd choice)
Millistak+® filter, X0HC/X0SP
media series (1st choice)
A1HC (2nd choice)

10,000 L
Millistak+® filter,
F0HC media series (1st choice)
B1HC (2nd choice)
Millistak+® filter, X0HC/X0SP
media series (1st choice)
A1HC (2nd choice)
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Non-mAb Expression Systems Decision Tree
The following decision tree is focused on non-mAb expression systems at all scales. Non-mAb expression systems
typically require more process development due to processing diﬀerences. Particle size distribution can vary
greatly between molecules/processes. The recommendations are based on historical experience and data.
Expression
System
Mammalian

Microbial:
Bacterial

Molecule Type

Application

Batch Type

Pretreatment Options/
Method of Cell Lysis

Primary
Clarification

Secondary
Clarification

Enzyme
(binds to DE)

Harvest

Perfusion

NONE

Millistak+® CE50

Polysep™ II CGW6

Polygard® CR 0.5 µm

Polysep™ II CGW6

Enzyme
(does not bind
to DE)

Harvest

Millistak+ C0HC

Millistak+® X0HC

Millistak+ F0HC

—

Secreted Protein

Harvest

Millistak+® C0HC

Millistak+® X0HC

Prostak™ 0.22 µm or
0.1 µm

—

Pellicon® 2 1000 kD
Biomax® V-screen

—

Clarisolve® 20MS

Millistak+® C0HC

Intracellular—
Soluble

Intracellular—
Inclusion Body

Microbial: Yeast

Vaccines

Perfusion

®

Lysate
Clarification

Batch

Batch

Lysate
Clarification/
IB Wash

Batch

Lysate
Clarification/
Refold Pool

Batch

Intracellular—
Inclusion Body

Lysate
Clarification

Batch

Egg-based
Influenza

Centrate
Clarification

Batch

Cell-based
Influenza

Centrate
Clarification

Batch

Viral Vector

Lysate
Clarification

Batch

Harvest
Clarification

Batch

pDNA

Virus-like Particle

Conjugated
Polysaccharide

NONE

®

NONE

Mechanical

Chemical or Enzymatic

Call Technical Service

Mechanical

Prostak™ MF 0.1 µm

—

Pellicon® 2 1000kD
Biomax® V-screen

—

Chemical or Enzymatic

Call Technical Service

NONE

Clarisolve® 20MS

(Millistak+® X0HC if needed)*

Clarisolve® 60HX

(Millistak+® X0HC if needed)*

Clarisolve® 60HX

Millistak+® C0HC

Pellicon® 2 1000kD
Biomax® V-screen

—

Polygard® CN 5.0 µm

—

Polygard® CR 5.0 µm

—

Clarisolve® 20MS

—

Polygard CR 5.0 or
3.0 µm

Clarigard® 1.0 or
0.5 µm

Mechanical

NONE

NONE

®

Mechanical

NONE

Clarigard® 3.0 µm

Polysep™ II CGW6

Pellicon® 2 0.65 µm
Durapore® V-screen

—

Pellicon® 2 0.1 µm
Durapore® V-screen

—

Pellicon® 2 1000kD
Biomax® V-screen

—

Precipitate
Clarification

Batch

NONE

Clarisolve® 60HX

—

Lysate
Clarification

Batch

Mechanical

Prostak™ 0.65 µm
Durapore®

—

Clarisolve® 20MS

—

Polygard® CN 5.0 µm

—

Prostak™ 0.1 µm
Durapore®

—

—

Batch

NONE

*If filtrate turbidity is greater than 15–20 NTU or sterile sizing does not meet your target directly after the primary depth filter, consider additional
polishing via X0HC.
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Pod Hardware
Description
Pilot-Scale Holder

Process-Scale Holder

Qty/Pk
For Pod configurations from 1 to 2 filters

1

MP0DPIL0T

For Pod configurations up to 5 filters

1

MP0DPILOTX

1-rack holder; Gemu® valves

1

MP0DSYS1A

1-rack holder; ITT valves

1

MP0DSYS1B

1-rack holder; no valves

1

MP0DSYS1N

1-rack expansion kit; no valves or casters

1

MP0DSYS1X

2-rack holder; Gemu valves

1

MP0DSYS2A

2-rack holder; ITT valves

1

MP0DSYS2B

2-rack holder; no valves

1

MP0DSYS2N

3-rack holder; Gemu valves

1

MP0DSYS3A

3-rack holder; ITT valves

1

MP0DSYS3B

3-rack holder; no valves

1

MP0DSYS3N

®

®

Small-Scale

Lab-Scale

Pilot-Scale

Process-Scale

Disposable Adapter Kit1
3 through adapters, 3 blind adapters

MP0DADAPT

6 through adapters, required if using Disposable Diverter Plate (MP0DDIVERTR)

MP0DADPTF

1
Note: Pod filters require the use of flow adaptors, which are sold separately (MP0DADAPT or MP0DADPTF). See the Millistak+® Pod
disposable depth filter hardware Data Sheet (DS3388EN00) for information on Pod filter holders.

A retrofit kit may be required in order to accommodate the new Clarisolve® depth filters in the Pod pilot- and process-scale holders.
Please contact your local sales representative for details.
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Millistak+® Lenticular Housings
Number of Cartridges*

Inlet/Outlet Connections

Cat. No.

1 x 12 in. 13- or 16-cell/6- or 9-cell

1 in. TC, ISO DN32

WM21 SET ET

2 x 12 in. 13- or 16-cell/6- or 9-cell

1 in. TC, ISO DN32

WM22 SET ET

3 x 12 in. 13- or 16-cell (4 x 12 in. 6- or 9-cell)

1 in. TC, ISO DN32

WM23 SET ET

4 x 12 in. 13- or 16-cell (5 x 12 in. 6- or 9-cell)

1 in. TC, ISO DN32

WM24 SET ET

1 x 16 in. 16-cell

2 in. TC, ISO DN40

WM61 SFT FT

2 x 16 in. 16-cell (3 x HC 16 in. 8-cell)

2 in. TC, ISO DN40

WM62 SFT FT

3 x 16 in. 16-cell (4 x HC 16 in. 8-cell)

2 in. TC, ISO DN40

WM63 SFT FT

4 x 16 in. 16-cell (6 x HC 16 in. 8-cell)

2 in. TC, ISO DN40

WM64 SFT FT

2 x 16 in. 8-cell (1 x DE, CE, A 16 in. 16-cell)

2 in. TC, ISO DN40

HC62 SFT FT

4 x 16 in. 8-cell (2 x DE, CE, A 16 in. 16-cell)

2 in. TC, ISO DN40

HC64 SFT FT

6 x 16 in. 8-cell (3 x DE, CE, A 16 in. 16-cell)

2 in. TC, ISO DN40

HC66 SFT FT

8 x 16 in. 8-cell (5 x DE, CE, A 16 in. 16-cell)

2 in. TC, ISO DN40

HC68 SFT FT

1 x 12 in. 13- or 16-cell/6- or 9-cell

1 in. TC

UM21 SET ET

2 x 12 in. 13- or 16-cell/6- or 9-cell

1 in. TC

UM22 SET ET

3 x 12 in. 13- or 16-cell/4 x 12 in. 6- or 9-cell

1 in. TC

UM23 SET ET

4 x 12 in. 13- or 16-cell/5 x 12 in. 6- or 9-cell

1 in. TC

UM24 SET ET

1 x 16 in. 16-cell

2 in. TC

UM61 SFT FT

2 x 16 in. 16-cell (3 x HC 16 in. 8-cell)

2 in. TC

UM62 SFT FT

3 x 16 in. 16-cell (4 x HC 16 in. 8-cell)

2 in. TC

UM63 SFT FT

4 x 16 in. 16-cell (6 x HC 16 in. 8-cell)

2 in. TC

UM64 SFT FT

2 x 16 in. 8-cell (1 x DE, CE, A 16 in. 16-cell)

2 in. TC

UC62 SFT FT

4 x 16 in. 8-cell (2 x DE, CE, A 16 in. 16-cell)

2 in. TC

UC64 SFT FT

6 x 16 in. 8-cell (3 x DE, CE, A 16 in. 16-cell)

2 in. TC

UC66 SFT FT

8 x 16 in. 8-cell (5 x DE, CE, A 16 in. 16-cell)

2 in. TC

UC68 SFT FT

CE Marked
Millistak+® Housings†
For 12 in. Diameter Millistak+® (DE, CE, A) Cartridges

For 16 in. Diameter Millistak+ (DE, CE, A) Cartridges
®

Millistak+® HC Housings†
For 16 in. Diameter Millistak+® HC Cartridges

ASME® Stamped
Millistak+® Housings†
For 12 in. Diameter Millistak+® (DE, CE, A) Cartridges

For 16 in. Diameter Millistak+® (DE, CE, A) Cartridges

Millistak+ HC Housings
®

†

For 16 in. Diameter Millistak+® HC Cartridges

* Millistak+® Housings are also compatible with many other commercially available lenticular cartridges.
†

The compression tool must be ordered separately (Compression kit assembly, Catalogue No.: 1 WM00 CAK 01).
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Prostak™ Microfiltration Modules
Packaging: 1/pack
Pore Size (µm)

2-Stak

4-Stak

10-Stak

20-Stak

Microporous Membranes – Hydrophilic PVDF Durapore® Membrane
0.1

PSVV AG0 21

PSVV AG0 41

PSVV AG1 01

SK2P 127 E1

0.22

PSGV AG0 21

PSGV AG0 41

PSGV AG1 01

SK2P 484 E0

0.45

PSHV AG0 21

PSHV AG0 41

PSHV AG1 01

SK2P 242 E9

0.65

PSDV AGO 21

PSDV AG0 41

PSDV AG1 01

SK2P 446 E0

Microporous Membranes – Hydrophobic PVDF Durapore Membrane
®

0.22

—

—

—

SK2P 344 W2

0.45

SK2P 012 W6

—

—

SK2P 013 W4

—

—

SK2R B30 A1

PZHK Membrane – Hydrophobic PVDF
—

200*

*Nominal Molecular Weight Limit in kDaltons.
There is one module per package. Sanitary gaskets are supplied with each module to provide a leak-free connection
between the module(s) and holder.

Pellicon® 2 Filters with V Screens (loose screen)
Membrane

0.1 m2/1.1 ft2

0.5 m2/5.4 ft2

2.0 m2/21.5 ft2

Biomax® Series – Modified Polyethersulfone
Biomax® 5

P2B0 05V 01

P2B0 05V 05

P2B0 05V 20

Biomax® 8

P2B0 08V 01

P2B0 08V 05

P2B0 08V 20

Biomax® 10

P2B0 10V 01

P2B0 10V 05

P2B0 10V 20

Biomax® 30

P2B0 30V 01

P2B0 30V 05

P2B0 30V 20

Biomax® 50

P2B0 50V 01

P2B0 50V 05

P2B0 50V 20

Biomax® 100

P2B 100V 01

P2B1 00V 05

P2B1 00V 20

Biomax® 300

P2B3 00V 01

P2B3 00V 05

P2B3 00V 20

Biomax 500

P2B5 00V 01

P2B5 00V 05

P2B5 00V 20

Biomax® 1000

P2B0 1MV 01

P2B0 1MV 05

P2B0 1MV 20

®

Ultracel® PLC Series – Regenerated Cellulose, Composite Construction
5 kD

P2C0 05V 01

P2C0 05V 05

P2C0 05V 20

10 kD

P2C0 10V 01

P2C0 10V 05

P2C0 10V 20

30 kD

P2C0 30V 01

P2C0 30V 05

P2C0 30V 20

100 kD

P2C1 00V 01

P2C1 00V 05

P2C1 00V 20

300 kD

P2C3 00V 01

P2C3 00V 05

P2C3 00V 20

1000 kD

P2C0 1MV 01

P2C0 1MV 05

P2C01MV 20

Durapore® – Hydrophilic PVDF
0.1 µm

P2VV PPV 01

P2VV PPV 05

P2VV PPV 20

0.22 µm

P2GV PPV 01

P2GV PPV 05

P2GV PPV 20

0.45 µm

P2HV MPV 01

P2HV MPV 05

P2HV MPV 20

0.65 µm

P2DV PPV 01

P2DV PPV 05

P2DV PPV 20
21
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Pod Depth Filters

The life science business of Merck KGaA, Darmstadt,
Germany operates as MilliporeSigma in the U.S. and Canada.
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Set-Up
NOTE A tubing kit is available, contact your local representative.
The Process Scale (surface area 0.11, 0.33, 0.55, 0.77, 1.1 and 1.4 m2)
Pod filters must be installed in a Pod Holder as described in the Holder User
Guide.
1. Connect the inlet port of the filter to the feed line.
2. Connect the outlet port of the filter to the collection line.
3. Connect the vent port of the filter to the vent line.
4. Install a pressure gauge on the inlet or vent line.
5. Attach a vent valve or clamp at the end of the vent tubing.
Pressure Gauge
(User Supplied)
Pod Filter

Tee
(User Supplied)

Inlet
Vent

Outlet

Pod Depth Filters User Guide

3

Flushing

Flushing Procedure

Flush devices with buffer or purified water prior to use. To fully
wet the media, flush the filter as listed in the following tables:

2. Attach a pressure gauge to the vent or inlet port to monitor
inlet pressure.

Clarisolve® Depth Filters

3. Attach a vent valve or clamp at the end of the vent tubing.

Media
20MS
40MS
60HX

1. Install new tubing on the inlet, outlet and vent lines of the filter.

Lab Scale Pod
0.0135

600

140

270

1100

300

70

135

100

23

45

0.027

4. Start flushing the filter at the flow rate listed in the tables.

Process Scale Pod

Flux
(LMH)

0.11

0.33

0.55

5. Open the vent to purge any air from the filter. Air purge may
be assisted by temporarily clamping the outlet line closed.

3300

5500

550

1650

2750

183

550

917

6. Close the vent and open the outlet line to allow flow through
the filter. For 100 and 300 LMH flow rates, back pressure is
recommended to wet the device. To create the back pressure,
partially close the outlet valve and completely close the vent
valve. Increase the pressure in the device up to 10 psig by
partially closing the outlet valve slowly, then vent slowly by
opening the outlet to purge any air.

Flow rate (mL/min)

Millistak+® Depth Filters

Media

Lab Scale
Pod

Flux
(LMH) 0.027 0.054 0.11

Process Scale Pod
0.55

0.77

1.1

1.4

Flow rate (mL/min)

7. Over about 30 seconds, gradually increase the flow to achieve
the desired flux rate.

CR

600

270

540

1100

5500

--

11000

--

8. Start the flush.

HC

600

270

540

1100

5500

--

11000

--

CE, DE

600

270

540

1100

--

7700

--

14000

9. Flush until the desired target volume or the desired TOC level is
reached (see Conductivity and TOC Test Results).
10.For optimal performance with a Pod filter, run the filtration
process with product at a flux of 100 to 300 LMH and a max
differential pressure of 2 bar (30 psi).

Millistak+® HC Pro Depth Filters

Media

Lab Scale
Pod

Flux
(LMH) 0.0135 0.027 0.11

Process Scale Pod
0.33

0.55

0.77

1.1

--

3850

--

Flow rate (mL/min)
D0SP

300

70

135

550

1650

C0SP

300

70

135

550

1650

--

3850

--

X0SP

300

70

135

550

--

2750

--

5500

NOTE

It is normal to observe an increase in the hydraulic
pressure on the process scale pod holder during
operation. Hydraulic pressure should never exceed
124 bar (1800 psi).
Optimal flux for CR media is application dependent. Flux
rate should be optimized through testing.

11.When filtration is complete, perform a blow down to recover
product held up in the device by connecting air supply tubing
to the vent port.

Pod Depth Filters User Guide

Blow Down Pressure

Media
Clarisolve

CR
CE
DE

Millistak+®
HC Pro

Time min

bar (psi)

®

Millistak+®

4

0.3 (5)

10

0.3 (5)

10

A1HC
B1HC
C0HC
D0HC
X0HC
F0HC

increase pressure at a rate of
0.1 bar/min (2 psi/min) until 1 bar
(15 psi) is reached

D0SP
C0SP
X0SP

increase pressure at a rate of
0.1 bar/min (2 psi/min) until 1 bar
(15 psi) is reached

up to 5

Test Results

CS40MS01L3 (CP2KA10848)
CS40MS01L3 (CP2KA10849)

Conductivity
(µS/cm)

TOC
Value
(ppm)

600

0.91

0.90

600

1.23

1.20

CS40MS01L3 (CP2KA10850)

600

1.29

1.10

CS60HX01L3 (CP2KA10842)

600

0.15

BDL

CS60HX01L3 (CP2KA10843)

600

BDL

BDL

CS60HX01L3 (CP2KA10844)

600

0.14

BDL

MD0HC01FS1 (CP3NA24863)

600

1.75

0.80

MD0HC01FS1 (CP3NA24864)

600

2.22

0.90

MD0HC01FS1 (CP3NA24864)

600

2.48

1.20

MC0HC01FS1 (CP3NA24866)

600

1.33

0.80

MC0HC01FS1 (CP3NA24867)

600

1.85

0.90

MC0HC01FS1 (CP3NA24868)

600

2.06

1.00

MX0HC01FS1 (CP3NA24878)

600

43.87

0.90

MX0HC01FS1 (CP3NA24879)

600

31.44

0.80

MX0HC01FS1 (CP3NA24880)

600

52.26

0.90

MA1HC01FS1 (CP3NA24860)

600

14.83

0.60

MA1HC01FS1 (CP3NA24861)

600

21.87

0.60

MA1HC01FS1 (CP3NA24861)

600

19.42

0.70

MF0HC01FS1 (CP9JN75883)

600

40.30

1.20

MF0HC01FS1 (CP9JN75884)

600

21.40

0.46

MCR4001FS1 (CP8SN71164-13

600

4.36

1.70

Media

40MS

60HX

Millistak+
10

D0HC

C0HC

The information below was generated from a flush with purified water.
X0HC

Conductivity and TOC Test Results
Millistak+® HC and Clarisolve ® filters were autoclaved for 60
minutes at 123 °C, then flushed with purified water at a flow
rate of 600 LMH to a throughput of 100L/m2. The filter effluent
was then tested for conductivity and TOC.
Millistak+ ® HC Pro devices were not autoclaved and were
flushed at a flow rate of 300 LMH to a throughput of 50 L/m2.

A1HC

F0HC

Test Results
Catalog Number
(Lot Number)

Flux
(LMH)

Conductivity
(µS/cm)

TOC
Value
(ppm)

Clarisolve®
20MS

Flux
(LMH)

®

Conductivity and TOC

Media

Catalog Number
(Lot Number)

CS20MS01L3 (CP2KA10821)

600

1.59

1.40

CS20MS01L3 (CP2KA10822)

600

0.80

1.80

CS20MS01L3 (CP2KA10823)

600

1.29

2.10

CR40

MCR4001FS1 (CP8SN71165-3)

600

4.57

1.80

MCR4001FS1 (CP8SN71166-12)

600

4.56

1.60

MCR4001FS1 (CP8SN71167-11)

600

4.24

1.40

MCR4001FS1 (CP8SN71168-25)

600

4.51

1.30

Pod Depth Filters User Guide
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Test Results
Media

Catalog Number
(Lot Number)

Flux
(LMH)

Conductivity
(µS/cm)

TOC
Value
(ppm)

Millistak+® HC Pro

D0SP

C0SP

X0SP

MD0SP23CL3 (W167597)

300

41.50

0.95

MD0SP23CL3 (W167612)

300

27.50

1.09

MD0SP23CL3 (W167613)

300

24.40

0.61

MD0SP01FS1 (W177017-005)

300

8.98

0.47

MD0SP01FS1 (W177016-011)

300

14.98

0.77

MD0SP01FS1 (W177016-012)

300

16.73

0.69

MD0SP01FS1 (W177016-013)

300

11.12

0.70

MD0SP01FS1 (W177015-005)

300

8.86

0.78

MC0SP23CL3 (W167602)

300

18.90

1.15

MC0SP23CL3 (W167603)

300

23.40

2.01

MC0SP23CL3 (W167604)

300

37.20

3.18

MC0SP01FS1 (W177025-005)

300

19.20

1.24

MC0SP01FS1 (W177024-011)

300

17.53

1.0

MC0SP01FS1 (W177024-012)

300

14.15

0.88

MC0SP01FS1 (W177024-013)

300

16.37

0.74

MC0SP01FS1 (W177023-005)

300

11.34

0.71

MX0SP23CL3 (W167607)

300

25.00

2.20

MX0SP23CL3 (W167608)

300

32.80

2.90

MX0SP23CL3 (W167609)

300

24.10

3.00

MX0SP01FS1 (W177033-005)

300

10.35*

4.9*

MX0SP01FS1 (W177032-014)

300

10.51*

2.95*

MX0SP01FS1 (W177032-015)

300

11.14*

2.95*

MX0SP01FS1 (W177032-016)

300

10.64*

3.39*

MX0SP01FS1 (W177031-005)

300

8.12*

1.6*

BDL = Below detection Limit
*TOC and conductivity testing was performed after a 30 minute
hold with pure water, followed by a 50 L/m² pure water flush at
300 LMH with 5 psi back pressure for these units.

Process Optimization
Measure inlet and outlet pressure, original process fluid
turbidity, and filtrate turbidity over time to provide data to
verify performance and calculate sizing estimates.

Pod Depth Filters User Guide
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Specifications

Component

Materials of Construction

Filter Media

Component

Material

Material

Millistak+® Depth Filters
Housing

Glass filled polypropylene

Adapters

Glass filled polypropylene

Gaskets and Plugs

Thermo Elastic Polymer (TPE)
CR

Activated Carbon and
cellulose fibers

CE

Cellulose fibers

DE

Cellulose fibers and
diatamaceuous earth

Filter Media

D0HC, C0HC,
F0HC, X0HC

Multiple layers of cellulose
fibers and diatamaceuous
earth

A1HC, B1HC

Multiple layers of cellulose
fibers and diatamaceuous
earth; 0.1 µm RW
membrane

HC

Nonwoven, Silica filter aid/
Polyacrylic fiber pulp

C0SP

Silica filter aid/Polyacrylic
fiber pulp

X0SP

Silica filter aid/Polyacrylic
fiber pulp

Operating Parameters
Parameter

Housing

Glass filled polypropylene

Adapters

Glass Filled Polypropylene

Gaskets and Plugs

Thermo Plastic Elastomer (TPE)
20MS, 40MS

Polypropylene and
cellulose fibers combined
with an inorganic filter aid

60HX

Polypropylene

HC Media

Effective Surface
Area
DE, CE
Media
Inlet, Outlet and Vent
Connections
Operating Temperature
Range

Typical Flush/Process Flux

Glass filled Polypropylene

Adapters

Glass Filled Polypropylene

Gaskets and Plugs

Thermo Plastic Elastomer (TPE)

Process Scale
Pod

Maximum
Differential
Pressure

0.027 m2, 0.054 m2

0.11, 0.55,
1.1 m2
0.11, 0.77,
1.4 m2

¼ in. (6 mm) Hose
barb

Flat Seal

4 to 37 °C

4 to 37 °C

2 cycles of 60 minutes
at 123° C

1 cycle of 60
minutes at 123°
C

100 to 600 LMH

Forward

2.1 bar (30 psid) at
4-37 °C

2.1 bar (30 psid)
at 25° C;
15 psid (1.0 bar)
at 80° C

Reverse

2.1 bar (30 psid) at
37 °C

2.1 bar (30
psid) at 25° C

2.1 bar (30 psid) at
37 °C

3.5 bar (50 psig)
at 25 °C; 15 psig
(1.0 bar) at 80°
C

Millistak+® HC Pro Filters
Housing

Lab Scale Pod

Millistak+® Filters

Sterilization

Clarisolve® Depth Filters

Filter Media

D0SP

Housing Operating Pressure

Pod Depth Filters User Guide
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Lab Scale Pod

Process Scale
Pod

Clarisolve® Depth Filters
Effective Surface Area

0.0135, 0.027 m2

0.11, 0.33, 0.55
m2

Inlet, Outlet and Vent
Connections

¼ in. (6 mm) Hose
barb

Flat seal

4 to 37 °C

4 to 37 °C

Autoclave for two
cycles of 60 minutes
at 123 °C

Autoclave for
one cycle of 60
minutes at 123
°C

Operating Temperature
Range
Sterilization
Typical Flush/Process Flux
Maximum
Differential
Pressure

100 to 600 LMH

Forward

2.1 bar (30 psid) at ≤
37 ºC

2.1 bar (30 psid) at
< 25 ºC
1.0 bar (15 psid) at
< 80 ºC

Reverse

2.1 bar (30 psid) at ≤
37 ºC

2.1 bar (30 psid) at
< 25 ºC

Housing Operating Pressure

2.1 bar (30 psig) at ≤
37 ºC

3.5 bar (50 psid)
at < 25 ºC
1.0 bar (15 psid)
at < 80 ºC

Millistak+® HC Pro Filters
D0SP,
Effective Surface C0SP
Area
X0SP
Inlet, Outlet and Vent
Connections
Operating Temperature Range
Sterilization
Typical Flush/Process Flux

0.0135 m2
0.027 m²
0.0135 m²
0.027 m²

0.11, 0.33, 0.77
m²
0.11, 0.55, 1.1 m2

1/4 in (6 mm) hose
barb

Flat seal

4 to 40 °C

4 to 40 °C

Integrity is maintained after 1 cycle of
60 minutes at 123 °C. Recommended
for post-use decontamination only.
100 to 600 LMH

Lab Scale Pod

Process Scale
Pod

Forward

2.1 bar (30 psid) at ≤
40 °C

2.1 bar (30 psid)
at ≤ 80 °C

Reverse

2.1 bar (30 psid) at ≤
25 °C

2.1 bar (30 psid)
at ≤ 25 °C

2.1 bar (30 psid) at
40 °C

3.5 bar (50 psid)
at 80 °C

Parameter
Maximum
Differential
Pressure

Housing Operating Pressure

Pressure must be monitored at inlet or vent connections.

Typical Hold-up and Void Volumes
Clarisolve® Depth Filters
Hold-up volume (L)
Parameter

Lab Scale Pod

Process Scale Pod

0.0135

0.027

0.11

0.33

0.55

after gravity
drain

0.260.32

0.510.57

3.1-3.4

8.4-9.0

13.514.5

after blow
down

0.130.19

0.300.35

0.500.70

1.8-2.4

3.1-4.1

after gravity
drain

0.260.32

0.510.57

3.1-3.4

8.4-9.0

13.514.5

after blow
down

0.130.19

0.300.35

0.500.70

1.8-2.4

3.1-4.1

after gravity
drain

0.300.36

0.530.59

3.2-3.5

7.7-8.3

12.813.8

after blow
down

0.100.16

0.240.29

0.300.50

3.3-3.6

3.0-3.4

20MS Media

40MS Media

60HX Media

Pod Depth Filters User Guide
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Millistak+® HC Pro Depth Filters
Hold-up volume (L)
Parameter

Lab Scale Pod

Process scale pod

0.0135

0.027

0.11

0.33

0.55

0.77

1.1

0.275

0.541

2.12

5.50

--

12.9

--

after gravity drain

0.198

0.397

1.00

2.50

--

6.30

--

after blow down

0.094

0.139

0.643

1.99

--

5.04

--

0.259

0.618

2.04

5.81

--

12.8

--

after gravity drain

0.188

0.506

1.13

2.81

--

6.62

--

after blow down

0.119

0.185

0.711

2.22

--

5.44

--

0.347

0.676

1.25

--

4.94

--

9.47

after gravity drain

0.188

0.395

0.801

--

3.32

--

6.72

after blow down

0.09

0.175

0.635

--

2.92

--

5.85

D0SP Media
Internal void volume (L)
Hold-up
volume (L)
C0SP Media
Internal void volume (L)
Hold-up
volume (L)

X0SP Media
Internal void volume (L)
Hold-up
volume (L)

Chromaflow columns
PROCESS COLUMNS

Chromaflow™ columns are a family of convenient to use,
process-scale columns. A patented nozzle in the top and bottom
of the column allows packing, unpacking, and cleaning when fully
assembled, that is with the lid in place. Chromaflow columns
simplify chromatographic procedures and offer:
•

convenience

•

saving of labor

•

reproducibility

•

contained packing

•

scalability

General column description
Chromaflow low-pressure columns (Fig 1) are available in a choice
of dimensions and materials. The complete range offers inner
diameters (i.d.) from 300 to 2000 mm (Table 1), with column tubes
manufactured from cast acrylic (Fig 1). All dimensions are available
with variable bed heights, providing a wide variety of bed volumes.
All columns are pressure rated for operation at 3 bar.
Chromaflow columns incorporate a patented, pack-in-place nozzle
(Fig 2) through which process liquids enter and exit. Manual or
automated versions of the nozzles are available. The automated
nozzle is controlled from the packing station or the nozzle control
unit. The nozzle has three positions to facilitate the different
aspects of column operation: packing, operation, unpacking and
cleaning. In addition to this pack-in-place functionality, the nozzle
also contains the process liquid flow path to provide a consolidated
solution to the process stream handling.
Bed supports are available in 316L stainless steel or polyethylene.
The multilayer, woven stainless steel bed supports have very high
chemical resistance and longevity for use in applications where
salt concentrations are low and pH is above 5. Polyethylene bed
supports are recommended for applications with low pH and
high salt concentrations. All other wetted parts in columns with
polyethylene bed supports are manufactured from plastic or
noncorrodible materials for use in low pH /high salt applications.

cytiva.com

Fig 1. A Chromaflow column, 2000 mm i.d.

Fig 2. The Chromaflow nozzle that enables packing in place in a fully
assembled column (Cytiva patent).

The construction materials include 316L stainless steel, acrylic,
polypropylene, polyethylene, PEEK 450 G, EPDM rubber and
FEP encapsulated silicone. These materials have high chemical
resistance to the liquids typically used in process chromatography
(Table 2). Furthermore, all polymeric materials are approved
according to USP class VI tests for toxicity.
As an option, a dedicated packing station is available for Chromaflow
columns. The packing station speeds up the packing procedure by
eliminating the more time-consuming, manual maneuvers (Fig 3).
Comprehensive documentation is delivered with each column
and includes a User manual, a Maintenance manual, assembly
drawings, a full spare part list, materials certificates, etc.
A Validation Support File containing information on column
component composition, materials of construction and toxicity
studies is also available.

Principle of operation
The column has a three-position nozzle located in the center
of the top and bottom bed support. These three positions enable
packing, unpacking, operation and cleaning to be performed
without any adjustments to the assembled column, that is the
lid remains in place.
Flow profiles from the two nozzles are identical. Packing direction
will depend on the characteristics of the media and packing
method used. The three positions are illustrated in Figure 4.
Packing position
The bottom nozzle is extended part of
the way (mid position) into the column.
The top nozzle is fully retracted. Slurry
enters the column via the bottom nozzle
and excess liquid exits via the top mobile
phase outlet. After packing, the slurry
lines are isolated from the mobile phase
and can be cleaned independently from
the rest of the column.

Running position
The bottom and top nozzles are
retracted. Mobile phase enters the
column directly into an annulus,
immediately behind the bed support.
The annulus is cut through at an
angle to ensure that linear flow is kept
constant during distribution of the
mobile phase across the bed.

Fig 3. Packing Chromaflow columns with the dedicated packing station is
convenient and simple.

Convenient and labor saving
Once the column is assembled and the lid in place, no
lifting gear is required for packing, operation, unpacking or
cleaning-in-place (CIP). This means that a single operator can
perform all column operations, thereby reducing labor costs
and increasing convenience in large-scale operations.

Reproducibility
Packing with the lid in place allows the packing parameters
to be easily set and fixed. Manual operation is minimized and
standard operating procedures can be followed, helping to give
reproducible column packing and results.

Contained packing
Improved safety is another advantage of the Chromaflow column
concept. Because all the column operations are performed in a
“closed system” environment, there is less risk of the operator
coming into contact with hazardous chemicals and of the target
product being exposed to contamination. In this way, overall
safety and hygienic operation are improved.
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Unpacking position
In this position, both bottom and top
nozzles are fully extended into the column
thereby exposing a third passage through
which medium leaves the column.
Cleaning solution can be pumped through
the nozzles and sprayed into the column. In
this way the column is easily and effectively
cleaned without exposing the interior or the
medium to the environment, and without
dismantling the column.

Fig 4. The three positions of the Chromaflow nozzle showing packing from
the top.

Scalability

Chromaflow 400 SFP columns

Chromaflow columns are available in a wide range of dimensions,
all designed and constructed around the same design principle.
Standard range columns come in dimensions from 400 to 1000 mm.
For more information about columns and dimensions, see Ordering
information. Scaling up a chromatographic process from small to
larger diameters is easily performed with maintained reproducibility,
safety and convenience.

Chromaflow 400 SFP (small flow path) columns are specially
designed for low-flow applications. The dimensions in the mobile
phase have been optimized to reduce dead volumes to a minimum
and the area behind the nozzle tip has also been reduced.

Column dimensions

Table 2 lists the major components of Chromaflow columns
in contact with process fluids (wetted parts) and Table 3 lists
the chemical resistance of materials using data compiled from
several published sources. It is important to note that columns
with stainless steel bed supports and other stainless steel wetted
components must be appropriately maintained when exposed to
NaCl. Since salt can be corrosive to stainless steel over time, it is
recommended that residual salt is removed by rinsing columns
with at least five column volumes (CV) of clean water.

A selection of Chromaflow columns in the range 400 to 2000 mm
i.d. are presented in Table 1. The adapter stroke length is a standard
200 mm. Variable bed heights are available in the ranges 100 to
300 mm, 200 to 400 mm and 300 to 500 mm.

Column materials and their chemical
resistance

Table 1. Weights, volumes and dimensions for variable bed height Chromaflow columns

Max operating
pressure (bar)

Description

Volume
(L)

Column overall
height (mm)

Weight,
dry (kg)

Footprint
(mm × mm)

Chromaflow column 400/100-300*

3

12.6–37.8

1568

230

700 × 700

Chromaflow column 600/100-300

3

28.3–84.9

1568

375

800 × 800

Chromaflow column 800/100-300

3

50.3–150.9

1572

610

1000 × 1000

Chromaflow column 1000/100-300

3

78.5–235.5

1573

930

1200 × 1200

Chromaflow column 1200/100-300

3

113.1–339.3
153.9–461.7

Chromaflow column 1400/100-300

3

Chromaflow column 1600/100-300

3

201.1–603.3

Chromaflow column 1800/100-300

3

254.5–763.5

Chromaflow column 2000/100-300

3

314.2–942.6

* The first figure in the column name indicates the inner diameter and the second figure indicates stroke length.

Table 2. Major components and their composition

In contact with
process stream

Component

Material

Column tube

Acrylic or stainless steel 316L

Column lids

Stainless steel 316L

No

Distributor

Polypropylene

Yes

Bed support

Stainless steel 316L or polyethylene

Yes

Chromaflow nozzle

Polypropylene, stainless steel 316L, PEEK 450 G

Yes

Seals

EPDM or FEP encapsulated silicone

Yes

Stand

Stainless steel 316

No

Yes

EPDM = ethylene propylene diene, FEP = fluoroethenepropene, PEEK = polyetherether ketone
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Table 3. Chemical resistance of materials used in Chromaflow columns (60 days)

Chemical

Acrylic

SS 316L

EPDM

FEP

PEEK 450 G

PE

PP

Acetic acid 1.7 M

+

+

+

+

+

+

+

EtOH 20%1

+

+

+

+

+

+

+

EtOH 40%

–

+

+

+

+

(+)

+

Ethylene glycol 50%

+

+

+

+

+

+

+

Formaldehyde 1.7 M

+

+

+

+

+

+

+

Formic acid 10%

(+)

+

+

+

+

+

+

Glycerol 100%

+

+

+

+

+

+

+

Hydrochloric acid 0.1 M

+

–

+

+

+

+

+

Isopropyl alcohol 30%

–

+

+

+

+

(+)

+

Nitric acid 0.1 M

+

+

+

+

+

(+)

+

Phosphoric acid 25%

+

(+)

+

+

+

+

+

Sodium chloride 0.5 M

+

+2

+

+

+

+

+

Sodium hydroxide 2 M3

+

+

+

+

+

+

+

Trifluoroacetic acid 0.1%

(+)

+

+

+

+

+

+

Triton™ X-100 100%

+

+

+

+

+

+

+

Urea 8 M

+

+

+

+

+

+

+

+ Resistant (+) Limited resistance

– Not recommended

1

Do not expose acrylic to concentrations of ethanol greater than 20%. Do not exceed the following parameters during storage: 5 yr, 23°C, 0.5 bar g.
2
NaCl can cause corrosion on stainless steel at pH <5. Do not use NaCl in storage solutions. Rinse with at least 5 CV of clean water after use with NaCl.
3
Maximum exposure 4 h.
SS=stainless steel, EPDM=ethylene propylene diene, FEP=fluoroethenepropene, PEEK=polyetherether ketone, PE=polyethylene, PP=polypropylene.

Sanitizing Chromaflow columns
The design of Chromaflow columns facilitates cleaning-in-place.
Below is a recommended cleaning protocol suitable for most
applications.
1. Circulate 1.5 CV of 20% acetic acid at a low flow velocity (60
cm/h) for 15 min, upward flow. Then reverse the flow for 15 min.
2. Repeat this procedure with 1.0 M NaOH.
3. Following step 2, slowly circulate 1.0 M NaOH in the column
for 60 min.
4. Re-equilibrate the column with a storing or starting buffer.

Chromaflow Packing stations
Chromaflow Packing stations make column priming and packing
a simple operation, reducing the operator’s time to a minimum.
The packing stations consist of a control panel with pumps and
valves fitted underneath (Fig 5). Valves and diaphragm pumps
are actuated pneumatically from the control panel. As they are
brought into operation indicators on the control panel display the
relevant flow paths. For operation, packing stations only require
a supply of compressed air. To select an appropriate packing
station for your column and media, refer to Tables 4 and 5.
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Fig 5. Chromaflow Packing station Pack 100.

Table 4. Specifications of Chromaflow packing stations

Designation*

Pump

Pump flow
capacity
(L/min)

Req. air
supply
(m3/min)

Inlet piping/
outlet i.d.
(mm)

TC
connections
(mm)

Weight,
dry
(kg)

Size
W×H×D
(mm)

Pack 50

Tapflo™ T53

10–50

0.5

22.1/22.1

50.5

115

810 × 1175 × 715

Pack 100

Tapflo T103

30–100

1.0

34.8/22.1

50.5

130

810 × 1175 × 715

* Packing stations, Pack 200 and Pack 400 with pump flow capacities of 60 to 200 l/min and 100 to 400 l/min are available as custom orders.

Table 5. Approximate packing flow rates for different media at two different bed heights

Column
diameter (mm)

400

Bed height (mm)
Flow

150

600
300

150

800
300

150

1000
300

150

300

cm/h L/min cm/h L/min cm/h L/min cm/h L/min cm/h L/min cm/h L/min cm/h L/min cm/h L/min

Sepharose™
Fast Flow media

500

11

250

Sepharose
Big Beads media

1600

34

1200

5.5

500

24

250

12

500

42

250

21

500

66

250

33

25

1600

75

1200

57

1600

134

1200

101

1600

209

1200

157

What else do I need?
The column
The columns are supplied ready for use and are equipped with
adjustable feet. Castors can be ordered separately for columns
up to 1000 mm in diameter.

Isolating the column after packing
We recommend using sanitary stainless steel valves (of the
appropriate inner diameter) on the mobile phase to prevent
contamination of the packed bed. For storage purposes,
blind flanges with a clamp and gasket can be used to seal
off the column.

Assembly or disassembly of the column
An adequate sized wrench is needed for assembly or disassembly
of the column. A hoist is needed to remove the adapter or top lid
from the column.

Spare parts to keep on site
It is recommended that nozzle seals, column seals, and column
bed support kits are kept as spare parts.

Useful accessories

Connecting the column to your system and
packing station

Safety valve: Precalibrated valve which releases pressure if
the calibrated value is exceeded. Recommended to install on the
mobile phase inlet if no other pressure sensor is included in the
chromatography system. The T-junction, clamps and gaskets
must be ordered separately.

Clamps and gaskets of suitable size are required to connect
the sanitary flanged inlet/outlet to either valves or tubing of
the same type. Preflanged tubing is also available.

Pressure sensor: The sensor is installed inline, preferably on
the mobile phase inlet. Clamps and gaskets have to be ordered
separately.
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Ordering information
Columns
Chromaflow columns
with acrylic tubes

Bed support
10 mm SS sinter

Bed support
20 mm SS sinter

Bed support
20 mm PE sinter

Stroke length 100-300

18-1150-40

18-1159-40

18-1161-40

Stroke length 200-400

18-1157-42

18-1159-42

18-1161-42

Stroke length 300-500

18-1157-44

18-1159-44

18-1161-44

Stroke length 100-300

18-1157-41

18-1159-41

18-1161-41

Stroke length 200-400

18-1157-43

18-1159-43

18-1161-43

Stroke length 300-500

18-1157-45

18-1159-45

18-1161-45

Stroke length 100-300

18-1170-53

18-1176-12

11-0011-85

Stroke length 200-400

11-0011-80

11-0011-83

11-0011-86

Stroke length 300-500

11-0011-82

11-0011-84

11-0011-87

Stroke length 100-300

11-0011-89

11-0011-91

11-0011-94

Stroke length 200-400

11-0011-88

11-0011-92

11-0011-95

Stroke length 300-500

11-0011-90

11-0011-93

11-0011-96

Stroke length 100-300

18-1150-60

18-1159-60

18-1161-60

Stroke length 200-400

18-1157-62

18-1159-62

18-1161-62

Stroke length 300-500

18-1157-64

18-1159-64

18-1161-64

Stroke length 100-300

18-1157-61

18-1159-61

18-1161-61

Stroke length 200-400

18-1157-63

18-1159-63

18-1161-63

Stroke length 300-500

18-1157-65

18-1159-65

18-1161-65

Stroke length 100-300

18-1150-80

18-1159-80

18-1161-80

Stroke length 200-400

18-1157-82

18-1159-82

18-1161-82

Stroke length 300-500

18-1157-84

18-1159-84

18-1161-84

Stroke length 100-300

18-1157-81

18-1159-81

18-1161-81

Stroke length 200-400

18-1157-83

18-1159-83

18-1161-83

Stroke length 300-500

18-1157-85

18-1159-85

18-1161-85

Stroke length 100-300

18-1150-10

18-1160-10

18-1162-10

Stroke length 200-400

18-1158-12

18-1160-12

18-1162-12

Stroke length 300-500

18-1158-14

18-1160-14

18-1162-14

Stroke length 100-300

18-1158-11

18-1160-11

18-1162-11

Stroke length 200-400

18-1158-13

18-1160-13

18-1162-13

Stroke length 300-500

18-1158-15

18-1160-15

18-1162-15

I.d. 400 mm Man. nozzle

I.d. 400 mm Auto. nozzle

I.d. 400 mm SFP* Man. nozzle

I.d. 400 mm SFP Auto. nozzle

I.d. 600 mm Man. nozzle

I.d. 600 mm Auto. nozzle

I.d. 800 mm Man. nozzle

I.d. 800 mm Auto. nozzle

I.d. 1000 mm Man. nozzle

I.d. 1000 mm Auto. nozzle

For column specifications other than listed in the table, please contact your local Cytiva representative.
* SFP = Small Flow Path on mobile phase, only available on 400 mm i.d. columns.

6

Packing stations
Min (L/min)

Max (L/min)

Code number

Pack 50

10

50

18-1163-74

Pack 100

30

100

18-1162-08

Pack 200

60

200

Custom order

Pack 400

100

400

Custom order

Accessories
Designation

Code number

Designation

Code number

Media stirrers

Valves
4 port 2 way, i.d. 10 mm, 25 mm TC

18-1012-56

Media stirrer, 80 cm

18-1149-80

4 port 4 way, i.d. 10 mm, 25 mm TC

18-1012-57

Media stirrer, 150 cm

18-1149-81

3 port 2 way, i.d. 15 mm, 25 mm TC

44-5499-90

4 port 4 way, i.d. 20 mm, 51 mm TC

44-2302-01

3 port 2 way, i.d. 22 mm, 51 mm TC

44-1583-01

3 port 2 way, i.d. 35 mm, 51 mm TC

44-5494-65

Valve sealing washer

18-1128-69

Fits 10 mm 2- and 4-way valves

Connectors
i.d. 10, 25 mm TC-3/4"-20 UNF threaded

18-1012-68

i.d. 10, 25 mm TC-i.d. 14, 51 mm TC

18-1027-25

i.d. 14, 51 mm TC-i.d. 22, 51 mm TC

18-1027-26

Chromaflow Nozzle control unit

18-1164-61

Chromaflow Nozzle pipings

PVC tubing with sanitary fitting 25 mm TC
i.d. 10 mm, 900 mm

18-1012-62

Chromaflow Nozzle piping 400 1/2"

18-1172-01

i.d. 10 mm, 1400 mm

18-1012-63

Chromaflow Nozzle piping 400 3/4"

18-1172-00

18-1012-64

Chromaflow Nozzle piping 400 1"

18-1171-99

i.d. 10 mm, 2000 mm

18-1012-87

Chromaflow Nozzle piping 600 1/2"

18-1172-06

i.d. 14 mm, 750 mm

18-1027-28

Chromaflow Nozzle piping 600 3/4"

18-1172-05

18-1027-29

Chromaflow Nozzle piping 600 1"

18-1172-04

Chromaflow Nozzle piping 800 1/2"

18-1171-94

Chromaflow Nozzle piping 800 3/4"

18-1171-93

Chromaflow Nozzle piping 800 1"

18-1171-92

i.d. 10 mm, 1700 mm

i.d. 14 mm, 1800 mm
PVC tubing with sanitary fitting 51 mm TC
i.d. 22 mm, 900 mm

44-1616-09

i.d. 22 mm, 1400 mm

44-1616-08

i.d. 22 mm, 2000 mm

44-1616-07

i.d. 22 mm, 4000 mm

44-1616-06

Chromaflow Nozzle piping 1000 1/2"

18-1172-09

Chromaflow Nozzle piping 1000 3/4"

18-1172-08

Chromaflow Nozzle piping 1000 1"

18-1172-07

Clamp gasket
25 mm i.d., 10 mm

18-1035-79

25 mm i.d., 12 mm

18-0200-00

51 mm i.d., 22 mm

44-7133-01

51 mm i.d., 38 mm

44-0515-01

Clamp 25 mm

18-1001-31

Clamp 51 mm

44-7134-01

Blind flange 25 mm incl. gasket

18-1001-25

Blind flange 51 mm incl. gasket

44-7135-01

Safety valve, 3 bar, 51 mm TC

18-5738-01

Safety valve, 5 bar, 51 mm TC

44-5498-97

T-junction i.d., 10 mm, 2×25 mm TC, 1×51 mm TC

18-1003-63

Castors, assembly kit 400-600

18-1171-51

Castors, assembly kit 800-1000

18-1171-52

The kit contains a complete set of wheels, fasteners
and adapters for a column.

Pressure sensor i.d. 10 mm, 25 mm TC

44-0507-02

Pressure sensor i.d. 22 mm, 51 mm TC

44-0507-03
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HyPerforma 2,000 L Single-Use Mixer

HyPerforma Single-Use Mixer
with Touchscreen Console
The next generation of efficiency and performance
The Thermo Scientific™ HyPerforma™ Single-Use Mixer
(S.U.M.) with Touchscreen Console offers enhanced
functionality, ease of use, and efficiency. The complete
HyPerforma S.U.M. system consists of a mixer tank,
available in 50, 100, 200, 500, 1,000, and 2,000 L sizes
with the Touchscreen Console. The HyPerforma S.U.M.
has a 5:1 turndown mixing ratio and maintains traditional
stirred-tank mixer design principles with a directly coupled
motor impeller drive assembly and a cylindrical tank with
a specific height-to-diameter ratio. This allows quick
turnaround times for both liquid-to-liquid mixing and
powder-to-liquid mixing.
2,000 L HyPerforma S.U.M. standard configurations
• AC motor
• 3x load cell weighing system
• Touchscreen Console
Critical upstream application steps
• Media preparation
• Final formulation steps
• Buffer preparation
• Large-volume mixing
Critical downstream application steps
• Pooling and liquid transfer
• Product suspension
• Mixing and storing multiple batches
• Buffer preparation
• Viral inactivation

Touchscreen Console capabilities
The Touchscreen Console offers state-of-the-art in-process
monitoring and automation capability for the HyPerforma
S.U.M. Its modular design allows for an easy-to-use custom
user interface. Capabilities include: control of agitation
speed, pumps, pinch clamps, and temperature control
unit. Users can easily view measurements from load cells,
pH sensors, conductivity sensors, resistance temperature
detectors (RTDs), and pressure sensors.
Simple, routine processes can be automated by utilizing
measurement values to control the pumps, temperature
control unit (TCU), and agitation motor. The Touchscreen
Console can help users semi-automate their formulation,
pH, or saline titrations, and viral inactivation processes.
This allows users to program their HyPerforma S.U.M. for
a process and trust that the measurements are accurate,
precise, and controlled. The data measured during a
process can be exported remotely via Ethernet, Profibus,
or Modbus remote terminal unit (RTU), and can also be
accessed locally with a USB flash drive.

HyPerforma S.U.M. design features and options
1. Powder hanger for 1 kg, 5 kg, and 25 kg
Thermo Scientific™ Powdertainer™ BioProcess
Containers (BPCs)

12. Standard tool set: 10 mm (3/8 in.) x 16.9 Nm
(150 in.-lb.)square torque wrench, load cell and motor
cap lockout wrench

2. Mixing assembly with shield

13. 0.95 cm (3/8 in.) dimpled jacket

3. Bearing port receiver with clamp

14. Stainless steel outer support container

4. Mixer motor

15. Rear door (for BPC loading), with sight window

5. Touchscreen Console

16. Bottom cutouts/pins for BPC attachment
and alignment

6. Drive shaft, stored
7.

17. Bleed valve (jacketed models only)

Cable management hooks

8. Probe access windows

18. 3.81 cm (1.5 in.) tri-clamp connection ports for water
inlet/outlet (jacketed models only)

9. Probe clip hangers

19. Leveling feet (3)

10. Liquid sight window
11. Shelves and basket (optional)
Front view

Back view

1

12

2
13

3
4

14

5

15

10

6

16

17

7

11
8

19

9
18

Note: Models without water jackets include the same features as the water-jacketed models shown here, but without the jacket and inlet/outlet ports.
Optional load cells and cable management system are not shown. See the accessories section for more information about these items.

HyPerforma S.U.M. design specifications
Front view

Top view

297 cm (116.9 in.) Powdertainer
BPC hanger height

171 cm (67.4 in.)
Overall length

144 cm (56.5 in.)
Cart width

225 cm (88.5 in.) Motor height

143 cm (56.4
in.)
Cart length

43 cm (17.0 in.)
Shelf width

182 cm (71.8 in.) Tank height

137 cm (53.7 in.)
Touchscreen height

36 cm (14.2 in.)
Electrical panel
width

190 cm (74.8 in.)
Overall width
31 cm (12.4 in.) Tank bottom
16 cm (6.3 in.) Cart height
0 cm (0 in.)

Touchscreen Console measurement options and specifications
Load cell
Accuracy after
calibration
Calibration
Resolution

±0.5%
of full scale
1 to 3 points and
zero/tare function
0.1 kg

Temperature

pH

Conductivity

0.2°C

±0.05 pH unit

±5%

1 to 3 points

1 to 3 points

1 to 3 points

0.01°C

0.01 pH unit

1 µS/cm

BPC and in-line
liquid pressure
±3.5% of full scale
(30 psi)
1 point;
zero/tare function
0.01 psi

Sensor range

0 to 3,300 kg

0 to 200°C

0 to 14

20 to 20,000 µS/cm

0 to 30 psi

Measurement units

kg

°C

pH units

µS/cm

Probe type

3 x Mettler Toledo
0745A load cells

RTD

Electrochemical
with 225 mm
S8 connector

Two-pole
conductivity sensor

psi
Single-use sensor
part of the BPC
and/or fluid transfer
assembly design

Accessories
Sensors and pinch valves
Reusable pH and conductivity probes as well as single-use
pressure sensors have been approved and qualified for
use with the Touchscreen Console. pH and conductivity
measurements can be used to control titration pumps,
which enable automatic titration capabilities. The pressure
sensors are used in the BPC or line sets to monitor the
BPC or liquid pressure, respectively. The BPC can be filled
with the proper amount of air when using the pressure
sensor in the BPC. The liquid pressure module in the
Touchscreen Console is used to control a transfer pump,
based on the liquid pressure. Optional pneumatic pinch
valves can be used on the fill and harvest line. These valves
automatically open and shut when using the fill and/or
harvest modules in the Touchscreen Console.
Ordering information
Standards

Manufacturer

Cat. No.

Thermo Fisher Scientific

SV51147.02

Mettler Toledo

SV51147.01

Broadley James

SV51147.03

JUMO

SV51148.01

Mettler Toledo

SV51148.02

Pressure sensor
(single use, included in
BPC and/or fluid transfer
assembly)

PendoTECH
3/8 in. ID tubing

SV20826.05

PendoTECH
1/2 in. ID tubing

SV20826.01

Pinch valve, harvest line

Thermo Fisher Scientific

SV51108.08

Pinch valve, fill line

Thermo Fisher Scientific

SV51108.05

pH sensor

Conductivity sensor

Heavy-duty tubing clamps
Heavy-duty clamps are used to pinch off line sets that are
not in use, to prevent process fluids from escaping. Prior to
sterile probe insertion, tubing clamps must be in place to
close off probe ports.

Ordering information
Description

Cat. No.

Heavy-duty tubing clamp (single)

SV20664.01

Heavy-duty tubing clamp (10 pack)

SV20664.04

Load cells
Load cells are typically radially mounted in sets of three.
The mounting location varies slightly for each size in order
to allow easy access to the bottom drain or sparging
mechanisms and tubing.

Probe clips
Probe clips are used to hold the probes in place on the
S.U.M. tank. The independently movable probe clips hang
on a thin brace above the probe port tank cutout.

Ordering information
Description

Cat. No.

4 plastic probe clips

SV50177P.01

Autoclave tray and probe assembly
The autoclave tray holds the electrochemical probes and
bellows in place during the autoclave sterilization process.
Design elements include the following:

Cable management system
The optional cable management system connects to the
left side of the S.U.M. and is used to properly route tubing
and cables along the side of the S.U.M.

• Fabricated from stainless steel
• Plastic handle provides for easy transport right
out of the autoclave
• Positions probes on 15% incline for greater probe and
membrane longevity
• Prevents probe bellows from collapsing
during sterilization
• Probe holder accommodates two probes
Threaded probe
attachment
Cable tie

Probe

Ordering information

Handle
Molded
bellows cover

Description

Cat. No.

Cable management system (500 L–2,000 L)

SV50992.03

Powdertainer arm
A Powdertainer arm is available as an option for
powder-to-liquid applications. It holds the container of
powder above the mixer and attaches it to the BPC with
a clamp. The arm adjusts vertically and swivels to enable
convenient lifting of the Powdertainer BPC onto the hanger.

Autoclave tray

Ordering information
Description

Cat. No.

Autoclave tray (stainless steel with
plastic carrying handle)

SV50177.01

Powdertainer hook

Powdertainer-to-BPC
port clamp

Tank attachment
mechanism

Powdertainer arm

Ordering information
Description

Cat. No.

Powdertainer arm (2,000 L)

SV51002.02

Standard 2,000 L S.U.M. hardware
2,000 L S.U.M. specifications

Motor

Agitation

Impeller

Mixer geometry

Jacketed and non-jacketed
Rated liquid working volume

2,000 L

Minimum liquid working volume

400 L (complete impeller coverage)

Total chamber volume (liquid and gas)

2,700 L

BPC chamber diameter

135 cm (53 in.)

BPC chamber shoulder height

185 cm (73 in.)

Liquid height at rated working volume

140 cm (55 in.)

Fluid geometry at working volume (height:diameter ratio)

1:1

Hold-up volume

<1 L

Overall mixer geometry (height:diameter ratio)

1.2:1

Tank baffles

None

Impeller (quantity x blade count)

1x3

Impeller scaling (impeller diameter:tank diameter)

1:5

Impeller blade pitch (angle)

45°

Impeller diameter

25.02 cm (9.85 in.)

Mixing rate range

20–356 rpm

Tip speed

39.4–459.7 cm/sec (77.6–904.8 ft/min)

Counterclockwise mixing flow direction

Down-pumping

Agitation shaft resolved angle

27°

Agitation shaft centerline offset

17.8 cm (7 in.)

Overall drive shaft length

192.5 cm (75.78 in.)

Drive shaft diameter

1.9 cm (0.75 in.)

Drive shaft poly-sheath outside diameter

2.54 cm (1 in.)

Impeller clearance from tank bottom

5.08 cm (2 in.)

Agitation motor drive (type, voltage, phase)

Motor torque rating

Induction, 208 VAC, 3 phase
745.7 W (1 hp)
Motor: 208 VAC, 3.2 A
18 Nm (159 in.-lb.)

Gear reduction

5:1

Motor communication methods

Via Touchscreen Console through communication ports

Ceiling height required for drive shaft loading

292.1 cm (115 in.)
100–120 VAC, 50/60 Hz, single, 15 A
220–240 VAC, 50/60 Hz, single, 10.4 A
12 mm diameter x 215–235 mm insertion length
x 13.5 PG (pipe) thread
<70 dB at 1.5 m

Motor power rating

General

Electrical power rating
pH & DO probe—autoclavable type
(Applisens, Broadley James, Mettler Toledo)
Noise level
Storage temperature

Motor speed

–25°C to 65°C
20–80% non-condensing
AC motor: 100% max. (without any dew condensation)
S.U.M.: 2–40 ± 0.1°C (36–104 ± 0.2°F)
AC motor: 0–40°C (32–104°F)
30–350 rpm

Volume range

500–2,000 L

Maximum static BPC pressure

0.03 bar (0.5 psi)

Maximum BPC pressure during operation

0.007 bar (0.1 psi)

Continuous operating time

21 days mixing at nominal volume only

Relative humidity
Recommended
operating
parameters

Operating temperature range

Standard 2,000 L S.U.M. hardware
2,000 L S.U.M. specifications

Support container Temperature
(without shelves/
Fluid jacket
control
basket)

Jacketed
Jacket area: full/half volume

5.3 m /3.3 m (57.3 ft /35.5 ft )

–

Jacket volume

26 L (6.9 gal)

–

Jacket flow rate at 3.4 bar (50 psi)

93 L/min (24.5 gal/min)

–

Process connection

1 in. sanitary tri-clamp

–

TCU model: maximum heating/cooling

TF24000: 22,500/24,000 W

–

Approximate liquid heat-up time (5–37°C)

2.7 hr

–

Approximate liquid cool-down time (37–5°C)

3.9 hr

–

RTD or thermocouple, 3.18 mm (1/8 in.) OD

Pt-100 (standard)

Pt-100 (standard)

Overall width

180 cm (70.7 in.)

180 cm (70.7 in.)

Overall length

171 cm (67.4 in.)

171 cm (67.4 in.)

Overall height (without Powdertainer arm)

225 cm (88.5 in.)

225 cm (88.5 in.)

Dry skid weight (mass)

755.1 kg (1,664.8 lb.)

551.1 kg (1,214.8 lb.)

Wet skid weight—rated working volume (mass)

2,755.1 kg (6,073.8 lb.)

2,551.1 kg (5,623.8 lb.)

Dimensions (W x H x D)
Construction material
Pumps
Load cells
Touchscreen Console

Non-jacketed

pH sensors supported
Conductivity sensors
Pinch valves
HMI
Alarms
Communication ports
E-stop
Data recording
File formats
Data exporting

2

2

2

2

250 x 520 x 234 mm (9.9 x 20.5 x 9.3 in.)
AISI 304 (stainless steel)
Supports various pumps with 4–20 mA signal control
Mettler Toledo MTB
Thermo Scientific, Mettler Toledo, and Broadley James
JUMO, Mettler Toledo
Bimba ACRO 935 pinch valve,
3/4 in. (19 mm) OD x 1/8 in. (3.175 mm) wall tubing
8.4 in. LCD panel with capacitive touchscreen
Factory-set and user-defined
USB, Ethernet, Profibus, Modbus RTU
Integrated safety circuit for entire system; external E-stop also available
User-defined data record transfer via Ethernet, Profibus, or Modbus RTU.
72-hour data storage exportable via USB
CSV
Local via USB flash drive
Remote via PC and network with Ethernet, Profibus, or Modbus RTU

HyPerforma S.U.M. BPCs
Open-top or closed-top Thermo Scientific™ BPC designs are available with Thermo Scientific™ CX5-14
and Aegis™ 5-14 film options.
1. Addition line

Impeller
3. Bottom drain

Back face
4. Powder addition port
2. Recirculation/sample line
Front face

Standard 2,000 L BPC for powder–to-liquid applications without probe ports
Line

Description

Tubing set (inner diameter x outer diameter x length)

End treatment

1

Addition line

12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 183 cm (72 in.)

Plugged 12.7 mm (1/2 in.) MPX body

2

Recirculation/sample line

12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 198 cm (78 in.) splits to
12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 61 cm (24 in.) and
12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 30 cm (12 in.)

Capped 12.7 mm (1/2 in.) MPX insert
Plugged 12.7 mm (1/2 in.) MPX body

3

Bottom drain

12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 122 cm (48 in.)

Plugged 12.7 mm (1/2 in.) MPX insert

4

Powder addition port

7.6 mm (3 in.) sanitary fitting, tri-clamp

Cap with gasket

Impeller
2. Recirculation/sample line

3. Fill line
4. Vent filter

5. Addition line

Front face
1. Bottom drain

Back face

Standard 2,000 L BPC for liquid-to-liquid applications without probe ports
Line

Description

Tubing set (inner diameter x outer diameter x length)

End treatment

1

Bottom drain

12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 122 cm (48 in.)

Capped 12.7 mm (1/2 in.) MPX insert

2

Recirculation/
sample line

12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 198 cm (78 in.) splits to
12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 61 cm (24 in.) and
12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 30 cm (12 in.)

Capped 12.7 mm (1/2 in.) MPX insert
Plugged 12.7 mm (1/2 in.) MPX body

3

Fill line

19.1 mm (3/4 in.) x 25.4 mm (1 in.) C-Flex x 183 cm (72 in.)

38.1 mm (1 1/2 in.) tri-clamp (SterilEnz™)

4

Vent filter

6.4 mm (1/4 in.) x 12.7 mm (1/2 in.) C-Flex x 10.2 cm (4 in.)

Sterile hydrophobic vent filter
(0.2 μm PVDF, Acro™ 50)

5

Addition line

9.5 mm (3/8 in.) x 15.9 mm (5/8 in.) C-Flex x 61 cm (24 in.)

Plugged 9.5 mm (3/8 in.) MPX body

2. Addition line

Impeller

3–4. Probe ports (2)

Front face
5. Unused

1. Recirculation/sample line

6. Thermowell/small-volume sample line

7. Bottom drain

Back face

8. Powder addition port

Standard 2,000 L BPC for powder-to-liquid applications with probe ports
Line Description
1
2
3–4
5
6
7
8

Tubing set (inner diameter x outer diameter x length)

End treatment

12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 198 cm (78 in.) splits to
Capped 12.7 mm (1/2 in.) MPX insert
Recirculation line 12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 61 cm (24 in.) and
Plugged 12.7 mm (1/2 in.) MPX body
12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 30 cm (12 in.)
Addition line
12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 122 cm (48 in.)
Plugged 12.7 mm (1/2 in.) MPX insert
Kleenpak™ aseptic connector
Probe ports (2)
None
KPCHT series (female)
Unused
None
Plug
Thermowell/
Thermowell adapter for 3.2 mm (1/8 in.) diameter 3.2 mm (1/8 in.) x
small-volume
Luer and SmartSite™ valve port
6.4 mm (1/4 in.) x 30 cm (12 in.)
sample line
Bottom drain
12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 122 cm (48 in.)
Capped 12.7 mm (1/2 in.) MPX body
Powder addition
7.6 mm (3 in.) sanitary fitting, tri-clamp
Cap with gasket
port

1-2. Probe ports (2)

Impeller
Front face

9. Unused

4. Recirculation/sample line

5. Fill line

8. Bottom drain
3. Thermowell/small-volume sample line

7. Addition line

6. Vent filter

Back face

Standard 2,000 L BPC for liquid–liquid applications with probe ports
Line Description

Tubing set (inner diameter x outer diameter x length)

End treatment

1–2

Probe ports (2)

None

3

Kleenpak aseptic connector KPCHT
series (female)
Luer and SmartSite valve port

5

Thermowell/
Thermowell adapter for 3.2 mm (1/8 in.) diameter 3.2 mm (1/8 in.) x
small-volume
6.4 cm (1/4 in.) C-Flex x 30 cm (1/2 in.)
sample line
Recirculation line 12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 198 cm (78 in.) splits to Capped 12.7 mm (1/2 in.) MPX insert
12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 61 cm (24 in.) and
Plugged 12.7 mm (1/2 in.) MPX body
12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 30 cm (12 in.)
Fill line
12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 183 cm (72 in.)
38.1 mm (1 1/2 in.) tri-clamp (SterilEnz)

6

Vent filter

6.4 mm (1/4 in.) x 12.7 mm (1/2 in.) C-Flex x 10.2 cm (4 in.)

7

Addition line

9.5 mm (3/8 in.) x 15.9 mm (5/8 in.) C-Flex x 61 cm (24 in.)

Sterile hydrophobic vent filter
(0.2 μm PVDF, Acro 50)
Plugged 9.5 mm (3/8 in.) MPX insert

8

Bottom drain

12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 122 cm (48 in.)

Plugged 12.7 mm (1/2 in.) MPX body

9

Unused

None

Plug

4

Bottom drain
Quick-connect fitting

Impeller

Sleeve (3/4 in. inner diameter tubing)

Standard open-top liners

Standard impeller sleeve

Description

Cat. No.

Description

Cat. No.

1,000 L standard open-top liner,
0 probes, CX3-9 film

SH30762.05

2,000 L impeller sleeve for open-top mixing*

SH30772.01

* The bearing hub needed for open-top mixing is automatically supplied with the tank hardware.

Custom BPC products
Category

Options/capability

Notes

Tubing type

C-Flex, platinum-cured silicone, PVC, PharMed™, PharmaPure™

More information is available in
the tubing selection guide

Tubing size

Ranges from 3.18 mm (1/8 in.) to 25.4 mm (1 in.) inner diameter in
various lengths

More information is available in
the tubing selection guide

Connectors

More information is available in
Luer, Colder Products Company™ (CPC) quick connects, SIP connectors, the connection system selection
guide. Note: the only option
tri-clamp, Kleenpak, SmartSite, Clave™, Lynx™ steam-thru, CPC steamfor probe port connections is
thru, Gore™ steam valve, Gore™ Mini TC, BioQuate™, SterilEnz, end plug
Kleenpak connectors

Probe ports/
line addition ports

Ports may be added if they are compatible with the hardware

The reusable probe port
connection uses a
Kleenpak connector

Disposable sensors

Pressure sensor: PendoTECH™ and Finesse Solutions (PendoTECH
comes standard on 500 L and 1,000 L S.U.M.); DO and pH sensor:
Finesse Solutions and PreSens™; pH sensor: Mettler Toledo

Choice of qualified
vendors available

Port sizes

Limited engineer-to-order customization only

Dependent on location in BPC
and fit with hardware (e.g.,
1 in. ID port on harvest line)

Rearrangement of
lines on existing
ports

Limited customization possible, such as moving sample/thermowell port
to a probe tube port, or swapping exhaust outlet line with liquid lines

Dependent on location in BPC
and fit with hardware

Dip tube lines

Limited customization possible

Length cannot interfere
with impeller and shaft

Filters on media and
supplement inlets

Limited engineer-to-order customization only. Choice of filters used to
sterilize incoming media or supplements are available

Note: Not all options are available for all ports. It is not possible to customize port type, port location, chamber dimensions, or mixing assembly.
For additional information, please see the selection guides in the product catalog.

BPC packaging
Description

Details

Outer packaging

Supplied flat-packed with two polyethylene outer layers

Label

Description, product code, lot number, and expiry date on outer packaging and shipping container

Sterilization

Irradiation (25 to 40 kGy) inside outer packaging

Shipping container

Durable cardboard carton

Documentation

Certificate of Analysis provided with each lot for each delivery

Ordering information
2,000 L S.U.M. hardware

Cat. No.

Non-jacketed, AC motor, Touchscreen Console, 240 V, with load cells

SUM2000.9003

Jacketed, AC motor, Touchscreen Console, 240 V, with load cells

SUM2000.9004

Models without water jackets may have slightly different dimensions than the water-jacketed model shown in this data sheet. See the drawings provided with your unit for exact dimensions for non-jacketed
models. Non-jacketed models do not have the capability to heat or cool the liquid inside the tank.

2,000 L S.U.M. BPC
Standard powder-to-liquid BPC

Standard liquid-to-liquid BPC

Standard powder-to-liquid BPC*

Standard liquid-to-liquid BPC*

Size

Probe ports*

Film type

Cat. No.

2,000 L

0

CX5-14

SH30770.01

2,000 L

0

Aegis 5-14

SH30973.05

2,000 L

0

CX5-14

SH30769.01

2,000 L

0

Aegis 5-14

SH30983.05

2,000 L

3

CX5-14

SH30770.02

2,000 L

3

Aegis 5-14

SH30974.05

2,000 L

3

CX5-14

SH30769.02

2,000 L

3

Aegis 5-14

SH30982.05

* All 2,000 L BPCs with probe ports are designed to allow probes to work properly at 5:1 turndown levels. These BPCs are only compatible with the HyPerforma hardware shown in this document. If you are
using an older version of the S.U.M. hardware, do not use these items; instead refer to the legacy S.U.M. user manual or data sheets.

Find out more at thermofisher.com/sum
For Research Use or Further Manufacturing. Not for diagnostic use or direct administration into humans or animals.
© 2019 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless
otherwise specified. Allen Bradley is a trademark of Allen-Bradley Company. Applisens is a trademark of Applikon B.V. Corporation. BioQuate
and PreSens are trademarks of General Electric Company. Broadley James is a trademark of Broadley-James Corporation. Clave is a trademark
of ICU Medical, Inc. Colder Products Company is a trademark of Dover Corporation. Gore is a trademark of W. L. Gore & Associates. Kleenpak
and Acro are trademarks of Pall Corporation. Lynx is a trademark of Merck KgAA. Mettler Toledo is a trademark of Mettler-Toledo AG. PharMed
and PharmaPure are trademarks of Saint-Gobain Performance Plastics Corporation. PendoTECH is a trademark of PendoTECH. SmartSite is a
trademark of Carefusion 303, Inc. SterilEnz is a trademark of PAW BioScience Products, Inc. COL8388 0119

Data Sheet

Millipore Express® SHF
Hydrophilic Filters
High flow sterilizing-grade PES filters for
validated process steps
Millipore Express® SHF (Sterile High-Flux) filters are
an unparalleled combination of quality and process
performance. A sterilizing-grade, hydrophilic
polyethersulfone (PES) membrane, these filters provide
sterility assurance, broad chemical compatibility, and
exceptionally high flow rates for your validated process
steps. Developed and designed for your validated sterile
filtration processes, manufactured in a highly controlled
process and supported by extensive documentation to
fulfill your regulatory requirements.

Benefits
• Highly efficient sterilizing-grade membrane
• Designed for validated filtration steps which require
sterility assurance

- Drug Master File available
- Retention testing on each lot of membrane and
filter device

- Each filter subject to the highest sensitivity integrity test in the industry

- Validation kits available

Filter Formats

Sterilization Capability

• OptiScale® small-scale disposable
capsule filters

• Autoclavable

• Opticap® XL and XLT disposable
capsule filters– autoclavable,
sterile and gamma compatible

• Gamma Compatible

• Cartridge filters

EMD Millipore Corp. is a subsidiary of Merck KGaA, Darmstadt, Germany

• Sterile

Regulatory Compliance

Reduced Surface Area and Lower Costs

• Filters are designed, developed and manufactured in
accordance with a Quality Management System
approved by an accredited registering body to the
ISO® 9001 Quality Systems Standard.

Millipore Express® SHF filters feature faster flow rates,
allowing you to process equivalent volumes with reduced
filtration area. This high-flux benefit has been shown to
deliver greater than 50% savings in filtration costs.

• Each filter and membrane lot is subjected to
bacterial retention testing.
• Every filter is subjected to the highest sensitivity
integrity test in the industry.
• All filters are shipped with a Certificate of Quality.
• A Validation Guide, which is a summary of the product
qualification, is available upon request.
• For traceability and easy identification, each filter
is identified with product name, lot number, and
serial number.
• Drug Master File is 16877DMF

Superior Flux
Relative Water Permeability of
10-inch Cartridges

Millipore Express® SHF Membrane Flux
Relative to Competitors

1.0

25

0.9
0.8

20

0.7

Flow Rate (mL/min – cm 2 ) at 10 psid

Relative water permeability (SHF)

0.6
0.5
0.4
0.3
0.2
0.1
0.0

Millipore Express® SHF Cartridge
Competitive Cartridge A
Competitive Cartridge B

15

10

5

0

Water

150 mM
Phosphatebuffered
saline

25%
Propylene
glycol *

0.1 M
Acetic
acid

1.0 M
Sodium
hydroxide

0.15 N
Hydrochloric
acid

Millipore Express® SHF Membrane
Competitor A
Competitor B₁
Competitor B₂

*Includes 0.2 M arginine-HCl, 0.5 M sodium phosphate

Specifications

Opticap® XL and XLT Disposable Capsules (Autoclavable)
Opticap® XL 3
Capsules

Opticap® XL 5
Capsules

Opticap® XL 10
Capsules

Opticap® XLT 10
Capsules

Opticap® XLT 20
Capsules

Opticap® XLT 30
Capsules

17.3 cm (6.8 in.)

21.6 cm (8.5 in.)

33.5 cm (13.2 in.)

37.6 cm (14.8 in)

62.5 cm (24.6 in)

87.1 cm (34.3 in)

Nominal Dimensions
Maximum length:
Fitting to Fitting
Sanitary flange to sanitary flange:

-

15.2 cm (6.0 in.)

15.2 cm (6.0 in.)

15.2 cm (6.0 in.)

Sanitary flange to hose barb:

-

17.5 cm (6.9 in.)

17.5 cm (6.9 in.)

17.5 cm (6.9 in.)

Hose barb to hose barb:

-

Filtration Area

0.16 m2 (1.7 ft2)

0.29 m2 (3.1 ft2)

0.54 m2 (5.8 ft2)

19.8 cm (7.8 in.)

19.8 cm (7.8 in.)

19.8 cm (7.8 in.)

0.54 m2 (5.8 ft2)

1.08 m2 (11.6 ft2)

1.62 m2 (17.4 ft2)

-

-

-

≤ 30 cc/min.

≤ 60 cc/min.

≤ 90 cc/min.

Materials of Construction
Filter membrane:

Hydrophilic polyethersulfone

Film edge:

Polypropylene

Supports:

Polypropylene

Structural components*:

Polypropylene

Core:

Polysulfone

Vent O-rings:

Silicone

Vent/Drain

¼ in. hose barb with double O-ring seal

Maximum Operating pressure

6900 mbar (100 psi) intermittent 23 C°

Maximum Differential Pressure
Forward:

5500 mbar (80 psi) at 25 °C
6900 mbar (100 psi) intermittent at 25 °C
1000 mbar (15 psi) at 80 °C

Reverse:

2100 mbar (30 psi) intermittent at 25 °C

Bubble Point at 23 °C

≥ 4000 mbar (58 psi) air with water

Air Diffusion at 23 °C

Through a water wet membrane at 2800 mbar (40 psi):
≤ 9.1 cc/min.

≤ 30 cc/min.

Bacterial Retention

Quantitative retention of 10 CFU/cm Brevundimonas diminuta ATCC® 19146 per ASTM® methodology.

Bacterial Endotoxin

Aqueous extraction contains <0.25 EU/mL as determined by the Limulus Amebocyte Lysate (LAL) Test (per 10-inch filter).

TOC/Conductivity

Autoclaved capsule effluent meets the WFI criteria for USP <643>, Total Organic Carbon and USP <645>, Conductivity, after a
WFI water flush of:

7

3.0 L
Oxidizable Substances

2

5.5 L

10 L

10 L

20 L

30 L

Meets the USP Oxidizable Substances Test requirements for sterile purified water after a water flush of:
1000 mL

1000 mL

1000 mL

1000 mL

2000 mL

3000 mL

Sterilization

May be autoclaved for 3 cycles of 60 minutes at 126 °C. (Cannot be steam sterilized in-line).

Non-Fiber Releasing

Component materials meet criteria for a “non fiber releasing” filter as defined in 21 CFR 210.3 (b) (6).

Component Material Toxicity

Component materials were tested and meet the criteria of the USP <88> Reactivity Test for Class VI plastics. Millipore Express®
SHF filters meet the requirements of the USP <88> Safety Test, utilizing a 0.9% sodium chloride extraction.

Toxicity

Non-toxic per MEM Elution ISO® 10993-05.

Good Manufacturing Practices

These products are manufactured in a facility which adheres to FDA Good Manufacturing Practices.

Indirect Food Additive

All component materials meet the FDA Indirect Food Additive requirements cited in 21 CFR 177–182.

* Cage, end caps and capsule housing
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≤ 16.4 cc/min.

Specifications

Opticap® XL and XLT Disposable Capsules (Sterile and Gamma Compatible)
Opticap® XL 3

Opticap® XL 5

Opticap® XL 10

Opticap® XLT 10

Opticap® XLT 20

Opticap® XLT 30

Maximum length:

17.3 cm (6.8 in.)

21.6 cm (8.5 in.)

33.5 cm (13.2 in.)

37.6 cm (14.8 in.)

62.5 cm (24.6 in.)

87.1 cm (34.3 in.)

Body diameter:

10.7 cm (4.2 in.)

10.7 cm (4.2 in.)

10.7 cm (4.2 in.)

-

-

-

Sanitary flange to sanitary flange:

-

-

-

15.2 cm (6.0 in.)

15.2 cm (6.0 in.)

15.2 cm (6.0 in.)

Sanitary flange to hose barb:

-

-

-

17.5 cm (6.9 in.)

17.5 cm (6.9 in.)

17.5 cm (6.9 in.)

Hose barb to hose barb:

-

-

-

19.8 cm (7.8 in.)

19.8 cm (7.8 in.)

19.8 cm (7.8 in.)

0.17 m2 (1.8 ft2)

0.31 m2 (3.3 ft2)

0.57 m2 (6.1 ft2)

0.57 m2 (6.1 ft2)

1.14 m2 (12.3 ft2)

1.71 m2 (18.4 ft2)

≤ 32.7 cc/min.

≤ 65.5 cc/min.

≤ 98.2 cc/min.

Capsule

Capsule

Capsule

Capsule

Capsule

Capsule

Nominal Dimensions

Fitting to Fitting

Filtration Area
Materials of Construction
Filter membrane:

Hydrophilic polyethersulfone

Film edge:

Polyethylene

Supports:

Polyester

Structural components*:

Gamma stable polypropylene

Core:

Polysulfone

Vent O-rings:

Silicone

Vent/Drain

¼ in. hose barb with double O-ring seal

Maximum Differential Pressure
Forward:

5500 mbar (80 psi) at 25 °C
6900 mbar (100 psi) intermittent at 25 °C
1000 mbar (15 psi) at 80 °C

Reverse:

2100 mbar (30 psi) intermittent at 25 °C

Bubble Point at 23 °C

≥ 4000 mbar (58 psi) air with water

Air Diffusion at 23 °C

Through a water wet membrane at 2800 mbar (40 psi):
≤ 9.5 cc/min.

≤ 17.4 cc/min.

≤ 32.7 cc/min.

Bacterial Retention

Quantitative retention of 10 CFU/cm Brevundimonas diminuta ATCC® 19146 per ASTM® methodology.

Bacterial Endotoxin

Aqueous extraction contains <0.25 EU/mL as determined by the Limulus Amebocyte Lysate (LAL) Test (per 10-inch filter).

TOC/Conductivity

Gamma sterilized capsule effluent meets the WFI criteria for USP <643>, Total Organic Carbon, and USP <645>, Conductivity,
after a WFI water flush of:

7

3.5 L
Oxidizable Substances

2

6.0 L

11 L

11 L

22 L

33 L

3000 mL

4500 mL

Meets the USP Oxidizable Substances Test requirements for sterile purified water after
a water flush of:
1000 mL

1000 mL

1500 mL

1500 mL

Sterilization
Gamma compatible:

Gamma compatible to 45 kGy. May be autoclaved for 3 cycles of 60 minutes at 123 °C. (Cannot be steam sterilized in-line).

Sterile capsules:

May be autoclaved for 3 cycles of 60 minutes at 123 °C. (Cannot be steam sterilized in-line.)

Sterility
Sterile capsules:

Meets current USP and AAMI guidelines for sterility utilizing a validated sterilization cycle.

Non-Fiber Releasing

Component materials meet criteria for a “non fiber releasing” filter as defined in 21 CFR 210.3 (b) (6).

Component Material Toxicity

Component materials were tested and meet the criteria of the USP <88> Reactivity Test for Class VI plastics. Millipore Express®
SHF filters meet the requirements of the USP <88> Safety Test, utilizing a 0.9% sodium chloride extraction.

Toxicity

Non-toxic per MEM Elution ISO® 10993-05.

Good Manufacturing Practices

These products are manufactured in a facility which adheres to FDA Good Manufacturing Practices.

Indirect Food Additive

All component materials meet the FDA Indirect Food Additive requirements cited in 21 CFR 177–182.

* Cage, end caps and capsule housing
Filters were tested post gamma radiation at 25-45 kGy
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QuikScale® Biochromatography Columns
Innovative chromatography columns for scalable, rapid purification
Biopharmaceutical manufacturers increasingly require
tools that maximize process yields, boost productivity,
and shorten time-to-market. To meet these demands,
the scalable family of QuikScale® columns delivers
greater product purity at faster linear velocities
than columns currently used in most pharmaceutical
processes. As a part of our total solution, these
innovative columns have been designed to be used
easily with any biochromatography system, such
as our K-Prime® systems, from small scale pilot
processes through complex development and
manufacturing operations.

Ultra high throughput with all media types
Designed to achieve ultra high throughput, robust
QuikScale® columns are easily, uniformly packed
to deliver optimal resolution across a wide range of
chromatographic applications, accommodating all
media types. The innovative flow distributor assures
full, uniform media utilization within the column,
assuring reproducible and reliable separations. Using
the high flow option with operating pressures up to
7 bar, flow rates up to 1000 cm/hr are achievable
enabling greater process design flexibility by allowing
greater bed heights when utilizing media with high
flow and/or backpressure requirements.

Benefits
• High linear velocity for maximum productivity
• Easy to pack and unpack
• Rapid scale-up with a full range of column size
from 70 mm to 630 mm
• Multiple tube materials that suit a wide variety
of applications
• Maximum flexibility — change tube material
and height in minutes

The life science business of Merck KGaA,
Darmstadt, Germany operates as
MilliporeSigma in the U.S. and Canada.

Fast packing and unpacking
Column packing, processing, and unpacking are
performed faster and with less effort. There’s no
heavy lifting or complex disassembly involved;
all components remain attached to the
column. An optional removable lower
end-cell makes unpacking simple and
quick. The simple design eliminates
the need for tools and hoists during
packing and unpacking.
A yoke and central screw
mechanism supports the flow
distributor, ensuring this
assembly easily moves during
packing and unpacking. The
flow distributor makes it easy
to pack uniform beds. The flow
distributor can be swiveled
to afford easy access for
maintenance without the
need to lift the adjuster
assembly from the column.

Flow distributor seal
technology ensures
reliable, fail-safe operation
To make packing simple and
efficient, the seal (patent
pending) is spring force
actuated and uses air to
deactivate the seal. This
design offers smooth vertical
movement, and allows the
flow distributor assembly to
be gently positioned and
secured, without disrupting
the packed bed.
The bed support, which is available for 10 μm, 20 μm
and 30 μm sizes, consists of stainless steel mesh
screens that enhance flow distribution efficiency. The
screens, unlike plastic supports, allow the passage of
air without requiring pre-wetting.

Predictable, scalable performance
Column materials and geometries were carefully chosen
to ensure consistent chromatographic performance
from lab scale to production. QuikScale® columns are
available in nine diameters from 70 mm to 630 mm.
Stainless steel mesh screens, flow cells and column
tubes for each column diameter are made of the
same materials and are designed to ensure reliable
performance across the range of column diameters.
Column materials, a unique seal design, and optimized
flow distribution, all contribute to creating predictable,
scalable processes.

Choice of three column tube materials,
for any application
QuikScale® columns meet a broad range of applications.
Tubes are offered in three materials:
• Cast acrylic, resistant to breakage with improved
ethanol resistance and low protein binding
• Glass, suitable for a wide range of
process application
• Stainless steel for improved corrosion
resistance and high cleanability
All materials used in the manufacture of the column that
come into contact with the process stream conform to
relevant sections of the FDA Code of Federal Regulations
Volume 21, parts 170 to 199, or have passed USP Class
VI tests for toxicity.

Dependable construction for long-lasting,
reliable performance
Durable frame design and construction, as well as
robust tube materials ensure excellent physical
stability to deliver years of trouble-free operation.
Specially developed tube manufacturing technology
results in excellent tube quality on a consistent basis.
This reliability, throughout the QuikScale® column
product line, is important for generating reproducible
performance critical in pharmaceutical manufacturing.

Modular design
A full line of accessories and installation kits enables
quick set-up. Versatile configurations make it easy to
adapt columns for use in multiple process applications.

QuikScale® Chromatography
Columns Featuring Industry Leading
Chromatography Resin

Eshmuno® Resin
Unique family of ion-exchange resins
specifically designed for highly productive
downstream purification.

Fractogel® Resin
Tentacle modified synthetic polymer resins for
ion exchange, hydrophobic interaction, size
exclusion and metal chelate affinity.

ProSep® Ultra Plus Resin
The highest dynamic binding capacity protein A
affinity chromatography media, designed for
cost effective, large-scale purification of
today’s higher titer therapeutic antibodies.

Chemical resistance of QuikScale® Columns*

22 mm Millipore Vantage® L Column
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450 mm Millipore QuikScale® Column

26

35

22

30

20

25

18

20

16

15

14

10

12

5

10
10

Conductivity (mS)

Absorbance (280 nm)

24

40

0
20

30

40

50

60

70

80

90

Elapsed Time (min)
Gradient Setpoint

Conductivity

Absorbance

Acrylic

Steel

Acetic acid (80%)

R

NR

R

Acetone

R

L

R

Acetonitrile

R

NR

R

Ammonium sulphate (10 – 40%)

R

R

R

Disodium phosphate

R

R

R

Ethanol (40%)

R

R

R

Ethylene glycol

R

R

R

Formaldehyde (50%)

R

R

R

Isopropanol

R

L

R

Methanol

R

L

R

Nitric acid (10%)

R

R

R

Peracetic acid (300 ppm)

L

L

L

Phosphoric acid (55%)

R

R

R

Potassium chloride (30%)

R

R

R

Potassium hydroxide (2M)

R

R

R

Sodium bicarbonate (20%)

R

R

R

Sodium chloride (2M)

R

R

R

Sodium hydroxide (2M)

L

L

L

Sodium hypochlorite (200 ppm)

L

L

L

Triton® X-100 surfactant

R

R

R

Urea (8M)

R

R

R

R = Resistant; suitable for continuous use
L = Limited resistance; depends on concentration
and contact time
NR = Not resistant, not recommended

Figure 1. Quick and reliable scale-up
Separation of ovalbumin from trypsin inhibitor was scouted on a
Millipore Vantage® L column (22 mm). The process was then linearly
scaled up (418X by volume, 20X by diameter) to a 450 mm QuikScale®
column with highly comparable results.

Before

Glass

* All substances are at 100% concentration (saturated
solutions) unless noted otherwise. Concentrations:
% refer to w/w. All data is referenced to room
temperature (15 °C – 25 °C). A more extensive and
detailed list is available in the product manual.

After
Simple and convenient to clean
and operate

Figure 2. Before and after images of riboflavin presence (green)
in a 100 mm QuikScale® column
Glass 100 mm and acrylic 450 mm Quikscale® columns were challenged
with a concentrated riboflavin solution and subsequently cleaned with
0.5 M NaOH.

QuikScale® columns are designed for clean-in-place
(CIP), low maintenance, and sanitary operation.
Smooth surface finish minimizes entrapment of
contaminants and prevents corrosion. The elimination
of O-rings in product contact areas prevents unswept
surfaces, providing better cleanability.
A riboflavin clearance test performed on QuikScale®
columns demonstrated that they can be effectively
sanitized. Glass 100 mm and acrylic 450 mm
Quikscale® columns were challenged with a
concentrated riboflavin solution and subsequently
cleaned with 0.5 M NaOH. The observable removal of
riboflavin (Figure 2) indicates that there are no dead
flow areas within the Quikscale® columns and that all
areas are swept with sufficient and consistent velocity.

Ordering information

Spare parts and accessories

QuikScale® Columns – GA and GS Range

The QuikScale® columns are complemented
by a range of spare parts and accessories,
including:

The QuikScale® column is available in two different configurations.
For applications that require frequent packing and unpacking,
the column may be ordered with a removable end cell (GA) and
optional transport dolly. For applications that require infrequent
packing a fixed bottom end cell is available (GS).
Standard QuikScale® Columns
Column Diameter
(nominal)

Material

Pressure
Rating (bar)

Acrylic

7

Glass

7

Acrylic

7

Glass

7

Acrylic

7

Glass

6

Acrylic

7

Glass

4.8

Acrylic

5

Stainless

5

Acrylic

5

Glass

3

Stainless

5

Acrylic

5

Stainless

5

Acrylic

5

Stainless

5

Acrylic
Stainless

3
3

70 mm

100 mm

140 mm

200 mm

250 mm

300 mm

350 mm

450 mm

630 mm

Catalogue Number
Tube Length
550 mm

800 mm

1100 mm

GA071711
GS071711
GA072711
GS072711
GA101711
GS101711
GA102711
GS102711
GA141711
GS141711
GA142611
GS142611
GA201711
GS201711
GA202511
GS202511
GA251511
GS251511
GA253511
GS253511
GA301511
GS301511
GA302311
GS302311
GA303511
GS303511
GA351511
GS351511
GA353511
GS353511
GA451511
GS451511
GA453511
GS453511
GA631321
GA633321

GA071712
GS071712
GA072712
GS072712
GA101712
GS101712
GA102712
GS102712
GA141712
GS141712
GA142612
GS142612
GA201712
GS201712
GA202512
GS202512
GA251512
GS251512
GA253512
GS253512
GA301512
GS301512
GA302312
GS302312
GA303512
GS303512
GA351512
GS351512
GA353512
GS353512
GA451512
GS451512
GA453512
GS453512
GA631322
GA633322

GA071713
GS071713
GA072713
GS072713
GA101713
GS101713
GA102713
GS102713
GA141713
GS141713
GA142613
GS142613
GA201713
GS201713
GA202513
GS202513
GA251513
GS251513
GA253513
GS253513
GA301513
GS301513
GA302313
GS302313
GA303513
GS303513
GA351513
GS351513
GA353513
GS353513
GA451513
GS451513
GA453513
GS453513
—
—

• High flow kit
• Process valves
• Connection kits
• Seals, clamps and adapters
• Bubble traps
• Column tube kits
• Replacement parts

Support for your application needs
We have the know-how to provide you
with everything you need for your process
development applications. Technical briefs
describe the benefits you will acquire when
using the QuikScale® columns. For more
information, call our Technical Service
department or ask your Application Specialists
for in-depth technical notes. An operator’s
manual contains full details of components,
packing, testing, procedures for cleaning and
sanitizing, troubleshooting and the spare
parts list.

To place an order or receive
technical assistance
In the U.S. and Canada, call toll-free
1-800-645-5476
For other countries across Europe
and the world, please visit:
emdmillipore.com/offices
For Technical Service, please visit:
emdmillipore.com/techservice

milliporesigma.com
Copyright © 2017 EMD Millipore Corporation. All Rights Reserved. MilliporeSigma, the vibrant M, K-Prime, Vantage, ProSep, Eshmuno, Fractogel and
QuikScale are trademarks of Merck KGaA, Darmstadt, Germany. Triton is a registered trademark of Union Carbide Corporation. All other trademarks are
the property of their respective owners. More information on our branded products and services on www.emdmillipore.com
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Viresolve

®

Prefilter

Custom protection for Viresolve NFP viral
clearance filters



Increases NFP capacity reducing overall
filtration costs



Improves robustness by decreasing the
impact of feed variability on the NFP filter



Maintain high product yields



Simple, predictable scale-up and scale-down

The Viresolve Prefilter improves robustness and
filtration economics of the viral clearance step by
protecting Viresolve NFP viral clearance filters and
decreasing the impact of feed stream variability.
Use of this prefilter with NFP will improve capacity
and increase the life of the NFP filter. Available in
scalable filter formats, this prefilter will easily fit in
existing development and manufacturing processes.

Improved Robustness
Table 1. Example of Cost Savings with Prefiltration
Economic Evaluation of Prefilter Benefits for a Low-Capacity Feed Stream
Utilizing Viresolve NFP Filters
Process Description

Without Prefilter

With Prefilter

Feed volume
Viresolve NFP capacity
Viresolve prefilter sizing

500 L
60 L/m2
—

500 L
300 L/m2
600 L/m2

Cost of viral clearance filter
Cost of Viresolve Prefilter

$54,000
—

$10,000
$
400

Total Cost

$54,000

$10,400

Filter Formats
 OptiScale®-40 disposable capsule filters
 Opticap® disposable capsule filters
 Pod disposable devices

DATA SHEET

Use of the prefilter improves the robustness of the
filtration step by decreasing the impact minor
changes in feed stream quality, such as batch-tobatch variability, effect of hold time, and freeze/
thaw, etc., could have on the Viresolve NFP filter.

Increased Capacity and Filter Life
Utilizing this prefilter in series with Viresolve NFP
filters (NFP) will allow you to take advantage of
NFP’s high flow rates and product yield. The prefilter
effectively removes fouling components of the feed,
leading to dramatic increases in the performance
of the Viresolve NFP filter. This improved capacity
significantly reduces the cost of the viral clearance
step.

Custom Prefiltration for Viresolve NFP
Filters
Viresolve NFP filters clear parvovirus from therapeutic feed streams without compromising flow rates,
adding speed and dependability to viral clearance
in therapeutic drug manufacturing applications.
These reliable filters are ideal for monoclonal
antibody polishing applications eliminating small
virus contaminants.

Table 2. Viresolve Prefilter Provides High Protein Yield

Yield Analysis Summary with OptiScale-40 Devices
Source

Recovered Mass

Filtrate

94.5%

Flush

2.2%

System hold-up loss

2.5%

Total

99.2%

Regulatory Compliance
Figure 1. Protection of Viresolve NFP Filter
Increases Capacity
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Human IgG (1 g/L, pH 7.2) was processed through the Viresolve Prefilter
at varying loading level. The filtrate from the prefilter was filtered through an
OptiScale-25 capsule with Viresolve NFP membrane and the capacity of the NFP
filter was measured.

Figure 2. Viresolve NFP Vmax Capacity for Prefilter
Scale-up
600

531

500

NFP Vmax (L/m2)

Viresolve Prefilters are designed, developed, and
manufactured in accordance with good manufacturing practices under an ISO® 9001 Quality
Management System. Opticap capsules and Pods
are integrity tested during manufacturing and
supported by a Validation Guide to assist in
compliance with regulatory requirements. For
traceability and easy identification, each filter is
labeled with the product name and identifying
characteristics. Every filter is shipped with a
Certificate of Quality.
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Prefilter Loading (L/m2)

Human IgG (1 g/L, pH 7.2) was filtered through 3 lots of OptiScale-40 capsules
with Viresolve Prefilter media, and 2 lots of 10-inch Opticap capsules with
Viresolve Prefilter media. The filtrates were then filtered through an OptiScale-25
with Viresolve NFP membrane and the filter capacity of the NFP was measured.

From process development to full-scale production,
Millipore has the right solution for you!
OptiScale-40 Small Volume
Disposable Capsule Filters

Opticap Disposable Capsule
Filters

Pod Disposable Devices

OptiScale-40 Filters

Opticap Capsule Filters

Pod Filters

OptiScale-40 disposable
capsule filters provide an active
filtration area of 5 cm2. These
small devices are useful for
process development and
optimization, and viral clearance
studies. A female Luer–Lok
fitting/male Luer slip connection
ensures fast and secure setup.
These capsules are used in small
volume applications where
feedstock requirements are
minimal.

Opticap disposable capsule
filters feature a patented design
that withstands high thermal and
hydraulic stress, assuring
sterilization compatibility.

Scalable from pilot to process
applications, this new innovative
NFF device format offers process
flexibility and linear scale-up.

A Mobius technology.
Mobius solutions feature a range of
disposable technologies and services
to optimize biopharmaceutical
processes.

Flexible Configurations
This patented technology consists
of three Pod sizes and an expandable holder system.
Pod Prefilters are offered in
0.11 m2, 0.55 m2 and 1.1 m2
filtration areas.
Two basic holders are available; the pilot scale holder is
configurable with extension rods
that can accommodate up to five
1.1 m2 Pods, while the process
scale holder expands to mount
from 5 to 30 Pod devices. The
stainless steel holder is not wetted
by product and the connectors
are disposable plastic. With the
compact, modular design of
Millipore’s new pod system, you
can increase productivity, shorten
cycle-time and reduce costs.

Specifications
Effective Filtration Area
Materials of Construction
Media:
Membrane:
O-ring:
Flat seal:
Housing:
Standard Connections
Vent/Drain
Maximum Operating
Line Pressure (at 23 °C)
Maximum Differential
Pressure (at 23 °C)
Forward:
Reverse:
Autoclaving
TOC/Conductivity

Metals

Bacterial Endotoxin
Component Material
Toxicity
Indirect Food Additive
Quality Standard

OptiScale-40

10 in. Opticap

0.11 m2 Pod

0.55 m2 Pod

1.1 m2 Pod

5.0 cm2

850 cm2

0.11 m2

0.55 m2

1.1 m2

Cellulose fibers with
inorganic filter aid
Mixed esters of cellulose
—
—
Polypropylene
Female Luer-Lok, male luer
slip fittings
—
4.1 bar (60 psi)

Cellulose fibers with
inorganic filter aid
Mixed esters of cellulose
Silicone
—
Polypropylene
3/4 in. Sanitary flange

Cellulose fibers with inorganic filter aid

1/8

Disposable vent
3.4 bar (50 psi)

in. Hose barb
5.5 bar (80 psi)

Mixed esters of cellulose
—
Thermoplastic elastomer
Glass-filled polypropylene
Disposable 11/2 in. TC fitting

2.1 bar (30 psi)
0.03 bar (0.5 psi)
May be autoclaved for 3 cycles
of 60 minutes at 123 °C.
—

2.1 bar (30 psi)
2.1 bar (30 psi)
0.35 bar (5 psi)
2.1 bar (30 psi)
May be autoclaved for 3 cycles
May be autoclaved for 3 cycles
of 60 minutes at 123 °C.
of 60 minutes at 123 °C.
Lot release testing on effluent
Lot release testing on effluent exhibited
exhibited TOC <3 ppm and
TOC <4 ppm and conductivity <10 µS/cm
conductivity <10 µS/cm after autoafter 3 autoclave cycles and a water
claving and a water flush of 10 L/ft2. flush of 100 L/m2.
—
Lot release testing on effluent exhibited the following values:
Pb < 0.01 mg/ft2
Pb < 0.01 mg/ft2
Hg < 0.01 mg/ft2
Hg < 0.01 mg/ft2
As < 0.01 mg/ft2
As < 0.012 mg/ft2
Fe < 0.1 mg/ft2
Fe < 0.1 mg/ft2
Al
< 0.5 mg/ft2
Al < 0.5 mg/ft2
Aqueous extraction contains <0.25 EU/mL as determined by the Limulus Amebocyte Lysate (LAL) test.
Component materials were tested and meet the criteria of the USP <88> Reactivity Test for Class VI Plastics.
Viresolve Prefilters meet the requirements of the USP <88> Safety Test, utilizing a 0.9% sodium chloride extraction.
All component materials meet the FDA Indirect Food Additive requirements cited in 21 CFR 177–182.
These products are manufactured in accordance with a Quality Management System that is approved by an
accredited registering body to the appropriate ISO 9000 Quality Systems Standard.

Ordering Information
Nominal
Process Volume

Connections

OptiScale-40 Capsule

100 mL

Female Luer-Lok, male luer slip fittings
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SSPV A40 NB9

10 in. Opticap Capsule

20 – 40 L

3/4

1

KSPV 01F F1

Device

0.11

m2

Pod Filter

0.55 m2 Pod Filter
1.1

m2

Pod Filter

Qty/Pk

in. Sanitary flange inlet and outlet

20 – 40 L

Disposable

in. TC inlet and outlet

1

MSPV 01 FS1

100 – 200 L

Disposable 11/2 in. TC inlet and outlet

1

MSPV 05 FS1

1

MSPV 10 FS1

200 – 400 L

Disposable

11/2

Catalogue No.

11/2

in. TC inlet and outlet

Millipore, Opticap, OptiScale and Viresolve are registered trademarks of Millipore Corporation.
Mobius is a trademark of Millipore Corporation.
ISO is a trademark of the International Organization for Standardization.
Luer-Lok is a registered trademark of Becton, Dickinson and Company.
Lit. No. DS1181EN00 Rev. C 4/07 Printed in U.S.A. 07-251
© 2005, 2007 Millipore Corporation, Billerica, MA 01821 U.S.A. All rights reserved

Data Sheet

Viresolve® Pro Solution
Proven viral safety solution designed to
provide the highest levels of retention
assurance and productivity
Robust. Productive. Proven.
The Viresolve® Pro Solution provides a comprehensive,
flexible template solution for virus filtration in biologics
manufacturing. This proven viral clearance solution
delivers the highest levels of retention assurance and
processing efficiency across a broad range of feed
streams.
The Viresolve® Pro Solution is comprised of the
innovative, high-performing Viresolve® Pro Device
in conjunction with the Viresolve® Pro Shield or the
Viresolve® Pro Shield H prefilters. These products are
designed to work togther to meet your needs providing
high parvovirus retention, capacity and flux. Our
industry-leading products and services, coupled with
our viral clearance expertise, will help you successfully
develop, implement, and validate the
Viresolve® Pro Solution.

Benefits
Viresolve® Pro Solution:
High-productivity Virus Filtration

Viresolve® Pro Device:
Robust Parvovirus Clearance

• Improved process economics with high mass capacity

• ≥ 4.0 log removal of parvovirus

• High flux for faster processing

• Devices are 100% integrity tested with air/water
diffusion and Binary Gas

• Consistent batch-to-batch performance
• Easy to install, use and integrity test
• Caustic sanitizable

The life science business of Merck KGaA,
Darmstadt, Germany operates as
MilliporeSigma in the U.S. and Canada.

• Robust retention maintained during process
interruption/depressurization

Prefilters: Viresolve® Pro Shield &
Viresolve® Pro Shield H

Virus Filter: Viresolve® Pro Device

Provides robust adsorptive (cation/mixed-mode)
prefiltration to remove fouling protein aggregates

Provides robust viral clearance

• Enhance throughput and process robustness of
Viresolve® Pro Devices

High Virus Retention

Enhanced Process Robustness
For feed streams with high levels of fouling protein
aggregates, the Viresolve® Pro Shield or Viresolve® Pro
Shield H can be used to improve the capacity of the
Viresolve® Pro Device.
These membrane prefilters adsorb protein aggregates
that foul or plug the pores in the Viresolve® Pro
membrane. Viresolve® Pro Shield and Viresolve® Pro
Shield H have different membrane surface modifications
to maximize adsorption of protein aggregates under a
broad range pH and conductivity conditions (Figure 1).
The Viresolve® Pro Prefilter Selector Guide
(TB1140EN00) provides guidance and information on
prefilter selection.

pH

Viresolve® Pro Shield

• ≥ 5.0 logs of Murine Leukemia Virus clearance
• Delivers high capacity

• Effective across a broad range of pH
and conductivity conditions
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• ≥ 4.0 logs of Minute Virus of Mice clearance

Retention performance of the Viresolve® Pro Micro
40 Devices, containing two lots of membrane, was
evaluated under aggressive processing conditions.
Testing was performed with a monoclonal antibody
feed stream at 60 psi to a filtration endpoint of
90% flow decay, followed by a 20 L/m2 buffer flush.
Samples were collected from final filtrate pools and a
summary of calculated log reduction values (LRV) is
shown in Figure 2. As can be seen from the results,
the Viresolve® Pro Solution achieved at least 5.8 logs
of MVM retention. These results demonstrate robust
virus clearance, even out to 90% flow decay, at high
pressure.
Virus retention performance of the Viresolve® Pro
Solution under a range of processing conditions is
summarized in the application note Virus Retention
Performance of Viresolve® Pro Devices under a Range
of Processing Conditions (WP3374EN).

Viresolve® Pro Shield H

Viresolve® Pro Shield or Shield H may be optimal

5

4

MVM Final Pool LRV

8.0
7.0
6.0
5.0
4.0
3.0
2.0
1.0
0.0

Lot 1

Figure 1.

Figure 2.

Contour plot showing the optimal pH and conductivity conditions for
Viresolve® Pro Shield and Viresolve® Pro Shield H.

Summary of MVM results for two membrane lots of
Viresolve Pro® Micro 40 Devices.

2

Lot 2

Building Quality
The virus retention performance and integrity
of Viresolve® Pro Devices is assured with our
comprehensive approach to quality.

End-User
Integrity
Testing and
Validation

Assuring Retention
Retention performance is assured with our proprietary
Binary Gas test which detects defects as small as 3-5
microns, that cannot be detected using a traditional air/
water diffusion test, Figure 3. This high sensitivity test
is especially valuable for Viresolve® Pro Devices, where
small defects could impact virus retention performance.
Every Viresolve® Pro Device must pass Binary Gas
testing before release, assuring the highest levels of
virus retention for your filtration operations.

Integral Viresolve® Pro Membrane

Device 100%
Integrity Tested in
Manufacturing
Process
& Product
Validation

Membrane
& Device
Release Tests

Non-Integral Viresolve® Pro Membrane
High Pressure Side
Slow Gas
Fast Gas
Liquid-Filled Pores

Low Pressure Side

Figure 3.
Principles of Binary Gas Test. This proprietary test measures the composition of a mixture of two gases on the upstream and downstream sides of
the Viresolve® Pro membrane to detect defects as small as 3-5 microns in size.
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High Capacity and Flux
The Viresolve® Pro Solution efficiently processes feed
streams of different pH, conductivities and protein
concentrations. When used upstream of Viresolve® Pro
Devices, Viresolve® Pro Shield and Shield H enhance
the throughput and processing robustness of filtration
operations.

Figure 4 shows the results of throughput testing with
Viresolve® Pro Devices alone (A) or in conjunction with
Viresolve® Pro Shield and Shield H (B). In most cases,
implementing the prefilter increased the capacity of
the Viresolve® Pro Device by an average of two-fold.
The Viresolve® Pro Solution enables rapid processing
delivering mass flux in the 1.25-2.5 kg/m2/hr range.
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Mass Capacity (kg/m2) for ≤ 4-Hour Process Time

9
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7
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5
4
3
2
1
0

10

5.4

4.6

5.4

9.5

10.4

25

6.4

5

8

4.9

5.2

7.2

5.2

3.9

2.5

Feed Protein Concentration (g/L)

Figure 4A.
Mass capacity on Viresolve® Pro Devices with mAbs of different protein concentrations. In all cases, processing time was less than four hours.

10
9
8
7

Viresolve® Pro V75 or 4 hrs. (kg/m2)

6
5
4
3
2
1

0
pH
Conductivity (mS/cm)

5
3

5.6
6.5

5.6
10

5.3
16

Shield + Device

5
20

5
14

5.6
45

Shield H + Device

5.7
45

6
45

7
20

8.1
13

Device only

Figure 4B.
Mass capacity of the Viresolve® Pro Solution across a range of pH and
conductivities. In all cases, processing was stopped at 75% flow decay
or four hours.
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Flexible Manufacturing
The Viresolve® Pro Shield, Viresolve® Pro Shield H and Viresolve® Pro Devices are easily
integrated into flexible, easy-to-use systems for pilot to full-scale manufacturing.

Viresolve® Pro/Pro+ Magnus Holders for
Viresolve® Pro Solution

Mobius® FlexReady Solution for Virus
Filtration

Viresolve® Magnus Holders are designed for large
volume processing. The Viresolve® Pro Magnus Holder
is designed to run the Viresolve® Pro Device alone,
while the Viresolve® Pro+ Magnus Holder is designed to
run the Viresolve® Pro Device coupled with either the
Viresolve® Pro Shield or Shield H.

The Mobius® FlexReady Solution for large-scale
virus filtration is an easy-to-use system featuring an
optimized single-use flow path designed to fully support
your virus filtration needs.

• Quick and easy loading and unloading

For more information on the Mobius® FlexReady
Solution for large scale virus filtration, refer to
datasheet DS1259EN00.

• No product contact
• Minimized holder footprint with vertical orientation
• Rods in multiple lengths for various sized installations
• Simple manual hydraulics

Viresolve® Pro+ Magnus Holder

Viresolve® Pro Magnus Holder

Mobius® FlexReady Solution

5

Partner with a leader in viral safety
Virus Filtration Process Development Service

Viral Clearance Services

Optimizing a virus filtration process involves evaluating
the effects of multiple process parameters to identify
conditions that will ensure a robust, consistent, and
economical operation. We work side-by-side with
development engineers and manufacturers, helping
them develop efficient, cost-effective filtration
operations.

Viral clearance studies are critical to the validation of
downstream processes, ensuring sufficient reduction
of potential viral contaminants during downstream
processing.

We can help you:
• Maximize filtration efficiency
• Maximize process robustness
• Meet your economic targets

BioReliance® viral clearance studies are designed
and executed by experts in regulatory, downstream
processing, and virology at our facilities in Singapore,
the U.S., and the UK. Our global experts can support
you with your IND and BLA studies in accordance
to regulatory guidelines for monoclonal antibodies,
recombinant proteins, and plasma derivatives. Our
dedicated project management support and local teams
of experienced technical experts accelerate your time
to results and minimize risk as you bring your product
to market.

Virus Filter Implementation Service
Our engineers can leverage the results of bench-scale
studies to help implement your pilot or production
scale virus filtration operation. This streamlines
implementation and avoids the pitfalls that can impact
production timelines and process economics.

The Viresolve® Pro Solution is
supported by the Emprove® Program your fast track through regulatory
challenges.
Complementing our product portfolio, the
Emprove® Program provides three types
of dossiers to support different stages of
development and manufacturing operations
such as qualification, risk assessment and
process optimization. The dossiers consolidate
comprehensive product-specific testing data,
quality statements and regulatory information
in a readily-available format to simplify your
compliance needs.
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Nominal Dimensions and Weights
Viresolve® Pro Shield, Viresolve® Pro Shield H, Viresolve® Pro Devices, and Holders
Nominal Eﬀective
Filtration Area

Nominal Weight

Height: 4.03 cm (1.59 in.)
Diameter: 4.37 cm (1.72 in.)

3.4 cm2

Empty: 14.73 grams

Modus 1.1

Length: 18.62 cm (7.33 in.)
Width: 9.22 cm (3.63 in.)
Height: 5.92 cm (2.33 in.)

0.017 m2

Empty: 0.37 Kg (0.8 lbs)

Modus 1.2

Length: 18.62 cm (7.33 in.)
Width: 9.22 cm (3.63 in.)
Height: 7.85 cm (3.09 in.)

0.07 m2

Empty: 0.63 Kg (1.4 lbs)

Modus 1.3

Length: 18.62 cm (7.33 in.)
Width: 9.22 cm (3.63 in.)
Height: 13.56 cm (5.34 in.)

0.22 m2

Empty: 1.39 Kg (3.1 lbs)

Magnus 2.1

Length: 34.30 cm (13.50 in.)
Width: 20.96 cm (8.25 in.)
Height: 4.42 cm (1.74 in.)

0.51 m2

Empty: 2.6 Kg (5.7 lbs)
Full of water: 3.4 Kg (7.5 lbs)

Magnus 2.2

Length: 34.30 cm (13.50 in.)
Width: 20.96 cm (8.25 in.)
Height: 9.50 cm (3.74 in.)

1.53 m2

Empty: 5.8 Kg (12.8 lbs)
Full of water: 8.3 Kg (18.3 lbs)

Viresolve® Pro Magnus Holder
(VPMH103000 / VPMH105000 /
VPMH107000)

Length: 78 cm (30.9 in.)
Width: 76 cm (30 in.)
Height: 127 cm (50 in.)

Not Applicable

141.5 Kg (312 lbs)

Viresolve® Pro+ Magnus Holder
(VPMH203000 / VPMH205000 /
VPMH207000)

Length: 104 cm (40.9 in.)
Width: 76 cm (30 in.)
Height: 127 cm (50 in.)

Not Applicable

186 Kg (410 lbs)

Size

Nominal Dimensions

Micro 40

Materials of Construction
Viresolve® Pro Shield, Viresolve® Pro Shield H, and Viresolve® Pro Devices, and Holders
Device

Membrane

Components

O-Rings/Gaskets

Micro 40

Polyethersulfone (PES)

Bottom Endcap/Top Endcap: Polyvinylidene fluoride (PVDF)

Not Applicable

Modus 1.1,
Modus 1.2,
Modus 1.3,
Magnus 2.1,
Magnus 2.2

Polyethersulfone (PES)

Bottom Endcap/Top Endcap: Polyvinylidene fluoride (PVDF)

Silicone

Shield and
Shield H

Membrane

Components

O-Rings/
Gaskets

Connections*

Micro 40

Polyethersulfone (PES)

Inlet Cap/Outlet Cap:
Polypropylene/Polyethylene
(copolymer)

Not
Applicable

Inlet and Vent: Female Luer-Lok™ Fitting
Outlet: Male Luer Slip

Modus 1.1,
Modus 1.2,
Modus 1.3

Polyethersulfone (PES)

Bottom Endcap/Top Endcap:
Polyvinylidene fluoride (PVDF)

Silicone

Inlet and Outlet: 1.91 cm (.75 in.) sanitary fittings
Integrated Vent: 0.32 cm (0.125 in.) with hose barb
with double O-ring seal

Magnus 2.1,
Magnus 2.2

Polyethersulfone (PES)

Bottom Endcap/Top Endcap:
Polyvinylidene fluoride (PVDF)

Silicone

Inlet and Outlet: 3.81 cm (1.5 in.) sanitary fittings
Vent: 1.90 cm (0.75 in.) sanitary fitting for the port

* Fittings sold seperately
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Materials of Construction (continued)
Viresolve® Pro Shield, Viresolve® Pro Shield H and Viresolve® Pro Devices, and Holders
Holders

Membrane

Components

O-Rings/
Gaskets

Connections

Viresolve® Pro Magnus Holder

Not Applicable

Plates & Frames: 316 L stainless steel

Not Applicable

Not Applicable

Not Applicable

Not Applicable

Silicone

Not Applicable

Clamp Rods: 300 series stainless steel
Fasteners, other components: 300 series
stainless steel
Viresolve® Pro + Magnus
Holder

Not Applicable

Plates & Frames: 316 L stainless steel
Clamp Rods: 300 series stainless steel
Fasteners, other components: 300 series
stainless steel

Fittings Kit

Not Applicable

Polyvinylidene fluoride (PVDF)

Specifications
Viresolve® Pro Shield, Viresolve® Pro Shield H and Viresolve® Pro Devices
ISO® 9001 Quality Standard

These products are manufactured in a facility whose Quality Management System is approved
by an accredited registering body to the appropriate ISO® 9001 Quality Systems Standard.

Particulate and Bioburden

These products are manufactured in an ISO® Class 8 (Per ISO® 14644-1) controlled
environment for particulate classification only.

Animal Origin

All components used in the manufacturing of these products are either animal-free or in
compliance with EMEA/410/01.

USP <87> Biological Reactivity Tests

Component materials for these products were tested and meet the criteria for non-cytotoxicity
for the USP <87> Cytoxicity L929 MEM Elution Tests.

USP <88> Biological Reactivity Tests

Component materials for these products were tested and meet the criteria for USP <88>
Biological Reactivity Tests for Class VI Plastics.

Bacterial Endotoxin

An aqueous extract from these products contains less than 0.25 EU/mL as determined by the
Limulus Amebocyte Lysate (LAL) test.

Membrane Bacteriophage Retention

Membrane samples exhibited ≥ 4.0 LRV of φX 174 bacteriophage at a minimum challenge
level of 107 pfu/cm2 in the presence of a model protein at V75.

Bacteriophage Retention

Viresolve® Pro Device samples exhibited ≥ 4.0 LRV of φX 174 bacteriophage at a minimum
challenge level of 107 pfu/cm2 in the presence of a model protein at V75.

Non-Fiber Releasing

These products are non-fiber releasing filters as defined in 21 CFR 210.3(b)(6).

Hydraulic Stress Test

Samples were integral based on an Air/ Water Diffusion Test, before and after a forward stress
to 4.1 bar (60 psid) at 25°C.

Manufacturing Integrity Test

All Viresolve® Pro Micro 40 Devices included in the Viresolve® Pro Micro 40 Device Kit must
pass the Binary Gas Test.
All Viresolve® Pro Modus and Magnus Devices must pass the Pressure Hold, Water Flow Rate,
Air/Water Diffusion Test and Binary Gas Test.
All Viresolve® Pro Shield and Viresolve® Pro Shield H must pass an aerosol particle challenge
and housing pressure hold.
All Viresolve® Pro Devices exhibited an air diffusion flow rate at 3.4 bar (50 psig) in water at
25 °C of less than or equal to:

Caustic Sanitization
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•

0.7 cc/min per Viresolve® Pro Modus 1.1 Device

•

2.7 cc/min per Viresolve® Pro Modus 1.2 Device

•

8.8 cc/min per Viresolve® Pro Modus 1.3 Device

•

20 cc/min per Viresolve® Pro Magnus 2.1 Device

•

60 cc/min per Viresolve® Pro Magnus 2.2 Device

These products may be sanitized by one 60-minute flush at 1.8 bar (25 psig) in 0.5 Normal
Sodium Hydroxide at 25 °C followed by a maximum 16-hour static soak.

Ordering Information
Description

Primary Use

Qty/Pk

Cat. No.

Viresolve® Pro Micro 40 Device Kit

Process Development or Viral Clearance Evaluations

9

VPMKVALNB9

Viresolve® Pro Modus 1.1 Device

Small-scale studies/pilot

1

VPMD101NB1

Viresolve Pro Modus 1.2 Device

Pilot/small-volume

1

VPMD102NB1

Viresolve® Pro Modus 1.3 Device

Pilot/small-volume

1

VPMD103NB1

Viresolve® Pro Magnus 2.1 Device

Large-volume processing

1

VPMG201NB1

Viresolve Pro Magnus 2.2 Device

Large-volume processing

1

VPMG202NB1

Viresolve® Pro Micro Shield Kit

Process Development or Viral Clearance Evaluations

9

VPMSKITNB9

Viresolve Pro Modus 1.1 Shield

Small-scale studies/pilot

1

VPPS101NB1

Viresolve® Pro Modus 1.2 Shield

Pilot/small-volume

1

VPPS102NB1

Viresolve® Pro Modus 1.3 Shield

Pilot/small-volume

1

VPPS103NB1

Viresolve Pro Magnus 2.1 Shield

Large-volume processing

1

VPPS201NB1

Viresolve® Pro Magnus 2.2 Shield

Large-volume processing

1

VPPS202NB1

Viresolve® Pro Micro Shield H Kit

Process Development or Virus Validation Studies

9

VPMHKITNB9

Viresolve® Pro Modus 1.1 Shield H

Small-scale studies/pilot

1

VPPH101NB1

Viresolve® Pro Modus 1.2 Shield H

Pilot/small-volume

1

VPPH102NB1

Viresolve Pro Modus 1.3 Shield H

Pilot/small-volume

1

VPPH103NB1

Viresolve® Pro Magnus 2.1 Shield H

Large-volume processing

1

VPPH201NB1

Viresolve® Pro Magnus 2.2 Shield H

Large-volume processing

1

VPPH202NB1

Viresolve Pro Device
®

®

®

Viresolve® Pro Shield

®

®

Viresolve® Pro Shield H

®

Holders, Accessories, Services and Spare Parts
Viresolve® Pro Magnus Holder

For 1 to 3 Viresolve® Pro Devices

1

VPMH103000

For 1 to 5 Viresolve® Pro Devices

1

VPMH105000

For 1 to 7 Viresolve Pro Devices

1

VPMH107000

For 1 to 3 Viresolve® Pro Devices and
1 to 3 Viresolve® Pro Shields or Viresolve® Pro Shield H

1

VPMH203000

For 1 to 5 Viresolve® Pro Devices and
1 to 5 Viresolve® Pro Shields or Viresolve® Pro Shield H

1

VPMH205000

For 1 to 7 Viresolve® Pro Devices and
1 to 7 Viresolve® Pro Shields or Viresolve® Pro Shield H

1

VPMH207000

1

VPMHINSERT

®

Viresolve® Pro+ Magnus Holder

Split clamp insert

1

VPMHRDKN0B

For 1 to 3 Viresolve® Pro Devices

2

VPMHRD0103

For 1 to 5 Viresolve® Pro Devices

2

VPMHRD0105

For 1 to 7 Viresolve® Pro Devices

2

VPMHRD0107

Fittings Kit (three 3.81 cm (1.5 in.) sanitary
fittings, two 3.81 cm (1.5 in.) blanks, one 1.27
cm (.5 in.) vent fitting and one 1.27 cm (.5 in.)
blank)

Viresolve® Pro and Pro+ Magnus Holder

1

VPMHADAPSK

3.81 cm (1.5 in.) Sanitary fittings

For feed/permeate port

6

VPMHADAPSF

3.81 cm (1.5 in.) Blanks

For feed/permeate port

6

VPMHADAPSB

1.27 cm (.5 in.) Vent fittings

For vent port

6

VPMHADAPVF

1.27 cm (.5 in.) Vent blanks

For vent

6

VPMHADAPVB

Hydraulic pump

1

MP0DHYPUMP

Pressure gauge

1

MP0DHYGAGE

Hydraulic fluid (1 liter)

1

MP0DHFLUID

Rod handle
Rods
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Ordering Information (continued)
Description

Primary Use

Qty/Pk

Cat. No.

Viresolve Pro and Pro+ Magnus Holder Services
®

IQ/OQ Protocol

Commissioning, installation and operational qualification
(IQ/OQ) protocol

1

DOCVMHIQOQ

IQ/OQ Protocol and Service

Commissioning, installation and operational qualification
(IQ/OQ) protocol and service

1

SSVIOQMGN

On-Site Preventive Maintenance (PM) Service

Equipment checks, testing for proper functionality,
adjustments and parts replacement (sold separately).

1

CSVOPMMGN

Mobius® FlexReady Solutions for Virus Filtration
Refer to data sheets (DS2562EN00 and DS1259EN00) for specific ordering information.

MilliporeSigma
400 Summit Drive
Burlington, MA 01803

To place an order or receive technical assistance
Please visit EMDMillipore.com/contactPS
For additional information, please visit EMDMillipore.com
2020 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved. MilliporeSigma, the vibrant M, Millipore, Flexware,
Mobius, and Viresolve are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their
respective owners. Detailed information on trademarks is available via publicly accessible resources.

Lit. No. DS0006EN00 Ver. 13.0
31916
06/2020

Specification Sheet

Mobius FlexReady Solution with
Smart Flexware Assemblies for TFF
®

®

Features
• Flexible design options
• Unique feed tank design and performance
• Smart Flexware® full single-use flow paths
• Excellent product recovery and purification
• Implement with ease and lower risks
• Full process automation with flexible recipes using
the Common Control Platform® (CCP®)

Benefits
• Ability to produce higher final concentrations
• Consistently deliver safety and quality with
less cleaning validation and lower risk of cross
contamination
• Ability to meet unique requirements
• Agile system able to perform at multiple scales for
both TFF and Chromatography

TF2S: 18L/min – 0.5 to 5.0 m2 Pellicon® cassettes or similar
TF3S: 40L/min – 2.0 to 10.0 m2 Pellicon® cassettes or similar

• Simplified training requirements

1

4

5

3
1. Tank cart

2

2. Pump and manifold cart
3. Smart cart with exchangeable
clamshell
4. Clamshell storage rack
5. Chamshell lift

The life science business of Merck KGaA,
Darmstadt, Germany operates as
MilliporeSigma in the U.S. and Canada.

General Specifications
System Dimensions
Carts connected H x L x W in. (mm)

TF2S

2022 x 2160 x 974 +/- 20 mm

TF3S

2022 x 2160 x 1014 +/- 20 mm

Net Weight
Tank cart 50 L

280 kg

Tank cart 100 L

310 kg

Tank cart 200 L

330 kg

Smart cart with clamshell

430 kg

Pump cart with 2 pumps and manifold

TF2S

200 kg

TF3S

260 kg

Environmental Operating Conditions
Product temperature range

2 to 45 °C

System operation temperature

2 to 30 °C (20 to 30 °C for TF3S)

Operating humidity

10%–90% (non-condensing)

Operating pressure

4 bar max: feed / retentate assemblies
2 bar max: transfer / filtrate assemblies
Atmospheric pressure: feed bag

Fluidic Sections
Feed Section
Feed container volume

TF2S

50 L/100 L/200 L in LLDPE or stainless steel container with jacket

TF3S

200 L in LLDPE or stainless steel container with jacket

Tank jacket volume

50 L tank 3.3 L
100 L tank 6.0 L
200 L tank 7.8 L

Pump model
Flow at 4 bar max
Minimal working volume (w/o cassettes feed volume)

TF2S

Quattroflow 1200 SU

TF3S

Quattroflow 4400 SU with 3° shaft

TF2S

2 to 20 L/min

TF3S

4 to 40 L/min

TF2S

0,7 L -1,8 L from 2 to 18 L/min*

TF3S

2,2 L -4,0 L from 4 to 40 L/min*

Maximum viscosity
Pressure sensor

35cP
Non-intrusive

0-4 bar +/-0.2 bar; Security switch set at 4.4 bar

Tank weight

0.3% FS

Control on feed pump

Fixed position (speed in %) or flow control or pressure drop control

Precision of calculated feed flow

+/-10% with feed pressure at least 1 bar

Temperature sensor feed container

2-45 °C +/-2 °C

*May vary slightly depending on the configuration system and other parameters.
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Transfer Section
Pump model
Flow at 2 bar

Quattroflow™ 1200 SU
TF2S

5m²: 2 to 9 L/min

TF3S

10m²: 2 to 20 L/min

Transfer pump control

Fixed position (speed in %) or level control

Pressure sensor

0-4 bar +/-0.2 bar; Security switch set at 2.3 bar

Retentate Section
Pressure sensor

Non-intrusive

Optional zero dead leg device – NovaSeptum® sampling solution
compatible

Sampling
Volume factor concentration

0-4 bar +/-0.2bar

VCF

Retentate PCV control

Precision better than 2%
Fixed position (% of closure) or TMP control or retentate pressure
control

Filtrate Section
Pressure sensor

Non-intrusive

0-4 bar +/-0.2bar

Conductivity and UV

In-line Singleuse Cell
(Optek) and
Multi-use

Conductivity: 0 to 100 µS/cm +2% FS

Weight with Mobius® weight scale

TF2S

0 to 600 Kg + 0.3 % FS

Weight with user supplied weight scale

TF2S

0 to 1000 Kg (accuracy linked to component connected)

TF3S

0 to 1500 Kg (accuracy linked to component connected)

Non intrusive
(ultrasonic by
Emtec)

From 2LPM: +/-5% MV

Flowmeter

Sampling

UV: 0 to 2 AU +2% FS
OPL: 10 mm
Wavelength: 280 nm / 300 nm

Below 2LMP: +/-0,12 LPM
Optional zero dead leg device
NovaSeptum® sampling solution compatible

Filtre PCV control

Fixed position (% of opening) or TMP

Important Note:
The single-use cell (SUC) is factory calibrated by Optek and for best performance the end-user should enter in the C8000 transmitter, the K factor
delivered with each new sensor assembly.
As calibration is dependent on each SUC installed, the calibration loop should be verified by the end-user prior and/or after each batch (as per
customer internal standard operating procedures.)
In consequence, during internal release test, only the proper wiring of the loops is tested using:
• Calibrated UV filters
• A conductivity tester supplied by Optek to simulate a conductivity value

Documentation
User guide on CD
Access to template recipes upon request
1. FDA Guidance for Industry Process Validation: General Principles and Practices – January 2011
2. Annex 15 to the EU Guide to Good Manufacturing Practice Qualification and Validation – July 2001
3. Mobius® FlexReady solution with Smart Flexware Assemblies for tangential – Flow Filtration
Performance Guide – AN4465EN00
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Smart Flowpath
The smart flowpath is a unique and patented fluid management device featuring fewer connections than
other designs. Fewer connections provide improved process eﬀectiveness through reduced working
volume and protein shearing, reduced leak risks, and maximum product recovery.
Feed
XV001, XV002: Normally Closed Valves
PIT/PSH001 : High Pressure Switch Sensor
Retentate
PCV001: Normally Opened Control Valve
XV004: Normally Opened Valve
PT002: Retentate Pressure Sensor

A

Filtrate
PCV101: Normally Closed Control Valve
PT101: Filtrate Pressure Sensor
Transfer
XV005: Normally Closed Valve
PIT/PSH401: High Pressure Switch Sensor
Drain/recovery

B

XV901, XV003: Normally Closed Valves
Filtrate drain
XV102: Normally Closed Valve

A: Internal door locks and sensors
B: Silicone Valve Pads

Endurance
Active process time
Valve pads longevity

12 h at 50 cycles per valve

CLAMTF2S

2500 cycles / 6 months

Wetted Materials
Tubing

Silicone

Smart Flexware® Assembly

Pureflex™ film and PE fittings

Feed Bag Assembly

Pureflex™ film

Pump Head

EPDM, Santoprene® and Polypropylene

Liners

Polysulfone

Connectors

Polypropylene and Polysulfone

Multi-use UV & Conductivity Sensors

Quartz, EPDM and stainless steel 316 L

Single Use UV & Conductivity Sensors

Polysulfone Quartz, EPDM and stainless steel 316 L (pins only)

Retentate Low Dead Volume TC Sampler

DMDA-1250 NT 7, sampler: HDPE O-ring: silicone

TFF Mixer Vortex Breaker & Diverter Plate

HDPE
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CL

Regulatory and Quality Compliance
USP <87> Biological reactivity in vitro, USP <88>
Biological Reactivity in vivo, Plastic Calss VI

Compliant

Irradiation dose

25–40 kG

21 CFR Part 11

Compliant ready

2004/108/CE Electromagnetic Compatibility (EMC)

Compliant

2006/42/CE Machinery Directive

Compliant

PSE

Exempt

ASME U-1 code

Tank Jacket is compliant

Data and System Control
PLC

Allen-Bradley CompactLogix™

Control software system

Microsoft® Windows® 7

Operator interface panel type

iFix®

Operator interface

12.1” tiltable touch screen

Languages

English, German, Spanish, Japanese, French, Italian, Chinese, Korean

Security

Based on Microsoft® Windows® operating system
Configurable user access group levels (4 pre-configured)

Data acquisition

Stored in Read Only Database

PC

B&R

Data

21 CFR Part 11 compliance ready

Manufacturing

GMP compliance ready

Utilities Connections
OPC server

RJ45

Keyboard

USB

External storage media

USB

Mouse

USB

Air

6–10 bar oil free at 4 L/min max

Power Supply
Smart Cart

220–240 VAC, 50/60 Hz, 1 phase, 3.9 A
Or 100-120 VAC, 50/60 Hz, 1 phase, 8.4 A
Maximum power consumption 1 kW

Tank Cart

220–240 VAC, 50/60 Hz, 1 phase, 0.4 A (50 L) – 1.8 A (100/200 L)
Or 100–120 VAC, 50/60 Hz, 1 phase, 0.8 A (50 L) – 3.7 A (100/200 L)
Maximum power consumption 0.1 kW (50L) to 0.4 kW (100/200L)

Pump cart (TF3S)

3 x 200–240 VAC, 50/60 Hz, 3 phases + neutral + ground, 10 A
Or 3 x 400–460 VAC, 50/60 Hz, 3 phases + neutral + ground, 5 A
Maximum power consumption 3 kW

5

Data Sheet

Pellicon® 3 Cassettes
with Ultracel® Membrane
The optimum tangential flow filtration devices for
monoclonal antibodies and other therapeutic proteins.
Pellicon® 3 cassettes with Ultracel® membrane are advanced, high-performance cassettes that
are ideal for today’s higher titer therapeutic antibodies, as well as for the more demanding
filtration processes that require higher operating pressures, temperatures, concentrations and
caustic cleaning regimes.
From small-scale to full-scale production, Pellicon® 3 cassettes are designed for use in research,
process scale-up/scale-down, applications development and full-scale manufacturing.
The Pellicon® 3 cassette design and automated manufacturing process provides unbeatable
performance consistency and enhanced linear scalability between cassette sizes. Pellicon® 3
cassettes also oﬀer greater cassette size selection for improved scale-up and scale-down process
development. The streamlined design allows operators to quickly and easily handle, install and
remove Pellicon® 3 cassettes. The materials of construction are compatible with a broad range
of chemical cleaning agents that many TFF systems require to ensure proper sanitization.

Benefits
• Optimum product recovery using proven
composite membrane technology
• Fast, reliable scale-up/-down from lab to
production scale
• Rugged, reliable design ideally suited to filtration
processes with higher operating pressures,
temperatures and caustic cleaning regimes
• Automated manufacturing delivers unbeatable
performance consistency and reliability
• Easy to install and clean
• Extreme temperature and chemical compatibility
• Choice of screens to best optimize your process

Applications
• Monoclonal antibodies
• Recombinant and non-recombinant proteins
• Vaccine
The life science business of Merck KGaA,
Darmstadt, Germany operates as
MilliporeSigma in the U.S. and Canada.

Specifications
Materials and Assembly
Materials of Construction

• Polypropylene
• Polyethylene
• Composite regenerated cellulose
• Thermoplastic elastomer
• Stainless steel (0.57 m2 and 1.14 m2 cassettes only)

Storage Solution

3-4% benzyl alcohol, 20% glycerin and water

Membrane

Ultracel® membrane – Composite regenerated cellulose (regenerated
cellulose membrane cast on a microporous polyethylene membrane)

Assembly Design

Automated assembly and testing of heat-sealed packets bound together
by an injection-molded polypropylene jacket

Maximum Operating Conditions
Recommended Feed Flow Rate

4–8 L/m2/min

Inlet Pressure

100 psi

Forward Transmembrane Pressure

80 psi (5.5 bar) at 4–40°C, 200 hours continuous
40 psi (2.7 bar) at 4–50°C, 50 hours continuous

Reverse Transmembrane Pressure

30 psi (2.1 bar) at 25°C, 3 min intervals, 10 cycles

Maximum Caustic Exposure (One Time)

0.5N NaOH at 50°C up to 50 hours

Operating pH Range

2–13

Regulatory Information
Component Material Toxicity

Component materials were tested and meet the criteria of the USP <88>
Biological Reactivity Tests for Class VI Plastics.

Good Manufacturing Practices

These products are manufactured in a facility that adheres to current
Good Manufacturing Practices.

ISO® 9001 Quality Standard

This product was manufactured in a facility whose Quality Management
System is approved by an accredited registering body to the appropriate
ISO® 9001 Quality Systems Standard.

100% Integrity Tested in Manufacturing

Each unit must pass our integrity test based on air flow through the
fully wetted membranes of the filter.

Validated Production Process

This product was fabricated using a validated manufacturing process.
Principles of statistical process control and determinations of process
capability have been applied to critical variables in the device fabrication
process. In-process controls are used to assure stability of the process.

Nominal Dimensions
Filtration Area

Length mm (in.)

Width mm (in.)

Thickness mm (in.)

C-Screen
88 cm2

206 (8.1)

56 (2.2)

8.3 (0.33)

2

206 (8.1)

56 (2.2)

24 (0.93)

0.57 m2

206 (8.1)

178 (7.0)

26 (1.03)

1.14 m2

206 (8.1)

178 (7.0)

42 (1.66)

88 cm2

206 (8.1)

56 (2.2)

8.3 (0.33)

0.11 m2

206 (8.1)

56 (2.2)

25 (0.98)

0.57 m

2

206 (8.1)

178 (7.0)

29 (1.13)

1.14 m2

206 (8.1)

178 (7.0)

45 (1.78)

0.11 m

D-Screen
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Hold-Up Volumes
Pellicon® 3 Cassettes with Ultracel®
membrane with C Screen

Pellicon® 3 Cassettes with Ultracel®
membrane with D Screen

Membrane Area

Feed
Channel (mL)

Permeate
Channel (mL)

Feed
Channel (mL)

Permeate
Channel (mL)

88 cm2

1.5

2.4

3.6

2.0

2

18

15

23

17

0.57 m2

85

68

118

75

1.14 m2

170

127

227

138

0.11 m

Ordering Information
Pellicon® 3 Cassettes
with Ultracel® Membrane
Description

Cat. No.

3kD NMWL with C-Screen

Accessories
Holder Type

Cassette Size

P3C003C00

Stainless Steel Mini-Holder

88 cm2 and 0.11 m2

2

0.11 m

P3C003C01

0.57 m2

P3C003C05

1.14 m2

P3C003C10

88 cm2

Area Range

Cat. No.

Pellicon® 3 Cassette Holders

5kD NMWL with C-Screen

88 cm2 to 0.55 m2

XX42PMINI

Acrylic Cassette Holder
Low Retentate Volume

2

0.57 m and 1.14 m

0.57 m2 to 5.7 m2

XX42PRV60

Stainless Steel Holder

0.57 m2 and 1.14 m2

0.57 m2 to 5.7 m2

XX42P0080

Stainless Steel Cassette
Holder and Assembly

0.57 m and 1.14 m

0.57 m to 5.7 m

XX42P0K80
XXPEL3MAP

2

2

2

2

2

P3C005C00

Manifold Support Plate

0.57 m2 and 1.14 m2

NA

2

0.11 m

P3C005C01

Process Scale Holder

2

0.57 m and 1.14 m

2

1.14 m and up

0.57 m2

P3C005C05

Contact Local
Representative

1.14 m2

P3C005C10

Hydraulic Process
Scale Holder

0.57 m2 and 1.14 m2

1.14 m2 and up

Contact Local
Representative

88 cm2

10kD NMWL with C-Screen

2

88 cm2

P3C010C00

0.11 m2

P3C010C01

0.57 m2

P3C010C05

Description

Cat. No.

Description

Cat. No.

P3C010C10

Sodium hydroxide solution
0.5 mol/L suitable for
biopharmaceutical production
EMPROVE® bio

137060

Diverter plate and silicone
gasket kit for 88 cm2 cassette

XXSPTFF01
XXSPTFF02

Sodium hydroxide solution
1 mol/L suitable for
biopharmaceutical production
EMPROVE® bio

137031

Diverter plate for 0.57 m2
and 1.14 m2 cassettes
Retentate collection plate for
0.57 m2 and 1.14 m2 cassettes

XXSPTFF03

Sodium hydroxide solution
25% low iron suitable for
biopharmaceutical production
EMPROVE® bio

480659

1.14 m2
30kD NMWL with C-Screen
88 cm2

P3C030C00

0.11 m2

P3C030C01

0.57 m2

P3C030C05

1.14 m2

P3C030C10

30kD NMWL with D-Screen
P3C030D00

88 cm2
2

0.11 m

P3C030D01

0.57 m2

P3C030D05

1.14 m

P3C030D10

2

Cleaning

Single-Pass TFF Accessories
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Application Note

A Hands-On Guide to Ultrafiltration/
Diafiltration Optimization using
Pellicon® Cassettes
In ultrafiltration (UF) tangential flow filtration (TFF)
systems, operating parameter selection will have far
reaching impact as the process is scaled to full-scale
manufacturing levels. While there are many factors that
contribute to final system design, several key parameters
should be optimized early in the process development
phase. The goal is to develop a robust process with the
following success criteria: superior product quality,
consistent and high product yield, reproducible process
flux and time, and a cleaning regime that allows extended
membrane reuse.
The following basic experiments should be considered
during development of processing methodology:
• Optimization
– Impact of transmembrane pressure (TMP) and feed

flow on process flux and retention
– Impact of product concentration and buffer

conditions on process flux and retention
– Impact of diavolumes on buffer exchange and

contaminant removal
• Paper design and full process simulation with chosen

processing parameters
Typically, the first three experiments are performed
sequentially to bracket process performance and obtain
data for analysis. This information is then combined with
actual manufacturing considerations (batch volume,
process time, etc.) to design a process simulation.

The purpose of a process simulation is to duplicate the
entire manufacturing process in a scale-down format, to
confirm sizing, and to assess preliminary product quality
and yield. The intent is to develop an optimized process,
on the bench, that will efficiently scale-up to meet fullscale manufacturing expectations.
Sequence
1. TMP Excursion at Initial Concentration
(Cb initial)

↓
2. Concentration / Volume Reduction
(Cb initial → Cb final)

↓
3. TMP Excursion at Final Concentration
(Cb final)

↓
4. Diafiltration / Buffer Exchange

↓
5. Product Recovery

Purpose
•
•
•
•

Determine TMP for UF/DF
Determine Feed Flow (QF) for UF/DF
Demonstrate Flux Stability
Confirm Retention of Product

• Determine Flux as Function of Concentration
• Determine Placement of Diafiltration Step
• Determine Flux as Function of Buffer Conditions
• Determine TMP for UF/DF
• Determine Feed Flow (QF) for UF/DF
• Confirm Retention of Product
• Determine Diavolume Requirement
• Confirm Retention of Product during DF
• Crude Assessment of Step Yield
• Product Quality Evaluation

Figure 1. Basic Optimization Experiments

Use this step-by-step guide to develop a robust UF/
DF process with Pellicon® cassettes (cutoffs of 100 kD
and lower) that will deliver superior product quality,
reproducible results, and high yields.

EMD Millipore is a division of Merck KGaA, Darmstadt, Germany

The following are step-by-step protocols for basic optimization experiments.

Set-up and Installation Procedure

Equilibration Procedure

Refer to the Maintenance Procedures for Pellicon® and
Pellicon® 2 Cassette Filters (P17512) or the Pellicon® 3 Filters
Installation and User Guide (AN1065EN00) when performing
actual set-up and installation of Pellicon® cassettes.

1. Add 3 L/m2 of the appropriate buffer to the feed tank.

1. Assemble the TFF system as shown in Figure 2.

with 0.1 m2 membrane area, Pellicon® 3 with 0.11 m2
membrane area) in the appropriate Pellicon® holder.
appropriate cleaning agent (per appropriate
maintenance guide), and flush again.
QR

PR

5. Direct the retentate and permeate to a waste

container.
6. When the feed tank level reaches the minimum level,

PF
Permeate

Feed

QP

Filtration
Module

Feed
Pump

– Retentate pressure of 2 – 15 psi (0.14 – 1.03 bar) to

in total recycle mode 1 and recirculate for 10 minutes;
verify that the pH and conductivity in the system have
been equilibrated to the level of the starting buffer.

PP
QF

– Feed flow of 5 L/min/m2

4. When half the buffer has been flushed, put the system

Retentate
Retentate
Valve

Feed
Tank

3. Start the feed pump and achieve the following

achieve approximately 30% conversion

3. Flush the system with water, clean with the

Diafiltration
Buffer

2. Direct the retentate and permeate to a waste container.

conditions by partially closing the retentate valve and
adjusting the pump speed:

2. Install the Pellicon® cassette(s) (Pellicon® 2 Mini

Figure 2. Schematic
of a TFF System

Example: 0.1 m2 membrane area x 3 L/m2 = 0.3 L buffer

open the retentate valve fully and stop the feed pump
to prevent the introduction of air into the system.

Part 1. TMP Excursion at Initial Concentration
1. Add sufficient volume of product to the feed reservoir

such that final volume or concentration target can be
reached or slightly exceeded (approximately 1 – 1.5 L
of final product at final concentration per m2).
Example: if Cinitial = 10 g/L and Cretentate = 80 g/L,
then the concentration factor is 8X. If the minimum
achievable final volume for 0.1 m2 is 0.1 L, calculate the
required initial volume:
Vinitial = Vminimum x VCF = 0.1 L x 8X = 0.8 L
2. Open the retentate valve fully and configure system in

total recycle mode.
conditions by partially closing the retentate valve
and adjusting the pump speed:
– Recommended feed flow (QF) rate for the membrane

device, typically 5
cassettes

that stable process flux is achieved 2.
5. Record temperatures, pressures, and flows; sample

feed and permeate for product retention 3.
6. Increase TMP by 5 – 10 psid (0.34 – 0.69 bar) by

manipulating the retentate valve while keeping the feed
flow constant. For more open membranes increase by
2 – 5 psid (0.14 – 0.34 bar). Repeat steps 4 and 5.
7. Repeat step 6 until flux begins to level off4;

typically 4 – 6 TMP values are evaluated in total.
8. Open the retentate valve fully and allow system to

3. Start the feed pump and achieve the following

L/min/m2

4. Recirculate the product for 10 – 15 minutes and ensure

for Pellicon® 2 and 3

continue in a total recycle.
9. Increase or decrease the feed flow by 2 – 3 L/min/m2

and repeat steps 4 through 8. If desired, a third feed
flow rate can be investigated.
10. Plot the data as shown in Figure 3.

– Minimal TMP, typically 2 – 5 psi (0.14 – 0.34 bar) for

more open membranes and 10 psi (0.69 bar) for
tighter membranes.
Tight membranes (1 kD, 5 kD, etc.)
Open membranes (50 kD, 100 kD, etc.)
2

Can use large TMP increases since optimum is typically > 30 psi
Can use small TMP increases since optimum is typically < 10 psi

200

Feed Flux = 5 L/min/m2
Feed ∆P = 20 psid

Optimum Point
TMP = 30 psid
Jf = 150 LMH

160

Figure 3.
TMP Excursion at
Two Feed Flows

Flux (LMH)

2

Feed Flux = 3 L/min/m
Feed ∆P = 10 psid

120
80

Optimum Point
TMP = 25 psid
Jf = 86 LMH

40
0
0

10

20

30

40

50

TMP (psid)

[m2]

A
QF [L/min]

Q1 = 5 L/min/m2

Q2 = 3 L/min/m2

Q1/Q2

Volume / Time / 150 LMH
(5 L/min/m2) x Volume / Time / 150 LMH

Volume / Time / 86 LMH
(3 L/min/m2) x Volume / Time / 86 LMH

0.57
0.95

Table 1. Membrane
Area vs. Pump Feed
Rate (Figure 3)

Calculations
The appropriate combination of feed flow rate and
TMP will maximize flux while minimizing the impact of
pumping and shear on the product. The appropriate
combination of these two parameters will also minimize
processing time and/or membrane area. To calculate the
optimum feed flow, compare the required membrane area
with the required pump rate at each of the two feed flow
conditions, as shown in Table 1.
[m2]

Membrane Area
=
Process Volume [L] / (Flux [LMH] x Process Time [h])
In Figure 3:
AreaQ1 = 0.57 x AreaQ2
Pump feed rate [L/min] =
Feed flux [L/min/m2] x Area [m2]
In Figure 3:
Pump feed rateQ1 = 0.95 x Pump feed rateQ2
In this example it is advantageous to run at the higher
feed flow, Q1, since it only requires 57% of the membrane
area used at the lower feed flow rate at almost the
identical pump feed rate.

Note:
• Anticipated final volume of over-concentrated product must exceed

minimum working volume of membrane system at selected feed flow rate
(QF); avoid introduction of air and maintain uniform mixing at end of volume
reduction.
• Move from least to greatest fouling conditions:
– Do not test into pressure-independent regime (past the knee of the flux

vs. TMP curve) 4
– Avoid exceeding 30 – 40% conversion ratios
• Check hysteresis if possible by returning the system to the initial conditions

and taking a final flux measurement; compare initial flux performance to
final flux performance at initial conditions.
• Ensure that choice of TMP and feed flow have corresponding retention

values that are acceptable (> 0.998) at both initial and final product
concentration and in each buffer 5.
• There is often very little performance difference versus feed flow rate at low

product concentration. However, at the higher concentrations that will be
investigated in Parts 2 and 3, the benefits of different feed flow rates should
become more pronounced.

3

Part 3. TMP Excursion at Final Concentration
1. Use the product from Part 2 at the final concentration in

the final buffer.

Calculations
Reference Part 1.

2. Repeat steps 2 – 10 of Part 1.

Note:
Reference Part 1 and Part 2 notes.

Part 4. Diafiltration
1. Use the product from Part 3 at the optimum

– Use 3 – 5 diavolumes as an initial estimate

concentration for diafiltration; dilute as needed using
the final buffer.
2. Configure the system for constant volume diafiltration.
3. Start the feed pump and achieve the optimum TMP and

feed flow as determined in Part 1 and Part 3.
4. Diafilter the product with the chosen number of

diavolumes:
– Choose the number of diavolumes based on the

for upstream UF/DF steps, or
– Use 7 – 12 diavolumes as an initial estimate for

final formulation UF/DF steps
5. Record temperatures, pressures, and flows at every

diavolume; sample feed and permeate for both product
retention, and retention and concentration of the
contaminant of interest.
6. Plot the data as shown in Figure 6.

product purity specifications (if known, see calculation
below) and add a safety factor of 2 diavolumes, or

Contaminant Retained
[% of original]

100
Figure 6. contaminant
removal vs. Diavolumes

10
1
R = 0.4

0.1

R = 0.2

0.01

0.001

R=0
0

5

Diavolumes

10

15

Calculations
The percentage of the original contaminant in the retentate
at each diavolume can be calculated from the retention
values using the following:
Remaining Contaminant [%] = 100 x e (Retention – 1) x N

diafiltration steps, such as final formulation. For upstream
steps, add 1 – 2 diavolumes. If the goal of diafiltration is not
to wash out a contaminant but rather to reach a target pH
or conductivity, then the measurement of that quality can
be plotted against the number of diavolumes instead.

where N is the number of diavolumes.
However, since contaminant concentration is being directly
measured in each feed sample throughout diafiltration, plot
these concentrations as a percentage of the original and
use the above equation to plot several lines of theoretical
retention, as shown in Figure 6. This plot will help demonstrate
the contaminant removal at various retentions.
Select the whole number of diavolumes based on the
acceptable contaminant levels for the product; always
add 2 – 3 diavolumes as a 10-fold safety factor for critical
6

Note:
• If it appears necessary to diafilter past ~ 14

diavolumes, any dead-legs or poor mixing areas in
the system will increase the apparent retention of the
contaminant and make further removal difficult.
• Ensure that choice of TMP and feed flow have

corresponding product retention values that are
acceptable (> 0.998) throughout diafiltration.

Paper Design and Process Simulation
The optimization parameters obtained from the previous
experiments can be combined to design a full process
simulation: concentration, diafiltration, (concentration,)
and recovery. If time permits, a process simulation should
be run immediately following the optimization work, and
should employ the following:
• New set of cassettes; same membrane type,

same cassette path length

After performing the process simulation, the system
should be cleaned with the appropriate solution according
to EMD Millipore recommendations11. If possible, the
process should be rerun using the cleaned membranes to
determine the effectiveness of the cleaning cycle and the
consistency of membrane performance from run-to-run.
If the cleaning cycle does not prove effective, the cleaning
parameters or cleaning solutions will need to be changed
and the cleaning cycle will have to be tested again.

• Fresh feedstock
• Fresh buffer(s)
• Optimized process parameters
• See detailed process simulation calculations below.

Calculations
The membrane area can be optimized to allow the
entire process (both concentration and diafiltration) to
be completed in the specified timeframe (3 – 4 hours is
recommended). The average flux for each concentration
and diafiltration step can be estimated from the
optimization data and combined with the desired volumes
to be processed. The approximate required membrane
area can then be calculated for both manufacturing scale
and scale-down runs.
Assume an example process scenario (this would have
been determined by optimization data, DF parameter, etc.):
• 2.9X Concentration:

10 g/L to 29 g/L; flux decreases from 150 LMH to 80 LMH
• 7X Diafiltration:

29 g/L; flux increases from 80 LMH to 85 LMH
• 3.4X Concentration:

29 g/L to 100 g/L; flux decreases from 85 LMH to 20 LMH
• Desired process time is 4 hours
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Manufacturing scale volumes as determined by the
customer:
• Feed volume = 5000 L
• Retentate volume at end of 2.9X concentration =

5000 L/2.9 = 1724 L
• Permeate volume removed during 2.9X concentration =

5000 L – 1724 L = 3276 L
• 7X Diafiltration buffer volume = 7 x 1724 L = 12,068 L
• Retentate volume at end of 3.4X Concentration =

1724 L/3.4 = 507 L
• Permeate volume removed during 3.4X concentration =

1724 L – 507 L = 1217 L

Average process flux for concentration step13:
Javg = Jfinal + 0.33 (Jinitial – Jfinal) = Jinitial x 0.33 + Jfinal x 0.67
For 2.9X concentration:
Javg = 150 LMH x 0.33 + 80 LMH x 0.67 = 103 LMH
For 3.4X concentration:
Javg = 85 LMH x 0.33 + 20 LMH x 0.67 = 41 LMH
Average process flux for diafiltration step:
For diafiltration the average flux can be estimated as the
initial and final process flux during the diafiltration step.
Required area:
Area = [(Permeate volume/Average flux) Concentration + (Permeate volume/Average flux) Diafiltration + … ] / Time
In this example:
Area = [(3,276 L/103 LMH) + (12,068 L/83 LMH) + (1,217 L/41 LMH)] / 4 hours = 51.6 m2
Add 20% safety factor:
Area = 62 m2
To perform a scale-down process simulation, the same
volume to area ratio is used and scaled based on either the
feed volume that can be used for the simulation or the area
of the desired filtration device. For example, if the process
is to be performed on one Pellicon® 2 Mini cassette (with
an area of 0.1 m2), then the required feed volume will be:
Scale-down feed volume = 0.1 m2 x (5000 L/62 m2) = 8 L
Instead, if there is a specific volume of feedstock to process
(example: 25 L), then the required membrane area will be:
Scale-down membrane area = 25 L x (62 m2/5000 L) = 0.3 m2
The process parameters, including Pellicon® device type,
should be consistent between scales, allowing the process
to be completed in a similar timeframe with similar fluxes,
pressures and loadings. The concentration factors, number
of diavolumes and feed quality should be kept consistent
at all scales to ensure robust scalability. However, to
demonstrate process robustness and repeatability, the
process should be tested at pilot scale before proceeding to
manufacturing.
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B/T® Process Pump
Systems
Efficient fluid transfer in
high-volume applications
Masterflex B/T process pump systems offer rugged
design and improved performance. They handle
the toughest applications, from pumping slurries,
abrasives, food additives, and media, to corrosive
fluids and polymers. Designed to be used with the
unique PerfectPosition® tubing, these complete
systems ensure reliable, continuous-duty pumping
with unparalleled ease of use.

1-800-637-3739
Masterflex.com

Rugged Design
– Cast-aluminum housing with epoxy-powder coating eliminates corrosion
– Robust gear reducer provides continuous-duty operation
– Simple latching mechanism allows easy opening and closing without the use of tools

Easy Tube Loading
– Enhanced tubing retention secures tubing firmly in place during loading process
– Revolutionary PerfectPosition® tubing features graduated markings for foolproof tubing alignment
– No need for extra fittings (potential sources of contamination)—use a single tube length from
source to delivery point

Improved Performance
– Rotor and occlusion bed design prevents “tubing roll” during operation, extending tubing life
– Housing design eliminates any chance of over- or under-squeezing the tubing in the pump head
– PerfectPosition® tubing retention marks make it easy to determine exactly where to load the
tubing to achieve optimal performance with minimal tubing wear

Enhanced Safety
– Integrated pump interlock shuts unit down when the head is opened
– Rugged housing with window protects user from moving internal
components—yet shows operator pump is working

1-800-637-3739 | 1-847-381-7050
Masterflex.com

NO MORE GUESSING
where to place your pump
tubing in the pump head!
– PerfectPosition retention marks make it easy
to load tubing to achieve optimal performance
– Tubing sizes ensure fully rated performance
under higher pressure applications

Pump Tubing

Performance Data
Pump tubing size
Inside diameter (nominal)

0.5" (12.7 mm)
1⁄2"

Hose barb size
Flow range (approximate)*
with 12 to 321 rpm drive

0.75" (19.0 mm)

(12.7 mm)

3⁄4"

(19.0 mm)

0.67 to 18.9 LPM
(0.17 to 5.0 GPM)

1.4 to 42 LPM
(0.4 to 11.1 GPM)

35 psi (2.4 bar)

30 psi (2.1 bar)

Maximum pressure†
Maximum

Tubing formulation

PerfectPosition pump tubing
B/T 87
B/T 91

vacuum†

26" Hg (660 mm Hg)

Suction lift†

Silicone
(platinum-cured)

Silicone
(peroxide-cured)

29 ft H2O (8.8 m H2O)

BioPharm Plus
Silicone
(platinum-cured)

*Determined under the following conditions: 0 psi at inlet, 0.5 psi at
outlet; water temperature at 72°F (22°C).
†Actual

performance varies depending on tubing formulation—
values shown are for firm tubing.

Puri-Flex™

C-Flex®

B/T 91

B/T 87

PharMed® BPT

PharmaPure®

Flow Performance for Watson-Marlow 700 Series Pump vs New B/T® Pump System

®

®

Masterflex B/T vs
Watson-Marlow 700 Series*
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B/T 87

B/T 91

• Smooth surface; low protein binding levels
• Fungus-resistant; phthalate- and latex-free
• Accommodates a wide temperature range

MK-96510-87

MK-96510-91

3 m (10 ft)/pk

3 m (10 ft)/pk

• Smooth surface for minimal particle
entrapment
• Very low extractables, with documented
biocompatibility for sensitive applications

MK-96400-87

MK-96400-91

3 m (10 ft)/pk

3 m (10 ft)/pk

MK-96445-87

MK-96445-91

3 m (10 ft)/pk

3 m (10 ft)/pk

• Heat sealable, weldable, and economical
• Long pump life when compared to silicone
or many other TPE tubings

MK-96419-87

MK-96419-91

3 m (10 ft)/pk

3 m (10 ft)/pk

• Heat sealable, weldable, economical
• Longest life of any C-Flex formulation
• Better resistance to pH fluctuations

MK-06424-87

MK-06424-91

3 m (10 ft)/pk

3 m (10 ft)/pk

• Over 10,000 hours of tubing life
• Resists ozone and UV radiation
• Ideal for tissue and cell culture work

MK-06507-87

MK-06507-91

3 m (10 ft)/pk

3 m (10 ft)/pk

• Nontoxic and nonhemolytic
• Great for tissue and cell work
• Low extractables and gas permeability

MK-06437-87

MK-06437-91

3 m (10 ft)/pk

3 m (10 ft)/pk

• Excellent chemical resistance
• Plasticizer-free inner liner
• Excellent biocompatibility

MK-06443-87

MK-06443-91

3 m (10 ft)/pk

3 m (10 ft)/pk

• Longest life of all Tygon formulations
• USP Class VI, EU Pharmacopoeia 3.2.9,
FDA 21

MK-06440-87

MK-06440-91

3 m (10 ft)/pk

3 m (10 ft)/pk

• Complies with FDA, NSF, 3A, and
EU food regulations
• Smooth inner surface unaffected by
common commercial sanitizers

MK-06418-87

MK-06418-91

3 m (10 ft)/pk

3 m (10 ft)/pk

MK-06399-87

MK-06399-91

3 m (10 ft)/pk

3 m (10 ft)/pk

• Very low extractable; biocompatible for
sensitive applications
• Longest tubing life of any silicone
pump tubing
• Lower spallation than regular silicone

37.9

10

30.3

8

B/T Size
87
Flow Performance for Watson-Marlow 700 Series Pump vs New B/T® Pump
System

12
15.1

4

B/T Size 91
WM 1” ID

37.9

10

Tygon® E-LFL

7.6

2

0

2

4

8

6

12

10

14

16

18

20

24

22

26

28

30

0
32

22.7

Pressure (PSIG)

6
4

15.1

2

7.6

0
0

2

4

6

8

10

12

14

16

18

20

22

24

26

Pressure (PSIG)

*Watson-Marlow is a trademark of Watson-Marlow Limited.

28

30

0
32

Flow (LPM)

30.3

8

0

Chem-Durance® Bio

WM 3/4” ID

Flow (LPM)

22.7

6

Flow (GPM)

Flow (GPM)

Tubing size

Description

B/T Size 87
WM 3/4” ID
B/T Size 91 ®
WMTygon
1” ID

E-Food
(B-44-4X)

Norprene® Food
(A-60-F)

• Ideal for high-temperature food
applications
• Resists heat, ozone, acids, and alkalies
• Complies with FDA and NSF food
regulations

1-800-637-3739 | 1-847-381-7050
Masterflex.com

B/T Pump Heads
®

Motor mount

NEMA Type 56C

IEC 72/ISO 71 with B5 flange

Mounting type

Direct-coupled

Motor size
rpm

Depends on specifications of type of
motor selected (requires minimum 0.5 hp; 1800 rpm maximum)

IP rating
Power

MK-77111-50

Catalog number

MK-77111-55

B/T Pump Systems
®

55

56

77111-37,
Zone 2
77111-30,
Except
-67, -77, -80 77111-80
-37
77111-30,
-37

Analog
Description
Flow range

Fixed-speed
18.9 or 42 LPM

Motor size
rpm

Amps
Catalog number

16 or 35 LPM

1 hp (0.75 kW)
321

IP rating
Power
(VAC, Hz)

Variable-speed

Specialty
Air-powered

0.71 to 42 LPM

0.71 to 42 LPM

1⁄2

3⁄4

hp (0.37 kW)

271

12 to 321

IP55

115 (60)

Digital
Modular dispensing

115 (50/60)

3⁄4

12 to 321

IP56

230 (50)

2.1 to 42 LPM

hp (0.56 kW)

35 to 321

IP56

230 (50/60)

90 to 130
(50/60)

IP56

190 to 260
(50/60)

Requires 24 cfm (0.68 m3)
100 psi (6.9 bar) minimum

12.6

6.3

5

2.5

10.5

5.7

—

MK-77111-30

MK-77111-37

MK-77111-60

MK-77111-67

MK-77111-70

MK-77111-77

MK-77111-80

1-800-637-3739 | 1-847-381-7050
4700A

hp (0.56 kW)

Masterflex.com

D. Material Safety Data Sheets
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Safety Data Sheet
SECTION 1: Identification
1.1. Product Identifier
Trade Name or Designation: Imidazole, Reagent
(Glyoxaline)
Product Number: 2-21660
Other Identifying Product Numbers: 2-21660-1, 2-21660-100G

1.2. Recommended Use and Restrictions on Use
General Laboratory Reagent

1.3. Details of the Supplier of the Safety Data Sheet
Company: Reagents Inc.
Address: 4746 Sweden Road
Charlotte, NC 28224 USA
Telephone: 800-732-8484

1.4. Emergency Telephone Number (24 hr)
CHEMTREC (USA) 800-424-9300
CHEMTREC (International) 1+ 703-527-3887

SECTION 2: Hazard(s) Identification
2.1. Classification of the Substance or Mixture (in accordance with OSHA HCS 29 CFR 1910.1200)
For the full text of the Hazard and Precautionary Statements listed below, see Section 16.

Hazard
Statement Precautionary Statements

Hazard Class

Category

Acute Toxicity - Oral

Category 3

H301

Skin Corrosion / Irritation

Category 1

H314

Eye Damage / Irritation

Category 1

H318

P264, P270, P301+P310, P321, P330, P405,
P501
P260, P264, P280, P301+P330+P331,
P303+P361+P353, P363, P304+P340, P310,
P321, P305+P351+P338, P405, P501
P280, P305+P351+P338, P310

Reproductive Toxicity

Category 2

H361

P201, P202, P280, P308+P313, P405, P501

Specific Target Organs/Systemic Toxicity Following Single
Exposure
Corrosive to Metals

Category 2

H371

P260, P264, P270, P308+P311, P405, P501

Category 1

H290

P234, P390, P406

Product Number: 2-21660
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Safety Data Sheet
2.2. GHS Label Elements
Pictograms:

Signal Word:

Danger

Hazard Statements:
Hazard Number
H290
H301
H314
H318
H361
H371

Product Number: 2-21660

Hazard Statement
May be corrosive to metals.
Toxic if swallowed.
Causes severe skin burns and eye damage.
Causes serious eye damage.
Suspected of damaging fertility or the unborn child.
May cause damage to organs.
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Precautionary Statements:
Precautionary Number
P201
P202
P234
P260
P264
P270
P280
P301+P310
P301+P330+P331
P303+P361+P353
P305+P351+P338
P308+P311
P308+P313
P310
P321
P330
P363
P390
P405
P406
P501

Precautionary Statement
Obtain special instructions before use.
Do not handle until all safety precautions have been read and understood.
Keep only in original container.
Do not breathe dust, fumes or mist.
Wash arms, hands and face thoroughly after handling.
Do not eat, drink or smoke when using this product.
Wear protective gloves and eye protection.
IF SWALLOWED: Immediately call a POISON CENTER or physician.
IF SWALLOWED: rinse mouth. Do NOT induce vomiting.
IF ON SKIN (or hair): Take off immediately all contaminated clothing. Rinse skin with water.
IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to
do. Continue rinsing.
IF exposed or concerned: Call a POISON CENTER or physician.
IF exposed or concerned: Get medical attention.
Immediately call a POISON CENTER or physician.
Specific treatment (Wash areas of contact with water).
Rinse mouth.
Wash contaminated clothing before reuse.
Absorb spillage to prevent material damage.
Store locked up.
Store in corrosive resistant container with a resistant inner liner.
Dispose of contents in accordance with local, state, federal and international regulations.

2.3. WHMIS Classification
WHMIS classification is not included based on the recommended option (Option 4) found in the Canada Gazette Part II, Vol. 149, No.3, page 458

2.4. Hazards not Otherwise Classified or Covered by GHS
Data not available.

SECTION 3: Composition / Information on Ingredients
3.1. Components of Substance or Mixture
Chemical Name

Formula

Imidazole

NHCH:NCH:CH

Product Number: 2-21660

Molecular Weight
68.07 g/mol

CAS Number
288-32-4

Weight%
100.00%
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SECTION 4: First-Aid Measures
4.1. General First Aid Information
Eye Contact: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue
rinsing.
Inhalation: Not expected to require first aid. If necessary, remove to fresh air.
Skin Contact: IF ON SKIN (or hair): Take off immediately all contaminated clothing. Rinse skin with water.
Ingestion: IF SWALLOWED: rinse mouth. Do NOT induce vomiting.

4.2. Most Important Symptoms and Effects, Acute and Delayed
May cause mild irritation to areas of contact.

4.3. Medical Attention or Special Treatment Needed

Immediately call a POISON CENTER or physician. Specific treatment (Wash areas of contact with water).

SECTION 5: Fire-Fighting Measures
5.1. Extinguishing Media

Not considered to be a fire or explosion hazard.

5.2. Specific Hazards Arising from the Substance or Mixture
Not considered to be a fire or explosion hazard.

5.3. Special Protective Equipment for Firefighters

Wear protective clothing and NIOSH-approved breathing equipment appropriate for the surrounding fire.

SECTION 6: Accidental Release Measures
6.1. Personal Precautions, Protective Equipment and Emergency Procedures
Wear protective gloves and eye protection.

6.2. Cleanup and Containment Methods and Materials

Absorb with suitable material and dispose of in accordance with local regulations.

SECTION 7: Handling and Storage
7.1. Precautions for Safe Handling and Storage Conditions
Store in corrosive resistant container with a resistant inner liner.

Product Number: 2-21660
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SECTION 8: Exposure Controls / Personal Protection
8.1. Control Parameters
Chemical Name

Limit Type Country

Exposure Limit

Information Source

Data not available. ()

8.2. Exposure Controls
Engineering Controls: No specific controls are needed. Normal room ventilation is adequate.
Respiratory Protection: No specific controls are needed. Normal room ventilation is adequate
Skin Protection: Wear protective gloves and eye protection.
Eye Protection: Wear protective gloves and eye protection.

8.3. Personal Protective Equipment
Wear protective gloves and eye protection.

Product Number: 2-21660
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SECTION 9: Physical and Chemical Properties
9.1. Basic Physical and Chemical Properties
Appearance: White to off-white solid
Physical State: Solid
Odor: Data not available.
Odor Threshold: Data not available.
pH: Data not available.
Melting/Freezing Point: 88 - 90°C
Initial Boiling Point /Range: Data not available.
Flash Point: 145°C closed cup [DIN 51758]
Evaporation Rate: Data not available.
Flammability: Data not available.
Flammability/Explosive Limits: Data not available.
Vapor Pressure: 0.003 hPa at 20°C
Vapor Density: Data not available.
Relative Density: 1.03
Solubility: 633 G/L at 20°C
Partition Coeffieient (n-Octanol/Water): -0.02
Auto-Ignition Temperature: Data not available.
Decomposition Temperature: Data not available.
Viscosity: Data not available.
ExplosiveProperties: Data not available.
Oxidizing Properties: Data not available.

SECTION 10: Stability and Reactivity
10.1. Reactivity and Chemical Stability
Stable under normal conditions of use and storage.

10.2. Possibility of Hazardous Reactions
Data not available.

10.3. Conditions to Avoid and Incompatible Materials
Keep only in original container.

10.4. Hazardous Decomposition Products
May emit irritating fumes when heated to decomposition.

Product Number: 2-21660
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SECTION 11: Toxicological Information
11.1. Information on Toxicological Effects
Acute Toxicity - Oral Exposure:
Toxic if swallowed. Wash arms, hands and face thoroughly after handling. Do not eat, drink or smoke when using this product. IF
SWALLOWED: Immediately call a POISON CENTER or physician. Specific treatment (Wash areas of contact with water). Rinse mouth. Store
locked up. Dispose of contents in accordance with local, state, federal and international regulations.
Acute Toxicity - Dermal Exposure:
Not applicable.
Acute Toxicity - Inhalation Exposure:
Not applicable.
Acute Toxicity - Other Information:
Data not available.
Skin Corrosion and Irritation:
Causes severe skin burns and eye damage. Do not breathe dust, fumes or mist. Wash arms, hands and face thoroughly after handling. Wear
protective gloves and eye protection. IF SWALLOWED: rinse mouth. Do NOT induce vomiting. IF ON SKIN (or hair): Take off immediately all
contaminated clothing. Rinse skin with water. Wash contaminated clothing before reuse. IF INHALED: Remove person to fresh air and keep
comfortable for breathing. Immediately call a POISON CENTER or physician. Specific treatment (Wash areas of contact with water). IF IN
EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Store locked up.
Dispose of contents in accordance with local, state, federal and international regulations.
Serious Eye Damage and Irritation:
Causes serious eye damage. Wear protective gloves and eye protection. IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing. Immediately call a POISON CENTER or physician.
Respiratory Sensitization:
Not applicable.
Skin Sensitization:
Not applicable.
Germ Cell Mutagenicity:
Not applicable.
Carcinogenicity:
Not applicable.
Reproductive Toxicity:
Suspected of damaging fertility or the unborn child. Obtain special instructions before use. Do not handle until all safety precautions have been
read and understood. Wear protective gloves and eye protection. IF exposed or concerned: Get medical attention. Store locked up. Dispose
of contents in accordance with local, state, federal and international regulations.

Product Number: 2-21660
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Specific Target Organ Toxicity from Single Exposure:
May cause damage to organs. Do not breathe dust, fumes or mist. Wash arms, hands and face thoroughly after handling. Do not eat, drink or
smoke when using this product. IF exposed or concerned: Call a POISON CENTER or physician. Store locked up. Dispose of contents in
accordance with local, state, federal and international regulations.
Specific Target Organ Toxicity from Repeated Exposure:
Not applicable.
Aspiration Hazard:
Not applicable.
Additional Toxicology Information:
Data not available.

SECTION 12: Ecological Information
12.1. Ecotoxicity
Not applicable.

12.2. Persistence and Degradability
Data not available.

12.3. Bioaccumulative Potential
Data not available.

12.4. Mobility in Soil
Data not available.

12.5. Other Adverse Ecological Effects
Data not available.

SECTION 13: Disposal Considerations
13.1. Waste Treatment Methods
Data not available.

Product Number: 2-21660
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SECTION 14: Transportation Information
14.1. Transportation by Land - Department of Transportation (DOT, United States of America)
UN Number:
Proper Shipping Name:
Hazard Class:
Packing Group:

UN3263
Corrosive solid, basic, organic, nos (Imidazole)
8
III

Hazard Placard Labels:

14.2. Transportation by Air - International Air Transport Association (IATA)
UN Number:
Proper Shipping Name:

UN3263
Corrosive solid, basic, organic, nos (Imidazole)

Hazard Class:

8

Packing Group:

III

Hazard Placard Labels:

SECTION 15: Regulatory Information
15.1. Occupational Safety and Health Administration (OSHA) Hazards
Not listed.

15.2. Superfund Amendments and Reauthorization Act (SARA) 302 Extremely Hazardous Substances
Not listed.

15.3. Superfund Amendments and Reauthorization Act (SARA) 311/312 Hazardous Chemicals
Not listed.

15.4. Superfund Amendments and Reauthorization Act (SARA) 313 Toxic Release Inventory (TRI)
Not listed.

15.5. Massachusetts Right-to-Know Substance List
Not listed.

Product Number: 2-21660
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15.6. Pennsylvania Right-to-Know Hazardous Substances
Not listed.

15.7. New Jersey Worker and Community Right-to-Know Components
Not listed.

15.8. California Proposition 65
Not listed.

15.9. Canada Domestic Substances List / Non-Domestic Substances List (DSL/NDSL)
Imidazole (CAS # 288-32-4): Present

15.10. United States of America Toxic Substances Control Act (TSCA) List
Imidazole (CAS # 288-32-4): Present

15.11. European Inventory of Existing Commercial Chemical Substances (EINECS),

European List of Notified Chemical Substances (ELINCS), and No Longer Polymers (NLP)

Not listed.

SECTION 16: Other Information
16.1. Full Text of Hazard Statements and Precautionary Statements
May be corrosive to metals. Toxic if swallowed. Causes severe skin burns and eye damage. Causes serious eye damage. Suspected of damaging
fertility or the unborn child. May cause damage to organs.
Obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Keep only in original container. Do
not breathe dust, fumes or mist. Wash arms, hands and face thoroughly after handling. Do not eat, drink or smoke when using this product. Wear
protective gloves and eye protection.
IF SWALLOWED: Immediately call a POISON CENTER or physician. IF ON SKIN (or hair): Take off immediately all contaminated clothing. Rinse
skin with water. IF INHALED: Remove person to fresh air and keep comfortable for breathing. IF IN EYES: Rinse cautiously with water for several
minutes. Remove contact lenses, if present and easy to do. Continue rinsing. IF exposed or concerned: Call a POISON CENTER or physician.
Specific treatment (Wash areas of contact with water). Wash contaminated clothing before reuse. Absorb spillage to prevent material damage.
Store locked up. Store in corrosive resistant container with a resistant inner liner.
Dispose of contents in accordance with local, state, federal and international regulations.

Product Number: 2-21660
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16.2. Miscellaneous Hazard Classes
Canadian Carcinogenicity Hazard Class: Not Applicable.
Physical Hazards Not Otherwise Classified (PHNOC): Not Applicable.
Health Hazards Not Otherwise Classified (HHNOC): Not Applicable.
Biohazardous Infectious Materials Hazard Class: Not Applicable.

16.3. National Fire Protection Association (NFPA) Rating
Health: 3
Flammability: 1
Reactivity: 0
Special Hazard:

3

1

0

16.4. Document Revision
Last Revision Date: 8/31/2015

DISCLAIMER
When handled properly by qualified personnel, the product described herein does not present a significant health or safety hazard. Alteration of its
characteristics by concentration, evaporation, addition of other substances, or other means may present hazards not specifically addressed herein and which
must be evaluated by the user. The information furnished herein is believed to be accurate and represents the best data currently available to us. No warranty,
expressed or implied, is made and REAGENTS, INC. assumes no legal responsibility or liability whatsoever resulting from its use.

Product Number: 2-21660
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SECTION 1: Identification
1.1. Product Identifier
Trade Name or Designation: Sodium Phosphate Dibasic Heptahydrate, ACS Reagent Grade
(Disodium Hydrogen Phosphate Heptahydrate)
Product Number: 1-32400
Other Identifying Product Numbers: 1-32400-1, 1-32400-3, 1-32400-5

1.2. Recommended Use and Restrictions on Use
General Laboratory Reagent

1.3. Details of the Supplier of the Safety Data Sheet
Company: Reagents Inc.
Address: 4746 Sweden Road
Charlotte, NC 28224 USA
Telephone: 800-732-8484

1.4. Emergency Telephone Number (24 hr)
CHEMTREC (USA) 800-424-9300
CHEMTREC (International) 1+ 703-527-3887

SECTION 2: Hazard(s) Identification
2.1. Classification of the Substance or Mixture (in accordance with OSHA HCS 29 CFR 1910.1200)
For the full text of the Hazard and Precautionary Statements listed below, see Section 16.

This product is not categorized as hazardous in any GHS hazard class.
2.2. GHS Label Elements
Pictograms: None required.

Signal Word: None required.
Hazard Statements: None required.
Precautionary Statements: None required.
Product Number: 1-32400
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2.3. WHMIS Classification
WHMIS classification is not included based on the recommended option (Option 4) found in the Canada Gazette Part II, Vol. 149, No.3, page 458

2.4. Hazards not Otherwise Classified or Covered by GHS
Data not available.

SECTION 3: Composition / Information on Ingredients
3.1. Components of Substance or Mixture
Chemical Name
Sodium Phosphate, Dibasic, Heptahydrate

Formula
Na₂HPO₄·7H₂O

Molecular Weight
Data not available.

CAS Number
7782-85-6

Weight%
100.00%

SECTION 4: First-Aid Measures
4.1. General First Aid Information
Eye Contact: May cause irritation, redness, pain, and tearing.
Inhalation: Not expected to require first aid. If necessary, remove to fresh air.
Skin Contact: May cause slight irritation to those allergic to phosphates.
Ingestion: Dilute with water or milk. Do not induce vomiting. Call a physician if necessary.

4.2. Most Important Symptoms and Effects, Acute and Delayed

May cause irritation to the eyes and skin. Wash areas of contact with water. Call a physician if irritation develops. Does not present any significant
health hazards. May be harmful if swallowed or inhaled.
EYE CONTACT: May cause irritation, redness, pain, and tearing. SKIN CONTACT: May cause slight irritation to those allergic to phosphates.
CHRONIC EFFECTS / CARCINOGENICITY: May sequester calcium and cause calcium phosphate deposits in the kidneys.

4.3. Medical Attention or Special Treatment Needed
Not expected to require special treatment.

SECTION 5: Fire-Fighting Measures
5.1. Extinguishing Media

Use any means suitable for extinguishing surrounding fire.

5.2. Specific Hazards Arising from the Substance or Mixture
Not considered to be a fire or explosion hazard.

5.3. Special Protective Equipment for Firefighters

Use protective clothing and breathing equipment appropriate for the surrounding fire.

Product Number: 1-32400
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SECTION 6: Accidental Release Measures
6.1. Personal Precautions, Protective Equipment and Emergency Procedures
Wear appropriate PPE for the size and nature of the spill. As a general rule, wear safety glasses and gloves.

6.2. Cleanup and Containment Methods and Materials

Pick up in a manner that does not generate dust. Powder may be moistened with water to aid in the clean-up.

SECTION 7: Handling and Storage
7.1. Precautions for Safe Handling and Storage Conditions

As with all chemicals, wash hands thoroughly after handling. Avoid contact with eyes and skin. Protect from physical damage. Keep in tightly closed
containers in a cool, dry area.

SECTION 8: Exposure Controls / Personal Protection
8.2. Exposure Controls
Engineering Controls: No specific controls are needed. Normal room ventilation is adequate.
Respiratory Protection: Normal room ventilation is adequate.
Skin Protection: Chemical resistant gloves.
Eye Protection: Safety glasses or goggles.

8.3. Personal Protective Equipment

Normal room ventilation is adequate. Chemical resistant gloves. Safety glasses or goggles.

Product Number: 1-32400
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SECTION 9: Physical and Chemical Properties
9.1. Basic Physical and Chemical Properties
Appearance: Colorless/white solid
Physical State: Solid
Odor: Data not available.
Odor Threshold: Data not available.
pH: Data not available.
Melting/Freezing Point: Data not available.
Initial Boiling Point /Range: Data not available.
Flash Point: Data not available.
Evaporation Rate: Data not available.
Flammability: Data not available.
Flammability/Explosive Limits: Data not available.
Vapor Pressure: Data not available.
Vapor Density: Data not available.
Relative Density: 1.70
Solubility: Data not available.
Partition Coeffieient (n-Octanol/Water): Data not available.
Auto-Ignition Temperature: Data not available.
Decomposition Temperature: Data not available.
Viscosity: Data not available.
ExplosiveProperties: Data not available.
Oxidizing Properties: Data not available.

SECTION 10: Stability and Reactivity
10.1. Reactivity and Chemical Stability
Stable under normal conditions of use and storage.

10.2. Possibility of Hazardous Reactions
Data not available.

10.3. Conditions to Avoid and Incompatible Materials
Reactive with acids, alkalis.

10.4. Hazardous Decomposition Products
Will not occur.
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Safety Data Sheet
SECTION 11: Toxicological Information
11.1. Information on Toxicological Effects
Acute Toxicity - Oral Exposure:
Not applicable.
Acute Toxicity - Dermal Exposure:
Not applicable.
Acute Toxicity - Inhalation Exposure:
Not applicable.
Acute Toxicity - Other Information:
LD50, Oral, Rat: (Sodium Phosphate, Dibasic, Heptahydrate) 12.93 g/kg, details of toxic effects not reported other than lethal dose value.
Skin Corrosion and Irritation:
Not applicable.
Serious Eye Damage and Irritation:
Not applicable.
Respiratory Sensitization:
Not applicable.
Skin Sensitization:
Not applicable.
Germ Cell Mutagenicity:
Not applicable.
Carcinogenicity:
Not applicable.
Reproductive Toxicity:
Not applicable.
Specific Target Organ Toxicity from Single Exposure:
Not applicable.
Specific Target Organ Toxicity from Repeated Exposure:
Not applicable.
Aspiration Hazard:
Not applicable.
Additional Toxicology Information:
Data not available.

Product Number: 1-32400
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Safety Data Sheet
SECTION 12: Ecological Information
12.1. Ecotoxicity
Not applicable.

12.2. Persistence and Degradability
Data not available.

12.3. Bioaccumulative Potential
Data not available.

12.4. Mobility in Soil
Data not available.

12.5. Other Adverse Ecological Effects
Data not available.

SECTION 13: Disposal Considerations
13.1. Waste Treatment Methods
Data not available.

SECTION 14: Transportation Information
14.1. Transportation by Land - Department of Transportation (DOT, United States of America)

Not regulated according to DOT Regulations.

Product Number: 1-32400
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14.2. Transportation by Air - International Air Transport Association (IATA)
UN Number:

N/A

Proper Shipping Name:
Hazard Class:
Packing Group:
Hazard Placard Labels:

SECTION 15: Regulatory Information
15.1. Occupational Safety and Health Administration (OSHA) Hazards
Not listed.

15.2. Superfund Amendments and Reauthorization Act (SARA) 302 Extremely Hazardous Substances
Not listed.

15.3. Superfund Amendments and Reauthorization Act (SARA) 311/312 Hazardous Chemicals
Sodium Phosphate, Dibasic, Heptahydrate (CAS # 7782-85-6): 5000 lb final RQ; 2270 kg final RQ

15.4. Superfund Amendments and Reauthorization Act (SARA) 313 Toxic Release Inventory (TRI)
Not listed.

15.5. Massachusetts Right-to-Know Substance List
Sodium Phosphate, Dibasic, Heptahydrate (CAS # 7782-85-6): Present

15.6. Pennsylvania Right-to-Know Hazardous Substances
Sodium Phosphate, Dibasic, Heptahydrate (CAS # 7782-85-6): Environmental hazard
Sodium Phosphate, Dibasic, Heptahydrate (CAS # 7782-85-6): Present

15.7. New Jersey Worker and Community Right-to-Know Components
Sodium Phosphate, Dibasic, Heptahydrate (CAS # 7782-85-6): sn 1723

15.8. California Proposition 65
Not listed.

15.9. Canada Domestic Substances List / Non-Domestic Substances List (DSL/NDSL)
Sodium Phosphate, Dibasic, Heptahydrate (CAS # 7782-85-6): Present

15.10. United States of America Toxic Substances Control Act (TSCA) List
Sodium Phosphate, Dibasic, Heptahydrate (CAS # 7782-85-6): Present

Product Number: 1-32400
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Safety Data Sheet
15.11. European Inventory of Existing Commercial Chemical Substances (EINECS),

European List of Notified Chemical Substances (ELINCS), and No Longer Polymers (NLP)

Not listed.

SECTION 16: Other Information
16.1. Full Text of Hazard Statements and Precautionary Statements

16.2. Miscellaneous Hazard Classes
Canadian Carcinogenicity Hazard Class: Not Applicable.
Physical Hazards Not Otherwise Classified (PHNOC): Not Applicable.
Health Hazards Not Otherwise Classified (HHNOC): Not Applicable.
Biohazardous Infectious Materials Hazard Class: Not Applicable.

16.3. National Fire Protection Association (NFPA) Rating
Health: 1
Flammability: 0
Reactivity: 0
Special Hazard:

1

0

0

16.4. Document Revision
Last Revision Date: 8/31/2015

DISCLAIMER
When handled properly by qualified personnel, the product described herein does not present a significant health or safety hazard. Alteration of its
characteristics by concentration, evaporation, addition of other substances, or other means may present hazards not specifically addressed herein and which
must be evaluated by the user. The information furnished herein is believed to be accurate and represents the best data currently available to us. No warranty,
expressed or implied, is made and REAGENTS, INC. assumes no legal responsibility or liability whatsoever resulting from its use.
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Date of Issue:
19 February 2019

SAFETY DATA SHEET
1. SUBSTANCE AND SOURCE IDENTIFICATION
Product Identifier
SRM Number: 723e
SRM Name:
Tris(hydroxymethyl)aminomethane (HOCH2)3CNH2 Acidimetric Standard
Other Means of Identification: Not applicable.
Recommended Use of This Material and Restrictions of Use
This Standard Reference Material (SRM) consists of highly purified tris(hydroxymethyl)aminomethane
(HOCH2)3CNH2 [2-amino-2-(hydroxymethyl)-1,3-propanediol; “Tris”; “THAM”], hereafter referred to as Tris.
SRM 723e is intended primarily for use in acidimetric standardization. A unit of SRM 723e consists of 50 g in a
clear glass bottle.
Company Information
National Institute of Standards and Technology
Standard Reference Materials Program
100 Bureau Drive, Stop 2300
Gaithersburg, Maryland 20899-2300
Telephone: 301-975-2200
FAX: 301-948-3730
E-mail: SRMMSDS@nist.gov
Website: https://www.nist.gov/srm

Emergency Telephone ChemTrec:
1-800-424-9300 (North America)
+1-703-527-3887 (International)

2. HAZARDS IDENTIFICATION
Classification
Physical Hazard:
Health Hazard:

Not classified.
Skin Corrosion/Irritation
Serious Eye damage/Eye irritation
STOT - Single Exposure

Category 2
Category 2A
Category 3

Label Elements
Symbol

Signal Word
Warning
Hazard Statement(s):
H315
Causes skin irritation.
H319
Causes serious eye irritation.
H335
May cause respiratory irritation.
Precautionary Statement(s):
P261
Avoid breathing dust.
P264
Wash hands thoroughly after handling.
P271
Use only outdoors or in a well-ventilated area.
P280
Wear protective gloves.
P302+P352
If on skin: Wash with plenty of water.
P304+P340
If inhaled: Remove person to fresh air and keep comfortable for breathing.
P305+P351+P338 If in eyes: Rinse cautiously with water for several minutes. Remove contact lenses, if present
and easy to do. Continue rinsing.
P322+P364
Take off contaminated clothing and wash it before reuse.
SRM 723e
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P332+P337+P313
P403+P233
P405
P501

If skin or eye irritation occurs: Get medical attention.
Store in a well-ventilated place. Keep container tightly closed.
Store locked up.
Dispose of contents and containers in accordance with all applicable regulations.

Hazards Not Otherwise Classified: Not applicable.
Ingredients(s) with Unknown Acute Toxicity: Not applicable.

3. COMPOSITION AND INFORMATION ON HAZARDOUS INGREDIENTS
Substance: Tris(hydroxymethyl)aminomethane
Other Designations: Tris [tris buffering agent; trishydroxymentylaminomethane; tris(methylolamino)methane; 1,1,1
tris(hydroxymethyl)methanamine; tris(hydroxymethyl)methylamine; tris(hydroxymethyl)methanamine]
Components are listed in compliance with OSHA’s 29 CFR 1910.1200; for the actual values see the Certificate of
Analysis.
Hazardous Component(s)
Tris(hydroxymethyl)aminomethane

CAS Number

EC Number
(EINECS)

77-86-1

201-064-4

Nominal Mass Concentration
(%)
100

4. FIRST AID MEASURES
Description of First Aid Measures:
Inhalation: If adverse effects occur, remove to uncontaminated area. If not breathing, give artificial respiration
or oxygen by qualified personnel. Seek immediate medical attention.
Skin Contact: Wash skin with soap and water for at least 15 minutes. Thoroughly clean and dry contaminated
clothing before reuse.
Eye Contact: Flush eyes with water for at least 15 minutes. If necessary, seek medical attention.
Ingestion: If a large amount is swallowed, get medical attention.
Most Important Symptoms/Effects, Acute and Delayed: Skin, eye, and possible respiratory irritation.
Indication of any immediate medical attention and special treatment needed, if necessary: If any of the above
symptoms are present, seek medical attention if needed.

5. FIRE FIGHTING MEASURES
Fire and Explosion Hazards: Negligible fire hazard. See Section 9, “Physical and Chemical Properties” for
flammability properties.
Extinguishing Media:
Suitable: Regular dry chemical, dry sand, water, and regular foam.
Unsuitable: None listed.
Specific Hazards Arising from the Chemical: None listed.
Special Protective Equipment and Precautions for Fire-Fighters: Avoid inhalation of material or combustion
byproducts. Wear full protective clothing and NIOSH approved self-contained breathing apparatus (SCBA).
NFPA Ratings (0 = Minimal; 1 = Slight; 2 = Moderate; 3 = Serious; 4 = Severe)
Health = 2

Fire = 0

Reactivity = 0

6. ACCIDENTAL RELEASE MEASURES
Personal Precautions, Protective Equipment and Emergency Procedures: Use suitable protective equipment;
see Section 8, “Exposure Controls and Personal Protection”.
Methods and Materials for Containment and Clean up: Keep out of water supplies and sewers. Do not touch
spilled material. Notify safety personnel of spills. Collect spilled material in appropriate container for disposal.
Isolate hazard area and deny entry.

SRM 723e
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7. HANDLING AND STORAGE
Safe Handling Precautions: Minimize dust generation. See Section 8, “Exposure Controls and Personal Protection”.
Storage: Store and handling in accordance with all current regulations and standards. Keep separated from
incompatible substances (acids, bases, metals, oxidizing materials).

8. EXPOSURE CONTROLS AND PERSONAL PROTECTION
Exposure Limits: No occupational exposure limits have been established. The exposure limits for Particulates Not
Otherwise Regulated are applicable.
OSHA (PEL): 15 mg/m3 (TWA, total particulates)
5 mg/m3 (TWA, respirable particulates)
Engineering Controls: Provide local exhaust or process enclosure ventilation system. Ensure compliance with
applicable exposure limits.
Personal Protection: In accordance with OSHA 29 CFR 1910.132, subpart I, wear appropriate Personal Protective
Equipment (PPE) to minimize exposure to this material.
Respiratory Protection: If workplace conditions warrant a respirator, a respiratory protection program that meets
OSHA 29CFR 1910.134 must be followed. Refer to NIOSH 42 CFR 84 for applicable certified respirators.
Eye/Face Protection: Wear splash resistant safety goggles with a face shield. An eye wash station should be readily
available near areas of use.
Skin and Body Protection: Personal protective equipment for the body should be selected based on the task being
performed and the risks involved and should be approved by a specialist before handling this product.
Chemical-resistant gloves should be worn at all times when handling chemicals.

9. PHYSICAL AND CHEMICAL PROPERTIES
Descriptive Properties:
Appearance (physical state, color, etc.):
Molecular Formula:
Molar Mass (g/mol):
Odor:
Odor threshold:
pH (solution):
Evaporation rate:
Melting point/freezing point (ºC):
Relative Density (g/L):
Vapor Pressure (mmHg):
Vapor Density (air = 1):
Viscosity (cP):
Solubility(ies):

Partition coefficient (n-octanol/water):
Particle Size (if relevant)
Thermal Stability Properties:
Autoignition Temperature (ºC):
Thermal Decomposition (ºC):
Initial boiling point and boiling range (ºC):
Explosive Limits, LEL (Volume %):
Explosive Limits, UEL (Volume %):
Flash Point (ºC)
Flammability (solid, gas):
SRM 723e

white crystalline, hygroscopic powder
C4H11NO3
121.1
odorless
not available
10.4 at 1.2 %
not applicable
171–172 (340–342 ºF)
not available
not applicable
not applicable
not applicable
water soluble (55 %); moderately soluble: methanol, ethanol,
ethylene glycol, dimethylformamide; slightly soluble:
acetone, ether; very slightly soluble: ethyl acetate,
cyclohexane, chloroform, carbon tetrachloride
log Kow = –1.56
not available
not available
not available
219–220 (426–428 ºF) at 10 mmHg
not available
not available
not available
not available
Page 3 of 6

10. STABILITY AND REACTIVITY
Reactivity: Stable at normal temperatures and pressure.
Stability:

X

Stable

Unstable

Possible Hazardous Reactions: None listed.
Conditions to Avoid: Avoid generating dust and exposure to moisture.
Incompatible Materials: Acids, bases, metals, and oxidizing materials.
Fire/Explosion Information: See Section 5, “Fire Fighting Measures”.
Hazardous Decomposition: Thermal decomposition will produce oxides of nitrogen and carbon.
Hazardous Polymerization:

Will Occur

X

Will Not Occur

11. TOXICOLOGICAL INFORMATION
Route of Exposure:

X

Inhalation

Skin

Ingestion

Symptoms Related to the Physical, Chemical and Toxicological Characteristics: Skin, eye, and possible
respiratory irritation.
Potential Health Effects (Acute, Chronic and Delayed):
Inhalation: Inhalation may cause irritation of the mucous membranes with tightness and pain in the chest,
coughing, and difficulty breathing.
Skin Contact: Skin exposure may result in irritation with redness, pain, and possibly sensitization. Dermatitis
may develop due to irritation or sensitization over time.
Eye Contact: Eye irritation with redness, pain, and possibly corneal damage may occur. Prolonged or repeated
exposure may result in conjunctivitis.
Ingestion: Ingestion of this material is unlikely under normal conditions of use. If ingested, gastrointestinal
irritation and possible burns to the mouth and stomach may result. A large does to laboratory animals caused
weakness, collapse, and death.
Numerical Measures of Toxicity:
Acute Toxicity: Not classified.
Rat, Oral LD50: >3000 mg/kg
Skin Corrosion/Irritation: Category 2
Rabbit, Dermal: 25 % moderate; 500 mg severe
Woman, Dermal: 1 % moderate
Serious Eye damage/Eye irritation: Category 2A, No data available on effects on the eyes, deemed to be a
Category 2A based on skin irritation data.
Respiratory Sensitization: Not classified; no data available.
Skin Sensitization: Not classified; no data available.
Germ Cell Mutagenicity: Not classified; no data available.
Carcinogenicity: Not classified.
Listed as a Carcinogen/Potential Carcinogen
Yes
X
No
Tris(Hydroxymethyl)Aminomethane is not listed by IARC, NTP or OSHA as a carcinogen.
Reproductive Toxicity: Not classified.
Rat, Oral TDLo: 12 000 mg/kg (prior to copulation 14 d, 4 d, continuous)
Specific Target Organ Toxicity, Single Exposure: Not classified; no data available.
Specific Target Organ Toxicity, Repeated Exposure: Category 3; May cause respiratory irritation of the
mucous membranes with tightness and pain in the chest, coughing, and difficulty breathing.
Aspiration Hazard: Not classified; no data available.

SRM 723e
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12. ECOLOGICAL INFORMATION
Ecotoxicity Data: No data available.
Persistence and Degradability: Biodegradation may be slow in the environment.
Bioaccumulative Potential: Potential for bioconcentration in aquatic organisms is low (estimated BCF equals 3).
Mobility in Soil: Very high mobility in soil.
Other Adverse effects: No data available.

13. DISPOSAL CONSIDERATIONS
Waste Disposal: Dispose of waste in accordance with all applicable federal, state, and local regulations.

14. TRANSPORTATION INFORMATION
U.S. DOT and IATA: Not regulated by DOT or IATA.

15. REGULATORY INFORMATION
U.S. Regulations:
CERCLA Sections 102a/103 (40 CFR 302.4): Not regulated.
SARA Title III Section 302 (40 CFR 355.30): Not regulated.
SARA Title III Section 304 (40 CFR 355.40): Not regulated.
SARA Title III Section 313 (40 CFR 372.65): Not regulated.
OSHA Process Safety (29 CFR 1910.119): Not regulated.
SARA Title III Sections 311/312 Hazardous Categories (40 CFR 370.21):
ACUTE HEALTH:
Yes.
CHRONIC HEALTH:
No.
FIRE:
No.
REACTIVE:
No.
PRESSURE:
No.
State Regulations:
California Proposition 65: Not listed.
U.S. TSCA Inventory: Listed.
TSCA 12(b), Export Notification: Not listed.
Canadian Regulations: WHMIS Information: Not provided for this material.

SRM 723e
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16. OTHER INFORMATION
Issue Date: 19 February 2019
Sources:

ChemAdvisor, Inc., SDS Tris(Hydroxymethyl)Aminomethane, 09 December 2015.
Hazardous Substances Data Bank, National Library of Medicine, Tromethamine CAS# 77-86-1, Full
Record, available at https://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?HSDB (accessed Feb 2019).
Center for Disease Control (CDC), NIOSH Pocket Guide to Chemical Hazards, Particulates Not
Otherwise Regulated, available at https://www.cdc.gov/niosh/npg/npgd0480.html (accessed Feb 2019).
Sigma-Aldrich, Vendor MSDS Trizma® base, 07 November 2017.

Key of Acronyms:
ACGIH
ALI
CAS
CEN
CERCLA
CFR
CPSU
DOT
EC50
EINECS
EPCRA
IARC
IATA
IDLH
ISO
LC50
LD50
LEL
MSDS
NFPA
MSHA

American Conference of Governmental Industrial
Hygienists
Annual Limit on Intake
Chemical Abstracts Service
European Committee for Standardization
Comprehensive
Environmental
Response,
Compensation, and Liability Act
Code of Federal Regulations
Coal Mine Dust Personal Sample Unit
Department of Transportation
Effective Concentration, 50 %
European Inventory of Existing Commercial Chemical
Substances
Emergency Planning and Community Right-to-Know
Act
International Agency for Research on Cancer
International Air Transport Association
Immediately Dangerous to Life and Health
International Organization for Standardization
Lethal Concentration, 50 %
Lethal Dose, 50 %
Lower Explosive Limit
Material Safety Data Sheet
National Fire Protection Association
Mine Safety and Health Administration

NIOSH

National Institute for Occupational Safety and Health

NIST
NRC
NTP
OSHA

National Institute of Standards and Technology
Nuclear Regulatory Commission
National Toxicology Program
Occupational Safety and Health Administration

PEL
RCRA
REL
RM
RQ

Permissible Exposure Limit
Resource Conservation and Recovery Act
Recommended Exposure Limit
Reference Material
Reportable Quantity

RTECS

Registry of Toxic Effects of Chemical Substances

SARA
SCBA
SRM
STEL
TDLo
TLV
TPQ
TSCA
TWA
UEL
WHMIS

Superfund Amendments and Reauthorization Act
Self-Contained Breathing Apparatus
Standard Reference Material
Short Term Exposure Limit
Toxic Dose Low
Threshold Limit Value
Threshold Planning Quantity
Toxic Substances Control Act
Time Weighted Average
Upper Explosive Limit
Workplace Hazardous Materials Information System

Disclaimer: Physical and chemical data contained in this SDS are provided only for use in assessing the
hazardous nature of the material. The SDS was prepared carefully, using current references; however, NIST does not
certify the data in the SDS. The certified values for this material are given in the NIST Certificate of Analysis.
Users of this SRM should ensure that the SDS in their possession is current. This can be accomplished by contacting
the SRM Program: telephone (301) 975-2200; fax (301) 948-3730; e-mail srmmsds@nist.gov; or via the Internet at
https://www.nist.gov/srm.
SRM 723e
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(54) Title: INFLUENZA RECOMBINANT SUBUNIT VACCINE

Influenza Mouse lmmunogenicity
H3 Ectodomain ELISA Antibody Titers

(Post 3 Vaccinations)

(57) Abstract: The invention provides influenza proteins, including subunit proteins and immunogenic compositions that can be
utilized, with or without adjuvants, as vaccines to protect against influenza infection in animal models and humans. The recombinant
proteins are expressed from transformed insect cells that contain integrated copies of the appropriate expression cassettes in their
genome. The invention uses a Drosophila melanogaster expression system to provide high yields of recombinant subunit proteins
with native-like conformation.

INFLUENZA RECOMBINANT SUBUNIT VACCINE
RELATED APPLICATION
[01]

This application claims the benefit of U.S. Provisional Patent Application No.

60/708,988, filed August 16, 2005, the disclosures and drawings of which prior application are

hereby incorporated by reference in their entirety.

INCORPORATION OF SEQUENCE LISTING
[02] A sequence listing file in ST.25 format on CD-ROM is appended to this application

and fully incorporated herein by reference. The sequence listing information recorded in
computer readable form is identical to the written sequence listing (per WIPO ST.25 para. 39,
the information recorded on the form is identical to the written sequence listing). With respect
to the appended CD-ROMs, the format is ISO 9660; the operating system compatibility is MSWindows; the single file contained on each CD-ROM is named "FLU.S2.ADJ.04.ST25.txt"
and is a text file produced by Patentln 3.3 software; the file size in bytes is 35 KB; and the date
of file creation is 16 August 2006. The contents of the two CD-ROMs submitted herewith are
identical.

BACKGROUND OF THE INVENTION
TECHNICAL FIELD
[03]

The invention relates to vaccine formulations designed to protect against influenza.

In particular, the vaccine formulations comprise recombinant subunit proteins derived from
influenza virus, and optionally include one or more adjuvants. "Subunit protein" is defined
here as any protein derived or expressed independently from the complete organism that it is
derived from. Furthermore, a subunit protein may represent a full length native protein
sequence or any fraction of the full length native protein sequence. Additionally, a subunit
protein may contain in addition to the full length or partial protein sequence, one or more
sequences, which may contain sequences that are homologous or heterologous to the organism
from which the primary sequence was derived. This definition is significantly broader than the
concept of a subunit protein as a single protein molecule that co-assembles with other protein
molecules to form a multimeric or oligomeric protein. The subunit proteins of the invention
are produced in a cellular production system by means of recombinant DNA methods and,
after purification, are formulated in a vaccine.
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the quality of the immune response is increased, and 3) the efficacy of subunit vaccines is
improved.
[032] There is a clear need for new technologies that can be used to respond quickly to

influenza outbreaks and pandemics, to produce sufficient doses of high quality and safe
vaccine for all populations (including the irαmunodef ϊ cient population), and to produce
improved vaccine formulations with increased immunogenicity and efficacy. Some of the
technical problems to be solved are engineering nucleotide sequences for immunogenic and
protective epitopes, expression and purification of the subunit proteins encoded by the
nucleotide sequences through methods that can be scaled up to commercial production, and
determining which adjuvants, if any, should be included in vaccine formulations containing the
subunit proteins. The invention disclosed herein meets the need of developing a new influenza
vaccine production method and solves associated technical problems.

SUMMARY OF THE INVENTION
[033]

The invention provides recombinant influenza subunit proteins and immunogenic

compositions that can be utilized as vaccines to afford protection against influenza in animal
models and humans. The recombinant subunit proteins of the invention are expressed from
stably transformed insect cells that contain integrated copies of the appropriate expression
cassettes in their genome. The insect cell expression system provides high yields of
recombinant subunit proteins with native-like conformation. The recombinant subunit proteins
of the invention represent full length or truncated forms of the native influenza proteins.
Additionally, multimeric forms of several of the recombinant subunit proteins have been
produced. Specifically, the subunits are derived from the HA and M l proteins of influenza.
More specifically the subunit proteins are secreted from the transformed insect cells and then
purified from the culture medium following the removal of the host cells. Avoiding lysis of the
host cells by either viral means or by physical means simplifies purification, improves yields,
and avoids potential degradation of the target protein.
[034] The invention also provides for the use of adjuvants as components in an immunogenic

composition compatible with the purified proteins to boost the immune response resulting from
vaccination. One or more preferred adjuvants are selected from the group comprising saponins
(e.g, GP-OlOO), or derivatives thereof, emulsions alone or in combination with carbohydrates

or saponins, and aluminum-based adjuvants (collectively, "alum" or "alum-based adjuvants")
such as aluminum hydroxide, aluminum phosphate, or a mixture thereof. Aluminum
hydroxide (commercially available as "Alhydrogel") was used as alum in the Examples. A
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sapogenin aglycone. Sapogenin is the nonsugar portion of a saponin. It is usually obtained by
hydrolysis, and it has either a complex terpenoid or a steroid structure that forms a practicable
starting point in the synthesis of steroid hormones. The saponins of the invention can be any
saponin as described above or saponin-like derivative with hydrophobic regions, especially the
strongly polar saponins, primarily the polar triterpensaponins such as the polar acidic
bisdesmosides, e.g. saponin extract from Quillsjabark Araloside A, Chikosetsusaponin IV,
Calendula-Glycoside C, chikosetsusaponin V, Achyranthes-Saponin B.
Calendula-Glycoside A, Araloside B, Araloside C, Putranjia-Saponin III, Bersamasaponiside,
Putrajia-Saponin IV, Trichoside A, Trichoside B, Saponaside A, Trichoside C, Gypsoside.
Nutanoside, Dianthoside C, Saponaside D, aescine from Aesculus hippocastanum or sapoalbin
from Gyposophilla struthium, preferably, saponin extract Quillaja saponaria Molina and
Quil A. In addition, saponin may include glycosylated triterpenoid saponins derived from
Quillaja Saponaria Molina of Beta Amytin type with 8-1 1 carbohydrate moieties as described
in U.S. Patent No. 5,679,354. Saponins as defined herein include saponins that may be
combined with other materials, such as in an immune stimulating complex ("ISCOM")-like
structure as described in U.S. Patent No. 5,679,354. Saponins also include saponin-like
molecules derived from any of the above structures, such as GPI-0100, such as described in
U.S. Patent No. 6,262,029. Preferably, the saponins of the invention are amphiphilic natural
products derived from the bark of the tree, Quillaia saponaria. Preferably, they consist of
mixtures of triterpene glycosides with an average molecular weight (Mw) of 2000. A
particularly preferred embodiment of the invention is a purified fraction of this mixture.
[035] The invention further provides methods for utilizing the vaccines to elicit the

production of antibodies against the various types and subtypes of influenza virus in a
mammalian host as a means of conferring protection against influenza. The vaccine
formulations are shown to induce strong overall antibody titers, as well as strong

hemagglutinin-inhibition antibody titers, in comparison to other formulations. Furthermore, the
vaccine formulations are shown to provide protection against influenza challenge in a mouse
model. In comparison to conventionally produced influenza immunogens, the proteins
produced by the invention have increased immunogenicity and efficacy, are less costly to
produce, and have a shorter production cycle.

BRIEF DESCRIPTION OF THE DRAWINGS
[036] FIG. 1. Lymphocyte proliferation of antigen stimulated splenocytes

[037] FIG. 2. IFN-γ production from antigen stimulated splenocytes.

We claim:
1. A method for producing a recombinant subunit influenza vaccine comprising:
expressing and secreting a recombinant influenza hemagglutinin ectodomain protein
subunit, wherein the protein subunit lacks a C-terminal transmembrane anchor and is
secreted as a soluble protein from stably transformed insect cells; and

formulating said recombinant protein subunit to produce an immunogenic composition
that induces the production of hemagglutinin antibody titers in a host vaccinated with the
immunogenic composition.
2. A method for producing a recombinant subunit influenza vaccine comprising:

expressing and secreting a recombinant influenza hemagglutinin head protein subunit,
wherein the protein subunit lacks a C-terminal transmembrane anchor, lacks an N-terminal
portion, and is secreted as a soluble protein from stably transformed insect cells; and
formulating said recombinant protein subunit to produce an immunogenic composition
that induces the production of hemagglutinin antibody titers in a host vaccinated with the
immunogenic composition.
3. A method for producing a recombinant subunit influenza vaccine comprising:

expressing and secreting a recombinant influenza hemagglutinin ectodomain protein
subunit, wherein the protein subunit lacks a C-terminal transmembrane anchor and is

secreted as a soluble protein from stably transformed insect cells;
expressing and secreting a recombinant influenza matrix 1 protein subunit, wherein the
protein subunit lacks a C-terminal transmembrane anchor, and is secreted as a soluble
tetrameric protein from stably transformed insect cells; and
formulating said recombinant hemagglutinin ectodomain and matrix 1protein subunits
to produce an immunogenic composition that induces the production of hemagglutinin
antibody titers in a host vaccinated with the immunogenic composition.
4. A method for producing a recombinant subunit influenza vaccine comprising:

expressing and secreting a recombinant influenza hemagglutinin head protein subunit,
wherein the protein subunit lacks a C-terminal transmembrane anchor, lacks an N-terminal
portion, and is secreted as a soluble protein from stably transformed insect cells;

expressing and secreting a recombinant influenza matrix 1 protein subunit, wherein the
protein subunit lacks a C-terminal transmembrane anchor, and is secreted as a soluble
tetrameric protein from stably transformed insect cells; and
formulating said recombinant hemagglutinin head and matrix 1 protein subunits to
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16. The method of claim 1 or 3, wherein the recombinant influenza hemagglutinin ectodomain

protein subunit has an amino acid sequence selected from the group consisting of SEQ ID
NO:1, SEQ ID NO:2, and SEQ ID NO:3.
17. The method of claim 2 or 4, wherein the recombinant influenza hemagglutinin head protein

subunit has an amino acid sequence selected from the group consisting of SEQ ID NO: 4,
SEQ ID NO:5, SEQ ID NO:6, and SEQ ID NO:7.
18. The method of claim 2 or 4, wherein the truncation points of the hemagglutinin head

protein subunit are selected from the group consisting of N-terminal, C-terminal, and Nterminal and C-terminal, wherein the one or both terminal points can be varied up to 10%
of the length of a nominal HA-head.
19. The method of claim 3, 4, or 6, wherein the recombinant influenza matrix 1 protein subunit

has an amino acid sequence of SEQ ID NO: 10.
20. The method of claim 5 or 6, wherein the recombinant influenza HA-foldon subunit has an

amino acid sequence selected from the group consisting of SEQ ID NO: 8 and SEQ ID
NO:9.
21. A method for raising an immunogenic response from a subject, comprising administering
in a therapeutically acceptable manner a therapeutically effective amount of the
immunogenic composition of claim 1, 2, 3, 4, 5, or 6, to said subject.
22. An immunogenic composition comprising a recombinant subunit influenza vaccine
comprising a recombinant influenza hemagglutinin ectodomain protein subunit, wherein
the protein subunit lacks a C-terminal transmembrane anchor and is expressed and secreted
as a soluble protein from stably transformed insect cells.
23. An immunogenic composition comprising a recombinant subunit influenza vaccine

comprising a recombinant influenza hemagglutinin head protein subunit, wherein the
hemagglutinin head protein subunit lacks a C-terminal transmembrane anchor, lacks an Nterminal portion, and is expressed and secreted as a soluble protein from stably transformed
insect cells.
24. An immunogenic composition comprising a recombinant subunit influenza vaccine

comprising a recombinant influenza hemagglutinin ectodomain protein subunit, wherein
the hemagglutinin ectodomain protein subunit lacks a C-terminal transmembrane anchor
and is expressed and secreted as a soluble protein from stably transformed insect cells,
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protein subunit lacks a C-terminal transmembrane anchor, and is expressed and secreted as
a soluble tetrameric protein from stably transformed insect cells.
25. An immunogenic composition comprising a recombinant subunit influenza vaccine

comprising a recombinant influenza hemagglutinin head protein subunit, wherein the
hemagglutinin head protein subunit lacks a C-terminal transmembrane anchor, lacks an Nterminal portion, and is expressed and secreted as a soluble protein from stably transformed
insect cells,
combined with a recombinant influenza matrix 1 protein subunit, wherein the matrix 1
protein subunit lacks a C-terminal transmembrane anchor, and is expressed and secreted as
a soluble tetrameric protein from stably transformed insect cells.
26. An immunogenic composition comprising a recombinant subunit influenza vaccine

comprising a recombinant influenza HA-foldon protein subunit, wherein the protein
subunit is expressed and secreted as a soluble protein from stably transformed insect cells.
27. An immunogenic composition comprising a recombinant subunit influenza vaccine

comprising a recombinant influenza HA-foldon protein subunit, wherein the HA-foldon
protein subunit is expressed and secreted as a soluble protein from stably transformed
insect cells,
combined with a recombinant influenza matrix 1 protein subunit, wherein the matrix 1
protein subunit lacks a C-terminal transmembrane anchor, and is expressed and secreted as
a soluble tetrameric protein from stably transformed insect cells.
28. The immunogenic composition of claim 22, 23, 24, 25, 26, or 27, wherein the influenza

virus is influenza A virus.
29. The immunogenic composition of claim 22, 23, 24, 25, 26, or 27, wherein the strain of

influenza virus is selected from the group consisting of H5 and H3.
30. The immunogenic composition of claim 22, 23, 24, 25, 26, or 27, wherein the carboxy-

terminal portion of the hemagglutinin protein subunit is truncated within 10% of the length
of a nominal ectodomain.
31. The immunogenic composition of claim 22, 23, 24, 25, 26, or 27, wherein the stably

transformed insect cells are Drosophila melanogaster S2 cells.
32. The immunogenic composition of claim 22, 23, 24, 25, 26, or 27, wherein the

immunogenic composition further comprises one or more adjuvants.
33. The immunogenic composition of claim 22, 23, 24, 25, 26, or 27, wherein the

immunogenic composition further comprises one or more adjuvants selected from the
group consisting of saponin and alum.
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immunogenic composition further comprises GPI-0100 adjuvant.
35. The immunogenic composition of claim 22, 23, 24, 25, 26, or 27, wherein the

immunogenic composition further comprises a pharmaceutically acceptable excipient.
36. The immunogenic composition of claim 22, 23, 24, 25, 26, or 27, wherein the protein

subunits are purified by immuno-affmity chromatography.
37. The immunogenic composition of claim 22, 23, 24, 25, 26, or 27, wherein the

immunogenic composition is administered to a subject in a vaccine.
38. The immunogenic composition of claim 22 or 24, wherein the recombinant influenza

hemagglutinin ectodomain protein subunit has an amino acid sequence selected from the
group consisting of SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3.

39. The immunogenic composition of claim 22 or 24, wherein the recombinant influenza

hemagglutinin ectodomain protein subunit has an amino acid sequence with at least 95%
sequence identity to an amino acid selected from the group consisting of SEQ ID NO:1,

SEQ ID NO:2, and SEQ ID NO:3.
40. The immunogenic composition of claim 22 or 24, wherein the recombinant influenza

hemagglutinin ectodomain protein subunit has an amino acid sequence with at least 90%
sequence identity to an amino acid selected from the group consisting of SEQ ID NO:1,
SEQ ID NO:2, and SEQ ID NO:3.

41. The immunogenic composition of claim 23 or 25, wherein the recombinant influenza

hemagglutinin head protein subunit has an amino acid sequence selected from the group
consisting of SEQ ID NO:4, SEQ DD NO:5, SEQ ID NO:6, and SEQ ID NO:7.
42. The immunogenic composition of claim 23 or 25, wherein the recombinant influenza

hemagglutinin head protein subunit has an amino acid sequence with at least 95% sequence
identity to an amino acid selected from the group consisting of SEQ ID NO:4, SEQ ID
NO:5, SEQ ID NO:6, and SEQ ID NO:7.
43. The immunogenic composition of claim 23 or 25, wherein the recombinant influenza

hemagglutinin head protein subunit has an amino acid sequence with at least 90% sequence
identity to an amino acid selected from the group consisting of SEQ ID NO:4, SEQ ID
NO:5, SEQ ID NO:6, and SEQ ID NO:7.
44. The immunogenic composition of claim 23 or 25, wherein the truncation points of the

hemagglutinin head protein subunit are selected from the group consisting of N-terminal,
C-terminal, and N-terminal and C-terminal, wherein the one or both terminal points can be

varied up to 10% of the length of a nominal HA-head.
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matrix 1 protein subunit has the amino acid sequence of SEQ ID NO: 10.
46. The immunogenic composition of claim 24, 25, or 27, wherein the recombinant influenza
matrix 1 protein subunit has an amino acid sequence with at least 95% sequence identity to
SEQ ID NO: 10.
47. The immunogenic composition of claim 24, 25, or 27, wherein the recombinant influenza
matrix 1 protein subunit has an amino acid sequence with at least 90% sequence identity to
SEQ ID NO: 10.
48. The immunogenic composition of claim 26 or 27, wherein the recombinant influenza HAfoldon protein subunit has an amino acid sequence selected from the group consisting of
SEQ ID NO:8 and SEQ ID NO:9.
49. The immunogenic composition of claim 26 or 27, wherein the recombinant influenza HAfoldon protein subunit has an amino acid sequence with at least 95% sequence identity to
an amino acid selected from the group consisting of SEQ ID NO:8 and SEQ ID NO:9.
50. The immunogenic composition of claim 26 or 27, wherein the recombinant influenza HAfoldon protein subunit has an amino acid sequence with at least 90% sequence identity to
an amino acid selected from the group consisting of SEQ ID NO:8 and SEQ ID NO:9.
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Title: Method for the production of Ad26 adenoviral vectors

The invention relates to the field of cell culture and adenovirus production. More
particularly, it concerns improved methods for the culturing of mammalian cells,
infection of those cells with adenovirus and the production of adenovirus particles
therefrom.

Background of the invention
Recent developments in the field of DNA vaccination using recombinant viral
vectors have created the need for large scale manufacturing of clinical grade material.
Processes are needed to be able to support the less and least developed world with
sufficient amounts of recombinant adeno-based vaccines to fight e.g. the Tuberculosis
and Malaria problem in the world. An evaluation of the birth cohort shows that more
than 150.000.000 births are expected for the less and least developed world in 20102015. Based on this birth cohort the projected annual demand for a vaccine could

reach approximately 1.5 x 10 19 virus particles (VP) on a yearly basis
(http://esa.un.org/unpp/index. asp ?panel=2).
Several processes for production of adenoviruses have been described. These
processes use adherent cell cultures in roller bottles, cell factories (Nunclon from
Nunc or CellStack from Corning), or Cell Cubes (Corning). Production processes on
adherent cell cultures cannot fulfill the worldwide demand for adeno-based vaccines.
Therefore the cells used in the adherent process are adapted to suspension cultures
(e.g. HEK293 and PER.C6 ® cell lines). With the use of suspension cultures it is

possible to scale-up production processes to large-scale bioreactors. Suspension cell
cultures for adenovirus production are routinely achieved between 3 to 20L scale and

successful scale-up has been reported up to 100L (Kamen et al, 2004), and 250L (Xie
et al, 2003). Experiments are reported in which scaling up to 10.000L is anticipated
(Xie et al, 2003).

However, a major disadvantage of scaling up to 10.000L is the high capital
investment (CAPEX), which is needed to design and build a 10.000L bioreactor
facility. Furthermore, the CAPEX commitment of building a 10.000L facility, under
BSL 2 conditions, must be realized before even knowing if the product will be
successful (Phase IV and beyond). The total investment cost for a 10.000L bioreactor

plant is reported between C225. 000.000 and C320.000.000 (Estape et al, 2006).
Therefore, preparation at lower scale, e.g. in 1000L or smaller bioreactors, would be
desirable.

With the use of currently existing processes, more than 150 batches at 1000L
scale a year must be produced in order to reach the target of 1.5xl0 1 VP/year.

Therefore, a need exists to improve systems for adenovirus production, to improve
yields of adenovirus particles in order to fulfil the world-wide demand of adenovirus
vaccines, preferably at non-prohibitive costs.
One of the issues encountered in adenovirus production optimization is the so-

called "cell density effect". In batch-mode operation, several references suggest the

existence of an optimal cell density at infection for adenovirus production. The
optimum lies between 0.5 - lxlO 6 cells/mL (Maranga et al, 2005; Kamen et al.,
2004). It was shown for adenovirus (Ad5) production in a batch stirred tank bioreactor

that the virus productivity per cell remains constant up to around 0.9xl0 6 cells/mL,
but drops abruptly at around lxlO 6 cells/mL (Altaras et al, 2005). Beyond 2xl0 6
cells/mL, no infectious particles were detectable. The breakpoint related to specific

production drop with cell densities at infection is medium dependent. No available
commercial medium to date has shown potential to support high yields of virus
particles, while maintaining the specific production optimal at cell densities beyond
lxlO 6 cells/mL (Kamen et al, 2004). The reasons for this drop is not known yet but
might be due to limited nutrient availability for virus production, or due to high
metabolites concentrations that are inhibitory for virus production.
Fed-Batch operations, like addition of glucose, glutamine and amino acids
allowed infections at cell densities up to 2xl0 6 cells/mL. However, the productivities
attained at high cell densities were lower than those obtained with infection at cell
densities of lxlO 6 cells/mL (Kamen et al., 2004).

In perfusion processes the cells are retained in the bioreactor by hollow fibers,
spin filters or acoustic separators while culture medium is perfused through the
bioreactor. In these processes cell densities of >100xl0 6 cells/mL can sometimes be
reached (e.g., Yallop et al, 2005).
Infected perfusion cells showed premature cell loss during perfusion with a
hollow fiber system. This might be related to their higher shear sensitivity due to the
viral infection (Cortin et al., 2004). The hydro-dynamical stresses induced in the
tubing, the hollow fibers, or the peristaltic pump on more fragile, infected cells was

most likely the cause for this phenomenon. Since infected cells are more fragile,
particularly the acoustic separator (Henry et al, 2004) has been suggested to be
desirable if the perfusion is to be maintained throughout the infection phase.

However, infections performed in perfusion mode could only be maintained for cell
densities up to 3xl0 6 cells/mL with a perfusion rate of 2 vol/day. Infection at a cell

density of 6x1 06 cells/mL led to a fivefold reduction in specific productivity (Henry et
al, 2004).
Despite the reported cell density effect by others, one report (Yuk et al, 2004)
described successful perfusion cultures of human tumor cells as a production platform
for oncolytic adenoviral vectors. That report described a high-cell-density perfusion

process using alternating tangential flow (ATF) technology. At an average viable cell
density at infection of 9 x 10 6 HeLaS3 cells/mL, an average viral titer of about 4 x
10 1 1 VP/mL was observed. The tumor cells used in that report are not preferred as

production cells, since use of tumor cells may pose safety risks when the produced
adenovirus particles are to be administered to humans. The recombinant adenovirus in
that report was based on Ad5. Such adenoviruses have limited possibilities for use as
vaccines since a majority of the human population contain pre-existing neutralizing
antibodies against Ad5, and recombinant adenoviruses from other serotypes are
therefore more suitable for use as vaccines (see e.g. WO 00/70071). Recombinant
adenoviruses especially advantageous for use as vaccines include Ad26 (WO
00/70071).

Limited information, if any, is available for the large scale production of
recombinant adenoviruses from other serotypes than Ad5, in particular for the
advantageous serotype 26. Some differences between Ad35 and Ad5 production at
large scale have been described previously in e.g. PCT/EP2009/064265. The

somewhat different physical properties of recombinant adenoviruses of different
serotypes may give rise to differences in production processes. Such potential

differences may especially be important at industrial scale, where even seemingly
small differences at small scale may have large economic consequences on the scale

envisaged for production of the annual world-wide demand. For instance, it was
shown by the applicant that the reported cell density effect for Ad5 was different for
Ad35 (PCT/EP2009/064265). Thus, rAd35 propagates differently in producer cells

than rAd5 during large scale production processes. Apparently, the propagation of
adenoviruses from different serotypes is very unpredictable.

In order to fulfil the world-wide demand of recombinant adenovirus serotype
26 (rAd26) vaccines, a need exists to improve systems for rAd26 production.

The present invention provides improved methods for industrial production of rAd26.

Summary of the invention
We have found herein that yet another serotype, i.e. Ad26 behaves differently than
other serotypes Ad5 and Ad35. Indeed, Ad26 tends to show a slight cell density
effect, yet not as accentuated as the density effect seen for Ad5. In addition, cells that
are infected with Ad26 tend to grow further after infection, while cells infected with

Ad35 show a decreased growth post infection.

These results again suggest that processes for specific adenovirus serotypes
may have to be fine-tuned for each serotype, in order to obtain optimal results. The
present invention provides an optimized system for production of rAd26 in terms of
yield, quality of the rAd26 obtained, and ease of handling of the harvest for down
stream processing.
The invention provides a method for producing recombinant adenovirus
serotype 26 (rAd26), the method comprising: a) culturing producer cells in suspension
with a perfusion system; b) infecting said cells at a density of between about lOxlO 6
viable cells/mL and 16xl0 6 viable cells/mL with rAd26; c) further culturing the
infected cells with a perfusion system to propagate said rAd26; and d) harvesting said
rAd26.
In certain embodiments said cells in step b) are infected with rAd26 at a
density of between about lOxlO 6 and 14xl0 6 viable cells/mL.
In certain preferred embodiments, said perfusion system in step c) is an
alternating tangential flow (ATF) perfusion system. In other preferred embodiments,
said perfusion system in step a) is an alternating tangential flow (ATF) perfusion
system. In a preferred embodiment, said perfusion system in both steps a) and c) is an

alternating tangential flow (ATF) perfusion system.
In certain embodiments, the method of the invention further comprises: e)
purifying the rAd26. In further embodiments, the method further comprises: f)
preparing a pharmaceutical composition containing the purified rAd26.
In certain embodiments, said recombinant adenovirus lacks at least a portion
of the E l region, and comprises heterologous nucleic acid.

In preferred embodiments, the physical particle to infectious particle (VP/IU)
ratio of the produced rAd26 is less than 30:1, preferably less than 20:1.
It is also an aspect of the invention to provide a method for producing at least
lxl0

1

rAd26 virus particles (VP)/mL, the method comprising: a) culturing producer

cells in suspension with a perfusion system; b) infecting said cells at a density of

between about lOxlO 6 viable cells/mL and 16xl0 6 viable cells/mL with rAd26; c)
further culturing the infected cells with a perfusion system to propagate said rAd26,
whereby the concentration of rAd26 virus particles reaches at least lxlO 12 VP/mL;
and d) harvesting said rAd26.
The invention also provides a bioreactor with a working volume of between
2L and 1000L, comprising: culture medium, producer cells, and at least lxl 0 12 rAd26
virus particles (VP)/mL. In certain embodiments, the bioreactor has a working volume
of between 50L and 500L. In preferred embodiments, the bioreactor is connected to
an ATF perfusion system.

Brief description of the Figures
FIG. 1. Infection at high cell density in shakers with rAd5.
FIG. 2 . Infection at high cell density in shakers and 2L bioreactor with rAd35.TB-S.
FIG. 3 . Infection at high cell density in shakers with rAd26.
FIG. 4 . Cell growth post infection with rAd26.
FIG. 5 . Cell growth post infection with rAd35.

Detailed description of the invention
The present invention describes a new process for the production of large
quantities of recombinant adenovirus rAd26. This optimized process relies on the
ability to infect cultures at high cell density with preservation of a high virus
productivity per cell. Herewith, it offers a method to obtain a harvested virus solution
with high virus concentration in a single bioreactor. Typical yields of current
processes for rAd26 are about 2-3x1 0 1 1 VP/mL. Indeed, it is believed that very large
quantities of rAd26 particles can be produced using the processes of the present
invention, for instance quantities of at least about 5x1 0 1 1 VP/mL, preferably at least
about 6, 7, 8, or 9xlO VP/mL. Preferably at least lxlO 12 VP/mL of rAd26 are
produced, more preferably at least 1.5x1 0 12 VP/mL, still more preferably at least
2xl0

12

VP/mL, e.g. between about lxlO 12 and 5xl0

12

VP/mL. Typically, the process

Claims
1.

A method for producing recombinant adenovirus serotype 26 (rAd26), the

method comprising:
a) culturing producer cells in suspension with a perfusion system;

b) infecting said cells at a density of between lOxlO 6 viable cells/mL and

16xl0 6 viable cells/mL with rAd26;
c) further culturing the infected cells with a perfusion system to propagate

said rAd26; and
d) harvesting said rAd26.

2.

A method according to claim 1, wherein said cells in step b) are infected with

rAd26 at a density of between about lOxlO 6 and 14xl0 6 viable cells/mL.

3.

A method according to any one of the preceding claims, wherein said

perfusion system in step c) is an alternating tangential flow (ATF) perfusion system.

4.

A method according to any one of the preceding claims, further comprising:
e) purifying the rAd26, and optionally

f preparing a pharmaceutical composition containing the purified rAd26.

5.

A method according to any one of the preceding claims, wherein said

recombinant adenovirus lacks at least a portion of the E l region, and comprises
heterologous nucleic acid.

6.

A method according to any one of the preceding claims, wherein said

perfusion system in step a) is an alternating tangential flow (ATF) perfusion system.

7.

A method according to any one of the preceding claims, wherein step a) is

performed in a first bioreactor, and steps b) and c) are performed in a second
bioreactor.

8.

A method according to any one of the preceding claims, wherein the physical

particle to infectious particle (VP/IU) ratio of the produced rAd35 is less than 30:1,
preferably less than 20: 1.

9.

A bioreactor comprising culture medium, producer cells, and virus particles

wherein said bioreactor has a working volume of between 2L and 1000L, preferably
between 50L and 500L, and characterized in that said bioreactor comprises at least
lxlO 12 rAd26 virus particles (VP)/mL.

10.

A bioreactor according to claim 9, connected to an ATF perfusion system.

11.

A bioreactor according to claim 9 or 10, wherein the rAd26 virus particles

have a VP/IU ratio of less than 30:1, preferably less than 20: 1.

12.

A method for producing at least lxlO 12 rAd26 virus particles (VP)/mL, the

method comprising:
a) culturing producer cells in suspension with a perfusion system;

b) infecting said cells at a density of between lOxlO 6 viable cells/mL and
16xl0 6 viable cells/mL with rAd26;
c) further culturing the infected cells with a perfusion system to propagate said

rAd26, whereby the concentration of rAd26 virus particles reaches at least lxlO 12
VP/mL; and
d) harvesting said rAd26.

